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‘Gutta cavat lapidem non vī sed saepe cadendo’ 
 
 
A droplet carves out a stone, not with force, but by persistently falling 
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Fibrosis is a major contributor to cardiac disease. No specific anti-fibrotic 
therapy is currently available. MicroRNA-21 (miR-21) has been implicated as 
a regulator of fibrosis and inhibitors of miR-21 are currently undergoing clinical 
trials. In this project, we used a proteomics approach to explore mechanisms 
of how miR-21 inhibition may attenuate fibrosis. First, primary murine cardiac 
fibroblasts were transfected with miR-21 mimics and inhibitors. Unexpectedly, 
proteomic analysis of their secretome showed limited changes in extracellular 
matrix (ECM) protein secretion despite a pro-proliferative effect of miR-21. 
Similarly, no significant differences were seen in the ECM of miR-21 null 
mouse hearts. In light of its ubiquitous expression, we searched for additional 
explanations as to how miR-21 might regulate fibrosis. In the year 2000 follow-
up of the community-based Bruneck study (n=660), we compared circulating 
miR-21 with a proteomic panel of 229 proteins associated with cardiovascular 
disease. Several platelet-derived pro-fibrotic factors significantly correlated 
with plasma miR-21 levels, including the latency-associated peptide of TGF-
β1. This correlation was confirmed by ELISA measurements of active TGF-β1 
in platelet-poor plasma collected during the Bruneck 2015 follow-up (n=332). 
Immunohistological staining of murine bone marrow sections revealed marked 
co-localisation of TGF-β1 with megakaryocytes, whilst immune-mediated 
thrombocytopaenia in mice indicated platelet dependency of plasma TGF-β1 
levels. When mice were treated with antagomiR-21, no differences were 
observed in the platelet count or their aggregation response. However, a 
proteomics analysis of the platelet releasate revealed TGF-β1 as differentially 
regulated. An attenuated TGF-β1 release after antagomiR-21 treatment was 
validated in platelets activated with collagen and a thrombin receptor-activating 
peptide. Mechanistically, Wiskott-Aldrich Syndrome protein, a negative 
regulator of platelet TGF-β1 secretion, was identified as a direct target of miR-
21. In conclusion, this study reports a previously unrecognised effect of 
pharmacological miR-21 inhibition on platelet TGF-β1 release. Furthermore, 
we observed significantly lower platelet counts in blood from miR-21 null mice. 
This novel effect of miR-21 on platelets highlights the bone marrow as a 
potential key contributor to the anti-fibrotic effects of miR-21 inhibition. 
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1.1. The pathobiology of cardiac fibrosis 
 
1.1.1 Heart failure and cardiac fibrosis: a clinical perspective 
Despite major advances in the past decades, cardiovascular disease 
(CVD) continues to cause 3.9 million deaths in Europe each year, accounting 
for 45% of all mortality.1 In addition, 85 million people are living with CVD, 
having a major impact on the loss of disability-adjusted life years. The longest 
CVD-related hospital stays are for patients suffering from heart failure. This 
clinical diagnosis is characterised by impairment of systemic perfusion, with 
the inability to meet the body's metabolic demands as a result of a structural 
and/or functional cardiac abnormality.2 The aetiology of heart failure is diverse, 
but can roughly be divided in three categories: diseases of the myocardium, 
such as due to a genetic predisposition or ischaemic, toxic, inflammatory or 
metabolic damage; abnormal loading conditions, caused by hypertension, 
volume overload, or structural defects to the heart; and arrhythmias such as 
atrial fibrillation. Regardless of the aetiology, heart failure is characterised by 
the attempt of the heart to structurally compensate for functional impairment, 
generally referred to as ‘cardiac remodelling’. This process initially enables the 
heart to sustain the required demand of force. Over the long term, however, 
the cardiac pump function decreases, ultimately rendering the heart too weak 
to generate sufficient cardiac output to maintain homeostasis. 
 
The cornerstone of current heart failure therapy mainly consists of 
symptom relief and delaying disease progression, with heart transplantation 
being the only cure. Heart failure therefore continues to be a major cause of 
morbidity and mortality. Several advances have been made with reducing the 
burden and slowing down progression of disease severity, such as the 
successful evaluation of a neprilysin inhibitor which has recently been added 
to the latest clinical guideline for heart failure treatment.2 However, the 2-year 
mortality rate of 20% in the intervention arm of the neprilysin inhibitor trial 
highlights that there is still a need for a therapy that can prevent progression 
of pathological cardiac remodelling or even reverse it.3 
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1.1.2 The fibroblast as a key cell type in cardiac fibrosis 
As mentioned previously, cardiac remodelling is key for the development 
of heart failure. Cardiac remodelling has been defined by the International 
Forum on Remodelling as ‘genomic expression that results in molecular, 
cellular, and interstitial changes and is manifested clinically as changes in size, 
shape, and function of the heart resulting from cardiac load or injury’.4 Cardiac 
remodelling can be either physiological or pathological, with the former 
progressing to the latter as the heart fails to compensate for loss of contractile 
function. 
 
At the basis of cardiac remodelling lies a complex of structural and 
functional changes in different cell types and the extracellular matrix (ECM) 
that form the myocardium. Whilst cardiomyocytes respond to increased 
stretching by becoming hypertrophic5, the tissue surrounding the 
cardiomyocytes changes both in composition and in volume. A main cellular 
constituent is the cardiac fibroblast (CF). Through producing a variety of matrix 
proteins and ECM-regulatory proteins, such as growth factors and proteases, 
CF play a major role in physiological maintenance of the ECM.6 The ECM is a 
major determinant of the biomechanical and electrical properties of the heart.7 
CF produce the fibrillar collagens I and III that together comprise approximately 
90% of all collagen in the heart, as well as many other less abundant structural 
and regulatory ECM molecules.8 
 
Fibroblasts are also crucial in the development of cardiac fibrosis. As 
adult human cardiomyocytes lack the ability to regenerate, cardiac repair is 
dependent on the formation of scar tissue. This is characterised by 
accumulation and qualitative changes of the cardiac ECM that can lead to 
marked stiffening of the myocardium. Myocardial ‘scarring’ occurs in response 
to acute injury such as myocardial infarction (MI), but is also a common feature 
of non-ischaemic cardiomyopathies.9 Interestingly, myocardial fibrosis shares 
mechanisms with scarring and wound healing in other tissues.10 In general, 
tissue injury leads to a cascade of overlapping events that can be roughly 
divided in an inflammatory phase and a tissue remodelling phase.7 The extent 
and pace of this sequence is dependent on the underlying cause, with 
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ischaemia resulting in massive cell necrosis and subsequent inflammation, 
whilst non-ischaemic fibrosis develops more gradually.  
 
These two types of remodelling correspond to the two subtypes of fibrosis 
that are often distinguished histopathologically: reactive or diffuse fibrosis 
results from expansion of existing collagen fibres without marked 
cardiomyocyte loss and is often localised in perivascular areas of the 
myocardium; whereas replacement or reparative fibrosis is a more focal form 
of scar formation, characterised by deposition of newly produced ECM 
proteins.11,12 In practice, there is often a mix of both fibrosis types at play. This 
is illustrated by the poorly understood phenomenon of reactive fibrosis at 
distant, non-infarcted areas that occurs in parallel with replacement fibrosis at 
the necrotic area after myocardial infarction.13 
 
Upon tissue injury, infiltration of inflammatory cells such as neutrophils 
cause the release of several bioactive peptides and cytokines, both from local 
tissue and from infiltrating cells. These factors are thought to then drive the 
opsonisation of debris by macrophages as well as neovascularisation in and 
around the injured tissue. Furthermore, inflammatory signals stimulate the 
production of ECM proteins by activated fibroblasts, called myofibroblasts. 
Unlike in wound healing of skin injury, the cardiac scar remains relatively cell-
rich14, harbouring a combination of fibroblasts and myofibroblasts, surviving 
cardiomyocytes, endothelial cells, vascular smooth muscle cells, and 
inflammatory cells. 
 
The phenotypic transition that fibroblasts undergo during this process is 
characterised by a more migratory phenotype, characterised by the expression 
of alpha-smooth muscle actin (a-SMA) and contractile bundles.9 Furthermore, 
myofibroblasts are more proliferative and more sensitive to signalling 
molecules, whilst they also express more adhesion molecules and receptors. 
This differentiation is not absolute and the fibroblast morphology remains 
pleiomorphic.15 Two main triggers determine the fibroblast transformation: 
feedback from the mechanical environment, and chemokines, with 
transforming growth factor beta-1 (TGF-β1) being most widely recognised.16 
The latter will be discussed in the following paragraphs.  
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In addition to resident CF, other cell types might also contribute to the 
myofibroblast pool in the injured heart. This may include endothelial and 
epithelial cells undergoing mesenchymal transition as well as bone marrow-
derived cells.17–20 In addition, circulating cells may also contribute to 
phenotypic switching by factors that they secrete, as was shown for circulating 
platelets and epithelial-to-mesenchymal transition in tumours.21 The extent to 
which endothelium- and epithelium/epicardium-derived (myo)fibroblasts play a 
role in cardiac fibrosis remains a matter of debate.9,22 Nevertheless, this 
paradigm shift highlights a growing appreciation of the interplay between tissue 
injury and systemic effects in the development of fibrosis.12 The importance of 
the systemic context for the study of fibrosis will be further argued in this thesis. 
 
1.1.3 TGF-b1 and pro-fibrotic signalling 
 
1.1.3.1 TGF-b1 secretion in the heart 
The most widely recognised factor in steering fibroblasts towards a pro-
fibrotic state, and thereby a ‘master switch’ of fibrosis, is TGF-b1.16,23 TGF-b1 
expression increases during functional as well as fibrotic tissue repair.24 Its 
activity appears to be key in the gradual shift from beneficial scar formation, 
compensating for tissue loss, towards adverse remodelling characterised by 
functional impairment of the tissue. Within the heart, its expression can be 
induced by an array of factors, including angiotensin II and mechanical 
stretch.25 TGF-b1 is synthesised and secreted by cardiomyocytes26 as well as 
fibroblasts.27,28 In addition, immune cells and platelets may also be important 
contributors to myocardial TGF-b1 activity. In particular, extravasated platelets 
appear to be a key source in the early stages of infarct healing as well as during 
cardiac overload-induced fibrosis.29,30 
 
Within the heart, TGF-b1 can also be found outside the cells, where it is 
stored in association with ECM proteins.31 TGF-b1 is secreted in an inactive 
form, by non-covalent binding of TGF-β1 to the cleavage product of pro-TGF-
β1, called the latency-associated peptide (LAP).32 The complex between a 
TGF-b1 homodimer and LAP is referred to as the small latency complex (SLC). 
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This association prevents TGF-b1 from binding to cell receptors, therefore 
rendering it biologically inactive. Upon secretion into the extracellular space, 
the SLC is contained within the ECM through associating with other latency-
associated proteins, in particular latent TGF-β1 binding protein-1 (LTBP1). 
Covalent binding of the SLC to LTBP1 and proteins with similar function 
constitutes the large latency complex (LLC). An illustration of the SLC and LLC 
is shown in Figure 1. Through this mechanism, TGF-b1 secretion and activity 
are uncoupled, requiring release from its latency complex rather than from a 
cell to activate signalling downstream of its receptors. Whilst there is 
constitutive secretion of TGF-b1 into the ECM in the healthy myocardium, 
TGF-b1 from other sources, with the circulation in particular, have also been 
implicated in cardiac remodelling.29,33,34 The role of circulating and platelet-











Figure 1. Transforming growth factor beta-1 (TGF-β1) and its latent forms.
A: Following synthesis of pro-TGF-β1, this precursor is cleaved into the latency-
associated peptide (LAP) and mature TGF-β1 by furin-like enzymes in the Golgi
apparatus. Antibodies used in the proximity extension assay (PEA) panel and
the ELISA that was used targeted different epitopes. B: Upon cleavage of the
precursor, TGF-β1 dimers remain noncovalently bound to LAP, forming a small
latency complex (SLC). A proportion of the SLC is by itself bound to latent-
transforming growth factor beta-binding protein (LTBP) by disulfide bonds,
forming a large latency complex (LLC).
Figure 1. Transforming growth factor beta-1 (TGF-β1) and its latent forms. A: 
Following synthe is of pro-TGF-β1, this precursor is cleaved into the latency-
associated peptide (LAP) and mature TGF-β1 by fur n-like enzymes in the Golgi 
apparatus. Antibodi s used in the proximity extension assay (PEA) pa el (see 3.14) 
and the ELIS  (see 3.16) that was used targeted different epitopes. B: Upon 
cleavage of t e precur or, TGF-β1 imers r main noncovalently bound to LAP, 
forming a small latency compl x (SLC). A proportion of the SLC is by itself bound to 
latent-transf rming growth fact r beta-binding prote n (LTBP) y disulfide bonds, 
formi g a large latency complex (LLC). 
 20 
1.1.3.2 Cardiac TGF-b as a potential therapeutic target 
Activation of TGF-β1 occurs through disruption of the non-covalent 
binding within the SLC. Several factors are capable of causing this disruption, 
such as mechanical force32, acidic pH levels35, or several proteins, including 
integrins36 and proteases such as matrix metalloproteinases37, plasmin and 
thrombospondin-1.38 After being released from its latency state, TGF-β1 can 
bind to the TGF-β type 2 receptor (TβRII) to activate the TGF-β type 1 receptor 
(TβRI), also known as activin receptor-like kinase 5, through phosphorylation. 
This subsequently leads to phosphorylation of intracellular Smad2/3. 
Phosphorylated Smad2/3 associates with Smad4 to enter the nucleus, where 
it can then affect transcription of an array of genes. In the heart, the 
phenotypical effects depend on the cell type, on one hand inducing 
cardiomyocyte hypertrophy, whilst driving the transition of fibroblasts to 
myofibroblast-like phenotypes with a concomitant increase in ECM protein 
deposition.24 
 
Given its major role in the pathophysiology of fibrosis, TGF-b1 and its 
downstream signalling cascade have often been suggested as a therapeutic 
target. However, this approach is hampered by the involvement of TGF-b1 and 
its downstream signalling in many cellular processes. Targeting TGF-b 
signalling therefore inadvertently carries the risk for off-target effects. This is 
illustrated by the fact that TGF-b1 null mice die 3-4 weeks after birth due to 
excessive immune cell infiltration of heart, lungs and other organs.39,40 Several 
studies have nevertheless evaluated pharmacological targeting of TGF-b 
signalling. In vivo inhibition of TGF-β1 in mice was shown to attenuate fibrosis 
and preserve cardiac function after transverse aortic constriction (TAC), a 
commonly used model of cardiac pressure overload.41 However, as expected 
from the broad effects of TGF-b1, several studies have reported significant 
side effects or even increased mortality.42,43 Interfering with downstream 
signalling of TGF-b1 may hold more promise for clinical utility, as this was 
shown to attenuate pulmonary fibrosis in mouse studies without concomitant 
side effects.44–46 With either approach, interfering with TGF-b signalling would 
require meticulous timing for therapeutic intervention, given the apparent shift 
from being a beneficial to a detrimental contributor after injury. This is 
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illustrated by evidence that interfering with TGF-b signalling too early after 
acute injury results in inadequate resolution of inflammation, thereby 
worsening the outcome.9 
 
In search for more specific effectors downstream of the TGF-b signalling 
cascade, Schafer et al recently reported interleukin-11 as a potential 
therapeutic target.47 Primary human fibroblasts were isolated from atrial tissue 
and were then treated with recombinant TGF-b1. Subsequent RNA 
sequencing analysis of these cells identified interleukin-11 to be highly 
upregulated. Furthermore, the authors argue that interleukin-11 is highly 
specific to fibroblasts, using RNA sequencing data from the publicly available 
Genotype-Tissue Expression project and from a panel of primary cells. Using 
an inducible interleukin-11 knockout mouse model under the control of the 
collagen I a-2 gene, fibrosis formation upon angiotensin II treatment was 
markedly attenuated. Based on these findings, interleukin-11 targeting is 
proposed as a promising therapeutic strategy against fibrosis. The reported 
fibroblast specificity in this study is surprising in the context of exisiting 
literature, as interleukin-11 has previously been described as a key driver of 
megakaryopoiesis in the bone marrow.48,49 Megakaryocytes and the bone 
marrow are not included in the RNA sequencing datasets used in this study. 
Furthermore, the authors do not assess whether the bone marrow or platelets 
were affected upon interleukin-11 targeting in mice. The suggested 
involvement of platelets in fibrosis, as described in the following paragraphs 
and as further argued by the findings of this thesis, warrant further evaluation 
of a platelet-mediated effect as an additional explanation of their findings. 
 
1.1.3.3 TGF-b secretion and signalling beyond the heart 
As mentioned earlier, TGF-b1 originating from other sources than 
cardiomyocytes or CF may also affect cardiac fibrosis and hypertrophy. The 
overlap between fibrogenesis, inflammation and tissue wound healing across 
tissues and organ systems, as well as the role of TGF-b signalling therein, 
further highlights that systemic inflammatory effects may orchestrate tissue 
remodelling. Plasma levels of TGF-b1 were significantly higher in patients with 
fibrotic liver disease.50 In the context of autoimmune diseases, higher levels of 
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TGF-b1 were found in plasma51 and inflamed synovial membranes52 of 
patients with rheumatoid arthritis. Similar findings have been reported in 
inflammatory infiltrates in the gut of patients suffering from ulcerative colitis or 
Crohn’s disease.53 Across these inflammatory conditions, TGF-b1 can both 
worsen and improve disease outcomes, depending on the timing and the site 
of action. From a translational perspective, this underscores that interfering 
with TGF-b signalling requires a time- and site-targeted approach to avoid off-
target effects.54 Although the cellular origin of TGF-b1 is often unclear, it is 
interesting to note that an influx of immune cells during inflammation is often 
accompanied by platelet influx. Platelets in particular have been recognised as 
a major source of TGF-b1.29,55 
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1.2 Blood platelets and heart failure 
 
1.2.1 Blood platelets beyond haemostasis 
Blood platelets are primarily recognised for their function in thrombosis 
and haemostasis. In this role, platelets respond to endothelial damage, where 
exposure of sub-endothelial matrix proteins such as collagen induces platelet 
adhesion and activation through its surface receptors.56 Being captured and 
bound together by von Willebrand factor (VWF)57, the accumulation of 
activated platelets at a site of injury initiates the formation of a blood clot 
through the release of platelet granules. During this process of degranulation, 
platelet aggregation is further amplified through fibrinogen-mediated 
interactions with surface receptors on activated platelets and through the 
release of secondary platelet agonists adenosine diphosphate (ADP) and 
thromboxane A2.58 In addition, thrombin is generated at the platelet surface, 
acting as a strong platelet agonist whilst also converting fibrinogen into fibrin. 
The result of this orchestrated process is the formation of a platelet-fibrin clot, 
forming a plug to halt blood loss. 
 
The function of platelets is not confined to haemostasis and thrombosis. 
Whilst the involvement of platelets in clot formation is well-recognised as a key 
event in coronary artery disease and stroke, their role in cardiovascular 
disease beyond thrombus formation has received less attention thus far. 
Nevertheless, there is increasing evidence for a role of activated platelets in 
the development and progression of heart failure and fibrosis.59 Platelet 
granules, in particular alpha (a)-granules, contain not only mediators of 
haemostasis, but also an array of pro-inflammatory cytokines, growth factors 
and enzymes. This includes TGF-β1, as previously mentioned, which is 
expressed in many different cell types but is highly enriched in platelets.60 
Furthermore, platelets harbour several surface receptors that suggest their 
involvement in inflammatory processes. Although platelets are small in size, 
their high numbers in the blood support the concept that their total surface area 
and volume exceeds that of the total of all circulating leukocytes.61 These 
observations are further supported by the role that platelets play in the wound 
healing response after haemostasis at a lesion site. As mentioned previously, 
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there is substantial overlap between the pathobiology of wound healing and 
the development of fibrosis across organs, rendering platelets an interesting 
potential source of mediators in the latter process as well. 
 
1.2.2 Heart failure and antiplatelet therapy 
Previous studies have indeed identified a role for platelets and platelet-
derived proteins in heart failure. Heart failure patients were found to have 
higher plasma levels of soluble cluster of differentiation 40 ligand62, pro-platelet 
basic protein (PPBP)63, thrombospondin-1 and TGF-b164, all proteins released 
from platelets. These results imply increased platelet reactivity or activation in 
heart failure patients. Several explanations have been suggested for this 
finding, including increased platelet reactivity due to endothelial damage, 
disturbed nitric oxide production, increased oxidative stress or higher cytokine 
levels, which are all able to affect platelets.65 
 
Based on the data implicating platelets in the pathophysiology of heart 
failure, antiplatelet therapy could be expected to delay its progression. Current 
therapy for heart failure consists of symptom relief with diuretics, combined 
with beta-adrenergic receptor blockers, angiotensin-converting enzyme 
inhibitors or angiotensin receptor blockers and aldosterone antagonists. These 
drugs do not treat the cause of heart failure but are aimed at inhibiting 
neurohumoral pathways that are thought to drive adverse cardiac 
remodelling.66 There is currently no evidence for a benefit of antiplatelet 
therapy on survival in heart failure patients, unless there is an additional 
indication such as atrial fibrillation or coronary artery disease.67 The survival 
benefit in these specific patients is likely due to the increased thromboembolic 
risk that these co-morbidities confer. Previous studies into antiplatelet therapy 
in heart failure did not evaluate whether there was a benefit on cardiac 
remodelling or the occurrence of fibrosis; outcome measures were solely 
based on all-cause mortality, major bleeding events and non-fatal 
cardiovascular events such as stroke, MI or embolisms. Nevertheless, current 
guidelines do not recommend routine prescription of antiplatelet drugs in heart 
failure patients.2  
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A potential explanation as to why platelet inhibition does not benefit heart 
failure patients is the increased bleeding risk that these drugs confer66, 
possibly outweighing benefits of inhibition on the development of fibrosis. 
Distinguishing the antithrombotic effects from a potential benefit of decreased 
platelet release of pro-fibrotic mediators would require drugs that specifically 
act on either of these two mechanisms, which are currently not available. 
 
1.2.3 Platelets in animal models of heart failure 
Several studies have evaluated the role of platelets in heart failure using 
animal models of cardiac hypertrophy and fibrosis. Evaluating post-ischaemic 
cardiac remodelling, Kalkman et al found that aspirin treatment in rats 
undergoing MI did not change the extent of hypertrophy or replacement fibrosis 
in the infarcted area, but did reduce interstitial and perivascular fibrosis in the 
rest of the heart.68 A study using a genetic model of cardiomyopathy in 
hamsters found that chronic aspirin treatment attenuated the development of 
hypertrophy and fibrosis.69 Pharmacological platelet inhibition using 
clopidogrel attenuated the inflammatory and fibrotic response in mice 
undergoing hypertension-induced cardiac remodelling70, whilst a similar 
benefit was seen for cardiac hypertrophy with the use of aspirin.71 In mice, a 
similar model combined with transplantation of platelets that had been isolated 
from P-selectin null mice showed a similar benefit72; P-selectin is normally 
released from activated platelets and is an important mediator of inflammatory 
cell recruitment at injury sites. A more recent study also evaluated this effect 
by injecting antibodies against P-selectin into mice undergoing TAC-mediated 
cardiac remodelling. This led to a significant reduction in platelet-monocyte 
aggregate formation and markedly reduced the extent of fibrosis and 
hypertrophy.73 In this same study, the effects of TAC in P2ry12 null mice were 
evaluated. This gene codes for the P2Y purinoreceptor 12 (P2Y12), a key 
platelet-activating receptor and the target of thienopyridine drugs such as 
clopidogrel and prasugrel. TAC was shown to increase platelet reactivity in 
wild-type mice, but this was reduced in the P2ry12 null mice. Consequently, 
fibrosis and hypertrophy were significantly reduced as well. This effect was 
reproduced by transplanting P2ry12 null bone marrow into wild-type mice, but 
abrogated when P2ry12 null mice received transfusions of wild-type platelets. 
Finally, inducing thrombocytopaenia with a CD41-targeting antibody also 
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alleviated TAC-mediated cardiac remodelling, abolishing the difference 
between P2ry12 null and wild-type mice. Altogether, these studies indicate that 
platelet activation contributes to cardiac remodelling in well-established animal 
models of heart failure. 
 
Focusing on platelet TGF-β1, studies in megakaryocyte/platelet-specific 
TGF-β1 null mice had less extensive cardiac hypertrophy and fibrosis in 
response to TAC when compared to wild-type mice.29 More recently, a study 
evaluating antiretroviral therapy-induced cardiomyopathy in mice found 
markedly higher levels of plasma TGF-b1, as well as a decrease in cardiac 
output with prominent fibrosis in wild-type mice. The same antiretroviral 
treatment in megakaryocyte-specific TGF-b1 null mice did not result in higher 
TGF-b1 plasma levels and these mice were protected from cardiac dysfunction 
and fibrosis.74 Hence, platelet-derived TGF-b1 may indeed be a key contributor 
to cardiac remodelling. 
 
As mentioned previously, platelets are known to be highly enriched in 
TGF-b1. Previous studies have shown that platelet TGF-b1 is synthesised in 
megakaryocytes in the spleen and bone marrow, where it is directly packaged 
into a-granules.75 During platelet activation, these a-granules are released. 
There is a distinct pattern however for the release of TGF-b1 from platelets, 
which challenges the dogma of rapid degranulation upon platelet activation. 
Whilst translocation of P-selectin to the platelet membrane surface, a widely-
used marker for platelet activation and a-granule secretion76, occurs rapidly, 
TGF-b1 release appears more gradual.77 This could be caused by a difference 
in solubility between the two proteins, but could also indicate that TGF-b1 is 
packaged in distinct particles, implying that there are different subtypes of a-
granules. Within a-granules, TGF-b1 is stored in two different forms: 60-65% 
is bound within the LLC, whilst 30-35% is stored as part of the SLC. It has been 
reported that release dynamics differ for these two complexes: LLC is rapidly 
released upon platelet degranulation, whereas SLC is retained within the 
platelet/clot and is released during clot resorption by plasmin.78 
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 In summary, heart failure and cardiac fibrosis are common features of 
CVD and there is great unmet demand for effective therapeutic strategies. 
Whilst locally resident CF are main contributors to the development of fibrosis, 
there is mounting evidence that systemic effects play an important role, with 
TGF-b1 being a major driver of pro-fibrotic signalling. The role of platelets as 
a source of TGF-b1 is still underappreciated in the context of HF despite 
previous animal studies showing that platelet-derived TGF-b1 can contribute 
to cardiac remodelling.  
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1.3 MicroRNAs in cardiovascular disease 
 
1.3.1 The discovery of non-coding RNA 
With completion of the Human Genome Project, it became apparent that 
only 1.5% of the human genome codes for genes that function in protein 
synthesis.79 Except for the small proportion of the DNA that encodes 
‘infrastructural RNA’ such as transfer and ribosomal RNA, the non-gene-
coding regions of the DNA were initially considered ‘junk DNA’. In the last two 
decades, there has been ongoing debate as to what proportion of the genome 
is functional. The ENCODE consortium claimed that 80% of the genome is 
“biochemically active”, a statement which was based on DNA sequences being 
copied into RNA.80 Others have however argued that the percentage of 
functional DNA is more likely to be around 10%, the main argument being that 
the genome needs ‘decoy’ DNA to cope with the relatively high rate of 
spontaneous mutations.81 Whilst this discussion continues, many aspects of 
both normal development and pathology have in the meantime been ascribed 
to transcription products of the non-coding part of the genome, generally 
referred to as ‘non-coding RNA’. Several categories of non-coding RNAs exist, 
comprising different subtypes of long non-coding RNAs and small non-coding 
RNAs. The subclass of functional non-coding RNA that has received most 
attention since their discovery in the early 1990’s are the small noncoding 
RNAs called microRNAs (miRNAs).82 In the following paragraphs, miRNA 
biosynthesis will be discussed briefly, followed by a summary of highlighted 
studies in the cardiovascular field and current analytical techniques as well as 
experimental applications. 
 
1.3.2 MicroRNA biosynthesis, function and quantification 
MiRNAs are short (~22 nucleotides) molecules that exert their function 
by binding to messenger RNA (mRNA), so-called ‘miRNA targets’, through 
sequence complementarity.83,84 A graphical representation of miRNA 
biosynthesis and function is shown in Figure 2. Of particular interest within the 
miRNA sequence is the ‘seed region’, a section of six to eight nucleotides at 
the 5’ end that is the critical determinant of miRNA-mRNA interaction. MiRNAs 
originate from primary transcripts (pri-miRNAs), derived from introns of protein 
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Figure 2. MicroRNA biosynthesis and function. MicroRNAs (miRNAs) originate 
from primary transcripts (pri-miRNAs) that are derived from introns (depicted in dark 
blue) of protein-coding genes or from intergenic regions within the genome. Primary 
transcripts are processed in the nucleus to a hairpin-shaped pre-miRNA by the 
Drosha/DiGeorge syndrome critical region 8 (DGCR8) complex, transported to the 
cytoplasm, and then processed to mature miRNA duplexes by the Dicer complex. To 
exert its function, the mature miRNA is incorporated into a ribonucleic acid-induced 
silencing complex (RISC). This leads to cleavage or translation repression of the 
mRNA, preventing a protein from being assembled. mRNA, messenger RNA; tRNA, 
transfer RNA. (Previously published in Barwari et al. 2016, Journal of the American 
College of Cardiology, reprinted with permission; see Appendix 2) 
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Figure 2. MicroRNA biosynthesis and function. MicroRNAs (miRNAs)
originate from primary transcripts (pri-miRNAs) that are derived from introns
(depicted in dark blue) of protein-coding genes or from intergenic regions within
the genome. Primary transcripts are processed in the nucleus to a hairpin-
shaped pre-miRNA by the Drosha/DiGeorge syndrom critical r gion 8
(DGCR8) compl x, t ansported to the cytoplasm, and then processed to mature
miRNA duplexes by the Dicer complex. To exert its function, the mature miRNA
is incorporated into an ribonucl ic acid-induced silenci g compl x (RISC). This
leads to cleavage or translation repression of the mRNA, preventing a protein
from being assembled. mRNA, messenger RNA; tRNA, transfer RNA.
(Previously published in Barwari et al. 2016, Journal of the American College
Cardiology, reprinted with permission)
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coding genes, introns/exons of noncoding genes, or intergenic regions within 
the genome.85,86 Pri-miRNAs are processed by the Drosha/DiGeorge 
syndrome critical region gene-8 (DGCR8) complex in the nucleus, folding the 
transcript into a 60-100 nucleotide-long hairpin structure, called pre-miRNA.87 
Pre-miRNAs are then transported from the nucleus to the cytoplasm by 
exportin-5.88 Here, pre-miRNAs are cleaved by the Dicer complex into 
duplexes consisting of two miRNA strands, designated guide strand and 
passenger strand, based on their subsequent relative levels.89 Both strands 
can function as a mature miRNA.90 
 
To exert their function, either one or both of the mature miRNA strands 
are incorporated into an RNA-induced silencing complex (RISC), consisting of 
a number of proteins including Argonaute. The miRNA within this complex 
serves as a guide to recognise target mRNAs. Depending on the base 
complementarity between the miRNA and its mRNA target, this can lead to 
cleavage or translation repression.91 Single miRNAs can suppress more than 
one gene, and miRNAs with similar seed regions may suppress a similar, but 
non-identical set of genes and to differing degrees. Gene suppression is 
usually partial rather than total and a single gene can have binding sites for 
multiple miRNAs. This organisational complexity, illustrated by a high false-
positive rate of target prediction algorithms92, presents challenges in both 
understanding the functions of miRNAs and manipulating their effects.93 
 
MiRNAs are relatively stable, and can be reliably measured in tissues, as 
well as in biofluids. Several techniques have been developed to identify and 
quantify miRNAs, each with benefits and disadvantages.94 Quantitative real-
time polymerase chain reaction (qPCR) is by far the most commonly used 
technique and can be regarded as the standard for miRNA quantification. 
Alternatively, methods with higher throughput include microarrays and RNA 
sequencing (RNAseq). Microarrays are suitable for relatively fast yet less 
accurate quantification of miRNAs, measuring hundreds of miRNAs in parallel. 
Similar to qPCR, microarrays rely on predefined primer sequences and are 
therefore not able to discover previously uncharacterised miRNAs. RNAseq 
provides “hypothesis-free” identification of RNA species, allowing for the 
discovery of new miRNAs and quantitative analysis of a comprehensive 
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miRNA transcriptome. The use of computational solutions to resolve reads into 
miRNAs suffers from the risk of reporting putative sequences which do not 
have real-world correlates.95 We have recently discussed in greater detail the 
benefits and potential pitfalls with these techniques.96 
 
To study the function of miRNAs across different cells and tissues, 
techniques have been developed to manipulate their expression levels. These 
methods include the conditional deletion of the gene encoding Dicer (see 
Figure 2), resulting in suppression of miRNA biosynthesis97, but more 
commonly involve the overexpression or inhibition of a single miRNA.98 When 
using isolated cells in culture, overexpression of a miRNA is most commonly 
achieved by binding synthetic miRNA mimics, identifical in sequence and 
chemistry to the naturally occurring single or duplex miRNA, to cationic 
molecules. MiRNA mimics bound to these reagents are then added to the 
medium, generally resulting in an efficient transfection of the mimics into the 
cytoplasm of the cultured cells. These mimics are naturally taken up by 
silencing complexes, resulting in a functional overexpression of the studied 
miRNA. Conversely, biological effects of a miRNA can be studied by inhibiting 
its expression, using anti-miRNA oligonucleotides, more commonly known as 
antimiRs.99 For in vitro use, these antimiRs generally consist of an antisense 
oligonucleotide that is a perfect reverse complement to the targeted miRNA. 
These oligonucleotides contain several chemical modifications to enhance 
their binding affinity and their ability to resist nuclease activity, hence 
increasing their efficacy in binding their target miRNA. Upon transfection 
across the cell membrane using similar techniques as for miRNA mimics, 
antimiRs inhibit the functioning of targeted miRNAs by steric inhibition or by 
degradation, depending on the chemistry used. When using antimiRs in vivo, 
additional modifications are required to ensure stability. This is discussed 
further in paragraph 1.5. 
 
1.3.3 MicroRNAs: from discovery to cardiovascular applications 
The first miRNA was identified in the Caenorhabditis elegans nematode. 
This molecule, called lin-4, was found during genetic screens aimed at 
developmental timing of gene expression. Lee et al showed that lin-4 was 
encoded by a sequence in the intron of a host gene and had sequence 
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complementarity to the 3’ untranslated region (UTR) of lin-14 mRNA. The 
resulting duplex repressed the accumulation of LIN-14 protein, which had 
previously been implicated in the L1-to-L2 transition during C. elegans post-
embryonic development.82 The discovery of a second short non-coding RNA 
called let-7100, which showed remarkable sequence conservation across 
species101, paved the way for the rapid emergence of this field. In the following 
years, a range of other miRNAs were identified in what was previously 
considered ‘transcriptional slop’.102,103 The initial focus of research was on the 
developmental effects of miRNAs in smaller species. However, a study 
showing tissue-specific differences in miRNA expression levels104 further 
sparked the interest in miRNAs. 
 
The earliest reports in the cardiovascular field were published in 2005, 
identifying miR-1 as a regulator of cardiac differentiation.105,106 Soon after, 
associations between miRNA levels and cardiovascular pathology were 
reported, including a landmark study by Van Rooij et al107 that found several 
dysregulated miRNAs in failing hearts of humans and mice. Importantly, this 
study showed that upregulation of miRNAs caused phenotypic changes, 
indicating that miRNA dysregulation may be a cause or mediator of disease 
rather than just a readout. This study, as well as the successful development 
of pharmacological strategies to target miRNAs in vivo108, ignited a surge of 
studies evaluating the effects of miRNAs in the cardiovascular field.  
 
1.3.4 MiR-21 in cardiovascular disease 
One of the most widely studied miRNAs is miR-21. Over the past decade, 
this miRNA has been at the forefront of proposed clinical utility, whilst also 
inciting controversy through reports with contradicting results. The gene coding 
for miR-21 in located on chromosome 11 (mouse) or 17 (human) within the 
penultimate intron of transmembrane protein 49, itself encoding a protein 
involved in vacuole formation and autophagy.109 Transcription of miR-21 and 
this gene are independent and levels of the encoded protein are not altered in 
miR-21 null mice.110 The earliest studies on miR-21 had an oncological focus, 
reporting it to be upregulated in glioblastoma cells where it had anti-apoptotic 
effects.111 The overexpression was confirmed in six other solid tumour 
types112, with another study identifying several targets that were implicated in 
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the observed effects on tumour growth and invasiveness.113 One of the first 
reports on miR-21 in the cardiovascular field was the study by Van Rooij et al, 
evaluating miRNA expression levels in cardiac hypertrophy and heart 
failure.107 Here, a substantial increase in miR-21 expression was found in 
hearts of mice undergoing TAC, as well as in transgenic mice expressing 
activated calcineurin A in the heart. Surprisingly, this study did not find 
increased miR-21 levels in human heart samples from idiopathic end-stage 
heart failure patients. Increased expression in hypertrophic rodent hearts114–
117 was however confirmed in several studies published soon after. These 
findings, combined with the association with apoptosis in several high-profile 
oncological studies, led miR-21 to become a major target of interest for 
potential therapeutic use. 
 
1.3.4.1 MiR-21 and cardiac fibrosis 
The first landmark study on miR-21 in heart failure and fibrosis was a 
study by Thum et al.118 Whilst confirming the previously reported increased 
levels of miR-21 in failing hearts of human and rodent origin, this study 
attributed the increase to CF rather than cardiomyocytes. This was in line with 
a study published at the same time, where a cardiomyocyte-specific knockout 
of Dicer, disrupting miRNA biogenesis, had a relatively limited effect on cardiac 
miR-21 expression.97 The findings by Thum et al were in line with previous 
reports on tumour cell apoptosis, concluding that miR-21 increased the 
survival of CF. As the responsible mechanism, targeting of Sprouty-1 was 
identified (see Table 1 for a table of key miR-21 targets). This inhibitor of anti-
apoptotic mitogen-activated protein kinase activity was found to be expressed 
only in the non-myocyte cell population of the heart. The authors argued that 
miR-21 and fibroblasts have a central role in the pathogenesis of heart failure, 
with miR-21 mediating enhanced CF survival and thus contributing to 
interstitial fibrosis and remodelling. Using antagomiR-21, a construct targeting 
miR-21 with a chemistry previously described for miR-122 inhibition108, the 
authors showed an attenuation of TAC-induced cardiac dysfunction. This 
beneficial effect of pharmacological miR-21 inhibition was considered a major 
breakthrough in the cardiovascular miRNA field and consequently fuelled the 
interest in this topic. 
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Table 1. Major miR-21 targets in cardiac fibrosis. 
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The results of Thum et al, however, were not reproduced in a subsequent 
study by Patrick et al.110 Here, miR-21 null mice as well as a pharmacological 
inhibitor with a different design compared to antagomiRs were used. MiR-21 
null mice as well as mice receiving this smaller miR-21 inhibitor had a normal 
baseline phenotype. Surprisingly, the extent of cardiac fibrosis in response to 
TAC and to angiotensin II, another common hypertension-based model of 
heart failure, was unaffected by miR-21 inhibition. In addition, MI was induced 
by ligation of the left anterior descending coronary artery in mice, whilst 
another approach included cross-breeding miR-21 null mice with mice 
expressing calcineurin A under the control of the myosin heavy chain (MHC) 
alpha isoform. None of these models showed a benefit of miR-21 inhibition or 
deletion. In contrast to the previous study by Thum et al, miR-21 inhibition was 
performed using Locked Nucleic Acid (LNA)-based octamers targeting the 
miR-21 seed sequence only. In response to the study by Patrick et al, Thum 
et al reported a side-by-side comparison of miR-21 inhibitors with different 
chemistry, confirming the lack of effect using the octamer whilst inhibition using 
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two types of 22-mer constructs did attenuate fibrosis.124 A subsequent 
response from Patrick et al then mentioned the use of tamoxifen-inducible 
miR-21 null mice, where miR-21 inhibition directly prior to the TAC also failed 
to affect the phenotype.  
 
 Despite these inconsistent results, numerous studies have since 
consolidated the relation between miR-21 and cardiac fibrosis. Animal studies 
have found increased levels of miR-21 in the heart using TAC125–131, a model 
of combined pulmonary valve insufficiency and stenosis132, angiotensin II123 or 
isoproterenol infusion133–135 to induce cardiac remodelling, with only one report 
showing contradicting results.136 Studies in human hearts were in line with 
these results, showing increased miR-21 in cardiac fibrosis due to aortic 
stenosis137, chronic atrial fibrillation138, arrhythmogenic right ventricular 
cardiomyopathy139 and combined pulmonary valve insufficiency and 
stenosis.132 In vitro studies have suggested that high glucose levels can 
increase miR-21 levels, inducing a myofibroblast-like phenotype in cultured rat 
CF.140 Lastly, afterload enhancement in engineered heart tissue from neonatal 
rat ventricle caused fibrotic changes which could be attenuated by pre-
treatment with a miR-21 inhibitor.141 
 
Altogether, different in vitro and in vivo models of cardiac fibrosis as well 
as samples from human fibrotic hearts provide evidence for the involvement of 
miR-21 in cardiac fibrosis.  
 
1.3.4.2 MiR-21 and myocardial ischaemia 
Fibrosis and cardiac remodelling are a common feature after MI. 
Consequently, numerous studies have evaluated miR-21 in the context of 
myocardial ischaemia and ischaemic pre-conditioning. Whilst studies have 
reported inconsistent results regarding the effect of ischaemia on cardiac miR-
21 levels142–144, specific evaluation of the infarct area and remote area after 
ischaemia revealed that miR-21 was reduced in the former but increased in 
the latter region.145–147 The miR-21 reduction could be prevented by subjecting 
the heart to ischaemia-reperfusion (I/R) prior to the infarct, whilst pre-treatment 
with a miR-21 mimic reduced the infarct size. A brief report by Yin et al showed 
that isolated miRNAs from ex vivo I/R-treated hearts contained high levels of 
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miR-21, whilst intra-cardiac injection of miR-21 mimic prior to MI resulted in a 
smaller infarct size.148 These studies imply that in the acute phase of 
myocardial ischaemia, induction of miR-21 expression has a beneficial effect. 
 
The hypothesis of miR-21 mediating the protective effect of I/R was 
supported by other studies. Beneficial effects of I/R were abolished by miR-21 
inhibition149 whilst transgenic miR-21 expression in cardiomyocytes146 or intra-
cardiac injection of miR-21 mimic150 reduced myocardial damage of ischaemia. 
Intramyocardial injection of skeletal muscle cells that had been 
pharmacologically preconditioned to mimic I/R treatment, improved the 
outcome of MI in rat hearts; this effect was abolished by pre-treatment with 
miR-21 inhibitors.151 Although most of these studies still focus on 
cardiomyocytes, Roy and colleagues reported that the miR-21 induction 
following I/R depended on CFs. Here, miR-21 targeting of phosphatase and 
tensin homologue (PTEN) resulted in increased expression of matrix 
metalloproteinase-2, a protease linked to cardiac dysfunction.119 
 
Developing a method to regenerate cardiomyocytes after myocardial 
damage can be seen as a holy grail in cardiology.152 Studying the potential 
involvement of miR-21 in this process, Xiao et al showed that cardiac 
progenitor cells secrete exosomes that contain miR-21. Both the release and 
the miR-21 content increased with hydrogen peroxide treatment and secreted 
exosomes were internalised by cardiomyocytes. Co-incubation with these 
exosomes restored hydrogen peroxide-induced downregulation of miR-21 and 
attenuated cardiomyocyte apoptosis.153 A similar example of miR-21 acting as 
a paracrine mediator was shown in another study for the miR-21 passenger 
strand (miR-21-3p). Here, Bang and colleagues demonstrated that miR-21-3p 
was transferred to cardiomyocytes in CF-derived exosomes, where it exerted 
a pro-hypertrophic effect.90 
 
In pursuit of a strategy to decrease the effect of micro-embolisation after 
percutaneous coronary interventions, Su et al used ultrasound-targeted 
microbubble destruction to deliver miR-21 in a pig model of coronary micro-
embolisation.154 Whilst miR-21 levels were not different after micro-
embolisation, delivery of miR-21 showed a marked reduction of inflammation 
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and consequently attenuated cardiac dysfunction. Whether this was a direct 
effect on the myocardium or an effect on inflammatory cells or platelets was 
not assessed. 
 
1.3.4.3 MiR-21 and atrial fibrillation 
Evaluating the effect of miR-21 in fibrosis with a different aetiology, Adam 
et al focused on atrial fibrillation, showing higher miR-21 levels in left atrial 
appendages of patients suffering from this arrythmia.155 MiR-21 levels 
correlated with the extent of fibrosis in a transgenic mouse model of atrial 
fibrillation156 and systemic antagomiR-21 treatment in these mice decreased 
the extent of atrial fibrosis.155 In line with these findings, Lavall et al showed 
that fibrosis due to chronic atrial fibrillation occurred through mineralocorticoid 
receptor stimulation and downstream miR-21 induction.138 Adding a 
therapeutic angle, Cardin et al used intra-atrial injection of an LNA-based 
inhibitor of miR-21, which significantly decreased the extent of atrial fibrosis, 
cardiac dysfunction and susceptibility to arrhythmia.157 Evaluating cardiac 
remodelling in response to ventricular tachypacing in dogs, Chen et al found 
miR-21 expression in the left atrium to increase with the development of 
fibrosis, whilst also showing that miR-21 was markedly enriched in CF 
compared to cardiomyocytes.158 Similar studies confirmed the increase of miR-
21 expression upon induction of atrial fibrillation and subsequent remodelling, 
with miR-21 inhibition attenuating adverse remodelling.122,159,160 Interestingly 
however, atrial appendage biopsies from patients with chronic atrial fibrillation 
exhibited higher miR-21 levels in the isolated cardiomyocyte fraction161, while 
another study found lower miR-21 levels in atrial biopsies and in plasma from 
atrial fibrillation patients.162 
 
1.3.4.4 MiR-21 and TGF-b 
As discussed previously, the TGF-b pathway is considered a major 
mediator in the development of fibrosis. Several studies have shown that miR-
21 expression can be induced by TGF-b signalling, affecting various steps 
throughout the maturation process. This suggests considerable overlap 
between effects of miR-21 and TGF-b signalling. The main downstream 
mediators of TGF-b receptor activation, such as the Smad proteins, were 
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shown to induce transcription of pri-mir-21163, the subsequent processing of 
pri-mir-21 to pre-mir-21 by Drosha164 as well as Dicer-mediated cleavage of 
pre-mir-21 into mature miR-21.129 In a murine MI model, both miR-21 and TGF-
b1 were induced, whilst subsequent in vitro experiments in murine CFs 
identified TGF-b receptor III (TbRIII) as a direct target of miR-21.121 As 
opposed to TGF-b receptor I and II, which together mediate TGF-b signal 
transduction, TGF-b receptor III acts as a reservoir for TGF-b receptor I/II 
ligands. Upregulation of this receptor appeared to prevent myocardial fibrosis 
from occurring in hypertensive rats.165  
 
In the context of atrial fibrillation, Tao et al identified WW domain-
containing protein 1 (WWP1) as a miR-21 target in CFs, causing decreased 
TbRI degradation and enhanced phosphorylation of Smad2.122 Lorenzen et al 
reported that osteopontin, a downstream mediator of TGF-b signalling 
previously implicated in myofibroblast differentiation and cardiac fibrosis166,167, 
contributed to miR-21 transcription in CF through inducing activator protein-
1.123 Inducing osteopontin through an adeno-associated virus serotype 9 
(AAV9) vector aggravated angiotensin II-mediated fibrosis, whilst systemic 
miR-21 inhibition attenuated the adverse remodelling. Several other studies 
showed that TGF-b signalling could increase miR-21 levels.132,168–171 
Importantly however, there is little attention for cell specificity of observed 
effects across the in vivo analyses in these studies. For example, AAV9-
mediated delivery implies cardiomyocyte-tropism rather than delivery to CF, 
whilst systemic miR-21 inhibition may also affect other cells within or beyond 
the heart. Nevertheless, miR-21 and TGF-b signalling seem to be tightly 
interwoven, with miR-21 levels in part depending on TGF-b activity whilst itself 
targeting inhibitors of the TGF-b signalling cascade. This suggests that miR-
21 may be part of a feed-forward loop of the TGF-b pathway. 
 
Conversely, miR-21 has also been shown to inhibit TGF-b signalling. One 
study found miR-21 to inhibit TGF-b1 expression and secretion in bone marrow 
stem cells.120  Mechanistically, this effect was explained by miR-21-mediated 
targeting of PTEN which enhanced Akt and nuclear factor kappa-light-chain-
enhancer of activated B cells (NF-kB) activity. Furthermore, miR-21 null stem 
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cells showed enhanced TGF-b1 secretion, which provided beneficial 
immunomodulatory effects when delivered to mice suffering from 
experimentally induced colitis. In a context of diabetic kidney disease, Lai et al 
found that miR-21 inhibited TGF-b signalling, with miR-21 inhibition 
aggravating TGF-b-induced glomerulosclerosis and podocyte apoptosis.172 
These studies seemingly oppose the previously mentioned observations that 
implied miR-21 to enhance TGF-b signalling. These observations highlight that 
the interaction between the two may be highly context- or cell-type dependent. 
 
1.3.4.5 MiR-21 and systemic effects 
Whilst the studies on miR-21, TGF-b and fibrosis focus on single cell 
types or organs, their results imply that an indirect or systemic effect of miR-
21 and its inhibition may also be at play. A study by Toldo et al aimed to 
evaluate the role of miR-21 on the bridge between post-ischaemic remodelling 
and inflammation. Treatment with hydrogen sulphide and sodium sulphide, 
which have previously been reported to dampen inflammation after ischaemia, 
induced miR-21 in rat cardiomyocytes and in the entire myocardium. Sodium 
sulphide administration indeed dampened experimental inflammation and 
improved survival after MI in mice. This response was however not seen in 
miR-21 null mice, implicating miR-21 as a mediator of the observed anti-
inflammatory effects. A study assessing miR-21 levels in obesity-induced 
cardiac hypertrophy using leptin receptor-deficient mice observed no effect on 
miR-21; nevertheless, systemic inhibition of miR-21 was able to decrease 
obesity and inflammation in white adipose tissue, highlighting the potential 
systemic and inflammatory effects of miR-21.173 
 
Using a model relying on a systemic response, Gupta et al heterotopically 
transplanted allogenic or isogenic hearts in mice.174 As allograft transplantation 
elicits a massive immune response, fibrosis develops very rapidly as part of 
the transplant rejection. Levels of miR-21 in these hearts significantly 
increased, an effect which was confirmed by elevated miR-21 levels in 
immune-rejected heart transplant specimens from humans. Interestingly, the 
authors observed that the increase in miR-21 levels was largely dependent on 
infiltrating CD45+ cells. Influx of platelets was not evaluated. Although systemic 
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inhibition of miR-21 decreased fibrocyte and T-cell accumulation, but not 
infiltration of macrophages, the degree of fibrosis was significantly attenuated. 
In addition, transplanting a wild-type heart into a miR-21 null mouse resulted 
in significantly less fibrosis, indicating extra-cardiac miR-21 to be a major 
determinant of the pro-fibrotic effects. These findings are a key indication that 
systemic effects of miR-21 may be at play in the development of fibrosis. 
Numerous studies have shown that in the heart, miR-21 is expressed not 
only in fibroblasts. Its presence in other cell types of the non-myocyte fraction 
of the cardiac cell population is highly relevant for the interpretation of previous 
and future studies, as well as for the application of miR-21 as a therapeutic 
Figure 3. MicroRNA-21-based therapy for plaque vulnerability and in-stent
restenosis. Delivery of miR-21 mimic to atherosclerotic plaques by ultrasound-
targeted microbubble destruction (UTMD) enhanced smooth muscle cell
proliferation, whilst also steering monocytes towards a reparative, anti-
inflammatory phenotype. Conversely, stents coated with miR-21 inhibitor (anti-
miR-21) prevented in-stent restenosis through their anti-proliferative effect on
smooth muscle cells. This highlights the context dependency for the effects of
miR-21. (Courtesy of Dr. M. Rienks)
Figure 3. MicroRNA-21-based therapy for plaque vulnerability and in-stent 
restenosis. Delivery of miR-21 mimic to atherosclerotic plaques by ultrasound-
targeted microbubble destruction (UTMD) enhanced smooth muscle cell proliferation, 
whilst also steering monocytes towards a reparative, anti-inflammatory phenotype. 
Conversely, stents coated with miR-21 inhibitor (anti-miR-21) prevented in-stent 
restenosis through their anti-proliferative effect on smooth muscle cells. This 
highlights the context dependency for the effects of miR-21. (Courtesy of Dr. M. 
Rienks; see Appendix 4) 
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target to treat fibrosis. In endothelial cells, miR-21 expression could be induced 
by TGF-b1 treatment, leading to endothelial-to-mesenchymal transition and 
thereby contributing to fibrosis formation.170 This effect, observed during TAC-
mediated cardiac pressure overload, could be inhibited by systemic 
administration of antagomiR-21. Brønnum et al reported that miR-21 was 
induced in epicardial cells after both TAC and MI, which subsequently induced 
epicardial-to-mesenchymal transition.126 
 
In addition to its pro-fibrotic role, miR-21 enhanced neo-intimal growth 
through pro-proliferative and anti-apoptotic effects on vascular smooth muscle 
cells. Genetic, systemic and local inhibition of miR-21 reduced neo-intima 
formation and in-stent restenosis in different animal models.175–178 However, 
whether the effects of miR-21 on smooth muscle cells are beneficial or 
detrimental is dependent on the context, as shown in Figure 3. We recently 
highlighted in an editorial commentary (see Appendix 4) two  studies reporting 
miR-21 to enhance stability of atherosclerotic plaques.179 One study focussed 
on the effects on macrophages, where miR-21 attenuated vascular 
inflammation and reduced plaque necrosis and instability.180 The second study 
found a similar beneficial role for miR-21, yet with a greater emphasis on its 
effects in vascular smooth muscle cells.181 Using a mouse model of 
atherosclerosis,  local delivery of miR-21 mimic using ultrasound-targeted 
microbubble destruction enhanced plaque stability. As we highlighted in our 
commentary, it remains challenging to reliably attribute observed effects after 
manipulating miR-21 to a specific cell type for in vivo findings. Nevertheless, 
these studies support the suggested immunomodulatory function of miR-21 
and its potential relation with cells in the circulation, whilst also adding to its 
potential as a therapeutic target. 
 
1.3.5 MicroRNAs in cardiac fibrosis 
In addition to miR-21, several other miRNAs have been implicated in 
fibrosis and CF biology. The most seminal findings will be highlighted in the 




Table 2. Key miRNAs implicated in cardiac fibrosis. 
A study by Van Rooij et al found that expression of miR-29b was 
significantly reduced in hearts after MI, a change in opposite direction from that 
of miR-21.184 Further experiments showed that miR-29b was mainly expressed 
in CF, where TGF-b signalling decreased its levels. In silico tools predicted 
several ECM proteins to be direct targets of miR-29b and collagen expression 
was indeed increased in hearts of mice after systemic miR-29b inhibition. A 
subsequent study from our group used a proteomic analysis of the CF 
secretome after miR-29 mimic and inhibitor transfections. This confirmed miR-
29b to be anti-fibrotic by demonstrating a marked effect of miR-29b 
overexpression on ECM protein secretion by CF in vitro.185 However, direct 






fibrotic? Effect in vivo 
miR-15b upregulated anti- - Systemic inhibition aggravated TAC-mediated fibrosis182 
miR-21 upregulated pro- 
- Systemic pharmacological inhibition 
attenuated  angiotensin II-123, TAC-
118,124,127,131,170, cardiac allograft 
transplant-174, and arryhtmia-
induced155,157,159 fibrosis; 
- Non-myocyte genetic inhibition 
attenuated TAC-induced fibrosis, yet 
myocyte inhibition aggravated TAC-
induced fibrosis131; 
- Cardiac injection attenuated arrhythmia-
induced fibrosis160; 
- Systemic pharmacological and genetic 
inhibition had no effect on TAC-, 
angiotensin II-, AMI-induced110 or obesity-
induced173 fibrosis. 




- Systemic inhibition induced collagen 
expression184;  
- Systemic inhibition attenuated fibrosis.187 
miR-101 downregulated (rodent) anti- 
- AAV9-mediated overexpression reduced 
fibrosis after MI in rats.188 
miR-125b upregulated pro- - Systemic inhibition attenuated angiotensin II-mediated fibrosis.189 
miR-133 downregulated anti- - Transgenic miR-133 expression improved TAC-mediated fibrosis in mice.190–192 
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attenuate adverse remodelling not only through regulating ECM synthesis but 
also by modulating paracrine signalling of inflammatory mediators. The latter 
mechanism was illustrated by adding conditioned media from CF that had 
been transfected with miR-29b mimic to cardiomyocytes in vitro, which had an 
anti-hypertrophic effect. Whilst both these studies implicate miR-29b as an 
anti-fibrotic and anti-hypertrophic miRNA, other studies have shown opposite 
effects. A phenotypic screen to evaluate the effects of several miRNAs on 
cardiomyocytes showed miR-29b to induce hypertrophy.186 More recently, 
Sassi et al showed that systemic inhibition of miR-29b attenuated 
cardiomyocyte hypertrophy and fibrosis using a TAC model in mice.187 
Interestingly, these observations were found to be the result of miR-29b on 
Wnt signalling in cardiomyocytes, putting these cells rather than CF at the 
centre of cardiac remodelling and suggesting miR-29b in cardiomyocytes to be 
pro-hypertrophic. These contradicting results for a single miRNA once more 
highlight the importance of the tissue and cell type context. 
 
In addition to its role in cardiac hypertrophy, miR-133 is considered anti-
fibrotic through targeting of connective tissue growth factor (CTGF), a key 
regulator of the fibrotic process downstream of the TGF-b signalling pathway 
190, as well as collagen I α-1, a main constituent of the cardiac ECM.191 miR-
15b, which is upregulated in failing hearts in rats, mice and humans, was also 
shown to target multiple constituents of the TGF-b pathway. Its 
pharmacological inhibition showed an increase in hypertrophy and fibrosis.182 
Another miRNA interfering with this pathway, miR-101, was found to be 
downregulated in MI and treatment to increase its levels led to a reduction in 
fibrosis.188 Using a similar MI model, lower miR-24 expression was found 
across the entire heart and intracardiac delivery of miR-24 using a lentiviral 
vector significantly reduced the infarct size. Mechanistically, direct targeting of 
furin was implicated as the mediator of this effect, in light of its function as a 
regulator of pro-TGF-b1 maturation.183 More recently, miR-125b was shown to 
suppress several pathways involved in CF proliferation and activation, and its 
inhibition consequently ameliorated cardiac fibrosis.189 
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1.3.6 MicroRNAs and cardiomyocytes 
Being the most prominent contributor to cardiac function, cardiomyocytes 
are key determinants of disease phenomena such as cardiac hypertrophy and 
reduced contractility. Furthermore, they constitute the majority of the 
myocardial cell volume. As mentioned in section 1.3.4.1, intial studies 
considered myocardial miR-21 to be derived from these cells. More recent 
studies however indicate CF to be the major source, in particular in the context 
of injury. Nevertheless, several miRNAs have been implicated in 
cardiomyocyte biology and pathology, which will be discussed in the following 
paragraphs. Key myocardial miRNAs based on next-generation sequencing193 
are listed in Table 3, with their implication in cardiomyocyte biology and/or 
fibrosis highlighted. Interestingly, this indicates that miRNAs with reportedly 
pivotal roles in cardiac remodelling are not necessarily highly abundant within 
the non-failing myocardium. 
 
In response to increased mechanical stretch caused by volume or 
pressure overload, several signal transduction pathways can be induced in 
cardiomyocytes, causing the cells to undergo significant transformation. This 
includes shifting towards expression of foetal gene programs.194 In addition to 
changes in the ECM, for which CF are thought to be the main responsible cell 
type, impaired cardiomyocyte function forms the second hallmark of 
cardiomyopathy and heart failure. 
 
In addition to its reported role in CF, miR-133 is highly abundant in 
cardiomyocytes. Its expression levels are reduced in animal models of 
hypertrophy107 and in patients with hypertrophic cardiomyopathy or coronary 
artery disease-related heart failure.195,196 In vitro and in vivo studies showed 
reactivation of foetal genes and increased hypertrophy upon miR-133 
inhibition195, whilst cardiac function was preserved upon miR-133 
overexpression. Targeting of the beta-1 adrenergic receptor pathway, central 
to the progression and treatment of heart failure, was implicated as the 
underlying mechanism in the latter study.197 A study inducing MI in rats after 
pre-treatment with the beta-1 adrenergic receptor blocker carvedilol, expected 
to preserve cardiac function, was associated with an increase in cardiac miR-
133 levels.198 MiR-133 is also expressed in skeletal muscle, albeit at lower 
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levels than in cardiomyocytes. Here, miR-133 inhibition again increased 
responsiveness to adrenergic stimuli and promoted differentiation to brown fat 
tissue.199 
 
Table 3. Key miRNAs in the myocardium. Next-generation sequencing was 
performed using RNA from left ventricular myocardium biopsies from unused human 
donor hearts (n=4). MiRNA highlighted in the context of fibrosis (paragraph 1.3.5) 
and/or a role in cardiomyocytes (paragraph 1.3.6) are marked with a hash (#) and/or 
asterisk (*), respectively. Obtained from supplemental information of Leptidis et al.193 
Rank MicroRNA ID 
1 miR-145 
2 miR-24 # 
3 miR-125a 
4 miR-30d 





10 miR-133 # * 
29 miR-29b # 
31 miR-125b # 
52 miR-21 * 
108 miR-15b # 
109 miR-25 * 
165 miR-208a * 
247 miR-101 # 
 
MiR-1, part of a cluster together with miR-133 and highly abundant in the 
myocardium (see Table 3), showed a similar reduction in its expression levels 
in heart failure patients.200 Both increased201 and reduced202 expression of 
miR-1 has been reported to cause electrophysiological abnormalities. 
Interestingly, miR-1 targets insulin-like growth factor-1 (IGF1), which itself 
represses processing of the pre-miR-1 transcript.200 The IGF1 pathway is an 
important contributor to cardiac hypertrophy and arrhythmias, and increasing 
miR-1 levels seem to improve cardiac function.203 
 
MiR-208 is also enriched in cardiomyocytes and regulates the balance 
between α- and β-MHC. Induction of the β-MHC isotype, the main isotype in 
the foetal heart, is a known maladaptive response to cardiac stress which 
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reduces contractility.204 MiR-208 knockout mice, and rats treated systemically 
with anti-miR-208, had a preserved balance between both MHC isotypes in 
response to experimental cardiac stress, with better cardiac function.205 These 
promising results suggested miR-208 inhibition could be a protective treatment 
in heart failure. However, β-MHC expression is not altered in normal hearts of 
miR-208 knockout mice, indicating that effects of this miRNA are either 
dependent on disease context or can be rescued by other miRNAs or other 
compensatory mechanisms.206 Furthermore, deep sequencing data from 
human hearts suggest that miR-208 expression is relatively low compared with 
other cardiac miRNAs, such as miR-1 and miR-133 (see Table 3).193,207 Pre-
clinical trials using miR-208 inhibition in heart failure were announced in 2011, 
but have not progressed further. 
 
In one study, miR-25 expression was repressed in failing human 
hearts208, but its expression was increased in another study.209 The former 
study described the targeting of deleterious embryonic gene programs that 
worsen cardiac function. The latter study however showed miR-25-mediated 
repression of sarcoplasmic/endoplasmic reticulum calcium adenosine 
triphosphatase, an important contributor to excitation–contraction coupling in 
cardiomyocytes. This subsequently improved cardiac function. Differences in 
timing and chemical properties of the anti-miR treatment, as well as the study 
duration, could explain these contradictory results.210 This highlights the 
challenges for translational research, as different types of oligonucleotides 
targeting the same miRNA may not achieve the same therapeutic benefit. 
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1.4 Circulating microRNAs 
 
A landmark study by Mitchell et al revealed that miRNAs are not just 
confined to the intracellular space of organ tissues, but are also present in the 
circulation.211 Whilst circulating cells and platelets contain substantial amounts 
of miRNA, there is also a pool of miRNAs that exists in the blood plasma. The 
finding that miRNAs could be detected in cell-free serum and plasma was 
surprising, given the high levels of RNase activity in the blood. In contrast to 
mRNA, miRNAs remain relatively stable in the circulation through several 
protective mechanisms: association with RNA-binding proteins and 
lipoproteins, or housing in shed microvesicles, such as exosomes or 
microparticles.212–214 These findings have opened another avenue for potential 
clinical application of miRNAs, where their circulating levels have potential to 
be used as biomarkers in cardiovascular disease and beyond. The relevance 
Figure	1	
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Rank	 Name	 Norm.	Count	 Name	 Norm.	Count	 Name	 Norm.	Count	 Name	 Norm.	Count	
	
1	 RNY4	5'	 22308	 miR-486	 15392	 RNY4	5'	 97325	 RNY4	5'	 101280	
2	 miR-486	 20832	 RNY4	5'	 5957	 miR-486	 22977	 miR-486	 22038	
3	 miR-92a	 2865	 miR-92a	 2417	 miR-26a	 15454	 miR-191	 16986	
4	 miR-191	 1651	 miR-22	 1168	 miR-191	 14051	 miR-26a	 14734	
5	 miR-423-5p	 1428	 miR-191	 897	 miR-92a	 10121	 miR-92a	 9482	
6	 miR-10b	 1336	 miR-423-5p	 894	 let-7f	 8248	 let-7f	 8999	
7	 RNY5	5'	 1213	 miR-16	 772	 miR-22	 8222	 miR-22	 8306	
8	 miR-22	 1191	 miR-26a	 689	 RNY4	3'	 7183	 let-7a	 6179	
9	 let-7f	 813	 miR-10b	 668	 let-7a	 5986	 miR-423-5p	 5803	
10	 miR-142	 810	 miR-142	 586	 miR-423-5p	 4367	 RNY4	3'	 5091	
11	 miR-26a	 808	 miR-451a	 553	 miR-181a	 3911	 miR-126-5p	 4900	
12	 RNY4	3'	 735	 RNY5	5'	 521	 miR-30d	 2943	 miR-181a	 3965	
13	 miR-181a	 726	 miR-181a	 515	 miR-151a-5p	 2846	 miR-21	 3658	
14	 miR-16	 528	 let-7f	 463	 miR-16	 2813	 miR-30d	 3526	
15	 miR-10a	 520	 miR-25	 341	 miR-126-5p	 2661	 miR-16d	 3069	
16	 let-7a	 409	 miR-126-5p	 327	 miR-423-3p	 2642	 miR-142	 2659	
17	 miR-126-5p	 397	 miR-10a	 326	 miR-222	 2349	 miR-151a-5p	 2425	
18	 miR-25	 390	 let-7a	 257	 miR-142	 2293	 miR-30e	 2088	
19	 miR-192	 357	 miR-27b	 241	 miR-21	 2221	 miR-151a-3p	 2076	
20	 miR-27b	 331	 miR-30e	 239	 RNY5	5'	 1892	 miR-423-3p	 1976	
21	 hsa-miR-30d-5p	 293	 RNY4	3'	 238	 hsa-miR-30e	 1845	 hsa-miR-27b	 1928	
22	 RNY1	3'	 255	 hsa-miR-30d	 235	 hsa-miR-151a-3p	 1724	 hsa-miR-222	 1837	
23	 hsa-miR-21-5p	 249	 hsa-miR-192	 210	 hsa-miR-409	 1438	 RNY5	5'	 1679	
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1 (PPP) Undetermined Undetermined 37.21 
2 (PPP) Undetermined Undetermined 37.40 
3 (PRP) 33.56 Undetermined 32.81 
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Figure 4. Next-generation sequencing of small RNAs in platelet-poor
plasma. Representative histogram of sequence lengths for small RNAs
identified in platelet-poor plasma. The two peaks correspond to miRNAs at 22-
23 nucleotides (nn) in length, and yRNAs at 32-33 nn. (Adapted from











Figure 4. Next-generation sequencing of small RNAs in platelet-poor plasma. 
Representative histogram of sequence lengths for small RNAs identified in platelet-
poor plasma. The two peaks correspond to miRNAs at 22-23 nucleotides (nn) in 
length, and yRNAs at 32-33 nn. (Adapted from Sunderland et al, Circ Res 2017, see 
Appe ix 3) 
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of extracellular miRNAs might however not be limited to their use as 
biomarkers, with several studies suggesting that miRNAs secreted from cells 
can act as mediators of paracrine or endocrine signalling.96,215 
 
 There are many more miRNAs encoded in the human genome than 
there are detectable in the circulation.216 We previously detected >200 miRNAs 
using next-generation sequencing (NGS) in platelet-poor and platelet-rich 
plasma samples (see Figure 4).217 Detectable miRNAs greatly vary in 
abundance. Not all miRNAs that are present in the circulation can be 
consistently detected with quantification cycle (Cq) values of <32 by qPCR, 
even after pre-amplification.  
 
The subset of miRNAs that are detected in the circulation have been 
released from different organs as well as circulating cells. Importantly, this 
explains the profound pre-analytical effects of sample preparation on miRNA 
analysis in plasma and serum. This is true in particular for miRNAs that are 
present in blood cells, as activation or rupture of these cells and incomplete 
depletion during centrifugation masks measurements of genuine extracellular 
miRNAs.96 Circulating miRNAs may be derived from several cell types, 
including bone marrow-derived cells and different organs. Interestingly 
however, our group has demonstrated that a sizeable subset of miRNAs that 
are detectable in the circulation show marked correlation, suggesting a shared 
cellular origin.218 Further analysis of this subset has shown that their levels are 
affected by administration of antiplatelet drugs prior to blood sampling, 
implicating platelets as a major source of circulating miRNAs.219 
 
1.4.1 Platelets and microRNAs 
 
1.4.1.1 The profile of microRNAs in platelets 
Due to their anucleate nature, platelets are incapable of transcribing new 
RNA. However, platelets do contain RNA, as well as the spliceosome 
machinery220 and ribosomes.221 Platelets are also believed to be capable of 
translating RNA into protein.222 Furthermore, miRNAs are abundant in 
platelets, and platelets carry the required machinery for miRNA-induced 
silencing.223,224 Over seven hundred different miRNAs have been identified in 
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platelets225, with miRNA expression profiles in healthy individuals showing 
remarkable stability when repeatedly measured over a course of ten days.226 
However, miRNA expression ranks across different profiling studies greatly 
vary (see Figure 5).96 This is likely not only due to inter-individual differences, 
but also because of differences in sample preparation and analysis. 
 
The profile of platelet miRNAs was found to be altered in different disease 
states. RNAseq profiling and qPCR analysis of platelet miRNAs in patients 
suffering an acute MI identified several miRNAs to be present at lower 
levels.227 In vitro analysis ascribed these changes to increased miRNA release 
from these platelets, as a result of a greater level of platelet activation. In 
another study, platelets from patients and mice with diabetes mellitus had 
lower levels of several miRNAs, which was found to be the result of 
hyperglycaemia on calpain-mediated cleavage of Dicer.228 
 
There are several potential explanations for variation in the platelet 
miRNA profile. As platelets are anucleate, changes cannot be the result of 
transcriptional regulation in the platelet itself. Therefore, platelets are thought 
to inherit their miRNA content during the maturation and shedding process 
from megakaryocytes.229 Consequently, the platelet miRNA profile may 
provide insights into megakaryocyte function in the bone marrow. There are 
however additional potential explanations for changes in miRNA levels: 
disease states that may affect miRNA precursor processing228, differential 
shedding of microparticles from the platelets227,230 and post-transcriptional 
modifications such as adenylation and uridylation.224 Furthermore, it has been 
shown that platelets are able to take up mRNA from vascular cells, which may 
also be the case for miRNAs.231 
 
In light of these observations, there is the opportunity to use platelet 
miRNAs as biomarkers as well as therapeutic targets. Our group has 
previously identified a loss of several miRNAs in the plasma of type 2 diabetes 
mellitus patients232 and in response to antiplatelet therapy.219 In addition, we 
found that a combination of plasma levels of three platelet-enriched miRNAs 


















































































































































































































































































































































































































































































































Figure 5. Platelet miRNA ranks across published studies. Relative
abundance of miRNAs in platelets was reported in eight studies (indicated by
first author and year of publication). The fifty highest ranking miRNAs on
average are presented here, indicating marked variation between different
studies for the miRNAs beyond the top ten. miR-21 is ranked as the thirteenth































































































































































































































































































































































































































































Figure 5. Platelet microRNA ranks across published studies. Relative abundance 
of miRNAs in platelets was re orted in eight studi s (i dicated by fir t author and ear 
of publicati n). The fifty high st r nking miRNAs on average are presented here, 
indicating marked variation b tween different studies for the miRNAs beyond the top 
ten. M R-21 is ranked as th  thirteenth most abundant miRNA in platele s. (Adapted 
fro  Sunderland et al, Circ Res 2017; see Appendix 3) 
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study.234 Plasma levels of platelet-enriched miR-126 were found to predict 
major adverse cardiac events in patients on dual antiplatelet therapy235, a 
result particularly interesting in the context of our finding that plasma miR-126 
significantly correlated with platelet activation markers.217 
 
1.4.1.2 Platelet function and microRNAs 
Platelet miRNAs might also reflect altered platelet function. Kondkar et 
al. isolated platelets from healthy volunteers and compared those from 
participants with relatively hyperreactive platelets to those with low reactivity. 
Transcriptomic analysis identified overexpression of vesicle-associated 
membrane protein 8 (VAMP8)/endobrevin in hyperreactive platelets, coding 
for a protein involved in a-granule secretion. MiR-96, harbouring a seed 
sequence predicted to target the 3’ UTR of VAMP8, was found at lower levels 
in hyperreactive platelets, implicating it as a regulator of VAMP8 translation.236 
In another study, racial disparity in survival of coronary heart disease was 
evaluated in the context of platelet function. Higher levels of 
phosphatidylcholine transfer protein-encoding mRNA were found in 
hyperreactive platelets. Subsequent miRNA profiling identified miR-376c as a 
regulator of this gene transcript.237 
 
To date, only three studies have evaluated the effects of inhibiting a 
specific miRNA on platelet function. Using miR-223 null mice, one study failed 
to observe any differences in platelet count or their activity despite this miRNA 
being among the most abundant in platelets (see Figure 5).238 A subsequent 
study however did observe modestly higher platelet activation in miR-223 null 
mice at low concentrations of agonists, resulting in increased thrombosis and 
embolisation after vascular injury. Proteomic analysis of platelets from these 
mice identified differences in protein abundance for coagulation factor XIII-A 
and kindlin-3, with the gene encoding the former being identified as a direct 
target of miR-223.228 Our group in a recent study found miR-126 to strongly 
correlate with markers of platelet activation in the community-based Bruneck 
cohort. Using systemic pharmacological inhibition of miR-126 in mice, platelet 
aggregation in response to a thromboxane A2 receptor agonist was 
significantly reduced. ADAM metallopeptidase domain 9 was identified as a 
direct target of miR-126.217 
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1.4.1.3 MiR-21 and platelets 
A combined rank table of miRNA abundance in platelets based on eight 
different miRNA profiling studies (see Figure 5) includes miR-21 among the 
fifteen most abundant miRNAs in human platelets. In parallel with several 
platelet-enriched miRNAs, miR-21 was detected at significantly lower levels in 
the plasma of diabetic patients and in leptin-deficient hyperglycaemic mice.232 
Using a limb ischaemia-reperfusion injury model in healthy volunteers, plasma 
miR-21 was identified as part of a cluster with platelet-enriched miR-126, -223, 
-197 and -24. Interestingly, it was identified as the most significantly increasing 
miRNA over seven days after reperfusion.233 Treating healthy volunteers with 
antiplatelet drugs prasugrel and acetylsalicylic acid over a period of three 
weeks significantly reduced plasma miR-21 levels.219 In the previously 
mentioned study comparing platelet reactivity in the context of ethnicity, miR-
21 was one of the miRNAs that was expressed significantly higher in blacks, 
which was associated with higher platelet reactivity.237 In a recent study, we 
showed that a comparison between platelet-poor plasma (PPP) and platelet-
rich plasma (PRP) using RNAseq identified markedly higher read counts of 
miR-21 in the latter. Furthermore, a platelet spike-in experiment, where we 
added increasing amounts of platelets to platelet-poor plasma, identified miR-
21 levels to significantly increase. Analysis of plasma from the community-
based Bruneck study showed significant correlation between miR-21 and 
platelet activity markers platelet factor 4 (PF4) and PPBP.217 
 
Taken together, these studies provide strong evidence for miR-21 as a 
key platelet miRNA. To date however, no studies have evaluated the effects 
of miR-21 inhibition on platelet function. 
 
1.4.2 Circulating microRNAs as biomarkers 
The finding that miRNAs are stable in the circulation and in other body 
fluids has attracted much interest in their potential use as biomarkers.211 
Biomarkers are defined by the National Institutes of Health Biomarkers 
Definitions Working Group as “a characteristic that is objectively measured and 
evaluated as an indicator of normal biological processes, pathogenic 
processes, or pharmacologic responses to a therapeutic intervention”.239 
MiRNAs harbour several features that make them well-suited for this purpose: 
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they can be measured noninvasively using commonly used techniques with 
high sensitivity and at relatively low cost. Furthermore, miRNAs display time-
related changes during disease progression and are thought to have a long 
half-life.83 On the other hand, however, there are several limitations that may 
explain why to date, miRNA biomarkers have not found their way to clinical 
application. Current quantification techniques require RNA isolation, followed 
by reverse-transcription (RT) and qPCR analysis, which is time-consuming 
and challenging to automate. Furthermore, these techniques generally rely on 
relative quantification, therefore complicating the identification of reference 
points for dysregulated levels. MiRNA quantification is therefore not well-suited 
for clinical use in an acute or sub-acute setting. In addition, as we will further 
argue in the discussion, pre-analytical factors can greatly interfere with levels 
of many miRNAs given their relative abundance in circulating cells compared 
to the freely circulating pool.96 
 
In the cardiovascular field, several miRNAs have been suggested as 
potential biomarkers. Cardiac miRNAs are detectable in the circulation at high 
levels early after MI, which could be used to reduce time to diagnosis.240 
Evaluation of miRNA levels thus far did not show a benefit over the currently 
used high-sensitivity troponins.241 Several studies have attempted to improve 
risk prediction models for MI using circulating miRNA levels. Karakas et al 
found a surprisingly strong correlation of single miRNAs with the risk of 
cardiovascular death, although this was in a highly selected population, and 
was not compared with traditional risk models.242 In contrast, the combination 
of a miRNA panel with traditional Framingham risk models may benefit the 
predictive power for future acute MI, as was shown in two studies.233,243 The 
miRNA panel in the study from our group233 included miR-126 and miR-223, 
showing positive and negative association with incident MI, respectively. 
Mechanistic links between these two miRNAs and platelet function were 
described earlier in this chapter. In the context of heart failure, higher levels of 
miR-29a correlated with both hypertrophy and fibrosis as features of 
hypertrophic cardiomyopathy244, but it is unclear whether this provides any 
clinical benefit over current diagnostic tools. 
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miR-21 was shown to be differentially expressed after MI, showing lower 
levels in the acute phase but increasing after a week.245 This rise in miR-21 
was later shown to be a predictor of poor neurological outcome.246 These 
findings are in line with studies comparing patients with stable and unstable 
coronary artery disease, where serum and plasma miR-21 levels were higher 
in the latter. Furthermore, miR-21 levels correlated with markers of 
inflammation247 and myocardial damage.248 The relation of circulating miR-21 
levels with cardiac damage was further evidenced by measuring serum levels 
after ablation of septal hypertrophy, which markedly increased its levels.249 
The increase persisted in a study with a follow-up of one year after a 
percutaneous coronary intervention.250 Whether these findings reflect release 
of miR-21 from the myocardium, from bone marrow-derived cells, or a 
combination, was not investigated in these studies. 
 
Looking at a patient group with more chronic clinical features, Villar et al 
showed that aortic stenosis patients had higher levels of miR-21 in the heart 
and plasma.137 Levels correlated with collagen abundance in the heart, 
implying it as a potential marker of cardiac remodelling and fibrosis. A study in 
hypertrophic cardiomyopathy patients confirmed this increase in miR-21 
levels, whilst also presenting it as part of a panel of eight miRNAs that were 
able to distinguish patients with diffuse fibrosis from those without signs of 
fibrosis based on plasma levels.251 In a more recent study, plasma miR-21 was 
found to increase in the compensated stage of diastolic dysfunction, but 
decrease in the later stages of heart failure.132 Altogether, these studies show 
that miR-21 is readily measured in the circulation and that its levels are 
affected in different disease states. None of these studies however determine 
the source of miR-21. Most studies infer that the observed changes in 
circulating miR-21 are reflecting changes in the miRNA content of the 
myocardium. However, circulating miR-21 changes could also be due to 
effects on other cellular sources such as leukocytes, the endothelium and 
platelets. 
 55 
1.5 MicroRNAs: therapeutic manipulation 
 
Several features of miRNAs have drawn the attention to evaluating their 
potential use as therapeutic targets. Whilst most traditional drugs rely on 
interfering with a single protein or receptor, miRNAs have been found to 
regulate the synthesis of several proteins that are biologically linked.252 This is 
elegantly illustrated by miR-29b, described earlier in this chapter, 
simultaneously targeting an array of ECM protein-coding gene transcripts. 
 
Furthermore, modified oligonucleotides were shown to potently reduce 
miRNA levels when administered locally or systemically.108 These anti-miRs 
consist of synthetic single strands of modified nucleotides that are 
complementary to the endogenous miRNA. Various structural modifications 
have been designed to bypass degradation in tissues and to enhance 
intracellular delivery.252 Importantly, despite being designed for the same 
purpose, the chemical properties of these different anti-miR agents may have 
a marked effect on its efficacy and side-effects. As will be pointed out in the 
discussion, contrasting outcomes between similar studies have been attributed 
to the differences in anti-miR designs.253 A commonly used anti-miR design 
involving phosphorothioate backbone modifications was found to induce 
platelet aggregation due to interaction with the collagen receptor on the platelet 
surface.254 In addition to miRNA inhibition strategies, cardiotropic adeno-
associated viruses (AAV) achieve efficient cardiomyocyte-specific miRNA 
delivery.131,255,256 As miRNA-based therapies approach clinical evaluation, 
there is increasing concern with regards to off-target effects, especially in light 
of the ubiquitous expression of most miRNAs. Hence, several methods have 
been proposed and evaluated to target miRNA mimics or inhibitors to a cell 
type or organ of interest.257 Local delivery of a miR-21 inhibitor and mimic have 
been used by means of a coated stent or ultrasound-targeted microbubble 
destruction, respectively (see Figure 3).177,179,181 Other techniques involve 
encapsulating molecules within nanoparticles or binding to polymers.257 A 
more recently reported strategy used the binding of photolabile groups to an 
antimiR, rendering the agent inactive until its exposure to light at a specific 
wavelength.258 Whilst these techniques all remain to be evaluated in a clinial 
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setting, the growing interest in their use implies a shift towards local therapeutic 
approaches rather than systemic miRNA inhibition. Currently, overexpressing 
a miRNA is generally considered less safe than inhibiting an endogenous 
miRNA. 
 
Several miRNA-based therapies are under clinical evaluation. The most 
advanced anti-miR at present is “Miravirsen”, targeting miR-122 for treatment 
of hepatitis C.108 A multicentre phase 2a trial259 for this anti-miR has been 
completed and this drug is currently being evaluated in a phase 2b trial. The 
selection of miR-122 as the first to be clinically evaluated highlights the two 
main challenges that exist for miRNA-based therapy, in particular for CVD. 
Firstly, miR-122 shows exquisite tissue specificity, whilst most other miRNAs 
are ubiquitously expressed. Second, anti-miRs are predominantly taken up by 
the liver and kidneys when administered systemically. Consequently, tissue 
specificity of miR-122 inhibition can be achieved without requiring any 
additional steps to steer the agent towards the intended site of action.259 
Targeting the heart or vasculature with systemic anti-miRs would require 
significantly higher dosing and efficiency may be low. 
 
Animal models have shown significant nephrotoxicity at higher doses of 
some anti-miRs, although the clinical trial of Miravirsen did not find significant 
renal injury in humans.259 The human immune system has evolved to detect 
viral RNA. Toll-like receptors recognize both single- and double-stranded 
RNA.260 High doses of synthetic oligonucleotides may elicit an immune 
response that could compromise efficacy and safety. Thus, cardiovascular 
applications will require solutions for local or cell type-specific delivery and 
clinically detectable, reliable read-outs to monitor successful target 
engagement. 
 
1.5.1 MiR-21 as a therapeutic target 
Anti-miR-21 therapy is currently being evaluated for the treatment of 
Alport syndrome, characterised by renal fibrosis.261 Whilst miR-21 is 
ubiquitously expressed and thus lacks the tissue specificity of miR-122, 
targeting the kidney requires only low doses of systemically delivered anti-miR, 
similar to the liver. 
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Alport syndrome is an inherited disorder characterised by 
glomerulonephritis, associated with haematuria and proteinuria, that during 
young adulthood progresses into glomerular and tubulointerstitial fibrosis. This 
rapidly causes renal failure. Other characteristics of this syndrome are hearing 
loss and lens deformities in the eye.262 Underlying these clinical features are 
mutations in the genes coding for three collagen type IV subunits that normally 
comprise a heterotrimer. This rare disorder almost inadvertently leads to renal 
failure that is only resolved by renal replacement therapy and transplantation 
of a donor kidney. In recent years, early start with angiotensin-converting 
enzyme inhibitors was found to delay progression towards renal failure, 
improving life expectancy of Alport syndrome patients.263 Whilst benefits of this 
therapy can in part be explained by its antihypertensive effects, mouse studies 
have suggested that angiotensin-converting enzyme inhibitors prevent renal 
fibrosis irrespective of the antihypertensive effect, by reducing myofibroblast 
activation and TGF-b signalling.264 
 
Evaluating Col4a3 null mice, a commonly used mouse model of Alport 
syndrome, miR-21 was found to be upregulated in the kidney at a young 
age.261 This preceded the development of inflammation or renal dysfunction. 
Mice developed kidney failure by nine weeks, whilst biweekly systemic 
treatment with anti-miR-21 preserved renal function and extended the survival 
time. Histological evaluation revealed markedly reduced glomerulosclerosis 
compared to vehicle-treated mice, as well as a reduction in the number of 
macrophages and aSMA-expressing myofibroblasts. Transcriptomic analysis 
of renal RNA from Col4a3 null mice and wild-type littermate controls identified 
upregulation of several ECM genes and markers of fibroblast activation. 
Furthermore, this analysis implicated peroxisome proliferator-activated 
receptor alpha as a direct target that was de-repressed by anti-miR-21 
treatment. This was shown to reduce mitochondrial ROS production as well as 
downstream effects of TGF-b signalling. Analysis of miR-21 null renal 
fibroblasts showed an increase in mitochondrial content and reduced ROS 
production, which persisted after TGF-b treatment. 
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First results from the evaluation of systemic anti-miR-21 treatment in 
Alport syndrome patients (ClinicalTrials.gov Identifier: NCT02855268) are 
expected this year. Whilst the aforementioned animal study implies a direct 
effect on renal fibroblasts, a systemic effect cannot be ruled out as a 
contributor to the observed effects. Furthermore, as these are the first results 
of miR-21 inhibition in humans, the outcome of this study will provide general 
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 There is an unmet clinical need for targeted therapeutic options against 
fibrosis. MiR-21 is widely described to be an important mediator of fibrosis in 
the heart and other organs. Pharmacological inhibition of miR-21 is currently 
undergoing clinical evaluation for renal fibrosis. Effects of miR-21 have mainly 
been seen after tissue injury and animal studies using miR-21 inhibition in the 
context of cardiac hypertrophy have been ambiguous. There is clear evidence 
for the involvement of circulating cells in tissue remodelling. MiR-21 is highly 
expressed in circulating cells, including monocytes and platelets. Thus, 
potential benefits of miR-21 inhibition may in part occur via indirect effects 
beyond the targeted organ. 
 
In the current project, we aimed to gain more understanding of how miR-
21 affects cardiac fibrosis. The following analyses were therefore performed: 
 
1. To analyse the direct effects of miR-21 in CF with a comprehensive and 
unbiased approach, we used a proteomic analysis of the CF secretome 
after transfection of miR-21 mimics and inhibitors. Furthermore, 
transfected cells were analysed for differences in gene expression and 
their proliferation rate. Hearts from miR-21 null mice were analysed to 
determine changes in ECM gene expression and protein levels. 
 
2. In a community-based cohort, we screened for associations of miR-21 
with other mediators and cell types that may affect fibrosis. Using 
plasma samples, correlations were assessed between miR-21 and a 
panel of proteins previously associated with CVD and inflammation. 
This screening drew our attention to blood platelets as a major source 
of miR-21 and pro-fibrotic mediators such as TGF-b1. Using an in vivo 
model of thrombocytopaenia and a human megakaryoblastic cell line, 
we aimed to assert the contribution of blood platelets to circulating pro-
fibrotic mediators and miR-21. 
 
3. Next, we assessed effects of pharmacological miR-21 inhibition on 
platelet count, aggregation response and their releasate. These 
experiments identified a link between miR-21 and platelet TGF-b1, as 
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well as a novel direct miR-21 target that could explain these 
observations. In addition, analysis of blood and bone marrow from miR-




















3.1 Isolation of murine cardiac fibroblasts 
Primary mouse CF were isolated from the hearts of male 8-10 week old 
C57BL/6 mice (Charles River) by collagenase II-based digestion as described 
previously.185 Housing and animal care was in accordance with the UK 
Animals (Scientific Procedures) Act 1986. Cells from individual animals were 
maintained as separate cell lines. Mice were anaesthetised using an 
intraperitoneal injection of pentobarbital, followed by excision of the heart, 
which was then transferred to ‘complete medium’, comprised of Dulbecco’s 
Modified Eagle’s Medium (DMEM; Gibco, cat. no. 10938025) supplemented 
with L-Glutamine (Gibco, cat. no. 25030024), 1% penicillin/streptomycin (100 
U/ml penicillin and 100 µg/ml streptomycin, Gibco, cat. no. 15140130) and 
10% heat-inactivated Foetal Bovine Serum (FBS; Gibco, cat. no. 10270106). 
Atria and blood vessels were removed and the ventricular tissue was washed 
and cut into 1 mm3 pieces, followed by pre-digestion in medium supplemented 
with 1% penicillin/streptomycin and 308.5 mg/L collagenase II (Worthington, 
cat. no. CLS-2) in a shaker-incubator for ten minutes at 37°C. The pre-
digestion volume was then replaced with fresh digestion solution and 
incubated for 1 hour. Digested samples were then washed, resuspended and 
plated in complete medium and cultured on gelatine-coated 6-well plates. 
Culturing was performed in a humidified atmosphere of 95% air and 5% CO2 
at 37°C. 0.05% trypsin-ethylenediaminetetraacetic acid (EDTA) (Gibco, cat. 
no. 25300054) was used to detach cells for passaging. As previously shown 
by vimentin staining185, the cell population after two passages predominantly 
consists of CFs. Cells at the third passage were used for transfections. Prior 
to transfection, cell viability was assessed by trypan blue (Sigma, cat. no. 
93595; 0.22µm filtered) staining and subsequent counting using a Neubauer 
chamber under bright-field microscopy. A proportion of trypan blue-negative 






















Figure 6. Workflow for the analysis of fibroblast conditioned media. A:
Murine cardiac fibroblasts were isolated from wild-type mice. Cells were
transfected with miR-21 mimic or LNA-21 (inhibitor) and their respective
controls. After 24 hours, cells were stimulated with TGF-β1 or control treatment
to induce a myofibroblast-like phenotype. B: 48 hours after transfection and
subsequent TGF-β1 treatment, conditioned media were collected. After
removing cell debris by centrifugation, samples were filtered and concentrated
using 3 kDa cut-off filter columns, removing contaminants such as amino acids
and salts. As secreted proteins and ECM proteins in particular are heavily
glycosylated, a sequential incubation with deglycosylating enzymes was
performed. Samples were then reduced and denatured, followed by separation
by sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE).
Proteins in the gel were visualised by silver staining to support subsequent gel
cutting. Proteins inside the gel pieces were digested into peptides using trypsin.
These peptides were then injected into an high-performance liquid













Figure 6. Workflow for the analysis of fibroblast conditio ed media. A: Murine 
CFs were isolated from wild-type mice. Cells were ransfected with miR-21 mimic or 
LNA-21 (inhibitor) and their respective controls. After 24 hours, cells were stimulated 
with TGF-β1 or control treatment to induce a myofibroblast-like phenotype.  B: 48 
hours after transf ction and subsequent TGF-β1 treatment, conditioned medi  were 
collected. After removing ell debris by centrifugatio , samples were filtered and 
concentrated using 3 kDa cut-off filter columns, removing contaminants such as 
amino acids and salts. As secreted proteins and ECM proteins in particular are 
heavily glycosylated, a sequential incubation with deglycosylating enzymes was 
performed. Samples were then reduced and denatured, followed by separation by 
sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE). Proteins 
in the gel were visualised by silver staining to support subsequent gel cutting. 
Proteins inside the gel pieces were digested into peptides using trypsin. These 
peptides were then injected into a high-performance liquid chromatography (HPLC)-
coupled mass spectrometer for identification and quantification of peptides. 
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3.2 MicroRNA transfection 
A schematic representation of transfections is shown in Figure 6, panel 
A. Cells (5x105 cells/well) were plated at 60-70% confluency in a six-well plate 
coated with gelatine, with equal volumes of a cell suspension added to each 
well to obtain an equal number of cells per well. Attachment of cells was 
confirmed by microscopy prior to transfection. The following mimics (miRIDIAN 
microRNA mimic, Dharmacon, GE Healthcare) were used: 
miR-21 (cat. no. C-300492-03-05): 5’-UAGCUUAUCAGACUGAUGUUGA-3’  
Negative Control #1 (cat. no. CN-001000-01-05): sequence not specified 
 
For miR-21 inhibition, Locked Nucleic Acid (LNA)-modified sequences 
were synthesised by Exiqon: 
LNA-21 (cat.no. 339121, ID: YI04100689):  
5’-CAACATCAGTCTGATAAGCT-3’; 
LNA-control (cat.no. 339126, ID: YI00199006):  
5’-TAACACGTCTATACGCCCA-3’. 
 
Transfections were carried out using Lipofectamine RNAiMAX (Life 
Technologies, cat. no. 13778075) in reduced serum medium (Opti-MEM; 
Gibco, cat. no. 31985070), according to manufacturer’s instructions, at a final 
concentration of 50 nM for all four sequences. Efficiency of transfection was 
tested using a fluorescently labelled miRNA (miRIDIAN microRNA Mimic 
Transfection Control with Dy547, Dharmacon, GE Healthcare, cat. no. CP-
004500-01-05) that was transfected in duplicate. 4',6-diamidino-2-
phenylindole (DAPI; Sigma, cat. no. D9542) staining, based on binding to 
double-stranded DNA, was used to visualise the cell nuclei. Fluorescence 
microscopy was used after twenty-four hours, using a wavelength of 461 nm 
(blue) for DAPI and 570 nm (red) for the transfected mimic. 
 
After 24 hours of incubation, cells were resuspended in serum-free 
medium after two washes. Cells were then stimulated with recombinant TGF-
b1 (Peprotech, cat. no. 100-21) at a concentration of 10 ng/ml. After 48 hours, 
conditioned medium was collected from each well and cleaned from cell debris 
by centrifugation at 3000 x g for 10 minutes. The supernatant medium 
(approximately 1900 µl) was stored at -80°C until further processing. The CF 
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were washed in phosphate-buffered saline (PBS; Sigma, cat. no. D8537), 
followed by lysis in QIAzol lysis reagent (Qiagen, cat. no. 79306). 
 
3.3 Conditioned media and cell processing for analysis 
The processing of conditioned media for mass spectrometry analysis is 
schematically shown in Figure 6, panel B. Collected supernatant medium was 
desalted using Zeba Spin desalting columns (Thermo Scientific, cat. no. 
89889), concentrated using concentration columns (Millipore, Amicon Ultra 0.5 
ml 3 kDa, cat. no. UFC500324), precipitated with 100% ethanol (VWR, cat. no. 
437433TDP), vacuum dried and then resuspended in 60 µL of deglycosylation 
buffer (50 mM sodium acetate, 50 mM Tris, pH 6.8, 25 mM EDTA), containing 
the following glycoprotein deglycosylation enzymes (Merck, cat. no. 362280): 
N-glycosidase F (1:200), β-1,4 galactosidase (1:200), β-N-
acetylglucosaminidase (1:200), endo-α-N-acetylgalactosaminidase (1:200), 
recombinant α-2-3,6,8,9-neuraminidase (1:200), chondroitinase (1:100), 
heparanase (1:500) and endo-β-galactosidase (keratinase; 1:500). Samples 
were deglycosylated by incubation at 25°C for 2 hours, followed by 37°C for 
48 hours in agitation. The deglycosylated samples were then used for sodium 
dodecyl sulphate (SDS)-polyacrylamide gel electrophoresis, followed by mass 
spectrometry (MS) or immunoblotting. 
 
3.4 Gel electrophoresis and silver staining 
Concentrated conditioned media samples were denatured, reduced and 
prepared for gel electrophoresis by adding sample loading buffer (100 mM 
Tris, 0.1% of 1 M SDS, 10% glycerol, 0.25% b-mercaptoethanol and 0.02% 
bromophenol blue). After incubation at 96°C for 5 minutes, gel-based 
separation was performed using Bis-Tris discontinuous 4-12% gradient 
polyacrylamide gels (NuPage, Invitrogen, cat. no. NP0315) in 3-(N-
morpholino)propanesulfonic acid-SDS running buffer (MOPS-SDS, NuPage, 
Invitrogen, cat. no. NP0001-02), using a voltage of 120 mV. Protein profiles of 
the gels were visualised by silver staining. All steps were performed with gentle 
shaking. Gels were incubated in fixing solution (50% methanol, 5% acetic acid) 
for 30 minutes, followed by three brief washes in H2O and an overnight 
rehydration step in H2O at 4°C. Next, gels were incubated for 1 minute in 
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sensitising solution (0.8M sodium thiosulphate in H2O), followed by three 1-
minute washes in H2O and silver staining for 30 minutes in 6 mM silver nitrate. 
After three brief washes in H2O, developing solution (180 mM sodium 
carbonate, 0.04% formaldehyde) was added and the gels were gently shaken 
until proteins were sufficiently visualised. After three short washes in H2O, 
stopping solution was added (5% acetic acid) for 10 minutes. Next, gels were 
washed three times for 5 minutes with H2O and placed in clear plastic bags to 
be scanned using a calibrated scanner (GS-800, Bio-Rad). 
 
3.5 Gel-based LC-MS/MS 
Each gel lane was divided into twelve pieces, followed by destaining and 
in-gel tryptic digestion using an Investigator ProGest (Digilab) robotic digestion 
system. Eluted peptides were lyophilised under vacuum at -55°C for 
approximately 5 hours (Christ Alpha 1-2 LD Freeze Dryer) and resuspended 
in 40 µl of 2% acetonitrile, 0.05% trifluoroacetic acid in H2O. Tryptic peptides 
were separated on a reversed-phase nano-flow high-performance liquid 
chromatography (HPLC) system (Dionex PepMap C18, 25 cm x 75 um, Dionex 
RSLC-nano) and eluted with a 70-minute gradient (0-3 min, 2-10% B; 3-37 
min, 10-35% B; 37-40 min, 35-40% B; 40-50 min, 99% B; 50-70 min, 2% B; 
where A=0.1% formic acid in HPLC-grade H2O and B=80% acetonitrile, 0.1% 
formic acid in HPLC-grade H2O). The sequentially eluted peptides were 
directly analysed by an Orbitrap mass analyser (LTQ Orbitrap XL, Thermo 
Scientific) using full ion scan mode over the mass-to-charge (m/z) range of 
400-1600, resolution 60000 (at m/z 400). Tandem MS (MS/MS) was performed 
using collision-induced dissociation in ion trap on the six most abundant ions 
in each full MS scan with dynamic exclusion. Raw files were searched against 
UniProt/SwissProt mouse and bovine databases (2015_02, 22689 protein 
entries), using Mascot software (version 2.3.01, Matrix Science). A mass 
tolerance of 10 ppm was selected for the precursor ions and at 0.8 Da for 
fragment ions. Carboxyamidomethylation of cysteine was set as a fixed 
modification and oxidation of methionine, proline and lysine (as hydroxylysine 
and hydroxyproline are common modifications on collagens) as variable 
modifications. Two missed cleavages were allowed. Search results were 
loaded into Scaffold (Proteome Software Inc., version 4.3.2) to validate the 
MS/MS-based peptide and subsequent protein identification and to calculate 
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the spectral count.265,266 Peptide identifications were accepted if they could be 
established at a probability >95% as specified by the Peptide Prophet 
Algorithm.265 Only tryptic peptides were included in the analysis. Protein 
identifications were accepted if they could be established at a probability >99% 
with at least two unique peptides.266 Before statistical analysis, protein spectral 
counts were normalised by multiplying the number of spectra assigned to each 
protein with the ratio between the total spectral count of a sample and the 
average number of spectra across the experiment. 
 
3.6 Cell proliferation assay 
To determine the effects on proliferation upon miRNA transfections in 
cultured CF, a proliferation assay was performed using the xCELLigence 
RTCA DP Instrument (ACEA Biosciences). Cells were transfected using the 
same methods and concentrations as described in 3.2 (i.e. 50 nM for all four 
oligonucleotides). After 24 hours, cells were trypsinised in 0.05% 
Trypsin/EDTA and resuspended in complete medium (see 3.1). Cells (5x103 
cells/well in a volume of 200 µl/well) were then seeded in an E-Plate VIEW 16 
(ACEA Biosciences, cat. no. 300600890) coated with 0.1% gelatine and 
allowed to attach whilst at room temperature for 30 minutes. Attachment of 
cells was confirmed by bright-field microscopy. Plates were then placed in the 
incubator at 37°C.  Four biological replicates were run in duplicate for each 
transfection condition. Two wells per plate were loaded with media only to 
assess background levels. Cell index values were recorded by 150 sweeps 
per interval every 30 minutes until 75 hours after plating, using proprietary 
software. Data was analysed using the difference (D) in cell index and slope 
analysis functions according to manufacturer’s instructions with the baseline 
recording reset at 4 hours. 
 
3.7 RNA isolation 
Total RNA was extracted using the miRNeasy Mini kit (Qiagen, cat. no. 
217004) according to the manufacturer’s recommendations, with some 
modifications. For RNA isolation from cultured or isolated cells, lysis was 
performed with 700 µl of QIAzol reagent. For isolation from heart, kidney and 
liver, a 1-2 mm piece was cut from the organ at anatomically consistent sites. 
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The tissue piece was directly placed into a tube containing Lysing Matrix D 
beads (MP Biomedicals, cat. no. 116913050) and 700 µl QIAzol reagent. Lysis 
was performed in a FastPrep-24 Homogeniser (MP Biomedicals) at 6000 rpm 
for two rounds of 20 seconds. Adequate lysis was macroscopically confirmed. 
Following brief incubation at room temperature, 140 µl of chloroform were 
added and the solution was mixed vigorously. Samples were then centrifuged 
at 12,000 x g for 15 minutes at 4°C. 280 µl of upper (aqueous) phase were 
carefully mixed with 420 µl of 100% ethanol and then applied to columns and 
washed according to the manufacturer’s protocol. Total RNA was eluted in 35 
µl of nuclease-free H2O by centrifugation at 9000 x g for 1 minute at 4°C. 
Concentration of cellular or tissue RNA was determined by spectrophotometry 
based on absorbance at 260 nm using NanoDrop 2000c (Thermo Scientific). 
The ratio of absorbance at 260 and 280 nm was calculated to assess the extent 
of protein contamination. 
 
For RNA isolation from plasma, a schematic representation is shown in 
Figure 7. Plasma samples were centrifuged for 10 minutes at 4000 x g at 4°C 
to pellet potential cell debris. 500 µl of QIAzol reagent were then combined 
with 100 µl of plasma and vigorously mixed. Following 5 minutes incubation at 
room temperature, 200 µl of spiking mixture were added. This mixture 










Figure 7. Plasma RNA extraction. For RNA isolation from plasma and other
biofluids with low RNA content, an exogenous miRNA (cel-miR-39) was spiked
into each sample to compensate for the lack of a suitable 'housekeeping'
reference gene transcript. Analysis was performed using a per-volume
approach, where the exogenous RNA allows for quality control and adjustment
of variability introduced throughout the sample processing. Upon combining
plasma with cel-miR-39 RNA and QIAzol lysis reagent, chloroform (CHCl3) was
added. After incubation, samples were centrifuged to obtain an aqueous (upper)
phase enriched in RNA. This RNA was precipitated onto a column using 100%
ethanol (EtOH), washed with a sequence of proprietary buffers, and then eluted
with nuclease-free H2O.
RNA
Figure 7. Plasma RNA extraction. For RNA isolation from plas a and other biofluids 
with low RNA content, an exogenous miRNA (cel-miR-39) was spiked into each 
sample to compensate for the lack of a suitable 'housekeeping' reference gene 
transcript. Analysis was performed using a per-volume approach, where the 
exogenous RNA allows for quality control and adjustment of variability introduced 
throughout the sample processing. Upon combining plasma with cel-miR-39 RNA and 
QIAzol lysis reagent, chloroform (CHCl3) was added. After incubation, samples were 
centrifuged to obtain an aqueous (upper) phase enriched in RNA. This RNA was 
precipitated onto a column using 100% ethanol (EtOH), washed with a sequence of 
proprietary buffers, and then eluted with nuclease-free H2O. 
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(Qiagen, cat. no. 219600; reconstituted in 100 µl and subsequently diluted 
1:4000 in nuclease-free H2O), 1.25 µl of carrier RNA from bacteriophage MS2 
(Roche, cat. no. 10165948001) and 194.75 µl of QIAzol reagent. Samples 
were then vigorously mixed and incubated for 5 minutes at room temperature. 
Further RNA isolation was performed similar to the protocol for cell and tissue 
RNA, with the difference that no NanoDrop analysis was performed. 
 
3.8 Reverse transcription and pre-amplification 
For relative quantification of miRNA by qPCR, 100 ng of RNA (or 3 µl for 
plasma RNA) were used as input in each RT reaction. Reactions (and a pre-
amplification step for plasma RNA) were set up according to the company’s 
recommendations. Briefly, miRNAs were reverse-transcribed using the 
TaqMan MicroRNA Reverse Transcription Kit (Applied Biosystems, cat. no. 
4366597), using 100 ng (or a fixed volume for plasma) RNA in 3 µl, 1 µl 10x 
RT buffer, 0.3 µl 100 mM deoxyribonucleotide triphosphate with 
deoxythymidine triphosphate, 1.2 µl 25 mM MgCl2, 0.2 µl RNase inhibitor, 1 µl 
of 10x Megaplex RT primers (Rodent Pool A v2.0  [cat. no. 4399970] or Human 
Pool A v2.1 [cat. no. 4399966], Applied Biosystems), 2 µl Multiscribe Reverse 
Transcriptase and 0.8 µl of nuclease-free H2O. The RT reaction was set up in 
a Veriti Thermal Cycler (Applied Biosystems) as follows: incubation at 16°C for 
2 minutes, then forty cycles of 42°C for 1 minute and 50°C for 1 second, 
followed by reaction termination by incubation at 85°C for 5 minutes). For 
plasma miRNAs, pre-amplification was performed using Megaplex PreAmp 
Primers (Human Pool A v2.1, cat. no. 4399233; Rodent Pool A, cat. no. 
4399203; Applied Biosystems), using 1 µl of undiluted RT product, 5 µl Pre-
amplification Mastermix (Applied Biosystems, cat. no. 4488593), 3 µl 
nuclease-free H2O and 1 µl of Megaplex PreAmp Primers. The pre-
amplification reaction was performed by heating the samples at 95°C for 10 
minutes, followed by twelve cycles of 95°C for 15 seconds and 60°C for 4 
minutes. Finally, samples were heated at 95°C for 10 minutes to ensure 
enzyme inactivation. Pre-amplification reaction products were diluted 1:72 with 
nuclease-free H2O before subsequent use in a qPCR reaction. 
 
For RT of messenger RNA, the reaction was performed using the 
SuperScript VILO cDNA Synthesis Kit (Invitrogen, cat. no. 11755250). Per 
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sample, 2 µl of VILO RT Master Mix were combined with 8 µl of sample in a 
25-100 ng/µl dilution. Thermal cycler stages were set as follows: incubation at 
25°C for 10 minutes and 42°C for 2 hours, followed by termination of the 
reaction at 85°C for 5 minutes. 
 
3.9 Real-time quantitative PCR 
TaqMan hydrolysis assays were used to assess relative levels of miRNA 
or gene expression. 2.25 µl of diluted RT product or pre-amplification product 
were combined with 0.25 µl of Taqman miRNA Assay (20X) (Applied 
Biosystems; see Table 4) and 2.5 µl of the Taqman Universal PCR Master Mix 
No AmpErase UNG (Applied Biosystems, cat. no. 4324020) to a final volume 
of 5 µl. Reactions were loaded onto 384-well plates using a Bravo Automated 
Liquid Handling Platform (Agilent). The qPCR reaction was performed on a 
ViiA7 Real-Time PCR System (Applied Biosystems) at 95ºC for 10 minutes, 
followed by forty cycles of 95ºC for 15 seconds and 60ºC for 1 minute. 
Calculations of relative quantity were performed using the 2-DDCq method267: Cq 
values for each assay were substracted from the corresponding reference 
gene transcript Cq value for each sample, yielding DCq values. For cellular and 
tissue RNA, the reference gene transcript was selected based on analysis of 
stability using the online RefFinder tool.268 This platform combines four major 
algorithms designed to determine transcript stability, providing a ranking of 
analysed candidate reference transcripts. For plasma RNA, the exogenous 
cel-miR-39-3p spike-in was used as the reference transcript. To obtain DDCq 
values, DCq values for each assay were then substracted from the average of 
the DCq values within the prespecified control group (control mimic or control 
LNA transfection in TGF-b1-untreated cells; or antagomiR-control treatment); 
or from the average DCq value of the calibrator sample in case of the Bruneck 
study samples. This calibrator sample consisted of a single RNA sample pool 
from a selection of samples of the cohort (separate sample pool for the 
Bruneck 2000 and 2015 evaluations). This calibrator was used throughout the 
entire analysis of each cohort evaluation and was run in duplicate on each 













Acta2 ACTA_MOUSE Mm01546133_m1  cel-miR-39-3p 000200 
Actb ACTB_MOUSE Mm02619580_g1  let-7d 002283 
Bgn PGS1_MOUSE Mm01191753_m1  U6 001973 
Col11a1 COBA1_MOUSE Mm00483387_m1  RNU48 001006 
Col1a1 CO1A1_MOUSE Mm00801666_g1  miR-1 002222 
Col1a2 CO1A2_MOUSE Mm00483888_m1  miR-21 000397 
Col3a1 CO3A1_MOUSE Mm00802300_m1  miR-24 000402 
Col4a2 CO4A2_MOUSE Mm00802386_m1  miR-29a 002112 
Col5a2 CO5A2_MOUSE Mm00483675_m1  miR-29b 000413 
Col6a1 CO6A1_MOUSE Mm00487160_m1  miR-30b 000602 
Ctgf CTGF_MOUSE Mm01192933_g1  miR-30c 000419 
Ctsl CATL1_MOUSE Mm00515597_m1  miR-31 002279 
Dcn PGS2_MOUSE Mm00514535_m1  miR-92a 000431 
Fbln2 FBLN2_MOUSE Mm00484266_m1  miR-93 001090 
Fbn1 FBN1_MOUSE Mm00514908_m1  miR-106a 002169 
Fn1 FINC_MOUSE Mm01256744_m1  miR-122 002245 
Fstl1 FSTL1_MOUSE Mm00433371_m1  miR-126 002228 
Gapdh G3P_MOUSE Mm99999915_g1  miR-126* 000451 
Grn GRN_MOUSE Mm00433848_m1  miR-133 002246 
Hspg2 PGBM_MOUSE Mm01181173_g1  miR-143 002249 
Igfbp4 IBP4_MOUSE Mm00494922_m1  miR-145 002278 
Itga2b ITA2B_MOUSE Mm00439741_m1  miR-146a 000468 
Lama4 LAMA4_MOUSE Mm01193660_m1  miR-150 000473 
Lamc1 LAMC1_MOUSE Mm00711820_m1  miR-191 002299 
Lgals3bp LG3BP_MOUSE Mm00478303_m1  miR-199a-3p 002304 
Ltbp1 LTBP1_MOUSE Mm00498234_m1  miR-223 002295 
Nid1 NID1_MOUSE Mm00477827_m1  miR-320 002277 
Pf4 PLF4_MOUSE Mm00451315_g1  miR-486 001278 
Postn POSTN_MOUSE Mm01284919_m1  miR-499 001352 
Ppbp CXCL7_MOUSE Mm00470163_m1    
Ppia PPIA_MOUSE Mm02342430_g1    
Ptprc PTPRC_MOUSE Mm01293577_m1    
Serpine1 PAI1_MOUSE Mm00435858_m1    
Serpinf1 PEDF_MOUSE Mm00441270_m1    
Sparc SPRC_MOUSE Mm00486332_m1    
Tgfb1 TGFB1_MOUSE Mm01178820_m1    
Tgfb2 TGFB2_MOUSE Mm00436955_m1    
Tgfb3 TGFB3_MOUSE Mm00436960_m1    
Tgfbr1 TGFR1_MOUSE Mm00436964_m1    
Tgfbr2 TGFR2_MOUSE Mm03024091_m1    
Tgfbr3 TGFR3_MOUSE Mm00803538_m1    
Vcam1 VCAM1_MOUSE Mm01320970_m1    
Was WASP_MOUSE Mm00494167_m1    
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3.10 Immunoblotting 
Samples were prepared and separated on Bis-Tris discontinuous 4-12% 
polyacrylamide gradient gels as described earlier. For immunoblotting, 
proteins were transferred from the polyacrylamide gel to a nitrocellulose 
membrane in ice-cold transfer buffer (25 mM Tris base and 200 mM glycine 
dissolved in 20% methanol) for 2 hours at 350 mA. Proteins were then stained 
with Ponceau S solution (Sigma, cat. no. P7170) to confirm adequate transfer. 
For conditioned medium samples, blots were scanned after Ponceau S 
staining. After washing in PBS with 0.1% Tween-20 (Sigma, cat. no. 
11332465001) (PBS-T), membranes were blocked with 5% fat-free milk in 
PBS-T for 1 hour at room temperature. Membranes were washed briefly in  
 






Laminin-ɣ1 Rat Immunoblotting (1:500) Abcam, ab17792 
Periostin Rabbit Immunoblotting (1:1000) Novus Biologicals, NBP1-30042 
Biglycan Rabbit Immunoblotting (1:500) Abcam, ab94460 
Decorin Rabbit Immunoblotting (1:130) Santa Cruz, sc-22753 
Argonaute2 Mouse Immunoprecipitation Abcam, ab57113 
Anti-CD41 Rat Flow cytometry, APC-labelled (1:10 to whole blood) BioLegend, 133913 
Anti-CD42b Rat Immunodepletion (4 mg/kg) Emfret Analytics, R300 
PF4 Rat Immunohistochemistry; immunoblotting (1:500) R&D Systems, MAB595 
WASp Rabbit Immunoblotting (1:1000) Cell Signaling, 4860 
TGF-β1 Rabbit Immunoblotting (1:1000); immunohistochemistry Abcam, ab179695 













HRP-anti-rat Goat Immunoblotting (secondary antibody, 1:5000) 
Jackson ImmunoResearch, 
112055175 
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PBS-T and incubated overnight in primary antibody solution (see Table 5) at 
a 1:200-10000 dilution in 5% bovine serum albumin (BSA; Sigma, cat. no. 
A9418) in PBS-T at 4°C while shaking. Membranes were then washed three 
times for 15 minutes in PBS-T, followed by incubation with a light chain-specific 
horseradish peroxidase (HRP)-conjugated secondary antibody (Dako) to 
detect the primary antibody, in a 1:5000 dilution in 5% fat-free milk in PBS-T 
for 1 hour. After three washes in PBS-T (15 minutes each), membranes were 
developed using enhanced chemiluminescence (ECL; GE Healthcare, cat. no.  
RPN2109) using X-ray films (Fujifilm, cat. no. AUT-300-040D) and a Xograph 
processor with exposure time dependent on signal intensity. Densitometric 
analysis was performed using ImageJ software (v.1.48v, NIH, USA). 
 
3.11 Three-step extraction for ECM protein enrichment 
Hearts from miR-21 null mice were a kind gift from Prof. Grillari’s 
laboratory at the University of Natural Resources and Life Sciences, Vienna, 
Austria. These mice were constructed as described by Patrick et al110, by 
introducing loxP sites at both ends of pre-miR-21, located within the 3’ UTR of 
the transmembrane protein 49 gene on chromosome 11. Cross-breeding the 
resulting homozygous floxed mice (miR-21fl/fl) with homozygous CAG-Cre-
expressing mice resulted in miR-21-/- mice at predicted Mendelian ratios. The 
removal of the miR-21-encoding locus did not affect the expression or protein 
levels of transmembrane protein 49 in the aorta, heart, kidney, liver, lung, 
spleen or skeletal muscle. Furthermore, no differences were observed in heart 
size and weight, or in cardiac function as determined by echocardiography. 
 
To extract cardiac ECM proteins from miR-21-/- mice and wild-type 
littermates, 50 mg of ventricular heart tissue per sample were diced and 
immediately placed in ice-cold PBS to remove plasma contaminants. For all 
buffers in this protocol, protease inhibitor cocktail was included according to 
the manufacturer’s instructions to inhibit a broad range of proteinase activity. 
To the PBS, 25 mM EDTA was added to ensure inhibition of 
metalloproteinases. Upon five washes in modified PBS, diced tissue pieces 
were incubated with 500 µl 0.5 M NaCl buffer (0.5 M NaCl, 10 mM Tris, 25 mM 
EDTA, pH 7.5). Samples were gently vortexed for one hour at room 
temperature. NaCl buffer was then removed and stored for later analysis. 
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Subsequently, tissue samples were incubated with 500 µl 0.1% SDS buffer 
(0.1% SDS, 25 mM EDTA) at room temperature for 16 hours with gentle 
vortexing to avoid mechanical disruption of the ECM. SDS solution was then 
removed and stored for later use. Finally, the samples were briefly washed in 
SDS buffer and then placed in 250 µl guanidine hydrochloride (GuHCl) buffer 
(4 M GuHCl, 50 mM sodium acetate, 20 mM EDTA, pH 5.8). Incubation was 
performed for 48 hours at room temperature and vortexed vigorously to 
enhance mechanical disruption of the ECM structure. GuHCl extracts were 
then collected and stored until later analysis. Protein concentrations in all three 
fractions were then determined by Bradford assay (BioRad, cat. no. 5000006) 
according to manufacturer’s instructions using bovine serum albumin standard 
curves prepared in corresponding buffers for each fraction. Proteins in the 
NaCl and GuHCl fractions were then prepared for MS analysis as follows: 15 
µg of protein was precipitated by adding a ten-fold volume of 100% ethanol to 
GuHCl samples and 100% acetone to NaCl samples. Samples were vortexed 
and stored at -20°C overnight. Proteins were further precipitated with 
centrifugation at 16000 x g for 40 minutes at 0°C. Supernatant volume was 
removed up to a residual volume of approximately 50 µl. Protein precipitates 
were fully dried using a SpeedVac Concentrator (ThermoFisher Scientific, 
Savant SPD131DDA) for approximately 20 minutes. Protein pellets were then 
resuspended in 20 µl deglycosylation solution as described earlier, but without 
N-glycosidase F. Samples were briefly vortexed and centrifuged, followed by 
incubation at 25°C for 2 hours and 37°C for 24 hours. Samples were then 
centrifuged and dried using the SpeedVac Concentrator for approximately 30 
minutes. Protein pellets were then resuspended in 20 µl of 1:100 N-
glycosidase F in H2O18. Samples were briefly vortexed and centrifuged, 
followed by incubation at 37°C for 48 hours. Samples were then stored at -
20°C until processing for MS. Following HPLC-MS/MS analysis, identified 
proteins were annotated using the Matrisome database.269 
 
3.12 In-solution digestion and HPLC-MS/MS analysis 
Deglycosylated GuHCl/NaCl extracts were denatured by the addition of 
9 M urea, 3 M thiourea in a 1:2 ratio (final concentration 6 M urea, 2 M 
thiourea). Samples were then reduced by adding 100 mM dithiothreitol (final 
concentration 10 mM) followed by incubation at 37°C for 1 hour. The samples 
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were then cooled down to room temperature before alkylation of proteins using 
iodoacetamide (final concentration 50 mM) followed by incubation in the dark 
for 1 hour at room temperature. Proteins were then precipitated using pre-
chilled (-20°C) acetone in a 6:1 volume ratio. Samples were briefly vortexed 
and centrifuged, followed by storage at -20°C overnight. Dried protein pellets 
were obtained as described in the previous section. For protein digestion, 
samples were resuspended in 30 µl trypsin solution, containing 0.01 µg/µl 
trypsin in 0.1 M triethylammonium bicarbonate, pH 8.2. Proteins were digested 
overnight at 37°C under agitation (240 rpm). The digestion was stopped by 
acidification of the samples with 10% v/v trifluoroacetic acid (final 
concentration 1%). Peptide samples were purified using a 96-well C18 spin 
plate (MicroSpin, Harvard Apparatus, cat. no. 745617). The resin was 
activated using 200 µl methanol and centrifuged at 1000 x g for 1 minute. Wash 
steps included 200 µl of 80% acetonitrile, 0.1% trifluoroacetic acid in H2O, and 
three equilibration steps using 200µl of 1% acetonitrile, 0.1% trifluoroacetic 
acid in H2O with centrifugation (1000 x g for 1 minute) after each step. Samples 
were loaded onto the resin and centrifuged at 2250 x g for 1 minute; the flow 
through was reloaded onto the resin a second time and centrifugation 
repeated. The resin was then washed three times with 200 µl 1% acetonitrile, 
0.1% trifluoroacetic acid in H2O (centrifugation at 2250 x g for 1 minute). 
Finally, the samples were eluted with 170 µl of 50% acetonitrile, 0.1% 
trifluoroacetic acid in H2O (centrifugation at 1000 x g for 1 minute); this step 
was repeated, combining the collected eluate. Samples were then dried down 
using the SpeedVac Concentrator for approximately 5 hours. Dried peptide 
samples were then resuspended in 0.05% trifluoroacetic acid in 2% acetonitrile 
and separated on a nano-flow LC system (Dionex UltiMate 3000 RSLC-nano). 
Samples were injected onto a nano-trap column (Acclaim® PepMap100 C18 
Trap, 5mm x 300um, 5um, 100Å), at a flow rate of 25 µL/min for three minutes, 
using 2% acetonitrile, 0.1% formic acid in H2O. The following nano-LC gradient 
was then used to separate the peptides at 0.3 µL/min: 0−10 min, 2-10% B; 
10−200min, 10-30% B; 200−210min, 30−40% B; 210-220min, 99%B, 220-
240min 2%B, where A=0.1% formic acid in H2O, B=80% acetonitrile, 0.1% 
formic acid in H2O. The nano column (Acclaim® PepMap100 C18, 50 cm x 75 
µm, 3µm, 100 Å) was set at 40°C and coupled to a nanospray source 
(Picoview, New Objective, US). Spectra were collected from a Q Exactive Plus 
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(Thermo Fisher Scientific) using full MS mode (resolution of 70,000 at 200 m/z) 
over the mass-to-charge (m/z) range 350–1600. Data-dependent MS2 scan 
was performed using the top fifteen ions in each full MS scan (resolution of 
17,500 at 200 m/z) with dynamic exclusion enabled. Thermo Scientific 
Proteome Discoverer software (version 1.4.0.288) was used to search raw 
data files against the human database (UniProtKB/Swiss-Prot version 
2017_02, 17,511 protein entries) using Mascot (version 2.6.0, Matrix Science). 
The mass tolerance was set at 10 ppm for precursor ions and 20 mmu for 
fragment ions. Trypsin was used as the enzyme with up to two missed 
cleavages being allowed. Carbamidomethylation of cysteine was chosen as a 
fixed modification; oxidation of methionine, lysine and proline, and deamidation 
of asparagine in the presence of O18 water were chosen as variable 
modifications. Scaffold (version 4.3.2, Proteome Software Inc., Portland, OR) 
was used to validate MS/MS-based peptide and protein identifications with the 
following filters; a peptide probability of greater than 95.0% (as specified by 
the Peptide Prophet algorithm), a protein probability of greater than 99.0%, 
and at least two independent peptides per protein. The normalised total 
precursor intensity was used for quantification. 
 
3.13 Bruneck study 
The Bruneck study is a community-based, prospective survey of the 
epidemiology and pathogenesis of atherosclerosis and cardiovascular 
disease.233,270 The study protocol was reviewed and approved by the Ethics 
Committees of Verona and Bolzano, and all participants provided their written 
informed consent before entering the study. At the 1990 baseline evaluation, 
the study population comprised an age- and sex- stratified random sample of 
all inhabitants of Bruneck aged 40-79 years (125 men and 125 women from 
each of the fifth through eighth decades of age, all white). Samples from the 
year 2000 (n=660) and 2015 (n=332) follow-up were used for the present 
study. Participant characteristics for both study evaluations are shown in Table 
6. Citrate plasma samples were drawn after an overnight fast and twelve hours 
of abstinence from smoking. During the 2000 follow-up, plasma was prepared 
within two hours from blood drawing by single centrifugation at 4000 x g for 15 
minutes at room temperature and aliquots were immediately stored at -80°C. 
Our work on circulating miRNAs and their relation with platelets96,217 drew 
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attention to the importance of platelets as a potential source of contamination. 
This had been reported by others, both in the context of protein 
measurements271–273 and miRNAs.274,275 As TGF-b1 became a focus of 
attention within this project, in part due to our observations from the Bruneck 
study 2000 follow-up, the importance of preanalytical variables became 
increasingly pertinent. Several studies have previously highlighted the 
importance of platelet activation as a major confounder of circulating TGF-b1 
measurements.29,64,276,277 We therefore devised a tailored protocol for platelet-
poor plasma preparation during the 2015 follow-up, based on previous 
studies29,64 and protocols previously devised for specific haematological 
analyses.278,279 First, PRP was isolated by centrifugation at 175 x g for 15 
minutes with slow brake. An aliquot of PRP was then supplemented with 
prostacyclin (PGI2, 2 µg/mL; Tocris Bioscience, cat. no. 2989) and centrifuged 
at 1000 x g for 10 minutes to obtain PPP. Samples were divided into aliquots 
and immediately stored at -80°C. 
 
Table 6. Clinical characteristics of Bruneck study participants during the 2000 
and 2015 evaluations. 
 Bruneck study 
Follow-up year 2000 2015 
Participants, n 660 332 
Age, mean (SD) 66.0 (10.3) 75.2 (7.2) 
Male sex, n (%) 324 (49.1) 168 (50.6) 
Diabetes, n (%) 70 (10.6) 24 (7.2) 
Antiplatelet therapy, n (%) 79 (12.0) 101 (30.4) 
 
3.14 Plasma proximity extension assays 
Low-abundant plasma proteins were analysed using Olink Proseek 
Proximity Extension Assays (PEA; CVD I [cat. no. 91201] and Inflammation I 
[cat. no. 91301] panels). Plasma samples were centrifuged for 1 minute at 
room temperature at 400 x g. All following centrifugations were performed 
using these settings. 1 µl of sample, interplate control or negative control was 
combined with 3 µl of incubation mix (prepared by combining 280 µl incubation 
solution and 40 µl of incubation stabiliser, A-probes and B-probes each) on a 
96-well plate. The plate was centrifuged and incubated overnight at 4°C. The 
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next day, 96 µl of extension mix was added to each well, made up of 9385 µl 
H2O, 1100 µl PEA solution, 55 µl PEA enzyme and 22 µl PCR polymerase. 
The plate was then vortexed and centrifuged. Samples were placed in a 
thermal cycler (Veriti, Applied Biosystems, cat. no. 4375786) and run with the 
following protocol: extension for 20 minutes at 50°C and a hot start of 5 minutes 
at 95°C, followed by seventeen PCR cycles of 30 seconds at 95°C, 1 minute 
at 54°C and 1 minute at 60°C. In a new plate, 2.8 µl of these samples were 
combined with 7.2 µl of detection mix (consisting of 550 µl detection solution, 
230 µl H2O, 7.8 µl detection enzyme and 3.1 µl PCR polymerase). Next, the 
primer plate was thawed and vortexed and both plates were then centrifuged. 
A 96.96 dynamic array integrated fluidics circuit (IFC; Fluidigm, cat. no. BMK-
M-96.96) was primed by emptying one 150 µl syringe of control line fluid 
(Fluidigm, cat. no. 89000021) into the accumulator. 5 µl of primer and 5 µl of 
sample were added to the inlets on respective sides of the fluidics circuit. The 
fluidics circuit was then run in an IFC Controller HX (Fluidigm, cat. no. BMK-
IFC-HX) to combine the primers with samples. Finally, the fluidics circuit was 
loaded in a Biomark HD system (Fluidigm, cat. no. BMKHD) and analysed 
using the following programme: thermal mixing by incubation at 50°C for 2 
minutes, 70°C for 30 minutes and 25°C for 10 minutes, followed by a hot start 
at 95°C for 5 minutes, followed by forty cycles at 95°C for 15 seconds and 
60°C for 1 minute. Results were analysed using NPX Manager Software 
(Olink). 
 
3.15 Plasma protein quantification by mass spectrometry 
For the mass spectrometry-based PlasmaDive kit (Biognosys AG, cat. 
no. Ki-3004), plasma samples were processed according to the manufacturer’s 
instructions with one exception: peptide standards were spiked in before and 
not after tryptic digestion and C18 clean-up. 10 µl of plasma samples were 
denatured, reduced and alkylated as described above. 20 µg of proteins were 
spiked with one hundred authentic heavy peptide standards. Seven proteins 
were below the limit of detection. An in-solution digestion was performed as 
described in paragraph 3.12. After solid phase extraction with 96-well C18 
spin columns, the eluted peptides were dried using a SpeedVac Concentrator 
and resuspended in 40 µl of LC solution. The samples were analysed on an 
Agilent 1290 LC system interfaced to an Agilent 6495 Triple Quadrupole MS. 
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10 µl samples were directly injected onto a 25 cm column (AdvanceBio Peptide 
Map 2.1 x 250 mm, Agilent, cat. no. 651750-902) and separated over a 23-
minute gradient at 300 µl/min. The data were analysed using Skyline software 
version 3.1 (MacCross Lab) and protein concentrations were calculated using 
the heavy/light ratio. 
 
3.16 Enzyme-linked immunosorbent assays (ELISA) 
Levels of TGF-b1 (R&D Systems, cat. no. DY1679 for mouse; DY240 for 
human) and PF4 (cat. no. DY595) were measured using DuoSet ELISA 
Development kits and DuoSet Ancillary Reagent Kits 1 and 2 (cat. no. DY007 
and DY008, respectively). Plates were coated with 100 µl capture antibody 
reconstituted in plate coating buffer and incubated at room temperature 
overnight. All incubations in the protocol were carried out at room temperature. 
Plates were washed three times with 300 µl washing buffer; all following 
washes throughout the protocol were carried out in a similar manner. Plates 
were then blocked with the appropriate block buffer for at least 1 hour. For 
mouse TGF-b1, 5 µl of sample were treated with 1.25 µl of 1 M HCl for 10 
minutes and then neutralised with 1.25 µl 1.2 M NaOH/0.5 M 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES). Samples were then 
diluted with reagent diluent to a final dilution of 45x. For human TGF-b1, 
plasma was pre-diluted by adding 6.6 µl of sample to 81.4 µl reagent diluent, 
followed by adding 22 µl 1 M HCl. After mixing and 10 minutes incubation, 22 
µl of 1 M NaOH/0.5 M HEPES were added to neutralise the samples. The 
resulting final dilution was 20x. For PF4, 1 µl of sample was diluted in 999 µl 
of reagent diluent to obtain a 1000x dilution. The ELISA plates were washed 
and 100 µl of diluted sample or the appropriate standard were loaded. Plates 
were incubated for two hours while gently shaking. Detection antibody was 
diluted in reagent diluent and 100 µl were added after washing. After two hours 
of incubation, plates were washed and 100 µl of streptavidin-HRP diluted in 
reagent diluent were added. After incubation in the dark for twenty minutes, 
plates were washed and 100 µl of substrate solution were added. After twenty 
minutes of incubation, 50 µl of stop solution were added to each well. 
Absorbance at 450 nm was then measured on a plate reader (Tecan Infinite 
200 Pro) using 570 nm as a reference wavelength. Results were calculated 
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using a four-parameter logistic fit for a 7-point standard curve consisting of 
serial twice-diluted recombinant protein in sample dilution buffer, analysed in 
duplicate. Furthermore, for each matrix and assay, a spike-recovery protocol 
was performed to assess linearity for serial dilutions of the neat and spiked 
matrix. For this purpose, a sample pool was generated for each assayed matrix 
(supernatant of activated PRP from antagomiR-treated mice; human PPP from 
the Bruneck study 2015 evaluation). A representative example of this analysis 
is shown in Figure 8. For the analysis of the Bruneck study 2015 PPP samples, 
the sample pool was run in triplicate on each ELISA plate. A ratio of the 
average measurement for this pool on each plate was calculated towards the 
A B
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Figure 8. ELISA standard curve and linearity measurements for murine
plasma. A: A 7-point standard curve was generated using serial dilution of
recombinant murine TGF-β1 in sample dilution buffer. Samples loaded in
duplicate. X-axis showing expected concentration, with the background-
corrected absorbance (optical density, OD) shown on the Y-axis. R2 indicates
goodness of fit for the shown 4-parameter logistic equation curve. B,C: A pool
consisting of equal amounts of each analysed plasma sample was generated to
assess linearity of the measurements using this matrix. A serial dilution of neat
sample pool (B) and sample pool spiked with recombinant murine TGF-β1
(rTGF-β1) was generated and analysed, showing linearity of the measurement
for both analyses. Samples analysed in duplicate; R2 indicates goodness of fit
for the shown linear regression curve.
Figure 8. ELISA stand r  curve and li earity measurements for mu ine plasma. 
A: A 7-point standard curve was gen rated using serial dilution of rec mbinant 
murine TGF-β1 in sample dilution buffer. Samples loaded in duplicat . X-axis showing 
expected concentration, with th  background-corrected absorbance (optical density, 
OD) shown on the Y-axis. R2 indicates goodness of fit for the shown 4-parameter 
logistic equation curve. B,C: A pool consisting of equal amounts of each analysed 
plasma sample was generated to assess linearity of the easurements using this 
matrix. A serial dilution of neat sample pool (B) and sample pool spiked with 
recombinant murine TGF-β1 (rTGF-β1) was generated and analysed, showing 
linearity of the measurement for both analyses. Samples analysed in duplicate; R2 
indicates goodness of fit for the shown linear regression curve. 
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average of all sample pool measurements across the plates. This ratio (<20% 
deviation from the average) was used as an adjustment factor for obtained 
sample measurements. 
 
3.17 Human plasma isolation from human blood 
Preparation of conventional plasma and PPP in the Bruneck cohort is 
described in the methods section of the Bruneck study. A schematic 
representation is shown in Figure 9, panel A. For preparation of PRP and PPP 
for PEA and NGS analysis, blood was drawn into syringes pre-filled with acid-
citrate-dextrose buffer (ACD; 85 mM trisodium citrate dehydrate, 66.6 mM citric 






















Figure 8. Plasma and platelet releasate isolation. A: For isolation of plasma
and platelets, blood was drawn into sodium citrate (NaCitrate) or acid-citrate-
dextrose (ACD) buffer with a final dilution of 3.2% or a blood:ACD ratio of 6:1,
respectively. Initial centrifugation was performed at low speed to obtain an
upper phase of platelet-rich plasma (PRP) which was carefully collected. For
subsequent faster centrifugation to obtain platelet-poor plasma (PPP) and the
platelet pellet, prostaglandin E1 (PGE1) was added to reduce platelet activation.
B: For platelet releasate isolation, the platelet pellet was washed twice, followed
by platelet activation with thrombin. The releasate was then isolated by
centrifugation. Human releasate samples were treated with either reducing or
non-reducing conditions with subsequent analysis by polyacrylamide gel
electrophoresis (PAGE). Separated proteins were then isolated from the gel
after silver staining and digested for mass spectrometric analysis.
Figure 9. Plasma and platelet releasate isolation. A: For isolation of plasma and 
platelets, blood was drawn into sodium citrate (NaCitrate) or acid-citrate-dextrose 
(ACD) buffer with a final dilution of 3.2% or a blood:ACD ratio of 6:1, respectively. 
Initial centrifugation was performed at low speed to obtain an upper phase of platelet-
rich plasma (PRP) which was carefully collected. For subsequent faster centrifugation 
to obtain platelet-poor plasma (PPP) and the platelet pellet, prostaglandin E1 (PGE1) 
was added to reduce platelet activation. B: For plat let releasate isolation, the platelet 
pellet was washed twice, followed by platelet activation with thrombi . The r leasate 
was then isolated by centrifugation. Human r l asate samples w e treated with 
either r ucing r n -reducing conditions with subsequent nalysis by 
polyacrylamide gel electrophoresis (PAGE). Separat d proteins were then isolated 
from the gel after s lver staining and digested for mass spectrometric analysis. 
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ACD:blood. All centrifugations were carried out at room temperature. PRP was 
first isolated by centrifugation at 190 x g for 30 minutes without brake. The top 
two-thirds of the upper phase was collected to stay clear of the buffy coat 
interphase. An aliquot of PRP was stored at -80°C for later analysis. The 
remainder of collected PRP was then further centrifuged at 280 x g to remove 
leukocytes after adding 1 µg/ml PGE1 (Sigma, cat. no. P5515) and 10 µM 
indomethacin (Sigma, cat. no. I7378) to inhibit platelet aggregation. The 
supernatant PRP was then centrifuged at 1180 x g for 10 minutes to pellet 
down platelets. Supernatant PPP was collected and stored at -80°C for later 
analysis.  
 
3.18 Human platelet releasate isolation and gel electrophoresis 
 For the human platelet releasate analysis, platelets were isolated as 
described in the previous paragraph. Isolation of the releasate is graphically 
shown in Figure 9, panel B. Pellets were washed twice in modified Tyrode-
HEPES buffer (NaCl 134 mM, KCl 2.9 mM, Na2HPO4 0.34 mM, NaHCO3 12 
mM, HEPES 20 mM, MgCl2 1 mM, Glucose 5 mM), supplemented with 1 µg/ml 
PGE1 and 10 µM indomethacin, with centrifugation at 1180 x g for ten minutes 
in between. The platelet pellet was then resuspended in modified Tyrode-
HEPES buffer without inhibitors and left to rest for 30 minutes. Platelet 
suspensions were then transferred to glass cuvettes. These were placed in an 
aggregometer (ChronoLog, cat. no. 490) that was pre-warmed to 37°C. 1 U/ml 
thrombin from human plasma (Sigma, cat. no. T7009) was then added, 
followed by incubation for 5 minutes at 37°C under constant stirring. Next, ice-
cold protease inhibitor cocktail was added. Subsequent centrifugation for 5 
minutes at 1000 x g and 1 hour at 20000 x g, both at 4°C, were performed to 
deplete the platelet releasate from any cellular material. Samples were then 
cleaned and concentrated to a 25 µl volume using Amicon 3 kDa concentration 
columns as described earlier. Protein concentrations were determined using 
the 3-(4-carboxybenzoyl)quinoline-2-carboxaldehyde protein quantitation kit 
(CBQCA, ThermoFisher, cat. no. C6667) according to the manufacturer’s 
instructions. Equal amounts of protein were aliquoted and adjusted to equal 
volumes with PBS. Samples were then separated in two equal parts, followed 
by addition of reducing sample loading buffer as described in paragraph 3.4 
or by adding non-reducing sample buffer that was free of b-mercaptoethanol 
 84 
but was supplemented with 100 µM maleimide (Sigma, cat. no. 129585). 
Samples with reducing buffer subsequently underwent heating at 95°C for 5 
minutes. A 5-15% polyacrylamide 20x25 cm gel was casted using a 2-
DEoptimiser (Nextgen) and a Dalt six gel casting tank (GE Healthcare). After 
allowing the gels to set overnight at 4°C, a 5% stacking gel was casted on top 
using an 18-well gel comb. After setting overnight at 4°C, samples were 
reduced and non-reduced samples were separated by electrophoresis at 2W 
for 15 minutes, 3W for 30 minutes and 30W for 200 minutes. Protein profiles 
of the gels were visualised by silver staining using the PlusOne Silver Staining 
Kit (GE Healthcare, cat. no. 17-1150-01) protocol. All steps were performed 
with gentle shaking. After electrophoresis, the gel was washed in H2O 
incubated in fixing solution (10% acetic acid, 40% v/v methanol) at room 
temperature for 60 hours. Next, the gel was washed in H2O three times and 
then incubated in sensitising solution (30% v/v methanol, 0.2% w/v sodium 
thiosulphate and 0.5 M sodium acetate) for 30 minutes at room temperature. 
After three 5-minute washes in H2O, protein bands were silver stained by 
incubation in 0.25% w/v AgNO3. After 20 minutes, the gel was washed twice 
for 1 minute in H2O, and then developed (2.5% w/v sodium carbonate, 
0.0148% w/v formaldehyde) for 3 minutes. Stopping solution (1.46% w/v 
EDTA-Na2•H2O) was then added for 10 minutes, followed by three 5-minute 
washes in H2O. The gel was then transferred to a clear plastic bag to allow for 
scanning (GS-800, Bio-Rad). Each gel lane (i.e. sample) was divided in forty-
eight gel pieces, that were subsequently processed using the ProGest system 
as described in paragraph 3.5. 
 
3.19 Platelet depletion 
Male C57BL/6J mice (Harlan) were treated with a rat anti-mouse 
glycoprotein Iba (GPIba) antibody (4 mg/kg, Emfret Analytics, cat. no. R300) 
or sterile PBS via intraperitoneal injection. After 48 hours, blood was collected 
by cardiac puncture into ACD in a ratio of 6:1 for blood:ACD. 50 µl of whole 
blood were added to QIAzol reagent for RNA isolation. Within 1 hour, the 
remaining blood was centrifuged at 1000 x g at room temperature for 10 
minutes to obtain PPP. A second centrifugation was performed at 10000 x g 
for 10 minutes at room temperature with addition of 1 µM PGE1 to reduce 
 85 
potential activation of residual platelets. Supernatant PPP was collected and 
stored at -80°C until further analysis. 
 
3.20 Argonaute2 immunoprecipitation 
Cells from a megakaryoblastic leukaemia cell line (MEG-01, ATCC) were 
cultured in RPMI-1640 medium (Life Technologies, cat. no. 52400) 
supplemented with 10% FBS, 100 U/ml penicillin and 100 µg/ml streptomycin 
at 37ºC in a humidified atmosphere of 5% CO2. Immunoprecipitation of 
ribonucleoprotein was carried out in 50-100 million MEG-01 cells after lysis in 
500 µl ice cold polysome lysis buffer (5 mM MgCl2, 100 mM KCl, 10 mM 
HEPES, pH 7.0, 0.5% Nonidet P-40) with freshly added 1 mM DTT, 100 U/ml 
RNase inhibitor (Life Technologies) and protease inhibitor cocktail for 15 
minutes. Centrifugation was performed at 14,000 × g at 4°C for 10 minutes. 
The supernatant was mixed with 500 µl of ice-cold NT2 buffer (50 mM Tris, pH 
7.4, 150 mM NaCl, 1 mM MgCl2, 0.05% Nonidet P-40) containing freshly added 
200 U/ml RNase inhibitor, 0.5% vanadyl ribonucleoside, 1 mM DTT, 15 mM 
EDTA and 50 µl mouse anti-human Ago2 (see Table 5) antibody-coated 
sepharose G beads (Dynabeads™ Protein G, ThermoFisher, cat. no. 
10004D). Incubation was carried out overnight at 4°C on a rocking platform. 
The following day, beads were washed five times with ice-cold NT2 buffer and 
used for RNA isolation, RT and qPCR as described above. RNA was isolated 
from washed beads coated with anti-Ago2-antibody or isotype control 
antibody, and from sample not incubated with beads (input). Cq values from 
qPCR analysis were inverted and normalised to each corresponding isotype 
control sample (-DCq). 
 
3.21 Platelet aggregometry with oligonucleotides 
To assess whether different miRNA-targeting oligonucleotide constructs 
induced platelet aggregation, light transmission aggregometry was performed 
using blood from healthy volunteers. Prior to the blood sample being taken, all 
healthy volunteers had abstained from aspirin, NSAIDs and any other anti-
platelet therapy for a minimum of fourteen days. Blood was drawn by 
venepuncture from the antecubital vein using a 19G butterfly needle into a 
syringe pre-filled with tri-sodium citrate (0.32% w/v final; Sigma, cat. no. 
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S1804). After transferring blood to 15 ml conical tubes, samples were 
centrifuged at 175 x g for 15 minutes at room temperature without brake. The 
top two-thirds of supernatant PRP was transferred and kept at 37 ºC until use. 
A PPP sample to serve as background reading was prepared by centrifugation 
at 15000 x g for 2 minutes of remaining upper phase and interphase blood 
from the initial centrifugation. Aggregation in response to different agonists 
was measured in a PAP-8E turbidimetric aggregometer (1200 rev/min, 37 °C; 
Bio/Data, cat. no. 106075), using adenosine diphosphate (ADP, 5 µM; 
Labmedics, cat. no. Chrono-Par 384) or Horm collagen (1 µg/ml) as agonists. 
Oligonucleotides were all reconstituted and diluted to 10 µM in sterile PBS. 
Blank PBS served as a negative control. 200 µl of PRP was placed in a glass 
cuvette containing a stir bar. After brief incubation, 25 µl of agonist, 
oligonucleotide (final concentration 1 µM) or PBS were added, followed by 
immediate initiation of aggregometry reading. Registration was performed for 
40 minutes, recoding maximal and final percent aggregation values. 
 
3.22 Systemic inhibition of miR-21 
Male C57BL/6J mice (Harlan) were treated with cholesterol-conjugated 
antagomiR constructs (Fidelity Systems, custom-made). Sequences were 
designed to target miR-21 (5’-U*C*AACAUCAGUCUGAUAAG*C*U*A*-
Chol*T-3’) or to serve as non-targeting control (5`-
A*A*GGCAAGCUGACCCUGAA*G*U*U*-Chol*T-3’), using a similar design as 
previously used for other miRNAs in our laboratory217,280,281 and in other 
studies.108,118 Constructs were reconstituted in sterile PBS at 37ºC and 
intraperitoneal injections were performed on three consecutive days in a dose 
of 25 mg/kg for the platelet releasate isolation, and 40 mg/kg for the 
aggregometry experiments, the ELISA measurements in plasma and the 
platelet isolation. Seven days after treatment initiation, mice were 
anaesthetised using pentobarbital for blood and tissue collection. Following 
blood collection (see 3.25 and 3.26), heart, kidney and liver were excised and 
washed in sterile PBS, followed by immediate freezing on solid carbon dioxide.  
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3.23 Mouse bone marrow analysis 
Femora were excised, washed, and stored in sterile PBS at 4ºC until 
processing. To isolate bone marrow cells, bones were cleaned of soft tissue 
and briefly washed in 70% ethanol, followed by washing in sterile PBS. Bones 
were then cut at the epiphysis at either end of the bone, exposing the bone 
marrow. Using a syringe pre-filled with sterile PBS and carrying a 25G needle, 
bone marrow cells were flushed out of the bone onto a 100 µm cell strainer 
(Corning, cat. no. 08-771-19) placed onto a 50 ml conical tube. Samples were 
centrifuged for 5 minutes at 350 x g at 4ºC. The supernatant was discarded 
and samples were resuspended in sterile PBS, followed by centrifugation at 
similar conditions. Supernatant was again removed and cells were 
resuspended in sterile PBS and centrifuged. After removal of supernatant 
PBS, cells were lysed in 700 µl QIAzol reagent for RNA isolation. 
 
3.24 Bone marrow immunohistochemistry 
Excised and washed femora were placed in 4% formaldehyde and stored 
at 4°C for three days. Bones were then washed in PBS twice and transferred 
to 0.38M EDTA in H2O, pH 7.0, and incubated at 4°C for three weeks, 
refreshing the EDTA solution twice per week. Following washing with PBS, 
bone tissues were dehydrated through a series of graded ethanol baths and 
then infiltrated with paraffin wax. Bone tissues were then embedded in paraffin 
for subsequent microtome sectioning (5 µm). After placing on glass slides, 
sections were baked at 60°C for 2 hours. Epitope unmasking was achieved 
using hot sodium citrate buffer incubation for 20 minutes. Sections were 
washed three times with PBS-T and incubated with primary antibodies of TGF-
b1 and PF4 or species-matched isotopes overnight at 4°C after blocking with 
10% FBS in PBS-T for 1 hour. Following three 5-minute washes in PBS-T, 
sections were incubated for 1 hour at room temperature with secondary 
antibody (Alexa Fluor 594 and 633, Life Technologies) in 10% FBS/PBS-T, 
according to the source of the primary antibody. Nuclei were stained with DAPI 
(1:1000 dilution) for 10 minutes. Sections were then mounted on a Vecta 
Mount (Vector Laboratories, cat. no. H-5000). Sections were visualised with a 
20X objective using an inverted Nikon NI-E microscope equipped with a 
Yokogawa CSU-X1 spinning disk confocal unit and an Andor iXon 3 EM-CCD 
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camera. Images were acquired using NIS-elements 4.0 software. 
Megakaryocyte counting was performed after blinding of immunostained 
sections using Fiji ImageJ software, version 2.0.0-rc-65/1.51w. 
 
3.25 Murine platelet and leukocyte count 
For flow cytometry-based platelet counting, blood was collected into ACD 
by cardiac puncture. Whole blood was diluted 25x with modified Tyrode-
HEPES buffer at 37ºC. To label platelets, samples were incubated with 5 µl of 
0.2 mg/ml allophycocyanin (APC)-labelled anti-mouse CD41 antibody in the 
dark for 15 minutes at room temperature. Unstained control samples were 
prepared by treatment with an equal amount of modified Tyrode-HEPES 
buffer. After incubation, samples were further diluted to a final dilution of 
1:1000 using the same buffer. Samples were then analysed using an Accuri 
C6 flow cytometer (BD Biosciences) with slow flow. A set volume of each 
sample was analysed to allow for absolute concentration calculation. Events 
corresponding to platelets were identified according to forward and side scatter 
as well as by identification of APC-positive events. Subsequent quantification 
of events was performed post-acquisition using FlowJo v7.4 (Tree Star). For 
miR-21 null mice and littermates, blood cell counting was performed using a 
Hemavet 950FS (Drew Scientific) using proprietary software according to 
manufacturer’s instructions. 
 
3.26 Murine platelet isolation 
For the isolation of washed platelets and the platelet releasate, blood was 
collected into ACD by cardiac puncture. ACD-blood was diluted 1:1 with filtered 
Tyrode-HEPES buffer, supplemented with 1 g/L bovine serum albumin. PRP 
was obtained by centrifugation at 100 x g for 8 minutes at room temperature 
without brake. The top two-third of supernatant was transferred and 
supplemented with 1 µl/mg PGE1, immediately followed by centrifugation at 
800 x g for 10 minutes at room temperature without brake. Supernatant PPP 
was transferred and the platelet pellet was washed twice by resuspending in 
modified Tyrode-HEPES buffer supplemented with 1 µl/mg PGE1, each time 
followed by centrifugation at 800 x g for 10 minutes at room temperature 
without brake. Platelets were then lysed by a freeze-thaw and by subsequent 
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lysis in ice-cold cell lysis buffer (Cell Signaling, cat. no. 9803) supplemented 
with protease inhibitor cocktail and phosphatase inhibitor (PhosSTOP, Roche, 
cat. no. 04906845001). Samples were then incubated on ice for 20 minutes, 
followed by centrifugation at 15000 x g for twenty minutes at 4ºC. The 
supernatant of this lysate was collected and the protein concentration was 
analysed using the BCA protein assay kit. 
 
3.27 Murine platelet releasate isolation 
For isolation of the platelet releasate from murine blood, ACD-blood was 
pooled per four mice, followed by centrifugation at 150 x g for 10 minutes at 
room temperature. The top two-thirds of the supernatant PRP was carefully 
transferred and combined with 10 µM indomethacin and 1 µM PGE1. Platelet 
pellets were obtained by centrifugation of PRP at 500 x g for 10 minutes at 
room temperature without brake. Supernatant PPP was collected, and the 
platelet pellet was washed twice with modified Tyrode-HEPES buffer, 
supplemented with 1 µM PGE1 and 10 µM indomethacin, with centrifugation at 
500 x g for 10 minutes at room temperature in between. The platelet pellet was 
then resuspended in 200 µl of modified Tyrode-HEPES buffer without PGE1 
and indomethacin, and platelets were activated with 1U/ml thrombin, followed 
by incubation for 5 minutes at 37°C under constant shaking. After 5 minutes, 
ice-cold protease inhibitor cocktail was added. Subsequent centrifugation for 
5 minutes at 1000 x g and 1 hour at 20000 x g, both at 4°C, were performed 
to isolate the platelet releasate. Samples were concentrated using Amicon 
3kDa concentration columns. Protein concentration was measured using the 
CBQCA Protein Quantitation Kit. Equal protein amounts were then separated 
by gel electrophoresis and processed for LC-MS/MS analysis as described in 
earlier in this chapter. Injection volumes for each sample were further adjusted 
based on quantitative densitometry of the silver-stained gel. Mass 
spectrometry analysis of the peptides was performed as described in 
paragraph 3.5, with the following differences: raw files were searched against 
UniProt/SwissProt mouse database (2015_02); only oxidation of methionine 
was set as a variable modification; peptide identifications were accepted if they 
could be established at a probability > 85% and protein identifications were 
accepted if they could be established at a probability > 99.9% with at least two 
unique peptides. Proteins with less than five identified spectra in both 
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treatment conditions were excluded from analysis. Gene ontology (GO) 
annotation was performed using the a-granule (GO:0031091), a-granule 
lumen (GO: 0031093) and dense (d) granule lumen (GO:0031089) terms. To 
enhance visualisation, key plasma, cytoskeletal and mitochondrial 
contaminants were removed unless previous detection in the human releasate, 
in previous literature282,283 or by GO annotation. For further illustration of 
effects on TGF-b1, peptide identifications were accepted if they could be 
established at a probability >95% and protein identifications were accepted if 
they could be established at a probability >80% with at least one unique 
peptide. 
 
3.28 Murine platelet aggregometry 
For platelet aggregometry from antagomiR-treated mice, blood was 
collected from the inferior vena cava using syringes containing lepirudin 
(Refludan, 25 μg/ml; Celgene/Bachem, cat. no. H-6618) for aggregometry 
experiments and ELISA measurements. Whole blood was diluted 1:1 with 
modified HEPES-Tyrode’s buffer supplemented with 1 g/l bovine serum 
albumin before centrifugation at 100 x g for 8 minutes at room temperature 
without brake. Half-area 96-well microtiter plates (Greiner Bio-One, cat. no. 
M8060) were pre-coated with hydrogenated gelatine (0.75% w/v; Sigma, cat. 
no. G1393) in PBS to block non-specific activation of blood. 4 μl of vehicle or 
agonist solution was then added to each well: arachidonic acid (AA; 0.03-0.6 
mM; Sigma, cat. no. A8798), Horm collagen (0.1–3 μg/ml; Nycomed, cat. no. 
2067474) and the PAR-4 activating peptide AYPGKF amide (PAR4 amide, 30–
100 μM; Bachem, cat. no. H-6046). To each well, 35 μl of PRP was added and 
the plate was then placed onto a heated plate shaker (Bioshake IQ, Q 
Instruments, cat. no. 1808-1021) at 37°C for 5 minutes mixing at 1200 rpm. 
Light transmission of each well was determined using a 96-well plate reader 
(Sunrise Absorbance Reader, Tecan, cat. no. 30825) at 595 nm. 
 
3.29 In silico target prediction 
Initial target prediction for the human and mouse WAS/Was gene by miR-
21 was performed using mirWalk 2.0284, which combines twelve algorithms to 
identify putative miRNA binding sites within a selected region of a gene. The 
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miRWalk score indicates the number of algorithms that identified putative 
targeting for a specific gene. The 3’UTR was selected for analysis to screen 
for canonical miRNA-mRNA interaction. Predicted targets from this analysis 
were combined with genes that are annotated to be experimentally validated 
targets of miR-21, using the manually curated amiGO database.285 Results are 
presented in Supplemental table 5. As the RNAhybrid platform286 was found 
to identify putative interaction for miR-21, this was further analysed in detail. 
Interaction sites were searched within the entire 3’UTR of the Was gene using 
a minimum energy threshold of -20 kcal/mol. 
 
3.30 Luciferase reporter assays 
The 3’-UTR of the mouse Was gene was cloned into the XhoI and PmeI 
linkers of the dual-luciferase reporter vector psiCHECK-2 (Promega, cat. no. 
C8021; see Figure 44A). The following primer set was used: 
WAS F: AGTCATCTTCCTTCCAGCAA; 
WAS R: TCTCTGTATAGCCCTGGCTG. 
The reporter constructs (200 ng) were transfected together with miR-21 mimic 
(5 nmol/L) or mimic control using Lipofectamine RNAiMAX as described in 3.2. 
Transfections were performed in quadruplicate into HEK293T cells, 12 hours 
after plating 2x105 cells/well in twelve-well plates. After two days, cells were 
harvested in 200 µL Glo Lysis Buffer (Promega, cat. no. E2661) and the 
activities of both Renilla and firefly were measured. Each lysate (20 µl) was 
analysed using Dual-Glo Luciferase reagents (Promega, cat. no. E1910). First, 
Luciferase Reagent II was added to the lysate and luciferase activity was 
measured for 10 seconds. Then, Stop and Glo reagent was added to stop 
firefly luciferase activity and catalyse the Renilla firefly activity. Samples were 
incubated for 2 seconds and then Renilla activity was measured for 10 
seconds. Firefly luciferase activity was normalised to constitutive Renilla 
luciferase activity for each well. Three independent experiments were 
performed. 
 
3.31 Statistical analysis 
MS data were quantified using normalised spectral counts. Qspec287 was 
used to detect differential expression in the fibroblast secretome analysis. 
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Qspec utilizes a hierarchical Bayes estimation of generalised linear mixed 
effects model (GLMM) to share information across proteins, which increases 
the power to detect differential expression. The false discovery rate (FDR) was 
calculated using an Empirical Bayes method and FDR <5% was considered 
significant. All other statistical analyses were performed with Microsoft Excel 
(version 15.41) and GraphPad Prism (version 7.0d). Distribution of data was 
analysed using the Shapiro-Wilk normality test, where a p-value >0.05 was 
considered to indicate normal distribution. When at least one sample group 
within an experiment showed non-normal distribution, non-parametric tests 
were used for the analysis. To reduce the risk of type II statistical error in the 
context of the limited sample size, parametric tests were used to analyse the 
gene expression and immunoblotting data of the transfected CF and their 
secretome. For unpaired data, a t-test with Welch’s correction or Mann-
Whitney ranks test was performed for parametric and non-parametric 
distribution, respectively. For paired data, a paired t-test or Wilcoxon’s 
matched-pairs signed ranks test were used, depending on the normality of 
data distribution. For comparison in more than one dimension, a two-way 
analysis of variance (ANOVA) was used, with post-hoc analysis of individual 
effects by Šidák’s test. Time course data of the CF proliferation assay was 
analysed using the non-parametric Friedman test with post-hoc analysis of 
differences between each targeting and non-targeting transfection type using 
Dunn’s multiple comparisons test. Comparison of gene expression and ECM 
protein abundance between miR-21 null or wild-type mice was performed 
using an FDR approach with the two-stage step-up method of Benjamini, 
Krieger and Yekutieli, with an FDR for significant discovery set to 5%. 
Relationships between the concentrations of plasma proteins and the relative 
quantities of miRNAs were investigated using Pearson correlations with p-
value adjustment (producing q-values) using FDR adjustment according to 
Benjamini, Krieger and Yekutieli. Data are shown as mean ± standard error of 
the mean (SEM) unless stated otherwise. ANOVA results are shown as F 
([degrees of freedom numerator],[degrees of freedom denominator]): [F 
distribution]. P-values or q-values <0.05 were considered significant, with * 


















4.1 MiR-21 and cardiac fibroblasts 
 
4.1.1 In vitro transfection of cardiac fibroblasts 
Primary CFs were isolated from the ventricles of eight mouse hearts, 
followed by transfections with miR-21 mimic or inhibitor (LNA), as well as their 
respective controls.185 To visualise adequate delivery, a fluorescently labelled 
oligonucleotide was transfected using similar reagents and conditions. After 24 
hours, localisation of the labelled miRNA was observed by fluorescence 
microscopy, as shown in Figure 10. The transfected Cy3-labelled miRNA was 
visible outside the nuclei of the CFs, suggesting cytoplasmic localisation.  
4.1.2 Proliferation assay 
Previous literature suggests that miR-21 may have an effect on CF 
apoptosis or survival. We therefore pursued an in vitro strategy to determine 
the effects of miR-21 mimic and inhibitor transfection on their proliferation rate. 
To analyse the effect of miR-21 manipulation, we used an electrical 
impedance-based assay (xCELLigence). This system measures the 
impedance of a low-voltage current between two gold electrodes in the well of 
an adapted cell culture plate, where the magnitude of impedance (represented 
as ‘cell index’) is dependent on cell number and size as well as their 
attachment. 
Figure 10. Transfection of cardiac fibroblasts. Isolated murine CFs were 
transfected with a microRNA labelled with red fluorescent dye (Dy547-mimic) to 
confirm transfection efficiency by microscopy. Nuclei were visualised by 4′,6-
diamidino-2-phenylindole (DAPI) staining. Transfected cells displayed signal around 
the nuclei, indicating cytoplasmic localisation. Shown images are representative of 




Figure 9. Transfection of cardiac fibroblasts. Isolated murine cardiac
fibroblasts were transfected with a microRNA labell d with red fluorescent dye
(Dy547-mimic) to confirm transfection efficiency by microscopy. Nuclei were
visualised by 4′,6- iamidino-2-phe ylindole (DAPI) staining. Transfected cells
displayed signal around the nuclei, indicating intracytoplasmatic localisation.
Shown images are repr sentative of the n=2 for this transfection. Scale bar
denotes 50 µm.
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Primary CFs were isolated from wild-type mice and transfected with miR-
21 mimic or LNA-21 and their respective controls. The cell index was recorded 
every 30 minutes up to 25 hours and the slope was recorded between 4 and 
15, 20 or 25 hours (see Figure 11, panel A and B). Normal distribution of 
these measurements was confirmed using a Shapiro-Wilk normality test 
(p=0.29 and 0.86 for miR-21 mimic and LNA-21, respectively). Two-way 
ANOVA analysis of the three slope recordings over time after miR-21 mimic 
transfections identified a significant effect of time (F (2,12)=13.7, p=0.0008), 
transfection type (F (1,6)=63.0, p=0.0002) and an interaction between these 
two variables (F (2,12)=13.7, p=0.0008). Post-hoc simple main effects analysis 
using Šidák’s multiple comparisons test showed significantly higher slopes in 
miR-21 mimic-transfected cells compared to control transfections at 15 hours 
(p<0.001), 20 hours (p<0.001) and 25 hours (p=0.0027). Similar analysis in 
LNA-transfected cells identified a significant effect of time (F (2,12)=15.4, 
p=0.0005) but not for transfection type (F (1,6)=3.4, p=0.11). A significant 
interaction between both variables was observed (F (2,12)=15.4, p=0.0005), 
with main effects analysis showing significant difference in slope only at 15 
hours (p=0.0262), but not at 20 hours (p=0.21) or 25 hours (p=0.93). 
 
30-minute readings of cell index, normalised to background readings, are 
represented in Figure 11, panel C and D. Cell confluence was reached after 
25 hours, limiting the ability to proliferate. Recordings beyond this point are 
therefore not included in the analysis. As the cell index data were not normally 
distributed, analysis of these readings was performed using the non-
parametric Friedman test with subsequent comparisons between the 
respective transfection types using Dunn’s multiple comparisons test. The 
Friedman test identified statistically significant differences across groups 
(p<0.0001) and subsequent comparison between control mimic and miR-21 
mimic transfection and LNA-control and LNA-21 identified significant 
differences for both (p=0.0095 and p<0.0001, respectively). Visual inspection 
of both graphs highlights in both mimic and LNA transfections that the 
difference in proliferation rate is most pronounced between 15 and 20 hours,  
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miR-21 mimic LNA-21 (inhibition)A B
Figure 10. Cardiac fibroblast proliferation after transfections. Murine
cardiac fibroblasts were transfected with miR-21 mimic or inhibitor (LNA-21)
and plated in a impedance-based proliferation assay plate (xCELLigence) for 25
hours. This method records a cell index value that is considered a readout of
cell number, size and attachment. Analysis of the normalised slope at different
time points is shown in A and B for miR-21 mimic and inhibitor, respectively.
Two-way ANOVA and post-hoc testing at 15, 20 and 25 hours identified a
significantly higher slope after miR-21 mimic transfection at all three time
points, whilst miR-21 inhibitor showed a significantly reduced proliferation only
after 15 hours. Normalised cell index readings over time, recorded each 30
minutes, showed significantly increased and reduced proliferation with miR-21
mimic and inhibitor transfection, respectively (C and D; Friedman test with post-
hoc Dunn's multiple comparisons test). Four biological replicates were analysed
for each condition.
control miR-21 LNA-21control











































Figure 11. Cardiac fibro last proliferation after transfections. Murine cardiac 
fibrobl sts were transfect d with miR-21 mimic or inhib tor (LNA-21) and plated in a 
impedanc -based roliferation assay pl te (xCELLigence) for 25 hours. This 
method records a cell index value that is considered a readout of cell number, size 
and attachment. The slope of the cell i dex over time, normalised t  the slop  of the 
control transfection for each biological replicate, is shown in A and B for miR-21 
mimic and inhibitor, respectively. Two-way ANOVA and post-hoc testing for the 
slope during analysis over 15, 20 and 25 hours identified a significantly higher slope 
after miR-21 mimic transfection at all three time points, whilst miR-21 inhibitor 
showed a significantly reduced proliferation only after 15 hours. Normalised cell 
index readings over time, recorded each 30 minutes, showed significantly increased 
and reduced proliferation with miR-21 mimic and inhibitor transfection, respectively 
(C and D; Friedman test with post-hoc Dunn's multiple comparisons test). Four 






































































































































Figure 11. MicroRNA levels after cardiac fibroblast transfections. RNA was
isolated from cardiac fibroblasts, transfected with miR-21 mimic or control (A)
and LNA-21 or LNA-control (B), and harvested 48 hours after TGF-β1 or vehicle
control (unstimulated) treatment. MicroRNA levels were determined by qPCR,
using sno202 as a reference gene. Statistical analysis was performed using























Figure 12. MicroRNA levels after cardiac fibroblast transfections. RNA was 
isolated from CFs, transfected with miR-21 mimic or control (A) and LNA-21 or LNA-
control (B), and harvested 48 hours after TGF-β1 or vehicle control (unstimulated) 
treatment. MicroRNA levels were determined by qPCR, using sno202 as a reference 




as also identified by the analysis of the slope coefficients. As the slope 
decreases, differences in normalised cell indices between both groups 
decrease as well. In conclusion, these data indicate that miR-21 significantly 
increases the proliferation rate of CF in vitro within a 24-hour time period. 
 
4.1.3 Validation of in vitro transfection and TGF-b1-treatment 
To determine effects of miR-21 on CF gene expression and protein 
secretion, miR-21 mimic, inhibitor or their respective controls were transfected 
into CFs, followed by treatment with recombinant TGF-β1 or a vehicle control 
(see Figure 6, panel A). Four biological replicates were used for each 
condition. Cells and their conditioned media were harvested after 48 hours of 
incubation. At this time, TGF-b1-treated CFs appeared larger and more 
elongated, suggesting induction of a myofibroblast-like phenotype. 
 
To determine the level of overexpression or knockdown after 
oligonucleotide transfection, miRNA levels were determined by qPCR in RNA 
isolated from CFs (see Figure 12). Transfection of miR-21 mimic resulted in 
increased expression levels compared to the control mimic (average paired 
fold change (FC) 17.2 and 12.8; paired t-test p=0.003 and p<0.001 for TGF-
β1-untreated and treated cells, respectively), whilst inhibition of miR-21 by 
transfection of inhibitor (LNA-21) reduced the expression of miR-21 in 
comparison to transfection of a non-targeting LNA sequence (FC 0.02 and 
0.03; p=0.042 and p=0.036). Levels of other fibroblast miRNAs did not show 
major differences between miR-21 overexpression or inhibition and their 
respective controls. 
 
In addition to the observed phenotypical changes upon TGF-β1 
treatment, several gene expression changes indicated the induction of a 
myofibroblast-like phenotype. At the transcriptional level, significant induction 
of miR-199a-3p could be observed (FC 1.34; p=0.004), whereas a marked 
reduction was found for expression levels of miR-30c (FC 0.51; p<0.0001). 
Levels of miR-21 were not significantly different between TGF-β1-treated and 
-untreated cells after control transfection (FC 1.05; p=0.59). Increased 
transcript levels were observed for genes commonly used as markers of the 
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myofibroblast-like phenotype (see Figure 13), such as a-SMA (Acta2; FC 
1.62; paired t-test p=0.005) and periostin (Postn; FC 3.20; p=0.014), as well 
as for the TGF-β signalling marker CTGF (FC 1.32; p=0.026) and for the gene 
transcript of TGF-β1 itself (FC 1.23; p=0.017).288,289 Conversely, transcript 
levels of the Igfbp4 gene, coding for insulin-like growth factor-binding protein 
4 (IBP4), were markedly lower in TGF-β1-treated cells (FC 0.25; p<0.0001). 
This downstream effect of TGF-β1 was previously reported in periosteal 
connective tissue.290 Gene expression for interleukin-11 was assessed in light 
of the recent identification as a downstream mediator of TGF-β signalling (see 
section 1.1.3.2); its expression levels in presence and absence of TGF-β1 
treatment remained below the limit of detection (average Cq 35). 
 
4.1.4 Differential regulation of proteins following transfection 
To determine effects of miR-21 on production of ECM proteins, the 
conditioned media of CFs were collected 48h after transfections, as mentioned 
before. Secreted proteins were prepared for analysis by mass spectrometry 
(see Figure 6, panel B). Overall, 144 ECM proteins were identified (see 
Supplemental table 1). Amongst the most abundantly secreted proteins were 
collagen I and III, fibronectin and fibulin-2, all common core constituents of the 
extracellular matrix.8 In line with the previously described induction of periostin 
gene expression, markedly higher spectral counts were identified in the 
conditioned media of TGF-β1-treated cells compared to control-treated cells 
for this protein after normalisation to total spectral counts (Figure 14). 
Strikingly, in comparison to previous analysis of murine CF secretome 
changes upon mimic or inhibitor transfection for a different miRNA185, there 
were relatively few differences after transfection of miR-21 mimic or LNA-21 
(see Figure 15). This apparent lack of miR-21 effects on ECM secretion was 
observed in both TGF-b1-stimulated and –unstimulated cells. 
 
Upon miR-21 mimic transfection, granulin (GRN; log2 FC 1.08; 
FDR=0.0003) and IBP4 (log2 FC 1.25; FDR<0.001) were more abundant in 
media from unstimulated CF (see Figure 15 and 16). In TGF-b1-stimulated 
CFs, granulin showed an increased abundance as well (log2 FC 0.89; 
FDR<0.0001), yet with a less than two-fold change. Similarly, cathepsin L1 
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(CATL1; log2 FC 0.59; FDR=0.0106) and the a1 chain of collagen XI (COBA1; 
log2 FC 0.44; FDR=0.0240) increased significantly but less than two-fold.  
Gene expression after TGF-β1 treatment
Figure 12. Gene expression after TGF-β1 treatment. In RNA isolated from
cardiac fibroblasts, gene expression levels for several markers of TGF-β
signalling and a myofibroblast-like phenotype were significantly induced. Ppia
was used as reference gene transcript. Analysis by paired t-tests, n=8 for each
treatment type.










































































Figure 13. Periostin levels in the fibroblast secretome after TGF-β1
treatment. Mass spectrometric analysis of periostin showed markedly higher
levels after TGF-β1 treatment. Spectral counts were normalised to the total
spectral count for each sample. Analysis by Wilcoxon matched-pairs signed
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Figure 14. Periostin levels in the fibroblast secretome after TGF-β1 treatment. 
Mass spectrometric analysis of periostin howed markedly higher levels after TGF-β1 
treatment. Spectral counts w re normalised to the total spectral count for each 
sample. Analysis by Wil oxon atched-pair  signed ranks test, n=8 per condition. 
Figure 13. Gene expression after TGF-β1 treatment. In RNA isolated from CFs, 
gene expression levels for several markers of TGF-β signalling and a myofibroblast-
like phenotype were significantly induced. Ppia was used as reference gene 
transcript. Analysis by paired t-tests, n=8 for each treatment type. 
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Figure 14. Murine cardiac fibroblast secretome after miR-21 transfections.
Volcano plots show proteins identified in the secretome of unstimulated and
TGF-β1-stimulated cells after transfection of miR-21 mimic or LNA-21 (miR-21
inhibitor). Fold changes constitute the ratios after miR-21 overexpression or
inhibition compared with a corresponding control transfection. FDR was
calculated using an Empirical Bayes method and an FDR< 0.05 was considered
significant; n=4 for each comparison. GRN, granulin; IBP4, insulin-like growth
factor-binding protein 4; VCAM1, vascular cell adhesion molecule-1; LG3BP,
















Figure 15. Murine cardiac fibroblast secretome after miR-21 transfections. 
Volcano plots show proteins identified in the secretome of unstimulated and TGF-β1-
stimulated cells after transfection of miR-21 mimic or LNA-21 (miR-21 inhibitor). Fold 
changes constitute the ratios fter miR-21 overexpression or inhibition compared with 
a corresponding co trol transfection. FDR was calculated using an Empirical Bayes 
method d an FDR< 0.05 was considered significant; n=4 for each comparison. 
GRN, gra ulin; IBP4, insulin-like growth factor-binding protein 4; VCAM1, vascular 
cell adhesion molecule-1; LG3BP, galectin-3 binding protein; CATL1, cathepsin L1; 
COBA1, collagen XI, ⍺1 chain. 
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Figure 16. Differentially expressed proteins in the cardiac fibroblast secretome 
after miR-21 overexpression or inhibition. Box plots are shown for proteins that 
were identified as differentially regulated in at least one of the studied conditions. The 
Y-axis represents the normalised spectral count (NSpC). The false discovery rate 
(FDR) was calculated using an Empirical Bayes method, with an FDR <0.05 
considered statistically significant; n=4 for each condition. TGF-β1 - and + 
















































































Figure 15. Differentially expressed proteins in cardiac fibroblast
secretome after miR-21 overexpression or inhibition. Box plots are shown
for proteins that were identified as differentially regulated in at least one of the
studied conditions. The Y-axis repr sents the normalised spectral count. The
false discovery r t (FDR) w s calculated using an Empirical Bayes method,
with an FDR <0.05 con idered statistically significant; n=4 for each conditio .
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Upon miR-21 inhibition, two consistently affected proteins were vascular cell 
adhesion molecule-1 (VCAM1) and galectin-3 binding protein (LG3BP), both 
increased by more than two-fold in the secretome of unstimulated (VCAM1: 
log2 FC 1.50; FDR<0.0001; LG3BP: log2 FC 1.73; FDR<0.0001) and TGF-b-
stimulated CFs (VCAM: log2 FC 1.25; FDR<0.0001; LG3BP: log2 FC 1.73; 
FDR<0.0001). There was no detectable change for these proteins upon miR-
21 mimic transfection. Conversely, granulin abundance was increased in the 
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Figure 16. Twenty most abundant proteins in the cardiac fibroblast
secretome. Mass spectrometric identification of proteins in the conditioned
media showed major overlap with other studies using a similar approach.
Interestingly, no differences were observed between miR-21 overexpression or
inhibition and their respective controls. This was equally the case in TGF-β1-
unstimulated (TGF-β1 -) and -stimulated (TGF-β1 +) cells. See Table 5 for
abbreviations and for full list of identified proteins.
Co l mi 1
Figure 17. Twenty most abundant proteins in the cardiac fibroblast secretome. 
Mass spectrometric identification of proteins in the conditio ed media showed major 
overlap wit  other studies using a similar approach. Interestingly, no differences were 
observ d between miR-21 overexpres ion or inhibitio  and their r spective cont ols 
(four iol gical replicat  for each condition). This was equally the case in TGF-β1-
unstimulated (TGF-β1 -) and -stimulated (TGF-β1 +) cells. See Supplemental table 1 
for a breviations and for a li t f i tifi  r t i . 
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similar direction as for miR-21 mimic transfection (log2 FC: 1.87; 
FDR<0.0001). 
 
Consistent with previous analyses in our own group as well as by 
others185,291, the most abundant proteins that were detected across the 
different samples included several subtypes of collagens, with collagen I and 
III having the highest average spectral counts, as well as fibronectin. In 
addition, as shown in Figure 17, several proteins associated with crosslinking 
these core proteins were also highly abundant amongst the identified spectra. 
These included several basement membrane proteins such as collagen type 
IV, laminin and perlecan (PGBM/Hspg2). Strikingly, no significant difference 
was observed for any of these proteins after miR-21 overexpression or 
inhibition.  
 
In conclusion, miR-21 mimic and inhibitor transfections in murine CF 
resulted in increased secretion of IBP4 and granulin, and LG3BP, VCAM1 and 
granulin respectively. These transfections did not significantly alter the 
secretion of major extracellular matrix proteins. 
 
4.1.5 Validation of proteomics data by immunoblotting  
To assess differences in protein abundance in the CF secretome using 
an additional technique, immunoblotting was performed with concentrated and 
deglycosylated conditioned medium samples. Analysing four different proteins 
showed stable detection across all samples, with most striking differences 
appearing between TGF-β1-treated and -untreated samples (see Figure 18). 
Densitometry was performed to evaluate relative differences in intensity on the 
blots (see Figure 19).  
 
Consistent with our gene expression and proteomics data, increased 
periostin secretion in response to TGF-β1 treatment was also observed using 
immunoblotting of concentrated conditioned media (FC: 4.51 and 10.26; 
p=0.0004 and p<0.0001 for mimic- and LNA-transfected samples, 
respectively). A similar increase was observed for the small leucine-rich repeat 
proteoglycan biglycan (Bgn/PGS1; FC: 3.46 and 6.96; p=0.0020 and 0.0015), 
which has previously been reported292, whilst no significant effect was 
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observed for basement membrane protein laminin g1 (Lamc1; FC: 0.80 and 
0.97; p=0.11 and 0.55) or another small leucine-rich repeat proteoglycan, 
decorin (Dcn/PGS2; FC: 1.13 and 0.89; p=0.38 and 0.11).  
 
In line with our proteomics findings, immunoblotting did not show major 
changes in protein levels after miR-21 mimic or inhibitor transfections in the 
secretome of either TGF-β1-treated and -untreated cells. Whilst the  g1 chain 
of laminin showed a significant increase after miR-21 overexpression in 
untreated CF (FC: 1.70; p=0.0500), this was not seen after TGF-β1 stimulation 
(FC: 0.91; p=0.32). Furthermore, miR-21 inhibition, both in TGF-β1-untreated 
and -treated cells, did not show an opposite effect for this protein (FC: 1.36 
and 1.22; p=0.15 and 0.14, respectively), suggesting non-specific changes. No 
significant changes were seen for any of the other analysed proteins. 
Altogether, these results indicate a marked effect of TGF-β1 on the induction 
of a myofibroblast-like phenotype but no modulation by either the miR-21 




Figure 17. Immunoblots of cardiac fibroblast secretome after
transfections. Immunoblotting was performed with concentrated and
deglycosylated conditioned media for several ECM proteins. Concomitant
Ponceau S stain is shown at the bottom. C = control mimic / LNA; 21 = miR-21
mimic / LNA-21. TGF-β1 + / - indicates treatment 48 hours prior to conditioned
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Cardiac fibroblast secretome
Figure 18. Immunoblots of cardiac fibroblast secretome after transfections. 
Immunoblotting was performed with concentrated and deglycosylated conditioned 
media for several ECM proteins. Concomitant Ponceau S stain is shown at the 
bottom. Four biological replicates were analysed for each condition. C = control mimic 
/ LNA; 21 = miR-21 mimic / LNA-21. TGF-β1 + / - indicates treatment 48 hours prior 






miR-21 mimic LNA-21 (inhibition)
Figure 18. Densitometry of cardiac fibroblast secretome immunoblots.
Relative differences in optical density were determined in the immunoblot
analysis of the fibroblast secretome. Whereas a marked effect of TGF-β1
treatment was seen for periostin and biglycan, no significant differences were
found between miR-21/LNA-21 and their respective controls. Statistical analysis
was performed using paired t-tests, with n=4 for transfection comparisons and
n=8 for effects of TGF-β1 treatment. TGF-β1 + / - indicates treatment 48 hours
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Figure 19. Densitometry of cardiac fibroblast secretome immunoblots. Relative 
differences in optical density were determined in the immunoblot analysis of the 
fibroblast secretome. Whereas a marked effect of TGF-β1 treatment was seen for 
periostin and biglycan, no significant differences were found between miR-21/LNA-21 
and their respective controls. Statistical analysis was performed using paired t-tests, 
with n=4 for transfection comparisons and n=8 for effects of TGF-β1 treatment. TGF-
β1 + / - indicates treatment 48 hours prior to conditioned media collection. AU, artificial 
units; n.s., not significant. 
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4.1.6 Differential expression of genes after transfections 
MiRNAs can repress the expression of genes by direct targeting, leading 
to either translational repression or degradation of mRNA strands (see Figure 
2).93 Our previously mentioned study, also using miRNA transfections in CF, 
showed a marked effect on gene expression levels of several ECM proteins 
upon miR-29 overexpression.185 To validate the findings of our current 
secretome analysis, we studied corresponding gene expression of the most 
abundantly secreted proteins, as well as those that showed differential 
regulation in the conditioned media upon transfection. 
 
In general, a similar pattern was seen for gene expression changes as 
was observed for protein abundance: there were profound effects of TGF-β1 
treatment, but few changes with miR-21 overexpression or inhibition. Induction 
of a-SMA, periostin, CTGF and TGF-b1 expression by TGF-β1 treatment have 
been described earlier in this chapter (Figure 13). To determine expression 
levels of genes encoding proteins that significantly changed in the secretome 
analysis after miR-21 manipulation, further qPCR analysis was performed. 
Resulting fold changes of gene expression levels are shown in the context of 
protein changes in Figure 20. The largest fold change was observed for the 
expression level of LG3BP (Lgals3bp) after LNA-21 transfection, both in TGF-
β1-treated and –untreated cells, in line with the proteomics analysis (FC: 2.63 
and 2.64; p=0.0091 and 0.0033, respectively). Concomitant reduction of 
Lgals3bp expression after miR-21 mimic transfections however failed to reach 
statistical significance (FC: 0.92 and 0.85; p=0.52 and 0.35). A similar pattern 
was seen for expression of granulin, significantly decreasing after miR-21 
overexpression in TGF-β1-treated cells (Grn; FC: 0.86; p=0.0247), whereas 
the concomitant upregulation fell short of statistical significance (FC: 1.29 and 
1.18; p=0.20 and 0.21). Expression of cathepsin L1 showed a minor but 
significant induction after miR-21 inhibition in TGF-β1-treated cells (FC: 1.11; 
p=0.0191), in contrast with the proteomics analysis where significantly higher 
protein levels of cathepsin L1 were seen after miR-21 mimic transfection. 
 
In addition to genes encoding differentially regulated proteins, we also 
performed qPCR analysis for expression levels of the twenty most abundantly 
identified proteins, comprising a panel of key ECM constituents (see Figure 
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21). In general, greater effects were observed with miR-21 mimic transfections 
than with LNA-21. Of these, the most striking induction was seen for periostin 
after miR-21 overexpression in both stimulated and unstimulated cells (FC: 
4.86 and 5.60; p<0.0001 and p<0.0001). Expression after LNA-21 transfection 
was not affected. The a1 chain of collagen I (Col1a1; FC: 1.27 and 1.51; 
p=0.0.0150 and 0.0015), the a2 chain of collagen V (Col5a2; FC: 1.57 and 
1.68; p=0.0058 and 0.0005), fibronectin (Fn1; FC: 1.24 and 1.43; p=0.0448 
and 0.0013) and fibrillin-1 (Fbn1; FC: 1.22 and 1.32; p=0.0219 and 0.0036) all 
showed expression changes in a similar direction, yet to a lesser extent. No 
corresponding reduction was seen for their expression levels after miR-21 
inhibition. The greatest decrease after miR-21 mimic transfection was 
observed for decorin (Dcn; FC: 0.53 and 0.48; p<0.0001 and p=0.0011) and 
biglycan (Bgn; FC: 0.81 and 0.85; p=0.0199 and 0.0122), with no concomitant 
induction after miR-21 inhibition. 
 
In summary, gene expression in CF showed major changes upon 
treatment with TGF-β1. Overexpression of miR-21 induced expression for a 
number of ECM genes, whilst the effect on periostin was most striking. These 
changes did not result in a concomitant change of protein levels as analysed 
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Figure 19. Fibroblast gene expression changes after transfection and their
corresponding secretome protein levels. Fibroblast expression was
determined for genes encoding proteins that showed a significant change in the
secretome analysis. Gene expression levels (bars) represent paired fold
changes over the respective controls as analysed in the lysed fibroblasts, using
Ppia as the reference gene transcript. Asterisk below bars denote p-values for
the comparisons with the respective controls, with * <0.05 and ** <0.01. Protein
levels (nodes) indicate fold changes over respective controls as determined by
mass spectrometric analysis of the fibroblast secretome after transfection. An




































































S/MS (FDR>0.05)miR-21 mic LNA-21
Figure 20. Fibroblast gene expression changes after transfection and their 
corresponding secretome protein levels. Fibroblast expression was determined 
for genes encoding proteins that showed a significant change in the secretome 
analysis. Gene expression levels (bars) represent paired fold changes over the 
respective controls as analysed in the lysed fibroblasts, using Ppia as the reference 
gene transcript. Four biological replicates were analysed for each condition. Asterisk 
below bars denote p-values for the comparisons with the respective controls, with * 
<0.05 and ** <0.01. Protein levels (nodes) indicate fold changes over respective 
controls as determined by mass spectrometric analysis of the fibroblast secretome 



























































































































































Figure 20. Gene expression after miR-21 transfections in cardiac
fibroblasts. Gene expression levels in cardiac fibroblasts were determined by
qPCR to evaluate effects of miR-21 overexpression (A) or inhibition (B). Gene
transcripts corresponding to the twenty most abundantly detected proteins in the
secretome were assessed. Expression is represented relative to corresponding
control samples. Ppia was used as reference gene transcript. Statistical
analysis was performed using a paired t-test, n=4 for each condition.































































































































Gene expression after transfection
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Gene expression after transfection





Figure 21. Gene expression after miR-21 transfections in cardiac fibroblasts. 
Gene expression levels in CFs were determined by qPCR to evaluate effects of miR-
21 overexpression (A) or inhibition (B). Gene transcripts corresponding to the twenty 
most abundantly detected proteins in the secretome were assessed. Expression is 
represented as the fold change between miR-21 mimic and control mimic 
transfection (A), or between LNA-21 and LNA-control transfection (B). The analysis 
was performed separately for TGF-β1-untreated and -treated cells. Ppia was used 
as reference gene transcript. Statistical analysis was performed using a paired t-test, 
n=4 for each condition. 
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4.1.7 Cardiac extracellular matrix in miR-21 null mice 
As described in previous paragraphs, pharmacological manipulation of 
CF in vitro showed an effect on their proliferation but did not result in any major 
effects on ECM protein secretion, as would be expected based on previous in 
vivo studies on miR-21 and on our own previous work using this approach for 
other miRNAs associated with fibrosis. Therefore, we aimed to further study 
the effects of miR-21 ablation on the cardiac ECM using miR-21 null hearts 
(see Figure 22), collected from six miR-21 null mice and six wild-type 
littermates. To determine whether there was an effect on miRNA and gene 
expression in these hearts, RNA was isolated from the apex and analysed by 
RT-qPCR. Furthermore, to evaluate changes in the composition of the ECM in 
these hearts, we performed mass spectrometry analysis of ECM proteins 
extracted using our 3-step method that has been developed for this 
purpose.8,293,294 
 
As shown in Figure 23 (panel A), several abundant miRNAs were 
analysed. Whilst absence of miR-21 was confirmed, none of the other 
analysed miRNAs were significantly dysregulated when compared to wild-type 
hearts. To evaluate potential changes in expression of genes that were studied 
in the CF analysis, we performed qPCR analysis for the twenty most 







Figure 21. MicroRNAs, gene expression and the cardiac ECM in miR-21
null mice. Hearts were dissected for RNA isolation and subsequent RT-qPCR
analysis for gene and miRNA expression. For three-step ECM protein
enrichment, another tissue piece from the ventricles was dissected, followed by
sequential incubation in sodium chloride (NaCl), sodium dodecyl sulphate
(SDS) and guanidine hydrochloride (GuHCl) buffers. Isolated proteins were
then deglycosylated, digested and analysed by mass spectrometry.
Figure 22. MicroRNAs, gen  xpression and the cardiac ECM in miR-21 null 
mice. Hearts were dissected for RNA isolation and subsequent RT-qPCR analysis 
for gene and miRNA expression. For three-step ECM protein enrichment, another 
tissue piece from the ventricles was dissected, followed by sequential incubation in 
sodium chloride (NaCl), sodium dodecyl sulphate (SDS) and guanidine 
hydrochloride (GuHCl) buffers. Isolated proteins were then deglycosylated, digested 
and analysed by mass spectrometry. 
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for the proteins that showed a significant change in any of the transfection 
conditions were assessed. To account for multiple testing, an FDR approach 
was used to determine statistical significance of differences in gene 
expression, with the Q set to 5% (see Supplemental table 2). Fold changes 
across proteins were limited, with the greatest changes observed for the a4 
chain of laminin (Lama4; FC: 1.14; q=0.1100) and for secreted protein acidic 
and rich in cysteine (Sparc; FC: 1.27; q=0.2983). However, none of the 
comparisons yielded a significant result. 
 
To determine changes at protein level, analysis of the cardiac ECM was 
performed. In brief, ventricular tissue was sequentially incubated in 0.5M NaCl 
buffer, 0.1% SDS buffer and 4M GuHCl buffer. Proteins in the NaCl and GuHCl 
fractions were then deglycosylated, followed by analysis by LC-MS/MS. 
Identified proteins were annotated using the Matrisome database for murine 
ECM proteins.269 In total, twenty-three and thirty-two proteins showed 
consistent detection across samples in the NaCl and GuHCl extracts, 
respectively (see Figure 23, panel B). Of these fifty-five proteins, significant 
overlap was seen with the twenty most highly identified proteins secreted by 
CF in vitro, as described earlier in this chapter. To determine differences 
between wild-type and miR-21 null extracts, a similar FDR approach was used 
as for the gene expression analysis. No significant protein changes were 
observed for the fifty-five analysed proteins (see Supplemental table 3).   
 
In summary, combined analysis of gene expression and the ECM of the 
miR-21 null heart did not reveal significant changes. These findings are in line 
with previous findings that reported no phenotypical or functional differences 






Figure 22. Comparison of miRNA and gene expression and ECM protein
abundance in miR-21 null hearts. A: MiR-21 levels were undetectable in the
heart, whilst other cardiac miRNAs did not show a significant difference in
expression. Similarly, expression of selected genes based on cardiac fibroblast
transfection experiments were unaltered. U6 and Actb were used as reference
transcripts, respectively. B: Levels of fifty-five ECM proteins identified in the
NaCl and GuHCl buffer extracts were not significantly different between hearts
from miR-21 null mice and littermate controls. There was marked overlap in
identified proteins when compared with the cardiac fibroblast secretome
analysis. An FDR-based approach was used for all three analyses with q<0.05
deemed statistically significant. See Table 6 and 7 for abbreviations.
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Figure 23. Comparison of microRNA and gene expression and ECM protein 
abundance in miR-21 null hearts. A: MiR-21 levels were undetectable in the heart, 
whilst other cardiac miRNAs did not show a significant difference in expression. 
Similarly, expression of selected genes based on CF transfection experiments were 
unaltered. U6 and Actb were used as reference transcripts, respectively. B: Levels 
of fifty-five ECM proteins identified in the NaCl and GuHCl buffer extracts were not 
significantly different between hearts from miR-21 null mice and littermate controls. 
There was marked overlap in identified proteins when compared with the CF 
secretome analysis. An FDR-based approach was used for all three analyses with 
q<0.05 deemed statistically significant. n=6 vs. 6 for both genotypes in both analyses. 
See Supplemental table 2 and 3 for abbreviatio s. 
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4.2 Circulating miR-21 and associated proteins in the Bruneck 
study 
 
Given the results of previous publications and our own analysis in CF, we 
proceeded to evaluate potential indirect effects of miR-21 in the context of 
cardiac fibrosis. MiR-21 is ubiquitously expressed across tissues and 
abundant in the circulation. Furthermore, as discussed in the introduction, 
previous studies of miR-21 consistently show that there is a pronounced effect 
of miR-21 manipulation only in a context of injury, where systemic effects are 
likely to be at play. Therefore, we hypothesised that there are potential indirect 
effects that may affect the outcome of pharmacological inhibition of miR-21. 
Several past studies in our group have assessed circulating miRNAs in 
samples from the Bruneck study. To investigate potential systemic effects of 
miR-21, additional analyses were performed in the Bruneck 2000 follow-up 
and new samples were collected during the 2015 evaluation to facilitate the 
study of miR-21 in the circulation. 
 
4.2.1 Plasma proteome screening for correlation with miR-21 
We first analysed correlations of miR-21 with circulating proteins 
previously associated with CVD and inflammation. In plasma samples from the 
Bruneck study year 2000 follow-up (n=660), levels of miR-21 were measured 
by qPCR, whilst proteins were analysed using a combination of predefined 
PEA panels, LC-MS/MS and ELISA (for PF4 and PPBP). 
 
Of the PEA panels, 132 proteins were in the stable detection range. 
When combined with measurements of the mass spectrometry-based 
PlasmaDive panel, a total of 229 proteins were quantified across the cohort. A 
graphical representation of the individual correlation coefficient and their 
statistical significance is shown in Figure 24, with proteins of potential interest 
highlighted. Interestingly, there was remarkable correlation between levels of 
miR-21 and two markers of platelet activation, PF4 (Pearson r: 0.73, q=3.0x10-
109) and PPBP (Pearson r: 0.69, q=4.3x10-94). Furthermore, the correlating 
proteins included several pro-fibrotic factors: high levels of correlation with 
miR-21 were found for the b unit of platelet-derived growth factor (PDGFb; 
Pearson r: 0.73, q=1.0x10-110) and epidermal growth factor (EGF; r: 0.72, 
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q=2.2x10-104). A striking correlation with miR-21 was also seen for the LAP of 
TGF-b1 (LAP-TGF-b1; r: 0.65, q=2.4x10-79), as well as other factors that have 
previously been linked to fibrosis, including eukaryotic translation initiation 
factor 4E-binding protein 1 (4E-BP1; r: 0.63; q=5.6x10-74) and tumour necrosis 
factor superfamily 14 (TNFSF14; r: 0.56; q=1.7x10-55).295,296 
 
As previously discussed in the introduction and as also implied by our 
observations in CF, TGF-b1 is widely described as a master regulator of 
fibrosis. Therefore, the correlation between TGF-b1 and miR-21 in the 
circulation (see Figure 25, panel A) warranted further investigation, in 
particular in relation to its release by platelets. 
 
4.2.2 Effects of plasma preparation on biomarkers 
As described in the paragraphs above, analysis in the Bruneck 2000 
follow-up showed a significant correlation between plasma levels of miR-21 
and LAP-TGF-β1. Furthermore, both were strongly correlated to markers of 
platelet reactivity. To further validate this association, new plasma samples 
were collected during the 2015 evaluation of the Bruneck cohort (see 
Appendix 1). Given the importance of plasma sample preparation, as we 
recently summarised in a review article (see Appendix 3), we used a tailored 
protocol to prepare PPP samples for additional analysis of miR-21 and 
associated proteins (see Figure 9, panel A).96 
 
To screen for differences between conventional plasma and PPP, the 
same two panels of PEA were analysed for low-abundant proteins in the 
collected PPP (n=332). Measurements of miR-21 levels were performed by 
qPCR. Pearson correlations and concomitant FDR-adjusted p-values (q-
values) were calculated between miR-21 and all proteins that were measured 
by PEA, as shown in Figure 24, panel B. All nineteen significantly correlating 
proteins in PPP had also been returned as such in the analysis using 
conventional plasma from the year 2000 follow-up. The opposite was however 
not the case; several proteins that showed high correlations in conventional 
plasma did not show the same in PPP (Figure 26). Among them, LAP-TGF-
β1 showed a striking difference in correlation with miR-21, with a Pearson r of  
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Figure 23. Correlation of miR-21 with pro-fibrotic factors and markers of
platelet activation in the Bruneck study cohort. Using a proteomics screen,
Pearson coefficients for the correlation of miR-21 with platelet activation
markers (PF4, PPBP) and LAP-TGF-β1, as well as other circulating proteins
associated with cardiovascular disease, inflammation and fibrosis were
determined. Analysis was performed using conventional plasma samples from
the year 2000 (A; n=660 in conventional plasma) and 2015 (B; n=332 in PPP)
evaluation of the community-based Bruneck study. Black points indicate a FDR-
adjusted significance <0.05, with red points indicating annotation for platelet
degranulation/activation gene ontology (GO) terms.
Plasma in Bruneck 2000 evaluation (n=660)
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Figure 24. Correlation of miR-21 with pro-fibrotic factors and arkers of 
platelet activation in the Bruneck study cohort. Using a proteomics screen, 
Pearson coefficients for the correlation of miR-21 with platelet activation markers 
(PF4, PPBP) and LAP-TGF-β1, as well as other circulating proteins associated with 
cardiovascular disease, inflammation and fibrosis were determined. Individual 
proteins are listed on the X-axis, with the corresponding Pearson correlation to miR-
21 shown on the Y-axis. Analysis was performed using conventional plasma 
samples from the year 2000 (A; n=660 in conventional plasma) and 2015 (B; n=332 
in PPP) evaluation of the community-based Bruneck study. Black points indicate a 
FDR-adjusted significance <0.05, with red points indicating annotation for platelet 
degranulation/activation gene ontology (GO) terms. 
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miR-21 (2-DDCq)
Figure 24. Correlation of plasma miR-21 and TGF-β1 in the Bruneck study
cohort. A: Scatter plot for relative plasma levels of miR-21 (as measured by
qPCR) and LAP-TGF-β1 (as measured by PEA) as measured in the Bruneck
year 2000 evaluation, indicating a marked correlation. B: ELISA and qPCR
measurements of mature TGF-β1 and miR-21, respectively, showed a marked
correlation in PPP collected during the Bruneck 2015 evaluation. C: Correlation
between PEA-based measurements of LAP-TGF-β1 and mature TGF-β1 as
measured by ELISA. NPX, normalised protein expression.
B
Bruneck 2000 (plasma)








Figure 25. Correlation of plas a miR-21 and TGF-β1 in the Bruneck study 
cohort. A: Scatter pl t for rel tive plasma levels of miR-21 (provided as relative 
quantity as easured by qPCR,  using the 2-DDCq formula with exogenous cel-miR-39 
and a sample pool serving as reference for the DCq and DDCq quantification, 
resp ctiv ly) and LAP-TGF-β1 (as determined by PEA) as measured in the Bruneck 
year 2000 evaluation, indicating a marked correlation. B: ELISA and qPCR 
measurements of mature TGF-β1 and miR-21, respectively, showed a marked 
correlation in PPP collected during the Bruneck 2015 evaluation. C: Correlation 
between PEA-based measurements of LAP-TGF-β1 and mature TGF-β1 as 
measured by ELISA. NPX, normalised protein expression. 
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0.65 (q=2.4x10-79) in conventional plasma but an r of 0.12 (q=0.22) in PPP. 
Similarly, strong correlations had been found for several other proteins, 
including 4E-BP1 and proteinase-activated receptor 1 (PAR-1; r: 0.66; 
q=2.6x10-84), whereas no significant correlation with miR-21 was found for 
these proteins in PPP (4E-BP1; r: 0.08; q=0.44; PAR-1; r: 0.14; q=0.14). For 
EGF, significant correlation was found in both conventional plasma and PPP 
(r: 0.58; q<1.0x10-15), whereas for heparin-binding EGF (HB-EGF), significant 
correlation was found only in conventional plasma (r: 0.56; q=7.1x10-56, versus 
r: 0.07; q=0.51 in PPP). 
 
To further explore this interference of residual platelets or other cell types 
during analysis of circulating proteins or RNA, an experiment was performed 
using PRP and PPP (see Figure 9, panel A). Both sample types were 
prepared from blood from two healthy volunteers. These were then separately 
analysed using the same PEA panels. For each individual, a ratio of the relative 
abundance between PRP and PPP was calculated for each analysed protein. 
The average of this ratio is shown for the proteins in Figure 26. 
 
In this analysis, most proteins that showed a correlation with miR-21 in 
conventional plasma and/or PPP, showed a FC (ratio) greater than one. As 
expected, LAP-TGF-β1 showed a PRP/PPP ratio of 1.2, implying its presence 
in platelets. For HSP-27 however, despite strong correlations with miR-21 in 
both plasma preparations (r: 0.79 and 0.51; q=3.7x10-141 and <1.0x10-15 in 
conventional plasma and PPP, respectively), no difference in abundance was 
seen between PPP and PRP (ratio 1.0). A similar trend, yet to a lesser extent, 
was seen for PDGFb, with similarly strong correlations (r: 0.73 and 0.59; 
q=1.0x10-110 and <1.0x10-15) in both plasma types but a PRP/PPP ratio of 1.1. 
Finally, for PAR-1, Dickkopf-related protein 1 (DKK1) and HB-EGF, significant 
correlations were seen in conventional plasma (r: 0.66, 0.59 and 0.56; 
q=2.6x10-84, 2.1x10-62 and 7.1x10-56), with no significant correlation with miR-
21 in PPP (r: 0.14, 0.13 and 0.07; q=0.14, 0.15 and 0.51) despite PRP/PPP 
ratios of 1.1, 1.1 and 1.2, respectively. Altogether, these results warrant further 




4.2.3 Analysis of non-reduced human platelet releasate 
To gain more insight in the release profile of platelets upon their 
activation, in particular with regards to TGF-β1, we performed a proteomics 
analysis of platelet releasate samples from healthy human volunteers (see 
Figure 9, panel B). Proteins were treated with either reducing or non-reducing 
conditions, followed by separation by gel electrophoresis. Each sample lane 




































































































































































































Proximity extension assay: different plasma preparations
Conventional plasma (Bruneck 2000)
Platelet-poor plasma (Bruneck 2015)
























































































Proximity extension assay: different plasma preparations
Conventional plasma (Bruneck 2000)
Platelet-poor plasma (Bruneck 2015)







q < 0.05 q > 0.05
q < 0.05
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Ratio
PRP/PPP
Figure 25. Comparison of conventional and platelet-poor plasma for
correlates of miR-21. Measurements of miR-21 and plasma proteins in the
2000 (n=660) and 2015 (n=332) evaluation of the Bruneck study were
compared, constituting conventional plasma and PPP, respectively. Whilst there
is a degree of overlap between both analyses, several proteins, including LAP-
TGF-β1, failed to be significantly correlated to miR-21 in PPP. Additionally, a
direct comparison between PRP and PPP was performed to determine potential
enrichment in platelets for individual proteins. The presented ratio represents












































































Proximity extension assay: different plasma preparations
Conventional plasma (Bruneck 2000)























































































Proximity extension assay: different plasma preparations
Conventional plasma (Bruneck 2000)
Platelet-poor plasma (Bruneck 2015)







q < 0.05 q > 0.05q < 0.05
1.1 1.1 1.2
Figure 26. Comparison of conventional and platelet-poor plasma for correlates 
of miR-21. Measurements of miR-21 and plasma proteins in the 2000 ( =660) and 
2015 (n=332) ev luation of the Bruneck study wer  compared, constituting 
conventional plasma and PPP, respectively. Whilst the  is a degree of ov rlap 
between both analyses, sev ral protei s, including LAP-TGF-β1, fa led to be 
significantly correlated to miR-21 in PPP. Additionally, a direct comparison between 
PRP and PPP was p rformed to determine potential enrichment in platelets for 
individual proteins. Th  prese ted ratio represents the average change between 
PRP-PPP sample pair (n=2 vs. 2). 
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MS/MS. This allowed for inference of the relative molecular mass of the protein 
or protein-complex from which each identified peptide was derived. 
 
Results for fibronectin, the b-chain of fibrinogen, TGF-β1 and LTBP1 are 
shown in Figure 27. For each protein, spectral counts for identified proteotypic 
peptides are shown in the corresponding location of the polyacrylamide gel 
where these were detected by the mass spectrometer. With reducing 
conditions, all proteotypic peptides for fibronectin were detected near its 
predicted relative molecular mass (Mr) of 263 kDa. Using non-reducing 
conditions however, a larger proportion of identified peptides were found in gel 
bands higher up in the gel, which may be in accordance with its homodimeric 
structure, consisting of two fibronectin monomers that are linked by disulphide 
bonds at their C-terminus.297 A similar result can be seen for the beta chain of 
fibrinogen. Here, reducing conditions led to identification of all peptides just 
below its predicted Mr of 57 kDa, potentially indicating cleavage at amino acid 
residue 44-45 by thrombin which produces a 50 kDa cleavage product.298 The 
secreted fibrinogen glycoprotein consists of two trimers, each consisting of 
three polypeptide chains (a, b and g) and with a relative molecular mass of 
approximately 340 kDa.299 Peptides of all three fibrinogen chains (only b is 
shown in Figure 27) were detected in segments derived from the top of the 
gel, above the protein marker of 260 kDa, consistent with its multimeric 
structure that is supported by disulphide bonds between the different chains. 
 
For TGF-β1, a different distribution of peptides was also seen between 
reducing and non-reducing sample preparation. As described in the 
introduction (see Figure 1, panel A), pro-TGF-β1 (predicted Mr 41.3 kDa, 
containing three glycosylation sites) is proteolytically cleaved into a LAP 
(predicted Mr 28.6 kDa, containing three glycosylation sites) and mature TGF-
β1 (predicted Mr 12.7 kDa). As shown in Figure 1 (panel B), TGF-β1 forms a 
non-covalent homodimer (predicted Mr 25.4 kDa) that is contained in the small 
latency complex (SLC) by two LAP. This SLC can be bound to a latency-
binding protein such as LTBP1 to form a large latency complex (LLC). As 
shown in Figure 27 (panel C), reducing conditions resulted in identification of 
peptides belonging to LAP and to mature TGF-β1 in two distinct parts of the 
gel, indicating a molecular mass of approximately 38 kDa and 12.5 kDa, 
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respectively. This is in accordance with monomeric conformation at the time of 
gel electrophoresis, with the Mr of 38 kDa for LAP being consistent with 
glycosylation at its three predicted glycosylation sites. These results, combined 
with the absence of simultaneous detection of LAP and TGF-β1 peptides in 
the 50 kDa region, indicate that none of the detected peptides in the releasate 
were derived from uncleaved pro-TGF-β1. 
 
Analysis of the platelet releasate using non-reducing conditions yielded 
detection of LAP and TGF-β1 peptides in distinct regions as well, yet at 
different locations in the gel compared to reducing conditions. TGF-β1 
peptides were all detected in the gel region relating to a relative molecular 
mass just above 20 kDa, suggesting a homodimer of TGF-β1. Again, no TGF-
β1 peptides were detected in the same region as LAP peptides, further 
supporting the absence of uncleaved pro-TGF-β1. LAP peptides were 
detected in gel pieces derived from the high end of the gel, above the 260 kDa 
protein marker. This suggests that LAP could be part of a complex with other 
proteins or has a conformation that hampers further migration of the protein 
through the gel. Identification of LAP in non-reduced samples occurred in the 
same gel pieces as the identification of LTBP1 peptides (see Figure 27, panel 
D), the major protein involved in the LLC (see Figure 1, panel B).32 The co-
detection in gel pieces above 260 kDa implies that the identified LTBP1 and 
LAP were part of a multimer. Additionally, LTBP1 peptides were detected at a 
lower molecular weight segment of the gel (estimated at 180-240 kDa) in the 
non-reduced samples, whereas for the reduced samples, all detected LTBP1 
peptides were found in the latter gel segment. This region is in accordance 
with the predicted molecular mass of LTBP1, which equates to 186.8 kDa 
without considering the seven potential glycosylation sites within this protein. 
 
Altogether, this analysis of the human platelet releasate using reducing 
and non-reducing conditions indicates that platelets release mature TGF-β1 in 
a cleaved homodimer form. Therefore, measurement of LAP and mature TGF-
β1 may not reflect the same biologically active component. These findings 
warrant further investigation of the previously identified correlation between 
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Figure 26. Human platelet releasate proteins under reducing and non-
reducing conditions. Releasate was isolated from platelets of healthy human
volunteers by thrombin-induced activation, followed by gel-based LC-MS/MS
analysis using reducing (R) and non-reducing (NR) conditions. A: For
fibronectin, non-reducing conditions indicated the presence of a monomer and
dimer. B: Fibrinogen β chain peptides were detected at a relative molecular
mass corresponding to 50 kDa, whilst non-reducing conditions corresponded to
the presence of the fibrinogen hetero-hexamer complex. C: Reducing
conditions identified LAP and TGF-β1 peptides in distinct gel regions that
corresponded with their individual relative molecular mass, indicating a post-
cleavage status of pro-TGF-β1. Non-reducing conditions identified the TGF-β1
peptides at a region corresponding to a dimeric form, whilst LAP peptides were
identified at a much higher gel region that also contained peptides of LTBP1

































































Figure 27. Human platelet releasate proteins under reducing and non-reducing 
conditions. Releasate was isolated from platelets of healthy human volunteers (n=4) 
by thrombin-induced activation, followed by gel-based LC-MS/MS analysis using 
reducing (R) and non-reducing (NR) conditions. A: For fibronectin, non-reducing 
conditions indicated the presence of a monomer and dimer. B: Fibrinogen β chain 
peptides were detected at a relative molecular mass (Mr) corresponding to 50 kDa, 
whilst non-reducing conditions corresponded to the presence of the fibrinogen hetero-
hexamer complex. C: Reducing conditions identified LAP and TGF-β1 peptides in 
distinct gel regions that corresponded with their individual Mr, indicating a post-
cleavage status of pro-TGF-β1. Non-reducing conditions identified the TGF-β1 
peptides at a region corresponding to a dimeric form, whilst LAP peptides were 
identified at a much higher gel region that also contained peptides of LTBP1 (D). This 
indicates platelet secretion of LAP as part of  large latency complex (LLC). 
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4.2.4 Correlation of miR-21 and TGF-b1 in the Bruneck study 
As shown in Figure 1, panel A, the epitope that is recognised as part of 
the PEA panel is part of the LAP and will hence recognise LAP-TGF-β1 and 
pro-TGF-β1. However, as shown by the comparison of reduced and non-
reduced human platelet releasate samples, TGF-β1 is released from platelets 
in a post-cleavage state. Quantification of TGF-β1 using an antibody that 
recognised the LAP and its correlation with plasma levels of miR-21 was 
shown to be affected by the plasma sample preparation method. Therefore, 
we set out to quantify TGF-β1 using an epitope that lies within the sequence 
of ‘mature’ TGF-β1. For this purpose, an ELISA was performed on PPP from 
the 2015 follow-up of the Bruneck study. 
 
Results for the ELISA measurements and their correlation with miR-21 
levels as well as LAP are shown in Figure 25, panel B and C. In contrast to 
the results of the PEA measurement of LAP, the TGF-β1-targeted ELISA 
showed a highly significant correlation with miR-21 (r: 0.63, p<0.0001). The 
latter correlation is also included in Figure 24, panel B, to highlight this major 
discrepancy. Both being derived from cleaved pro-TGF-β1, a correlation 
between TGF-β1 and LAP was indeed found (r: 0.44, q<0.0001), yet this 
correlation was less pronounced than the correlation with miR-21. 
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4.3 In vivo study of miR-21 and platelets 
 
4.3.1 Antibody-mediated platelet depletion in mice 
To determine the effect of a reduced platelet count on circulating levels 
of TGF-β1 as well as miR-21, a mouse model of immune-mediated 
thrombocytopaenia was used. Male wild-type mice were injected 
intraperitoneally with a single dose of anti-CD42b antibody (see Figure 28, 
panel A) or an equal volume of PBS as a control. At the dose of 4 mg/kg 
antibody, the platelet count is reduced for several days.300 After 48 hours, 
animals were sacrificed and blood was prepared for RNA isolation and protein 
analysis, using whole blood as well as PPP. 
 
Analysis of RNA isolated from whole blood showed a significant decrease 
in levels of the platelet-specific gene transcripts for integrin a-IIb (Itga2b; FC: 
0.05; p<0.0001), Pf4 (FC: 0.06; p<0.0001) and Ppbp (FC: 0.03; p<0.0001), 
indicating a severe reduction in platelet numbers (see Figure 28, panel B). 
Consistent with the hypothesis of platelets being a major source of circulating 
TGF-β1, transcript levels of Tgfb1 were significantly reduced as well, yet not 
to the same extent as aforementioned platelet-specific transcripts (FC: 0.43; 
p<0.0001). To determine effects on other circulating cells, gene transcripts of 
protein tyrosine phosphatase, receptor type, C (Ptprc; encoding the CD45 
antigen) were measured. In contrast with the platelet-specific or platelet-
enriched transcripts, Ptprc transcript levels were not significantly affected by 
the anti-CD42b treatment (FC: 1.17; p=0.70). 
 
Next, circulating levels of miRNAs were analysed. PPP was prepared for 
this purpose by sequential centrifugation of blood. In contrast with the whole 
blood mRNA analysis, miRNA changes showed a trend towards higher levels 
after platelet depletion (see Figure 29, panel A), suggesting a possible 
release during immune-mediated thrombocytopenia either from platelets or 
other cell types. The only significant change after 48 hours was observed for 
miR-320 (FC: 1.37; p=0.0177). Some platelet-enriched miRNAs such as miR-
24 (FC:1.33; p=0.11) showed a trend in the same direction. No change was 
observed for miR-106a (FC: 1.31; p=0.34), miR-126 (FC: 1.27; p=0.34), miR-
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21 (FC: 1.12; p=0.76), miR-146a (FC: 0.98; p>0.99) and miR-223 (FC: 0.97; 
p>0.99). 
Using PPP, protein levels were analysed by ELISA. First, levels of the 
platelet-specific PF4 were analysed. As shown in Figure 29, panel B, PF4 
concentrations were markedly reduced after anti-CD42b treatment (median 
[IQR] 1.6 [1.6-1.6] ng/ml) compared to the control group (median [IQR] 106.6 
[82.4-128.7] ng/ml), showing a statistically significant difference when 
analysed by the Mann-Whitney test (p=0.0013). A similar effect was seen for 
levels of TGF-β1, yet to a lesser extent (see Figure 29, panel B): levels in 
control-treated animals had a median [IQR] of 1.9 [1.6-2.1] ng/ml, whilst levels 
after platelet depletion were significantly reduced (p=0.0025), with a median 
[IQR] of 0.78 [0.73-0.84] ng/ml. These results further highlight platelets as a 
major source of circulating TGF-β1. 
 
Figure 28. Immune-mediated platelet depletion in mice. A: Wild-type mice were 
treated with a monoclonal antibody directed against GPIb" (anti-CD42b; 4 mg/kg 
intraperitoneally; n=7) or PBS (control; n=5). Whole blood and PPP were collected 48 
hours after injection. B: Expression levels of several platelet genes, as well as Tgfb1, 
were significantly lower in whole blood after platelet depletion. Expression of Ptprc, 
widely expressed in leukocytes, was not altered. Gapdh was used as reference gene 












Figure 27. Immune-mediated platelet depletion in mice. A: Wild-type mice
were treated with a monoclonal antibody directed against GPIb! (anti-CD42b; 4
mg/kg intraperitoneally). Whole blood and PPP were collected 48 hours after
injection. B: Expression levels of several platelet genes, as well as Tgfb1, were
significantly lower in whole blood after platelet depletion. Expression of Ptprc,
widely expressed in leukocytes, was not altered. Gapdh was used as reference









































Control (n=5) Anti-CD42b (n=7)
*** *** *** ***
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4.3.2 Argonaute-2 immunoprecipitation in megakaryoblastic cells 
As shown in Figure 2, miRNAs regulate translation of mRNA through 
their inclusion in the RISC, which subsequently mediates the targeting of 
mRNA in the cytoplasm. Therefore, analysing miRNAs that are co-precipitated 
when using an antibody targeting Argonaute2 (Ago2), a main component of 
the miRNA processing machinery and the RISC, can provide additional 
information on functional miRNAs within a cell type. To study this in the context 
of platelets, a human oncological megakaryoblastic cell line (MEG-01) was 
used. Sepharose beads coated with anti-Ago2 antibody were incubated with 
Figure 29. Effects of platelet depletion in mice on plasma TGF-β1 and microRNA 
levels. A: Platelet depletion did not significantly alter miR-21 levels in PPP, whilst 
other miRNAs showed a trend towards higher levels after platelet depletion. 
Exogenous cel-miR-39 was used as reference. B,C: Plasma levels of PF4 were below 
the limit of detection for the majority of samples from anti-CD42b-treated mice. TGF-
β1 was detectable in both treatment groups, yet its levels were significantly reduced 
after platelet depletion. Both proteins were measured using an ELISA. Data shown as 
median (IQR). qPCR and ELISA measurements were analysed using the Mann-





































Figure 28. Effects of platelet depletion in mice on plasma TGF-β1 and
miRNA levels. A: Platelet depletion did not significantly alter miR-21 levels in
PPP, whilst other miRNAs showed trend towards higher l vels aft r platelet
depletion. Exogenous cel-miR-39 was us d as reference. B,C: Plasma levels
of PF4 wer below the li it f detection for the jority of samples from anti-
CD42b- reated mice. TGF-β1 was detectable n both treatment groups, yet its
levels were significantly reduced after platelet epletion. Both proteins were
measured using an ELISA, data shown as median (IQR). qPCR and ELISA





MEG-01 cell lysate (see Figure 30, panel A). Beads were then washed and 
RNA was isolated from the bound complexes. A non-specific IgG was used as 
control. Analysis by qPCR showed marked enrichment of miR-21 (average Cq 
17.1, 24.7 and 24.5 for anti-Ago2, IgG control and input sample), whilst this 
was not observed for small RNAs U6 and RNU48 (see Figure 30, panel B). 
Enrichment of miR-126 and -223 was shown as a positive control, as we 
previously found these miRNAs to be highly enriched in the RISC of MEG-01 









Figure 29. Argonaute2 immunoprecipitation in megakaryoblastic cells. A:
Cells from a megakaryoblastic tumour cell line (MEG-01) were used to
determine enrichment of miRNAs in argonaute2 (Ago2) complexes. Lysed
MEG01 cells were incubated with anti-AGO2 antibody-coated beads. Co-
precipitated RNA was isolated from antibody-bound complexes and analysed by
qPCR. B: qPCR measurements are expressed as the difference in Cq value
when anti-AGO2 mediated pull-down was compared with a control IgG
antibody. Marked enrichment was observed for miR-21, as was previously









































Figure 30. Argonaute2 immunoprecipitation in megakaryoblastic c lls. A: Cells 
from a megakaryoblastic tu our cell line (MEG-01) were used to determine 
enrichment of miRNAs in argonaute2 (Ago2) complexes. Lysed MEG01 cells were 
incubated with anti-AGO2 antibody-coated beads. Co-precipitated RNA was isolated 
from antibody-bound complexes and analysed by qPCR. B: qPCR measurements 
are expressed as the difference in Cq value when anti-AGO2 mediated pull-down was 
compared with a control IgG antibody. Marked enrichment was observed for miR-21, 
as was previously shown for miR-126 and miR-223. Two replicates from different 
passages were used. U6 and RNU48 were used as control RNAs. 
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4.3.3 In vitro effect of oligonucleotides on platelet activation 
Next, we set out to determine effects of in vivo inhibition of miR-21 to 
identify mechanisms that might be at play in the context of fibrosis and anti-
fibrotic treatment using miR-21 inhibitors. As described in the introduction, 
several strategies have been conceived to systemically target specific miRNAs 
using modified oligo(deoxy)nucleotides. Importantly, a report by Flierl et al 
showed the ability of oligonucleotides with a length of 18 nucleotides or greater 
and with PS backbone modifications to activate platelets by interaction with 
platelet surface glycoprotein VI, the receptor for collagen.254 To evaluate 
whether we could confirm this for the oligonucleotides that we intended to use 
for systemic miR-21 inhibition in mice, we performed light transmission 
aggregometry experiments using PRP from human volunteers incubated with 
different designs of miRNA-targeting oligonucleotides (see Figure 31, panel 
A) as agonist. 
 
PRP was isolated from citrate-anticoagulated blood from healthy human 
volunteers by centrifugation. Using a light transmission aggregometer, various 
preparations of oligonucleotides were added, alongside with saline as negative 
control and collagen and ADP as positive controls for receptor-mediated 
platelet aggregation. Maximum aggregation was recorded for a period of 40 
minutes after adding saline, oligonucleotide or platelet aggregation agonist. 
PRP was placed in a glass cuvette in the aggregometer at 37°C whilst stirring, 
followed by adding of fully phosphorothioate-modified oligonucleotides using 
an LNA backbone, with lengths varying from 15-23 nucleotides. Furthermore, 
an antagomiR consisting of 22 nucleotides was used, harbouring two and four 
PS backbone modifications at the 5’ and 3’ end, respectively. Apart from the 
15-nucleotide LNA, all oligonucleotides were cholesterol-conjugated. Whilst 
ADP and collagen consistently induced platelet aggregation, none of the 
oligonucleotides tested showed an effect (see Figure 31, panel B). 
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Figure 31. Effect of anti-miRs on platelet aggregation in vitro. A: Human PRP 
was incubated with several anti-miR constructs. All LNA-based anti-miRs had 
phosphorothioate (PS) backbone modifications in the entire molecule, whereas 
antagomiR constructs had such modifications only at two and four nucleotides on the 
5' and 3' end, respectively. AntagomiR nucleosides were modified by adding a methyl 
group to the 2' hydroxyl of the ribose moiety (2'-O-Me) across the molecule, whereas 
LNA constructs harboured a methylene group connecting the 2' oxygen and 4' carbon 
of the ribose moiety in each nucleoside. Cholesterol conjugation was used in all 
tested oligonucleotides except for the 15-nucleotide LNA. B: Maximum aggregation 
within 40 minutes was measured using conventional light transmission aggregometry 
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Figure 30. Effect of anti-miRs on platelet aggregation in vitro. A: Human
PRP was incubated with several anti-miR constructs. All LNA-based antimiRs
had phosphorothioate (PS) backbone m dific tions i the entir molecule,
whereas antagom R constructs had such modifications only at two and four
nucleotides on the 5' and 3' end, respectively. AntagomiR nuc osides were
modified by adding a methyl group to the 2' hydroxyl of the ribos moiety (2'-O-
M ) across the molecule, whereas LNA contructs harboured a methylene group
connecting the 2' oxygen and 4' carbon of the ribose moiety in each nucleoside.
Cholesterol conjugation was used in all tested oligonucleotides except for the
15-nucleotide LNA. B: Maximum aggregation within 40 minutes was measured
using conventional light transmission aggregometry in response to PBS,





4.3.4 Systemic miR-21 inhibition using antagomiR 
Based on the results from the Bruneck study and subsequent 
experiments, we aimed to study the effects of miR-21 inhibition on platelets 
using an in vivo approach. Inhibition was achieved through delivering 
intraperitoneal injections of antagomiR-21 or a non-targeting sequence 
(control) antagomiR, on three consecutive days. This approach was chosen 
due to previous experience in our laboratory for other miRNAs, resulting in 
stable and efficacious inhibition.217,280,281 Collection of blood and tissues was 
performed on the seventh day after therapy initiation.  
 
Efficacy of miR-21 inhibition by the antagomiR was evaluated in several 
tissues. RNA was isolated from bone marrow, heart, liver and kidney samples, 
followed by qPCR analysis of miR-21 and several other miRNAs. It is well 
established that penetrance and targeting efficacy varies between different 
tissues, with liver and kidney generally taking up the greatest amount after 
systemic delivery.108 As shown in Figure 32, significant downregulation was 
achieved in bone marrow, heart, liver and kidney. In bone marrow, miR-21 
Figure 32. Effect of antagomiR-21 across tissues. Analysis of miR-21 levels by 
qPCR in RNA from bone marrow (BM), heart, liver and kidney showed a significant 
downregulation after antagomiR-21 treatment when compared to antagomiR-control. 
The effect on liver and kidney miR-21 was most pronounced. U6 (BM) and sno202 
(heart, liver and kidney) were used as reference transcripts based on the 
comprehensive Ref Finder score within each tissue type. Statistical analysis was 
performed using Mann-Whitney tests; n-numbers are shown on each bar. 
miR-21
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Figure 31. Effect of antagomiR-21 across tissues. Analysis of miR-21 levels
by qPCR in RNA from bone marrow (BM), heart, liver and kidney showed a
significant downregulation after antagomiR-21 treatment when compared to
antagomiR-control. The effect on liver and kidney miR-21 was most
pronounced. U6 (BM) and sno202 (heart, liver and kidney) were used as
reference transcripts based on the comprehensive Ref Finder score within each
tissue type. Statistical analysis was performed using Mann-Whitney tests; n-












levels were 73% of those detected after control treatment (FC: 0.73; Mann-
Whitney test p=0.0137), whilst in heart samples, miR-21 levels were down to 
64% (FC: 0.64, p<0.0001). As expected, the liver and kidney showed a more 
pronounced inhibition, with levels being reduced to 53% (FC: 0.53; p=0.0079) 
and 34% (FC: 0.34; p<0.0001) of that detected after control antagomiR 
treatment, respectively. 
 
In addition to quantifying the inhibition of the targeted miRNA, we 
evaluated effects on other miRNAs in these tissues. AntagomiR treatment can 
have off-target effects due to non-specific inhibition, as well as through 
secondary effects that occur as a result of the intended miRNA inhibition. In 
the heart (see Figure 33, panel A), miR-1 was significantly inhibited (FC: 0.90; 
p=0.0150), although the relative change was much lower than that of miR-21. 
In the bone marrow (see Figure 33, panel B), no significant differences in 
expression levels were found for the five miRNAs that were quantified in 
addition to miR-21. In the liver and kidney (see Figure 33, panels C and D), 
no significant effects were seen for the analysed miRNAs, although the liver 
showed a downward trend for the liver-specific miR-122 (FC: 0.87, p=0.056).  
 
4.3.5 Platelet count after antagomiR-21 treatment 
To evaluate the effect of systemic miR-21 inhibition on platelets, we first 
assessed the platelet count. Whole blood was drawn into ACD buffer and 
incubated with APC-conjugated anti-CD41 antibody, targeting the platelet- and 
megakaryocyte-specific transmembrane glycoprotein IIb. Samples were 
diluted for flow cytometry, with analysis performed by quantification of detected 
events in a predefined volume. Gating windows, based on forward and side 
scatter, were selected for platelets and for RBC/WBC, as shown in Figure 34, 
panel A. Platelets constituted 26.0% (22.6-28.3; median [IRQ]) of the total 
number of recorded events. Subsequent analysis of the platelet scatter 
population showed a median (IQR) of 64.8% (58.9-75.8) of events to be 
positive for CD41-APC signal (Figure 34, panel B). 
 
Comparison of control-treated and antagomiR-21-treated animals 
showed similar platelet counts. Using gated platelets based on scatter (see 
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Figure 32. Effect of antagomiR-21 on other microRNAs. Levels of abundant
miRNA in different tissues were analysed to assess secondary or off-target
effects of systemic antagomiR-21 treatment. A: In heart tissue, a significant yet
slight reduction of the miR-1 was observed, yet with a fold change much lower
than that of miR-21. Sno202 was used as reference transcript; n=13 vs. 17. B,
C, D: In bone marrow (n=9 vs. 9), liver (n=5 vs. 5) and kidney (n=8 vs. 12), no
significant changes were seen for the assessed miRNAs. U6 was used as a
reference transcript for bone marrow, whilst sno202 was used for liver and



































































































































































Figure 33. Effect of antagomiR-21 on other microRNAs. Levels of abundant 
miRNA in different tissues were analysed to assess secondary or off-target effects of 
systemic antagomiR-21 treatment. A: In heart tissue, a significant yet slight reduction 
of the miR-1 was observed, yet with a fold change much lower than that of miR-21. 
Sno202 was used as reference transcript; n=13 vs. 17. B, C, D: In bone marrow (n=9 
vs. 9), liver (n=5 vs. 5) and kidney (n=8 vs. 12), no significant changes were seen for 
the assessed miRNAs. U6 was used as a reference transcript for bone marrow, whilst 
sno202 was used for liver and kidney. Statistical analysis was performed using Mann-
Whitney tests. 
blood was observed in control animal samples, whilst this was 2.3 (1.5-2.7) 
x109/ml blood in samples from antagomiR-21-treated animals. Analysis of  
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CD41+ events showed a similar result (see Figure 34, panel D), with median 
(IQR) concentrations of 0.81 (0.57-0.91) x109 and 0.61 (0.57-0.87) x109 events 
per ml of blood from control- and antagomiR-21-treated mice, respectively. 
Both these parameters were not significantly different when tested by the 







































































Figure 33. Platelet count after pharmacological miR-21 inhibition. Blood
was taken from mice after systemic treatment with antagomiR-21 or antagomiR-
control (n=5 vs. 5). Whole blood was incubated with APC-conjugated anti-CD41
antibody (CD41-APC) prior to dilution for flow cytometry. A: A representative
image of the selected gating window for platelets and for red and white blood
cells (RBC/WBC) based on forward (FSC) and side scatter (SSC). Median
percentages are shown to indicate the proportion of gated events in relation to
the total events. B: Gated platelets were analysed for CD41-APC intensity, with
quadrant 3 and 4 (Q3 and Q4) corresponding to stained and unstained platelets,
respectively. Median percentages relating to the total gated platelet population
are shown in each quadrant. C,D: The concentration of gated platelets and of
CD41-positive events was not significantly different between control- and
antagomiR-21-treated mice. Lines and error bars indicate median (IQR).
Statistical comparisons were performed using the Mann-Whitney test. n.s., not
significant.
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Figure 34. Platelet count after pharmacological miR-21 inhibition. Blood was 
taken from mice after antagomiR-21 or antagomiR-control treatment (n=5 vs. 5). 
Whole blood was incubated with APC-conjugated anti-CD41 antibody (CD41-APC) 
prior to dilution for flow cytometry. A: A representative image of the selected gating 
window for platelets and for red and white blood cells (RBC/WBC) based on forward 
(FSC) and side scatter (SSC). Median percentages are shown to indicate the 
proportion of gated events in relation to the total events. B: Gated platelets were 
analysed for CD41-APC intensity, with quadrant 3 and 4 (Q3 and Q4) corresponding 
to stained and unstained platelets, respectively. Median percentages relating to the 
total gated platelet population are shown in each quadrant. C,D: The concentration 
of gated platelets and of CD41-positive events was not significantly different between 
control- d antagomiR-21-treated mice. Lines and error b rs indicate medi n (IQR). 
Mann-Whitney tests were used for tatistical c mparisons. n.s., not significant. 
 134 
4.3.6 Platelet aggregation after antagomiR-21 treatment 
In addition to platelet counts, an important assessment in the context of 
platelet function is the evaluation of their aggregation response to different 
agonists. This technique depends on changes in light transmission over time 
upon inducing platelet aggregation in PRP (see Figure 35, panel A). For the 
evaluation of mouse platelets after antagomiR treatment, we have previously 
used a method based on light transmission of diluted PRP on a 96-well plate 
that had been pre-coated with platelet agonists in varying concentrations.217,301 
Using a similar approach, we assessed whether there were any differences in 
the platelet aggregation response after miR-21 inhibition. 





















































Figure 34. Platelet aggregation after pharmacological miR-21 inhibition.
A: Blood was taken from mice after systemic treatment with antagomiR-21 or -
control. Using sequential centrifugation, PRP was isolated. This was then
added to wells of a 96-well plate containing platelet agonists in varying
concentrations. Light transmission was measured after 5 minutes, with
simultaneous readings in untreated PPP and PRP samples serving as positive
and negative reference. B: Platelet aggregation was assessed in response to
increasing concentrations of arachidonic acid (AA), protease activated receptor
4-activating peptide (PAR4 amide) or collagen. Whilst increasing
concentrations of PAR4 amide and collagen caused increasing platelet






Figure 35. Platelet aggregation after pharmacol gical miR-21 inhibition. A: 
Blood was taken from mice after syst mic tr atment with antagomiR-21 or -control (n 
=5 vs. 5). Using sequential centrifugation, PR  was isolated. This was then added to 
wells of a 96-well plate containing platelet agonists in varying concentrations. Light 
transmission was measured after 5 minutes, with simultaneous readings in untreated 
PPP and PRP samples serving as positive and negative reference. B: Platelet 
aggregation was assessed in response to increasing concentrations of arachidonic 
acid (AA), protease activated receptor 4-activating peptide (PAR4 amide) or collagen. 
Whilst increasing concentrations of PAR4 amide and collagen caused increasing 




Results of the platelet aggregation analysis are shown in Figure 35, 
panel B. Untreated PRP and PPP prepared from each blood sample served 
as the references for 0% and 100% aggregation, respectively. PRP was 
incubated on the plate for 5 minutes, followed by measurement of light 
transmission. AA induced aggregation up to 52.0±10.1% when using 0.3 µM 
and 62.8±8.8% with 0.6 µM. Two-way ANOVA analysis did not show a 
significant effect of agonist concentration (F (1,16): 0.60; p=0.45) or antagomiR 
treatment type (F (1,16): 0.59; p=0.45). However, for PAR4 amide, a thrombin 
receptor-activating peptide, a significant effect of the concentration was seen 
(F (2,24): 26; p<0.0001), with aggregation measuring 9.3±3.2%, 60.5±9.5% 
and 76.2±5.3% for 30, 50 and 100 µM of this agonist, respectively. This 
aggregation-inducing effect was not different between control and antagomiR-
21-treated mice (F (1,24): 0.090; p=0.77). Using collagen as an agonist 
showed a similar response, with a significant effect of the agonist 
concentration (F (2,23): 28; p<0.0001), inducing 5.5±2.3%, 11.5±3.6% and 
55.9±7.7% aggregation with 0.1, 0.3 and 1 µg/ml of collagen, respectively. 
Here, too, no difference was seen between the two antagomiR types (F (1,23): 
1.2; p=0.28). 
 
4.3.7 Murine platelet releasate proteome after antagomiR-21 treatment 
Having analysed the platelet count and their aggregation response after 
systemic antagomiR-21 treatment, we then evaluated effects on the proteins 
that platelets secrete upon activation. To screen for differences in this context, 
platelets were isolated and washed after treatment with antagomiR-21 or 
control, followed by activation with thrombin, a potent platelet agonist. The 
supernatant of the aggregated and activated platelets, i.e. their releasate, was 
then analysed by gel-based LC-MS/MS (see Figure 36, panel A). 
 
Identified proteins with at least five identified spectra in at least one of the 
two compared groups were included in the analysis. As shown in 
Supplemental table 4, proteins that were identified in the murine releasate 
showed major overlap with the previously analysed human platelet releasate. 
Abundant proteins included thrombospondin-1, with a normalised spectral 
count (NSpC) of 421.9±54.4 and 289.4±31.2 in control and antagomiR-21 (log 
 136 
2 FC: -0.54, p=0.12), and the three chains of fibrinogen: a-chain (FIBA: NSpC 
154.7±44.1 vs. 55.4±14.3), b-chain (FIBB: NSpC 111.5±35.5 vs. 44.2±14.3) 
and g-chain (FIBG: NSpC 110.0±36.5 vs. 25.8±8.9) for control vs. antagomiR-
21, respectively. Differences between the two treatment types did not reach 
statistical significance for any of these three chains (log2 FC: -1.48, -1.34 and 








n=3 vs. 3 (pools of n=12 vs. 12)
A
B ↓ after antagomiR-21 ↑ after antagomiR-21
Figure 35. Murine platelet releasate after pharmacological miR-21
inhibition. A: Blood from antagomiR-treated mice was pooled per four mice,
followed by isolation and washing of platelets. The platelet releasate was
obtained by thrombin-induced aggregation, which was then processed for gel-
based LC-MS/MS analysis. B: Significantly decreased release was seen for
TGF-β1 (TGFB1), as well as for von Willebrand factor (VWF) and fibronectin
(FINC). Gene ontology (GO) annotation of identified proteins showed that in
addition to these three proteins, several other α-granule showed a trend
towards lower levels in the releasate of antagomiR-21-treated mice. One
identified protein was annotated with presence in the dense (ẟ) granule lumen.





Figure 36. Murine platelet releasate after pharmacological miR-21 inhibition. A: 
Blood from antagomiR-treated mice was pooled per four mice, followed by isolation 
and washing of platelets (final n=3 vs. 3 for antagomiR-21 and control). The platelet 
releasate was obtained by thrombin-induced aggregation, which was then processed 
for gel-based LC-MS/MS analysis. B: Significantly decreased release was seen for 
TGF-β1 (TGFB1), as well as for von Willebrand factor (VWF) and fibronectin (FINC). 
Gene ontology (GO) annotation of identified proteins showed that in addition to these 
three proteins, several other α-granule showed a trend towards lower levels in the 
releasate of antagomiR-21-treated mice. One identified protein was annotated with 
presence in the dense (ẟ) granule lumen. Statistical analysis was performed using 
Welch's t-test. 
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As shown in Figure 36, panel B, three proteins were identified at 
significantly lower levels in the releasate from antagomiR-21 treated mice: 
fibronectin (FINC, log2 FC: -2.18; p=0.0300), von Willebrand factor (VWF, log2 
FC: -2.67; p=0.0400) and TGF-b1 (TGFB1, log 2 FC: -2.86; p=0.0472). As 
indicated by the colour-coding of the individual items on the Volcano plot, GO 
annotation of the releasate proteins identified these three as present in the 
platelet  a-granule lumen (GO: 0031093). Whilst not reaching statistical 
significance, a large proportion of the proteins that were detected at lower 
levels after antagomiR-21 carried this same annotation. These include the 
three fibrinogen chains and thrombospondin-1, as mentioned above, as well 
as PF4 (log2 FC: -1.69; p=0.2638), commonly used as a marker of a-granule 
release. Extracellular matrix protein 1 (ECM1) was the only identified protein 

































Figure 36. Platelet TGF-β1 release after pharmacological miR-21
inhibition. Using gel-based LC-MS/MS analysis allowed for identification of
specific peptides in relation to their migration level during gel electrophoresis.
Using lower threshold settings to enhance identification of low-abundant
peptides, the gel representation showed a reduced identification of both LAP
and TGF-β1 peptides in the releasate from antagomiR-21-treated mice (A).
Sequence coverage across the pro-TGF-β1 sequence is shown in B. Mr,





Figure 37. Platelet TGF-β1 release after pharmacological miR-21 inhibition. 
Using gel-based LC-MS/MS analysis allowed for identification of specific peptides in 
relation to their migration level during gel electrophoresis. Using lower threshold 
settings to enhance identification of low-abundant peptides, the gel representation 
showed a reduced identification of both LAP and TGF-β1 peptides in the releasate 
from antagomiR-21-treated mice (A). Sequence coverage across the pro-TGF-β1 
sequence is shown in B. Mr, relative molecular mass; aa, amino acid residues. 
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When looking at the decreased release of TGF-b1 more closely, peptide-
specific analysis is in line with the results from the human platelet releasate. 
This is illustrated more clearly when comparing the antagomiR-21 and control 
platelet releasate using a lowered protein and peptide threshold setting to 
enhance detectability of low abundant peptides. As shown in Figure 37, panel 
A, identification of peptides occurred in two distinct regions of the gel, for both 
control and antagomiR-21 releasate samples. Decreased levels in the latter 
samples appeared to be consistent across both gel regions. Individual peptide 
identification showed that LAP peptides and TGF-b1 peptides were identified 
in the higher and lower segment, both in agreement with the corresponding 
relative molecular mass (see Figure 37, panel B). 
 
4.3.8 Platelet releasate analysis by ELISA 
The importance of TGF-b1 and its release from platelets in tissue repair 
and the pro-fibrotic response was discussed in the introduction. We therefore 
aimed to validate the observation of reduced TGF-b1 platelet release after 
systemic antagomiR-21 treatment. For this purpose, measurement of TGF-b1 
was performed by ELISA in the supernatant of platelets after activation with 
different agonists in several dosages, as described in the aggregometry 
experiment (see Figure 38, panel A). 
 
As shown in Figure 38, panel B, TGF-b1 levels in PPP after antagomiR-
21 treatment did not differ from controls. Adding increasing concentrations of 
agonists to PRP significantly increased TGF-b1 release for PAR4 amide (F 
(2,24): 8.6, p=0.0015) and collagen (F (2,23): 7.0, p=0.0043), but not for AA (F 
(1,16): 1.9, p=0.18). In line with the proteomics analysis of the thrombin 
releasate, TGF-b1 release after PAR4 (F (1,24): 11.0, p=0.0029) and collagen 
(F (1,23): 6.1, p=0.0210) receptor activation was attenuated after antagomiR-
21 treatment when using a high dosage of either agonist. This effect was not 
observed for AA (F (1,16): 1.7, p=0.21). Post-hoc analysis of the individual 
comparisons at different dosages, using Šidák’s test, confirmed the significant 






















Figure 37. ELISA measurements in activated platelet supernatant after
pharmacological miR-21 inhibition. A: Blood from antagomiR-21 or -control
mice was centrifuged to obtain PRP. Platelets were activated with different
agonists, followed by centrifugation of samples to obtain the supernatant. B:
Levels of TGF-β1 in PPP did not differ between both antagomiR types.
Conversely, supernatant from PRP treated with PAR4 amide and collagen
showed a dose-dependent increase of TGF-β1 levels, which was significantly
less pronounced in PRP from antagomiR-21-treated mice. C: For PF4, a similar
dose-dependent increase was seen for PAR4 amide and collagen, which was
however not significantly affected by antagomiR-21 treatment. Statistical












































































































Figure 38. ELISA measurements in activated platelet supernatant after 
pharmacological miR-21 inhibition. A: Blood from antagomiR-21 or -control mice 
(n=5 vs. 5) was centrifuged to obtain PRP. Platelets were activated with different 
agonists, followed by centrifugation of samples to obtain the supernatant. B: Levels 
of TGF-β1 in PPP did not differ between both antagomiR types. Conversely, 
supernatant from PRP treated with PAR4 amide and collagen showed a dose-
dependent increase of TGF-β1 levels, which was significantly less pronounced in PRP 
from antagomiR-21-treated mice. C: For PF4, a similar dose-dependent increase was 
seen for PAR4 amide and collagen, which was however not significantly affected by 
antagomiR-21 treatment. Statistical analysis was performed using a two-way ANOVA 
with post-hoc analysis using Šidák's test. 
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To assess whether the observed effect of antagomiR-21 treatment was 
part of a general effect on a-granule release, levels of PF4 were quantified by 
ELISA in the same samples (see Figure 38, panel C). Whilst a significant 
effect on PF4 release was seen with increasing concentrations of PAR4 amide 
(F (2,24): 12.4, p=0.0002) and collagen (F (2,23):7.0, p=0.0043), no effect was 
seen for AA (F (1,16): 1.5, p=0.24). This is in line with the observations for 
TGF-b1. In contrast to TGF-b1, despite showing a trend towards lower PF4 
release, individual comparisons between antagomiR-21 and control for the 
high-dose PAR4 amide (p=0.12) and collagen (p=0.49) did not reveal a 
significant difference. 
 
4.3.9 TGF-b1 gene expression after antagomiR-21 treatment 
The observation of decreased TGF-b1 release from platelets after 
antagomiR-21 treatment could imply two effects: lower platelet TGF-b1 
content, or an effect on its release. We first evaluated whether there was a 
difference in expression of TGF-b1 and related genes. Megakaryocytes 
comprise <0.1% of the total cell population in the bone marrow, limiting the 
ability to isolate these cells from the total bone marrow. We therefore evaluated 
expression levels in the isolated whole bone marrow. As shown in Figure 39, 
panel A, no significant difference was seen for Tgfb1 expression between 
bone marrow from antagomiR-21- and control-treated mice (FC: 1.11, p=0.23 
for Welch’s t-test). Similarly, no differences were observed for any of the TGF-
b receptors (FC: 1.09, 1.02, 1.18 for Tgfbr1, Tgfbr2 and Tgfbr3, with p=0.37, 
0.99 and 0.34, respectively) or for Ltbp1 (FC:1.06; p=0.35). Expression of 
Tgfb2 and Tgfb3 was below the threshold of reliable detection (average Cq 
37.5 and 34.1, respectively). This is markedly lower compared to expression 
of Tgfb1 (average Cq 25). 
 
Potential effects of antagomiR-21 on Tgfb1 gene expression in tissues 
were also evaluated. As shown in Figure 39, panel B, expression levels in the 
heart, liver and kidney were not significantly affected by systemic antagomiR-
21 treatment (FC: 0.99, 1.12 and 0.94, with p=0.96, 0.45 and 0.60, 




4.3.10 Bone marrow histology after antagomiR-21 treatment 
We were not able to analyse Tgfb1 expression in isolated 
megakaryocytes due to their low abundance within the bone marrow 
population. Therefore, we aimed to determine TGF-b1 protein levels in the 
megakaryocytes resident in the bone marrow. Femora from antagomiR-21-
treated mice and respective controls were harvested, fixed and decalcified to 
allow for histological sectioning and immunofluorescent staining (see Figure 
40, panel A). In addition to using an anti-TGF-b1 antibody, megakaryocytes 





































Figure 38. Gene expression after pharmacological miR-21 inhibition. A: To
determine effects of systemic antagomiR-21 treatment on gene expression,
qPCR analysis was performed in isolated bone marrow cells. Expression levels
of Tgfb1, the three TGF-β receptors and Ltbp1 were not significantly different
between control- and antagomiR-21-treated mice (n=9 vs. 9). Gapdh was used
as reference transcript. B: Transcript levels of Tgfb1 were analysed in other
tissues after antagomiR-21 treatment, showing no significant difference after
miR-21 inhibition. Gene transcripts of Actb, B2m and Ppia were used as
reference in heart, liver and kidney, respectively, based on RefFinder stability
ranking within each tissue. Numbers on bars reflect the sample size of each



















































Figure 39. Gene expression after phar acological i -21 inhibition. A: To 
determine effects of systemic antagomiR-21 treatm nt on ge e expression, qPCR 
analysis was performed in isolated bone marr w cells. Expre sion levels of Tgfb1, 
the three TGF-β rec ptors and Ltbp1 were ot significantly differe t between control- 
and antagomiR-21-treated mice (n=9 vs. 9). Gapdh was used as reference transcript. 
B: Transc ipt l vels of Tgfb1 were analysed in other tissu s after antagomiR-21 
treatment, showing no significant differ ce after miR-21 nh bition. Gene transcripts 
of Actb, B2m and Ppia were used as reference in heart (n=5 vs. 5 for control vs. 
antagomiR-21), liver (n=6 vs. 6) a d kidney (n=8 vs. 12), respectively, based on 
RefFinder stability ranking within each tissue. Numbers on bars reflect the sample 
size of each group. Statistical analyses were performed using Welch's t-test. 
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Representative images are shown in Figure 40, panel B and C. 
Localisation of TGF-b1 and PF4 were both equally distributed, with punctate 
enrichment appearing throughout the section. The species-specific control IgG 
staining showed low background signal for both stainings. As can be seen from 
the yellow signal in the overlay image, there was remarkable co-localisation of 









Figure 39. Immunohistochemistry in the murine bone marrow. A: After
systemic treatment with antagomiR-21 or -control, mouse femora were
processed for histological analysis by fixation and decalcification. Transverse
sections were stained for TGF-β1 (red), PF4 (green) and a nuclear counterstain
(DAPI, blue). B: Punctate localisation of TGF-β1 as well as PF4 was seen
throughout the sections. Overlay of both channels showed remarkable overlap
as indicated by yellow signal. Scale bar denotes 200 µm. C: Analysis at 60x
magnification allowed for a more detailed appreciation of overlapping TGF-β1
and PF4 signal, identifying the cellular and lobulated nuclear morphology
characteristic of megakaryocytes. Scale bars denote 200 µm and 20 µm for 20x
and 60x panels, respectively.
TGF-β1 PF4Overlay














Figure 40. Immunohistochemistry in the murine bone marrow. A: After systemic 
treatment with antagomiR-21 or -control, mouse femora were processed for 
histological analysis by fixation and decalcification (n=3 vs. 4 for control and 
antagomiR-21-treated mice). Transverse sections were stained for TGF-β1 (red), 
PF4 (green) and a nuclear counterstain (DAPI, blue). B: Punctate localisation of TGF-
β1 as well as PF4 was seen throughout the sections. Overlay of both channels 
showed remarkable overlap as indicat d by yellow signal. Scale bar denotes 200 µm. 
C: Analysis at 60x magnificati n allow  for a more detailed appreciation of 
overlapping TGF-β1 and PF4 signal, identifying the cellular and lobulated nuclear 
morphology characteristic of megakaryocytes. Scale bars denote 200 µm and 20 µm 
for 20x and 60x panels, respectively. 
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and lobulated nuclei in the cells that stained positive for both proteins, a key 
characteristic of the morphology of megakaryocytes.302 In addition, signal 
intensity beyond the areas of co-localisation was negligible. Images of sections 
















Figure 40. Bone marrow immunohistochemistry after pharmacological
miR-21 inhibition. Immunohistological analysis was performed for bone
marrow samples of mice treated with antagomiR-21 or -control. Distribution of
PF4-positive cells, as well as the intensity of TGF-β1, did not show a difference
between both treatment types. Scale bar denotes 200 µm.
Figure 41. Bone marrow immunohistochemistry after pharmacological miR-21 
inhibition. Immunohistological analysis was performed for bone marrow samples of 
mice treated with antago iR-21 (n=4) or -co trol (n=3). Distribution of PF4-positive 
cells, as well as th  intensity of TGF-β1, did not show a ifference between both 
treatment types. Scale bar denotes 200 µm. 
 144 
from all animals are shown in Figure 41. Whilst co-localisation of TGF-b1 and 
PF4 was seen consistently across the samples, the levels of TGF-b1 did not 
seem to differ between sections from antagomiR-21-treated animals and those 
treated with control antagomiR. 
 
4.3.11 Immunoblot analysis of platelets after antagomiR-21 treatment 
As the quantitative accuracy of immunohistochemistry is limited, we also 
determined TGF-b1 levels in platelets that were isolated after systemic 
antagomiR treatment (see Figure 42, panel A). In addition to TGF-b1, we 
determined levels of Wiskott-Aldrich Syndrome protein (WASp), encoded by 
the Was gene. Whilst playing an important role in actin polymerisation in 
leukocytes, this protein had previously been reported to control the release of 
TGF-b1 from platelets.77 Interestingly, this protein is exclusively expressed in 
haematopoietic cells. Therefore, we investigated whether decreased platelet 
TGF-b1 release after systemic inhibition of miR-21 could have been explained 
by regulation of this protein. 
 
Immunoblot analysis of isolated platelets confirmed our previous 
observations of TGF-b1 levels in megakaryocytes, with no significant 
difference being observed between platelets from antagomiR-21- and control-
treated mice (see Figure 42, panel B and C). No differences were observed 
for PF4 levels (see Figure 42, panel B and E). Interestingly however, a 
difference was indeed observed for levels of WASp, with significantly higher 
levels in the platelets of antagomiR-21-treated mice. This difference was 
confirmed by relative densitometry (see Figure 42, panel B and D). 
 
4.3.12 Identification of Was as a direct target of miR-21 
Regulation of the Was gene by miR-21 was further studied in the bone 
marrow by qPCR. In contrast to the expression levels of Tgfb1 (Figure 39), 
Was levels in the bone marrow were significantly higher after antagomiR-21 












Figure 41. Immunoblot of lysed platelets isolated after pharmacological
miR-21 inhibition. A: After systemic treatment with antagomiR-21 or -control,
blood platelets isolated by sequential centrifugation were washed and lysed. B:
Immunoblotting was performed to determine levels of WASp and TGF-β1, whilst
levels of β-actin served as a loading control. C,D: Densitometric analysis
showed significantly higher levels of WASp in platelets from antagomiR-21-
treated mice, whilst no difference was found for TGF-β1 and PF4. Signal
intensity was normalised to the signal of β-actin for C and D. Statistical testing






























































































Figure 42. Immunoblot o  lysed platelets isola ed after pharmacol gical miR-21 
inhibition. A: After systemic treatment wi h antagomiR-21 or -control (n=4 vs. 4), 
blood platelets isolated by s quential ce trifugation were washed and lysed. B: 
Immunoblotting was performed to determine levels of WASp, TGF-β1 and PF4, whilst 
levels of β-actin served as a loading control. C,D: Densitometric analysis showed 
significantly higher levels of WASp in platelets from antagomiR-21-treated mice, whilst 
no difference was found for TGF-β1 and PF4. Signal intensity was normalised to the 
signal of β-actin for C and D. Statistical testing was performed using Welch's t test. 
Mr, relative molecular mass; AU, arbitrary units; n.s., non-significant. 
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In silico analysis for target prediction was performed next using the 
miRWalk algorithm, which combines the algorithms of twelve individual 
prediction tools.284 Results of this analysis were combined with manually 
curated GO annotation of genes that were experimentally validated miR-21 
targets (see Supplemental table 5). One prediction algorithm, RNAhybrid286, 
predicted base pairing between the miR-21 seed sequence and the 3’ UTR of 
the Was transcript (see Figure 43, panel B). As antagomiR-21 treatment had 
a significant effect on Was/WASp levels in mouse platelets and bone marrow, 
we used a luciferase reporter assay to determine direct targeting of Was by 
miR-21. Given that the in silico prediction was based on one algorithm and 
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Figure 42. Bone marrow Was expression and predicted targeting by miR-
21. A: An increased expression of Was corroborated the immunoblotting
findings in lysed platelets. Transcript levels of Gapdh were used as reference
and statistical comparisons were performed using Welch's t-test. B: In silico
prediction algorithms identified a potential interaction between the 3' UTR of the
Was gene transcript by miR-21, suggesting canonical targeting. Predicted
targeting according to the RNAhybrid algorithm (Rehmsmeier et al., 2004) is
shown.

























Figure 43. Bone marrow Was expression a d predicted targeting by miR-21. A: 
An increased expression of Was in bone marrow cells after control (n=9) or 
antagomiR-21 tr atment (n=9) corroborated the immunoblotting findings in lysed 
platelet . Transcript levels of Gapdh wer  used as reference and statistical 
comparisons were performed using W lch's t- st. B: In silico prediction alg ri ms 
identified a potential interaction between th  3' UTR of the W s ge e transcript by 
miR-21, suggesting canonical targeting. Predicted targeting according to the 






















B Was 3’ UTR
Control miR-21 mimic
Figure 43. Luciferase reporter assay for targeting of Was by miR-21. A:
The 3' UTR of the Was gene transcript was cloned into a vector, between the
Renilla and firefly luciferase reporter genes. This construct was transfected into
HEK293T cells together with miR-21 mimic or a non-targeting control. Targeting
of the 3' UTR would result in a reduced Firefly reporter activity, whilst Renilla
reporter activity would not be affected. B: Three independent experiments were
performed, each time using triplicates and quadruplicates for control and miR-
21 transfection, respectively. Firefly reporter activity, normalised to constitutive
Renilla reporter activity, was significantly reduced after miR-21 mimic
transfection in all three experiments. This indicates direct targeting of the cloned
Was 3' UTR sequence by miR-21. Statistical analysis was performed using a
paired t-test.


















Figure 44. Luciferase reporter assay for targeting of Was by miR-21. A: The 3' 
UTR of the Was gene transcript was cloned into a vector, between the Renilla and 
firefly luciferase reporter genes. This construct was transfected into HEK293T cells 
together with miR-21 mimic or a non-targeting control. Targeting of the 3' UTR would 
result in a reduced Firefly reporter activity, whilst Renilla reporter activity would not 
be affected. B: Three independent experiments were performed, each time using 
triplicates and quadruplicates for control and miR-21 transfection, respectively. Firefly 
reporter activity, normalised to constitutive Renilla reporter activity, was significantly 
reduced after miR-21 mimic transfection in all three experiments. This indicates direct 
targeting of the cloned Was 3' UTR sequence by miR-21. Statistical analysis was 
performed using a paired t-test. 
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Supplemental table 5), we cloned the entire 3’ UTR sequence of Was into a 
dual-luciferase (Renilla and firefly) reporter vector. These constructs were 
transfected into HEK293T cells together with miR-21 mimic or a non-targeting 
control sequence (see Figure 44, panel A). After 48 hours, normalised firefly 
luciferase activity was significantly reduced in miR-21-transfected cells (FC: 
0.71; p=0.0010), indicating direct targeting of the Was 3’ UTR by miR-21 (see 
Figure 44, panel B). 
 
4.3.13 Analysis of blood and bone marrow from miR-21 null mice 
Previous studies into miR-21 and cardiac fibrosis have highlighted a 
discrepancy between pharmacological and genetic inhibition of this miRNA. 
110,118 In line with the observations by others110, the size, weight and behaviour 
did not differ between miR-21 null mice and their littermate controls. Survival 
over several months was not different between both genotypes and there were 
no signs of spontaneous bleeding. To assess potential changes in platelets in 
miR-21 null mice, we first performed a whole-blood platelet count using a 
Hemavet haematology analyser (see Figure 45). In contrast to short-term 
pharmacological inhibition of miR-21, blood from miR-21 null mice showed 
significantly lower concentrations of platelets, with a mean (SEM) count of 647 
(48) x109/L and 527 (27) x109/L for miR-21 null and wild-type blood, 
respectively (p=0.0333). Numbers of leukocyte subtypes were also 
significantly lower in miR-21 null mice, with mean (SEM) counts of 3.3 (0.4) 
x109/L and 1.5 (0.3) x109/L for lymphocytes (p=0.0020) and 132 (34) x106/L 
and 37 (10) x106/L for monocytes (p=0.0055), respectively. For the latter two 
cell types, average counts for the miR-21 null mice still fell within the normal 
reference range. 
 
To determine whether these changes in the blood were accompanied by 
changes in the bone marrow, immunohistological staining was performed in 
decalcified femoral sections. As shown in Figure 46, panel A and B, a 
significant increase in megakaryocyte numbers was seen in miR-21 null bone 
marrow, with a median (interquartile range) count per mm2 of 84.7 (78.0-90.0) 
and 106.3 (99.5-121.2) for wild-type and miR-21 null mice, respectively 
(p=0.003 for Mann-Whitney test). We next studied gene expression levels in 
the bone marrow of these mice (see Figure 46, panel C). No significant 
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difference was seen for expression of Tgfb1 or Ptprc (CD45). However, 
transcript levels of several megakaryocyte-specific genes were significantly 
induced (FC: 1.70 [p=0.005] for Itga2b, 1.72 [p=0.026] for Pf4, 1.90 [p=0.030] 
for Ppbp). Altogether, platelet and megakaryocyte numbers were significantly 
altered in miR-21 null mice. 
Figure 45. Hemavet blood count in miR-21 null mice. Automated blood cell 
counting identified significantly lower numbers of platelets, lymphocytes and 
monocytes in miR-21 null mice (n=10) compared to wild-type littermates (n=6). 
Welch’s t-test was used for statistical comparison. 
Figure 44. Hemavet blood count in miR-21 null mice. Automated blood cell
counting identified significantly lower numbers of platelets, lymphocytes and
monocytes in miR-21 null mice (n=10) compared to wild-type littermates (n=10).


















Figure 46. Bone marrow analysis in miR-21 null mice. A: Representative image 
of immunohistochemical analysis for TGF-β1 (red), PF4 (green) and a nuclear 
counterstain (DAPI, blue) in femoral bone marrow sections of miR-21 null mice 
(n=10) and littermate controls (n=6), identifying a higher number of PF4-positive 
cells. Scale bar denotes 200 µm. B: Blinded counting of megakaryocytes, identified 
as PF4-positive cells, showed significantly higher numbers in bone marrow from miR-
21 null mice. Counting was performed using Fiji ImageJ software, with statistical 
comparison using the Mann-Whitney test. C: Expression levels of megakaryocyte-
specific genes in isolated bone marrow cells, including Pf4, were significantly higher 
in miR-21 null mice. Transcript levels of Tgfb1 and Ptprc (CD45) were not affected. 

































Figure 45. Bone marrow analysis in miR-21 null mice. A: Representative
image of immunohistochemical analysis for TGF-β1 (red), PF4 (green) and a
nuclear counterstain (DAPI, blue) in femoral bone marrow sections of miR-21
null mice (n=10) and littermate controls (n=6) identified a higher number of PF4-
positive cells. Scale bar denotes 200 µm. B: Blinded counting of
megakaryocytes, identified as PF4-positive cells, showed significantly higher
numbers in bone marrow from miR-21 null mice. Counting was performed using
Fiji ImageJ software, with statistical comparison using the Mann-Whitney test.
C: Expression levels of megakaryocyte-specific genes in isolated bone marrow
cells, including Pf4, were significantly higher in miR-21 null mice. Transcript
levels of Tgfb1 and Ptprc (CD45) were not affected. Statistical comparisons






















5.1 Direct effects of miR-21 in the heart 
 
To this day, there is an unmet clinical need for treatment options of heart 
failure. Therefore, there is much interest in disentangling the underlying 
molecular processes that cause or worsen this clinical syndrome. MiR-21 has 
been widely implicated in the development and progression of fibrosis, a key 
feature of heart failure. Contradicting results from studies using different 
strategies to target miR-21 highlight the need for a better understanding of 
mechanisms that are at play. As the main source of ECM proteins, fibroblasts 
are widely regarded to be the main drivers of fibrosis. The scientific emphasis 
has therefore primarily been on the effects of miR-21 in these cells. This has 
indeed identified several potential mechanisms. However, there are limitations 
with the experimental approach that has been used so far. This includes the 
use of relatively crude methods to determine cell specificity of findings, as well 
as selection bias due to evaluation of pre-selected proteins rather than those 
identified through a wider screening approach. We therefore used a proteomic 
screening approach to analyse miR-21-mediated changes in the CF 
secretome. In addition, we validated results using immunoblotting for selected 
proteins and performed gene expression analysis for abundant and 
dysregulated proteins. In light of previous reports, we analysed the CF 
proliferation rate after transfection of miR-21 mimics and -inhibitors. To 
complement these strategies, we screened for differences in gene expression 
and protein levels in miR-21 null hearts. 
 
5.1.1 The cardiac fibroblast secretome after transfections 
Myocardial cells are generally subdivided into either cardiomyocytes or 
non-myocytes. Whilst this dichotomy is widely accepted, the latter population 
is often presumed to predominantly consist of fibroblasts. We will discuss the 
consequences of this assumption in paragraph 5.1.5. To enhance the 
confidence that an effect or observation indeed occurred in fibroblasts, several 
cell markers have been proposed. Despite an array of markers being in use, 
their specificity is contested, as pointed out in a recent study.303 However, it 
can be argued that ECM production is primarily a readout of fibroblasts within 
the non-myocyte fraction of the heart.12 Therefore, the ECM secretome 
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analysis of CF may to a certain extent bypass the discussion of fibroblast 
specificity in the non-myocyte cell population. 
 
Most techniques determine changes in protein levels using antibodies. 
Though offering a straightforward method for protein quantification, there is 
bias towards selection of what proteins are analysed and for which ones 
appropriate and technically suitable antibodies are found. In contrast, the use 
of MS allows for a comprehensive identification and quantification of proteins. 
Although MS has many advantages, there is an extent of bias as well: 
untargeted MS favours detection of larger and more abundant proteins, which 
are more readily identified, whilst smaller and less abundant proteins can 
remain undetected in complex protein mixtures. Furthermore, without 
authentic reference standards MS data cannot be used to accurately compare 
quantities across different proteins. Using the CF secretome for MS analysis 
offers the opportunity to analyse an accumulation of ECM changes over a 
longer time course, for a wide range of proteins. This markedly increases the 
sensitivity. As miRNAs fine-tune protein synthesis, changes upon manipulating 
miRNA levels can be small and therefore challenging to detect. Previous 
studies using the same approach were indeed able to identify a marked effect 
of miRNA manipulation185 and hypoxia291 on CF protein secretion. We 
therefore used a similar approach to study effects of miR-21. 
 
Significant changes of miR-21 levels were seen in transfected CF, 
indicating successful overexpression and inhibition. Furthermore, a marked 
effect of TGF-b1 treatment was seen at the transcriptional and protein level. A 
significant induction was seen for expression and secretion of periostin, as well 
as other commonly used markers of a myofibroblast-like phenotype. Despite 
the identification of 144 different proteins, there was a surprising lack of 
changes in the CF secretome after miR-21 overexpression and inhibition. 
Strikingly, no significant effect was observed on any of the key structural ECM 
proteins, as will be discussed in paragraph 5.1.1.5. 
 
Despite having no major effect on ECM protein secretion, the secretome 
analysis did identify some proteins of potential interest. Upon miR-21 inhibition, 
VCAM1 and LG3BP levels increased in the secretome, whilst overexpression 
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had no effect. Gene expression analysis for LG3BP was in line with these 
findings. For IBP4 and granulin, higher levels were observed after miR-21 
overexpression, although granulin levels also increased after miR-21 
inhibition. Whilst these changes are unlikely to explain the reported effects of 
miR-21 inhibition in cardiac fibrosis, potential significance of these findings will 
be discussed. 
 
5.1.1.1 Vascular cell adhesion protein 1 
VCAM1 is a cell adhesion molecule that has been described extensively 
for its function in tissue inflammation304 and CVD, such as atherosclerosis.305 
Expression of VCAM1 in endothelial cells is stimulated by inflammation, 
facilitating the adhesion of leukocytes to the vascular endothelium. Binding to 
VCAM1 has downstream signalling effects that enhances leukocyte 
transmigration into the underlying stroma. Pharmacological disruption of the 
VCAM1-leukocyte interaction is currently being used in the treatment of 
multiple sclerosis, indicating a pivotal role for this protein in inflammation.306 
 
Expression of VCAM1 in endothelial cells has been widely described, yet 
its presence has also been reported in other cell types. These include vascular 
smooth muscle cells307 and CF, where its expression could be induced through 
phosphorylation of p38 MAP kinase, one of the signalling pathways 
downstream of TGF-b activity.308 A more recent report studied the role of 
VCAM1 in pulmonary fibrosis.309 Here, VCAM1 levels were increased in 
plasma and in pulmonary fibroblasts from patients with idiopathic pulmonary 
fibrosis, as well as in bleomycin-induced fibrotic lungs in mice. This study 
confirmed induction downstream of TGF-b, using in vitro TGF-b1 treatment of 
human lung fibroblasts. Silencing VCAM1 in fibroblasts had an anti-
proliferative effect, implicating its expression in pro-fibrotic signalling. It 
remains unanswered what the in vivo effect of fibroblast VCAM1 is in the 
context of inflammation and fibrosis. 
 
Increased secretome levels of VCAM1 after miR-21 inhibition could also 
be derived from residual endothelial cells.  These cells are thought to succumb 
when cultured in fibroblast media, which is indeed supported by both 
microscopic and qPCR analysis after our CF isolation and subculture protocol. 
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Nevertheless, some residual endothelial cell presence in the non-myocyte 
culture cannot be ruled out. Transfection of miR-21 inhibitor promoted 
proliferation of endothelial cells that had been treated with rapamycin, a known 
inhibitor of endothelial cell proliferation and migration.310 Other studies have 
shown that miR-21 enhances endothelial cell differentiation311 and 
proliferation.312 The latter supports the hypothesis that transfection of miR-21 
inhibitor into residual endothelial cells may have enhanced their survival, 
causing an increased level of endothelial cell-derived VCAM1. Of note, miR-
21 in endothelial cells also increased VCAM1 expression, through targeting 
peroxisome proliferator-activated receptor-α. This implies an effect directly 
opposite to our observation.313 Altogether, these findings suggest that VCAM1 
identified in the secretome is unlikely to have been endothelial cell-derived. 
 
5.1.1.2 Galectin-3-binding protein 
The second protein that showed significantly increased levels after miR-
21 inhibition was LG3BP. This member of the macrophage scavenger receptor 
cysteine-rich domain superfamily314 has previously been implicated in 
modulating cell-cell and cell-matrix adhesion during inflammation.315,316 
Fibroblasts were shown to secrete LG3BP. Binding studies revealed 
interactions with fibronectin and several collagens, but secretion levels were 
found to be much lower than e.g. fibronectin, implicating it as an ECM 
component without being a major structural component.315 We recently 
identified LG3BP as part of a four-biomarker signature of high-risk 
atherosclerotic plaques, implicating it as a circulating marker of plaque 
instability that is derived from the vascular ECM.317 
 
To our knowledge, there have been no reports on the role of LG3BP in 
cardiac fibrosis. However, its secretion from a breast cancer cell line had anti-
fibrotic effects through inhibiting monocyte-derived fibrocyte differentiation.318 
LG3BP and its binding partner galectin-3316, previously shown to be pro-fibrotic 
in response to MI319 and cardiac inflammation320, were shown to compete in 
their anti- and pro-fibrotic effects, respectively.318 In light of this, increased CF 
secretion of LG3BP upon miR-21 inhibition could imply that miR-21 has a pro-
fibrotic effect through targeting LG3BP, enhancing galectin-3-induced fibrocyte 
and fibroblast differentiation and consequently fibrosis. 
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Increased expression and secretion of LG3BP upon miR-21 inhibition 
could imply de-repression of a direct target. However, we did not find a 
decrease in its secretion or gene expression upon miR-21 mimic transfection, 
as would be expected in the case of direct targeting. We also did not find a 
supposed anti-fibrotic effect reflected in decreased secretion of other ECM 
proteins. Nevertheless, our in vitro analysis does not allow for detection of 
potential paracrine effects of LG3BP. Further study would be required to 
determine if increased LG3BP secretion upon miR-21 inhibition could 
attenuate cardiac fibrosis. 
 
5.1.1.3 Insulin-like growth factor binding-protein 4 
Increased secretome levels of IBP4 were found after miR-21 mimic 
transfection in unstimulated CF. IBP4 expression and secretion has previously 
been reported in human fibroblasts321 and in rat lung fibroblasts, where it was 
shown to control IGF-mediated cell proliferation. Accumulation in the 
conditioned media of lung fibroblasts occurred in response to treatment with 
various growth factors, including PDGF and fibroblast growth factor 2.322,323 
IGFs regulate an array of biological processes, mainly related to growth 
hormone signalling. In the circulation, they are bound to a set of binding 
proteins (IGFBP; IBP) 324 that on one hand regulate IGF activity, but act 
independently of their IGF ligand. The mechanisms and actions of both IGF-
regulating and IGF-independent activity vary for the different IBP subtypes.325 
 
Focusing on IBP4, in vitro and mouse studies showed its ability to block 
IGF activity in bone formation326 and muscle growth.327 Endothelial 
overexpression inhibited IGF-induced angiogenesis328 and adipose tissue 
expansion in adipocytes.329 In the heart, IBP4 enhances cardiomyocyte 
differentiation. Furthermore, it is required for cardiomyogenesis through a 
mechanism independent of IGF.330,331 These observations corroborate the 
suggested mode of action for IBPs, regulating the bioavailability and activity of 
IGF. However, in contrast with these observations, systemic administration of 
IBP4 increased bone formation and serum IGF levels, suggesting its ability to 
enhance IGF signalling through impeding IGF clearance.326,332 A similar 
mechanism has been suggested for storage of IBP-bound IGF in the ECM, 
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which could play a part in wound healing325 and may therefore be involved in 
fibrosis formation. 
 
Increased levels of IBP4 in the CF secretome after miR-21 mimic 
transfection could have several explanations. First, pro-proliferative effects of 
miR-21 may result in increased IBP4 synthesis and secretion. Alternatively, 
decreased cleavage due to lower levels of IGF or other proteolytic enzymes 
could have caused a relative increase of IBP4. IGF, reported to be the main 
determinant of IBP4 cleavage323, fell below the threshold of reliable detection 
in the secretome samples and was therefore excluded from analysis. 
Regardless, the absence of an effect in TGF-b1-stimulated CF or upon miR-
21 inhibition on IBP4 levels in the secretome challenges the relevance of our 
finding in the context of myocardial fibrosis. 
 
5.1.1.4 Granulins 
Granulins showed increased levels in media from both unstimulated cells 
transfected with miR-21 mimic and in TGF-b1-stimulated cells transfected with 
miR-21 inhibitor. In addition, a significant increase, yet with less than a two-
fold change, was seen after transfection of miR-21 mimic in TGF-b1-stimulated 
CF. 
 
The recent discovery that mutations in the progranulin gene give rise to 
frontotemporal dementia has resulted in an increased interest in this protein.333 
The progranulin protein is a secreted glycoprotein that can be cleaved into 
seven complete and one half mutually homologous peptides by 
metalloproteinases such as matrix metalloproteinase 9.334 In addition to the 
brain, granulins are widely expressed across tissues and cell types, including 
fibroblasts, where they are induced upon tissue injury.335 Interestingly, a later 
study, focussing on inflammation and wound repair, found that uncleaved 
progranulin and cleaved granulins have opposing effects.336 Cleavage is 
regulated by two molecules, with elastase digesting progranulin into the 
individual granulins, whilst the binding of secretory leukocyte protease inhibitor 
(SLPI) to progranulin protects it from elastase-mediated cleavage. Elastase is 
released from neutrophils during inflammation, while SLPI is released from the 
epithelium as well as macrophages and neutrophils. Thus, the balance 
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between elastase and SLPI and the concomitant balance between progranulin 
and its cleavage products is under control of different but overlapping sources 
of inflammatory mediators. 
 
Functionally, progranulin was shown to stimulate cell proliferation 
through activating MAP kinase and phosphoinositide 3-kinase337, whilst 
cleaved granulins inhibited growth of epithelial cells.336 In contrast, granulins, 
but not progranulin, were shown to attract neutrophils through triggering 
epithelial release of interleukin-8, whilst progranulin inhibited neutrophil 
activation and spreading. Furthermore, progranulin has a rate-limiting effect on 
wound healing in SLPI-deficient mice where progranulin cleavage is impaired. 
This implies that granulins promote inflammation, whilst progranulin enhances 
re-epithelialisation and wound healing. In light of the pathophysiology of 
fibrosis, uninjured tissue is abundant in SLPI and consequently progranulin, 
preventing inflammation from occurring. Upon injury, infiltrating leukocytes 
release elastase, cleaving resident progranulin into granulins that impede 
tissue regeneration and promote further activation of the inflammation 
response.336,338 
 
Increased secretion of granulin upon miR-21 mimic transfection is in line 
with the previously described induction of both miR-21 and granulin in 
fibroblasts upon tissue injury. The simultaneous increase in granulin release 
upon miR-21 inhibition may at first seem inconsistent. However, activity of 
progranulin and its cleavage products is highly dependent on the context of 
inflammatory cells. Consequently, the observed increase is unlikely to have a 
functional effect on cardiac fibrosis by itself. Despite having received little 
attention outside of the field of neuroinflammation, the 
progranulin/SLPI/elastase system may be of importance in the context of 
cardiac injury. Further study of this axis, as well as the effect of miR-21 
inhibition in vivo, is warranted to assess its relevance for the pathophysiology 
of cardiac fibrosis. 
 
In summary, we found no significant effect of miR-21 mimic or inhibitor 
transfection on fibroblast secretion of ECM proteins, in contrast to a previous 
report using a similar technique for a different miRNA.185 Upon miR-21 
 159 
inhibition, we did observe an increased secretion of VCAM1, a leukocyte cell 
adhesion molecule that may be involved in pro-fibrotic signalling but could also 
have been derived from residual endothelial cells; and for LG3BP, which may 
have anti-fibrotic effects through inhibiting fibroblast differentiation. None of the 
changes upon miR-21 mimic transfection in TGF-b1-stimulated cells reached 
statistical significance whilst showing a greater than two-fold change. In 
unstimulated cells, the observed increase in IBP4 secretion may have 
occurred as a downstream effect of miR-21 signalling, where its presence in 
the ECM may enhance pro-proliferative signalling by IGF through inhibiting 
IGF clearance. The changes that were seen for progranulin appear unspecific 
and are unlikely to be of significance without the context of the leukocyte-
derived factors that determine its signalling effects. 
 
5.1.1.5 Major ECM proteins 
As expected in the secretome of fibroblasts, the majority of identified 
proteins were key structural proteins such as collagens and major 
glycoproteins, as illustrated by Figure 17. A relatively large proportion of the 
total identified spectra consisted of peptides from type I and type III collagen. 
These fibrillar collagens are the most abundant collagens in the myocardium, 
accounting for approximately 80% and 10% of total myocardial collagen 
content, respectively.11,339 Fibronectin was identified as third most abundant 
protein. This glycoprotein mediates the attachment of collagen fibrils to the 
sarcolemma together with basement proteins such as collagen type IV and 
laminin, both being linked together by perlecan.340 High levels of all these 
proteins were identified in the CF secretome. 
 
There is striking similarity regarding identified proteins between this 
analysis and those previously reported by our own group185 and recently by 
others.291 However, in contrast to both other studies, no significant changes 
were observed upon miR-21 manipulation, regardless of the presence or 
absence of TGF-b1 stimulation. In contrast, marked effects were seen with 
TGF-b1 stimulation itself. Whilst this is not surprising, it does indicate the ability 
of the used experimental setup to identify changes in gene expression and 
protein secretion. This further supports the conclusion that direct effects of 
miR-21 on ECM secretion by CF are limited. 
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5.1.2 Cardiac fibroblast proliferation after transfections 
In contrast to the lack of changes on ECM secretion, a significant effect 
of miR-21 was seen on CF proliferation. This is consistent with the observed 
induction of periostin gene expression after miR-21 overexpression, which is 
a key marker of fibroblast proliferation and differentiation.289 Upon miR-21 
mimic transfection, a 24-hour follow-up identified a significantly higher 
proliferation rate, whereas transfection of miR-21 inhibitor showed the opposite 
effect when compared to its respective control. This finding is in line with 
previous observations from one of the first studies on miR-21 and cardiac 
fibrosis; here, miR-21 transfection increased CF survival in vitro as assessed 
by annexin V expression.118 This effect was confirmed in a smaller report 
published recently, using a 3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium 
bromide (MTT) assay.135 
 
As described in the Methods chapter (paragraphs 3.3-3.5), proteomic 
analysis of the CF secretome was performed using equal volumes of media 
and equal cell numbers for each sample at the start of the experiment. 
Therefore, an effect on proliferation would have also affected protein levels in 
the secretome. This was however not observed, for which several explanations 
can be given. Firstly, the difference in proliferation rate was relatively modest, 
both after miR-21 overexpression and inhibition, which could mean that the 
effect is insufficient to cause significant changes in protein secretion over a 48-
hour period. Second, to reduce the contamination of conditioned media with 
bovine serum, secretome analysis was performed using culture in serum-free 
medium. This may have suppressed proliferation overall, potentially 
compromising the ability to observe an effect of miR-21 manipulation. Previous 
analyses however were able to detect marked and extensive changes in gene 
expression and protein secretion by CF using a similar serum-free culture 
protocol.185,291 Lastly, secretome analysis was performed using conditioned 
media containing proteins that accumulated over a 48-hour period. The CF 
proliferation assay implied a trend towards decreasing differences after 24 
hours, implying contact inhibition as cells reach a state of confluence within 
the well (see Figure 11). It cannot be ruled out that a similar effect limited the 
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sensitivity of the CF secretome analysis to detect proliferation-driven 
differences. 
 
5.1.3 Analysis of miR-21 null mouse hearts 
Previous studies on miR-21 and cardiac fibrosis have used both 
pharmacological and genetic inhibition in mice, combined with different 
pathological scenarios. Results from two main studies on miR-21 and cardiac 
fibrosis were diametrically opposed. The first study showed a profound benefit 
of systemic antagomiR-21 treatment118, whilst the second study found no 
difference, neither after pharmacological inhibition using an octamer-based 
LNA inhibitor specifically targeting the miR-21 seed sequence, nor in miR-21 
null mice.110 The latter study also reported a normal phenotype of miR-21 null 
mice at baseline. This evaluation included the relative heart weight, fractional 
shortening as determined by echocardiography and protein levels of previously 
reported miR-21 targets. However, no analysis of gene expression or protein 
levels for ECM proteins was provided. Therefore, we used a proteomics 
approach focussed on the ECM, using a three-step protein extraction protocol 
as extensively used in previous work from our group.8,294 In addition, we 
performed gene expression analysis for several cardiac miRNAs and for 
transcripts encoding the most highly abundant proteins in the secretome 
analysis, as well as the significantly changing ones. 
 
Apart from the absence of miR-21, no significant differences were found 
for levels of the other analysed miRNAs, nor for the gene transcripts that were 
quantified. For the ECM protein analysis, there was remarkable overlap 
between the proteins that were detected at high levels and those that were 
found at the highest levels in the CF secretome. Despite the stable detection 
of fifty-five ECM proteins, no significant differences were observed between 
the miR-21 null and wild-type mouse hearts. Proteins that showed the greatest 
trends towards differences, although none reaching statistical significance, 
were microfibrillar-associated protein 5 (MFAP5), an ECM glycoprotein that 
has been reported to be a target of anti-fibrotic miR-29 and is involved in 
myofibroblast differentiation341; annexin A7 (ANXA7), a protein involved in 
calcium handing and electrical conduction in the heart342; and the collagen VI 
a6 chain. MFAP5 and collagen VI have both been reported to induce 
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myofibroblast differentiation in the heart.343 Whilst these could be interesting 
proteins to study further, validation of these findings would be required, in 
particular given the lack of significant changes for any of these proteins. 
Furthermore, as the used mouse model is a global miR-21 null mouse, it 
cannot be ruled out that these findings are an indirect effect due to the lack of 
miR-21 in other tissues or cell types. Importantly, the analysis of miR-21 null 
hearts underlines that miR-21 confers pro-fibrotic effects only in presence of 
tissue injury and a concomitant systemic response. 
 
5.1.4 Contradicting results in previous studies 
Whilst a remarkable benefit of systemic miR-21 inhibition has been widely 
reported, studies with opposing outcomes have disputed this conclusion. 
Several studies and commentaries have attributed disparate results to 
differences in the miR-21-targeting strategy. The first major study that failed to 
observe a benefit of miR-21 used both miR-21 null mice and short LNA 
octamers targeting miR-21.110 The lack of effect in miR-21 null mice could be 
due to compensatory mechanisms that occur due to embryological absence of 
miR-21253, or due to effects in other tissues that indirectly affect the fibrotic 
phenotype upon myocardial injury. Our observation of reduced platelet and 
leukocyte counts are an example of an extracardiac factor that may have 
affected the outcome. A head-to-head comparison of different anti-miRs 
indeed highlighted the disparity between pharmacological strategies.124 
Furthermore, phosphorothioate backbone modifications, a commonly used 
feature in anti-miRs, may induce platelet activation254, which may have had a 
marked effect on the outcomes of different studies. Besides, these findings 
may impede their clinical application if platelet aggregation is indeed induced. 
As reported in paragraph 4.3.3, we were unable to detect a platelet 
aggregation-inducing effect using light transmission aggregometry. Further 
safety studies specifically addressing this point are crucial prior to clinical 
evaluation. 
 
Differences in oligonucleotide design also affects their penetrance and 
retention across various tissues.344 A particular oligonucleotide design may 
target a certain cell type more efficiently. Contradicting results between studies 
using anti-miRs could therefore be explained by different pharmacodynamics. 
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The findings from our study, implicating miR-21 in systemic effects that may 
affect fibrosis, emphasises the importance of this aspect. Varying levels of 
penetrance in tissues beyond the targeted organ may be a relevant contributor 
that is insufficiently appreciated. 
 
5.1.5 Contributing cell types in cardiac fibrosis 
As pointed out in the introduction, the landmark study by Thum et al118 
concluded that the differential expression of miR-21, as well as the supposed 
therapeutic mechanism of miR-21 inhibition, depended on CF. The conclusion 
that miR-21 was primarily a fibroblast miRNA in the heart was subsequently 
confirmed in other studies.97,119,127,132,158 However, its expression in other cell 
types within and beyond the heart, such as endothelial cells and skeletal 
muscle cells, was also shown soon after. Expression in those cell types was 
linked to angiogenesis dysfunction345 and cell survival.151 The ubiquitous 
expression of miR-21 is of importance for the interpretation of previous and 
future studies. 
 
Conclusions about miR-21 expression within the cardiac cell population 
requires a critical appraisal of the experiments that underlie the attribution to 
fibroblasts. In most studies that determine cell type-specific changes and 
effects of miR-21 in the heart, a dichotomous approach is used. This means 
that cells are classified as either cardiomyocytes or ‘fibroblasts’. Detection of 
miR-21 is either carried out using in situ hybridisation in diseased tissues119,127, 
or by qPCR analysis or Northern blotting of isolated cells. Cell isolation 
techniques depend on differential attachment to a cell culture dish or 
differential sedimentation of cardiac cells obtained by enzymatic tissue 
digestion.118,132,158 These commonly used techniques separate 
cardiomyocytes from other cell types, yet the composition of the latter is not 
limited to fibroblasts. Several studies have aimed to characterise the non-
myocyte fraction, however this has so far been limited to fibroblasts, vascular 
cells such as smooth muscle cells and endothelial cells, and leukocytes.14,131 
Interestingly, a recent report in rat hearts identified miR-21 specifically in 




In an attempt to clarify some of the controversy regarding the responsible 
cell types for miR-21 induction in injured hearts and the therapeutic benefit, 
Ramanujam et al aimed to distinguish effects in different cell types.131 To do 
so, viral vectors with different tissue tropism were used. Whilst AAV9 was 
highly selective for cardiomyocytes, Moloney murine leukaemia virus (MMLV) 
targeted the non-myocyte cells but not cardiomyocytes. A further analysis of 
the composition of the non-myocyte fraction was in line with previous 
literature14, showing endothelial cells, fibroblasts and immune cells. MiR-21 
expression was found to be highest in the fibroblasts. Using an MMLV-green 
fluorescent protein (GFP) vector for visualisation, 60% of endothelial cells and 
fibroblasts appeared infected, whereas CD45+ immune cells did not acquire a 
detectable GFP signal. Similar results were found when treating miR-21fl/fl mice 
with AAV9 and MMLV vectors harbouring codon-improved Cre recombinase 
(iCre). Successful infection with this vector should result in iCre-mediated miR-
21 knockdown. MMLV-iCre significantly reduced miR-21 expression in CF, but 
not in cardiomyocytes or in the kidney, liver, lung or spleen. AAV9 on the other 
hand reduced miR-21 expression in cardiomyocytes as well as in the liver. 
 
When inducing cardiac remodelling using TAC, inhibiting miR-21 in 
cardiomyocytes worsened fibrosis, potentially by inducing apoptosis. Non-
myocyte inhibition however showed a strong attenuation of fibrosis and 
cardiomyocyte hypertrophy. From the seemingly opposing roles of miR-21 
inhibition depending on which cell type is targeted, and the lack of disease 
attenuation in global miR-21 null mice, the authors argue that miR-21 may act 
systemically as a modulator of inflammation. In this context, it is striking that 
effects of pharmacological inhibition of miR-21 on the fibrotic phenotype are 
only observed in presence of tissue damage. As this is likely to be 
accompanied by a systemic response, an indirect effect of miR-21 becomes a 
more likely hypothesis. This is supported by high expression levels of miR-21 
in cells of hematopoietic origin. 
 
Although these results highlight the importance of both fibroblasts and 
other systemic effects in the development of cardiac fibrosis, platelets were 
not included in the analysis despite previous evidence for their 
involvement.29,34,70,347–349 In addition to immune cells, platelets have also been 
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shown to infiltrate the diseased heart tissue.350 The link between platelets and 
tissue fibrosis has been suggested in other tissues such as the liver.351,352 
Although these studies imply platelet activation and/or sequestration within 
injured tissue, it is challenging to experimentally differentiate between blood 
contaminants and ‘resident’ cells. The sequence of washing and enzymatic 
digestion steps that is used during isolation of the different cardiac cell fractions 
is likely to lyse the platelets that were present within the tissue. Whilst the 
potential effects of the isolation methods on leukocytes has been determined, 
there is no mention of potential effects on cells that may have been lost during 
this process.14 
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5.2 Systemic effects of miR-21 
 
In addition to being expressed in a wide range of somatic cells, miR-21 
has also consistently been found in cells of hematopoietic origin.353 Whilst its 
expression in bone marrow progenitor cells is relatively low, this increases as 
the different progenitors progress through the differentiation stages towards 
mature cells.354–356 The involvement of an immune response during tissue 
remodelling may therefore contribute to the reported functions of miR-21. 
Expression and processing of the miR-21 precursor is enhanced by TGF-b 
signalling. Increased tissue expression might therefore reflect changes 
secondary to the inflammatory response.  
 
Furthermore, increased cardiac levels of miR-21 may also reflect the 
influx of immune cells rather than induction of miR-21 expression in resident 
tissue cells.346 Transfer of miRNAs from circulating cells to infiltrated tissue 
may modulate the translation of proteins in the inflamed organ.353,357 Thus far, 
most studies have attributed changes in miR-21 expression to resident cell 
types only. The contribution of circulating cells may therefore have been 
overlooked. As we have recently pointed out however, it is debatable how 
plausible miRNA transfer is as a modulator of mRNA translation in a recipient 
cell, given the several orders of magnitude difference in abundance between 
circulating and cellular miRNA levels.96 
 
5.2.1 Inflammatory cells and miR-21  
Whilst miR-21 induction in inflammatory cells is widely described, it 
appears that it acts as an ‘emergency brake’ on inflammation.179 Expression 
of miR-21 increases in endotoxin-treated macrophages upon the engulfment 
of apoptotic cells, resulting in an attenuation of the inflammatory response.358 
During macrophage polarisation in vitro, changes in miR-21 expression are not 
as pronounced359, suggesting that miR-21 induction only occurs in the 
presence of tissue damage. In macrophages, miR-21 directly targets the pro-
inflammatory programmed cell death protein 4, thereby increasing the 
secretion of anti-inflammatory interleukin-10.358,360 In addition, targeting of 
PTEN steers macrophages towards a reparative phenotype361, promoting 
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resolution of inflammation and tissue recovery.362 Altogether, miR-21 
activation appears to modulate the inflammatory response, in part through 
steering monocyte differentiation towards a more reparative macrophage 
phenotype. 
 
Canfrán-Duque et al showed that miR-21 is the most abundant miRNA in 
macrophages.180 Studying its effects on atherosclerosis, miR-21 accumulated 
in murine atherosclerotic plaques, along with the macrophage marker CD68. 
Using a combination of double miR-21-/-/LDLr-/- mice, macrophage deficiency 
of miR-21 promoted vascular inflammation and plaque necrosis. Deficiency of 
miR-21 in bone marrow cells in LDLr-/- mice resulted in larger and less stable 
atherosclerotic plaques due to increased vessel wall infiltration. Furthermore, 
miR-21-/- macrophages produced higher levels of cytokines upon endotoxin 
stimulation and cleared less apoptotic material in vitro but were more 
susceptible to apoptosis and lipid accumulation. These results are in line with 
the previously mentioned immunomodulatory effects of miR-21 in 
macrophages. A recent study by Jin et al found more advanced plaque 
formation at an early age in Apoe-/-miR21-/- mice, with a concomitant increase 
of macrophage infiltration and foam cell formation. Factors that are secreted 
from Apoe-/-miR21-/- macrophages could suppress vascular smooth muscle 
cell proliferation in vitro.181 
 
The suggested role of miR-21 as an ‘emergency brake’ on the 
inflammatory response is not limited to monocytes and macrophages. Through 
targeting interleukin-12p35, miR-21 steers T-cells towards a Th2 
response363,364, which is considered a mechanism to counterbalance the pro-
inflammatory Th1 cells. Consequently, higher levels of miR-21 are associated 
with auto-immune diseases such as allergic airway inflammation365 and 
psoriasis366, pathologies believed to be mediated by Th2 cells. These findings 
have led to landmark papers on leukocyte miR-21 as a therapeutic target, 
where miR-21 inhibition in mice improved psoriasis366 and lupus 
erythematosus.367 From an oncological perspective, miR-21 is considered an 
‘oncomiR’ for its effects on tumour cell proliferation, but also because of its 
inhibitory effect on the immune response to tumour cells.112 These results 
underline the potential side effects of systemic or local miR-21-targeting 
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therapy, whilst also supporting the notion that systemic miR-21 inhibition may 
act through circulating cells. Our findings of miR-21 inhibition affecting TGF-
b1 release may indeed be an example of this hypothesis, where increased 
release of this pleiotropic cytokine can have widespread effects on 
inflammation depending on the timing after injury.368 
 
In our study, we have identified WASp as a direct miR-21 target in 
megakaryocytes and platelets. Whilst this protein plays a key role in 
inflammatory cells (see 5.3.6.2), it remains to be determined whether this 
targeting and potential downstream consequences upon miR-21 inhibition also 
occur in leukocytes. We have discussed in the introduction that miRNA 
targeting can be highly dependent on tissue or cell-type.369 Our analysis of 
blood cells in miR-21 null mice identified differences in the number of 
circulating platelets and leukocyte subtypes. Whilst this finding has not been 
reported previously, to our knowledge, it emphasises that miR-21 inhibition has 
key effects on the bone marrow and bone marrow-derived cells. Whether the 
effects on platelet WASp levels and blood cell counts contribute to the role of 
miR-21 on inflammation remains to be studied. 
 
5.2.2 miR-21 and associated proteins in the circulation 
Circulating miRNAs and other non-coding RNAs have been studied 
extensively in the context of cardiovascular disease. Initial studies focussed 
mainly on their biomarker potential. More recent studies however implicate 
circulating miRNAs as functional or pathological mediators, either in 
leukocytes and platelets or by transfer to cells in the vessel wall.96,227 In this 
study, we used a proteomics approach to screen for associations of circulating 
miR-21 with proteins involved in CVD and inflammation. 
 
Given the complexity and large dynamic range of the plasma proteome, 
a hybrid strategy was used to quantify proteins. MS can provide quantification 
for relatively high-abundant proteins using heavy-labelled peptide standards 
that are added to the samples during sample preparation.370 To quantify 
smaller and less abundant proteins, proximity extension assays were used. 
This technique relies on amplification of annealed DNA tags that are attached 
to antibody pairs targeting neighbouring epitopes within a single protein.371 
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With previous studies linking several miRNAs, including miR-21, to platelets 
as a major source, conventional sandwich ELISAs were used to complement 
measurements with markers of platelet activation. This strategy allowed us to 
quantify a broad panel of proteins in the plasma samples collected as part of 
the Bruneck study. 
 
In line with previous findings, this analysis showed marked overlap 
between proteins correlating with miR-21 and those indicating platelet 
activation. This suggests that a distinct proportion of the protein panel shared 
its source with miR-21. Interestingly, miR-21 showed pronounced correlation 
with several proteins implicated in wound repair and fibrosis. This is not 
surprising in light of the established role of platelets in tissue injury. Of the 
highly correlating proteins, one of major interest from the perspective of fibrosis 
was LAP-TGF-b1. TGF-b1 has previously been reported to be abundant in 
platelets55 with its release being implicated in cardiac disease29,34 but also in 
other disease processes such as cancer metastasis.21 These findings 
prompted the hypothesis that miR-21 inhibition may affect fibrosis through 
modulating the role of platelets in tissue remodelling. 
 
5.2.3 Cellular contaminants of circulating biomarkers 
Platelets contain a vast range of proteins inside their granules, many of 
which are released upon their activation. During preparation of blood plasma 
or serum for experimental or clinical analysis purposes, centrifugation is 
applied to separate blood cells from the cell-free fraction. The use of blood 
tubes containing anticoagulants such as citrate, heparin or EDTA is aimed at 
obtaining cell-free plasma whilst preventing activation or lysis of blood cells 
prior to or during sample preparation. The preparation of serum depends on 
clot formation inside the blood container after venepuncture, either 
spontaneously or enhanced with clot-activating factors. Whilst serum is often 
described as ‘plasma minus fibrinogen and clotting factors’, this statement 
overlooks the fact that platelet activation during clotting causes degranulation 
with a concomitant increase in platelet-derived protein levels. This is reflected 
in the significantly higher levels of PF4 in serum samples when compared with 
plasma271 as well as a markedly different proteome.372 For proteins that are 
 170 
abundant in platelets, this consequently means that serum measurements do 
not reflect protein levels of the cell-free fraction of the circulating volume. 
 
Previous work has shown that protein analysis using plasma is 
profoundly affected by pre-analytical variables. Several factors can perturb 
sample quality, such as pre-centrifugation delay, freeze-thaw cycles and 
haemolysis. A recent study determined effects of such variables on plasma 
proteins measured by the same two proximity extension assay panels as used 
in our study.373 Whilst freeze-thaw cycles had no major impact, the time and 
storage temperature between venepuncture and centrifugation was found to 
have a significant effect on protein levels. This is in line with findings from 
previous studies.372 
 
Another potential contaminant during plasma preparation is the 
unintended activation or residual presence of blood platelets. This introduces 
significant variation in the plasma composition, with regards to both 
proteins271–273 and miRNAs (see Figure 47).274,275 We have recently published 
a set of recommendations regarding sample preparation for the measurement 
of circulating miRNAs, most of which equally apply for proteins (see Appendix 
3).96 Samples should be handled carefully to avoid haemolysis. To avoid 
platelet activation, samples should be handled at room temperature and 
centrifugation should be performed in two steps at a consecutive lower and 
higher speed and in presence of platelet activation inhibitors. 
 
Focussing on the observed correlation between plasma miR-21 and LAP-
TGF-b1, there have been several reports that indicate the importance of 
sample preparation for this protein specifically. Wakefield et al in 1995 
highlighted the importance of platelet activation when measuring its plasma 
levels276, arguing that plasma rather than serum needs to be used for the 
measurement of TGF-b1. More recent studies emphasise the confounding 
effects of residual platelet content and platelet activation on TGF-b1 
measurements.29,64,277 Despite evidence for its importance in preclinical 
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Figure 46. The platelet contamination continuum in blood samples. A:
Workflow for the preparation of PPP from PRP by two-step centrifugation.
Addition of prostaglandin such as PGE1 or PGI2 inhibits platelet activation
during centrifugation. B: Concerns with regards to miRNA and protein
measurements in the different samples range from a contamination with
leukocytes in PRP, proteolytic activity in serum to residual platelets in plasma.
PRP and serum should reflect a combination of plasma and platelet content;
PPP should reflect in vivo platelet release; plasma samples reflects extracellular
miRNA and protein content but may additionally reflect either cell content or
release. This continuum is dependent on the amount of residual platelets in the
plasma samples and platelet activation during plasma preparation, in particular
during centrifugation.
Platelet miRNA content
Figure 47. The platelet contamination continuum in blood samples. A: Workflow 
for the preparation of PPP from PRP by two-step centrifugation. Addition of 
prostaglandin such as PGE1 or PGI2 inhibits platelet activation during centrifugation. 
B: Concerns with regards to miRNA and protein measurements in the different 
samples range from contamination with leukocytes in PRP and proteolytic activity in 
serum to residual platelets in plasma. PRP and serum should reflect a combination 
of plasma and platelet content; PPP should reflect in vivo platelet release; plasma 
samples reflects extracellular miRNA and protein content but may additionally reflect 
either cell content or release. This continuum is dependent on the number of residual 
platelets in the plasma samples and platelet activation during plasma preparation, in 
particular during centrifugation. 
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hampered by inadequate pre-analytical procedures. The highly variable 
baseline measurements for TGF-b1 appear to have prevented further research 
from being taken forward. Altogether, this context underscores a more tailored 
analysis of plasma and platelet samples to study the interaction between miR-
21 and platelet TGF-b1. 
 
5.2.4 Circulating and platelet-derived TGF-b1 
Previous studies have shown that large pools of TGF-b1 are stored within 
platelets, mainly in its latency-associated form.60,78 In addition to carrying 
substantial amounts of TGF-b1, platelets are also the only cell type known to 
constitutively express the surface-docking leucine-rich repeat-containing 
protein 32.374 Through this receptor, platelets do not only carry TGF-b1 
secreted from its own granules, but can also capture TGF-b1 that is secreted 
from other cell types.375 A recent study by Rachidi et al found that through this 
receptor, platelets are a key determinant of the activation of circulating TGF-
b1.368 This is functionally in line with a previous study that showed activation 
factors being co-released with latent TGF-b1 upon activation.376 Altogether, 
these studies indicate that platelets play a crucial role in delivering active TGF-
b1 during their activation. 
 
5.2.4.1 Protein complexes in the human platelet releasate 
To provide further insight into platelet-released TGF-b1, we performed a 
comprehensive analysis of the human platelet releasate by MS analysis, 
comparing reduced and non-reduced supernatant from thrombin-activated 
washed platelets. The ability of this approach to differentiate between 
biologically relevant multimeric complexes was shown for several proteins; as 
examples, fibrinogen and fibronectin were presented in the results section. 
Analysis of TGF-b1 in the releasate using this approach highlighted two key 
aspects. Firstly, reducing conditions showed that all detected TGF-b1 and LAP 
peptides were found separate from each other, indicating that there was no 
detectable presence of uncleaved pro-TGF-b1. Second, comparison of 
reducing and non-reducing conditions indicated that all TGF-b1 peptides were 
detected at a part of the gel that implies a homodimer not bound to LAP. On 
the other hand, LAP peptides were detected much higher than the predicted 
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molecular mass of LAP itself or the SLC, indicating binding to other proteins. 
Co-localisation in the gel with peptides derived from LTBP1 indicate the 
presence of the canonical LLC. 
 
These findings indicate that within five minutes of thrombin-mediated 
activation, the platelet releasate contains TGF-b1 in its active form, either as a 
result of rapid activation by co-released factors or due to active TGF-b1 release 
per se. As protease inhibitors were added 5 minutes after thrombin activation, 
pro-TGF-b1 cleavage or SLC/LLC dissociation is unlikely to have occurred 
beyond this time point. In the context of plasma measurements for TGF-b1, 
these results indicate that an approach using antibodies that target the LAP 
rather than the active segment of this protein might provide a suboptimal 
readout for TGF-b1. This was highlighted by our analysis in PPP using 
separate measurements for LAP and active TGF-b1, as discussed in the 
following paragraph. 
 
5.2.4.2 Correlations after optimised sample preparation 
For the 2015 Bruneck study follow-up, we collected samples taking into 
account the concerns described in the literature as well as our own analysis of 
the platelet releasate. To minimise platelet contamination, we optimised a 
protocol that involved similar features as recently reported by Mancini et al to 
be the optimal conditions for the analysis of plasma TGF-b1.64 Using PPP, 
measurement of miR-21 by qPCR and a plasma protein panel by PEA allowed 
us to compare their correlations and assess their dependence on sample 
preparation. Additionally, the analysis in PPP provided a readout more likely 
to reflect the in vivo situation in the circulation. 
 
In PPP, several proteins were also found to strongly correlate with miR-
21, overlapping with those identified in conventional plasma from the Bruneck 
study 2000 follow-up. Conversely however, there was a marked proportion of 
proteins that did not show any correlation in PPP whilst doing so in the previous 
analysis using conventional plasma. Interestingly, one of the proteins that 
showed a markedly lower correlation with miR-21 in PPP compared to that in 
conventional plasma, was LAP-TGF-b1. A comparison of PRP and PPP 
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confirmed platelet dependency but is unable to differentiate between platelet 
content and release. Our PPP preparation method is aimed at decreasing both 
ex vivo platelet activation as well as reducing the number of residual platelets 
in the plasma. The previously mentioned study by Rachidi et al showed that 
TGF-b1 is released from its latency complex whilst being retained on the 
GARP receptor at the platelet surface.368 Although this study does not provide 
any details as to what happens to LAP after TGF-b1 is released from the 
latency complex that is captured by GARP, their findings could suggest that 
LAP stays behind within this receptor on the platelet membrane. 
Consequently, this would result in a disproportionately high amount of LAP to 
be detected with higher levels of residual platelets in plasma. 
 
To bypass the dependency on measurements that measure LAP as a 
readout for TGF-b1, we performed ELISA measurements that selectively 
detect active TGF-b1, as shown in Figure 1. In contrast to the PEA-based 
measurement of LAP-TGF-b1, a strong correlation was indeed found between 
miR-21 and the ELISA-based TGF-b1 measurement. Correlation between 
LAP-TGF-b1 and active TGF-b1 was relatively moderate however. In the 
context of studies aimed at optimising plasma TGF-b1 measurements, the 
average concentration found in the Bruneck 2015 PPP was in a similar range 
as those reported by both Mancini et al and Wakefield et al.64,276 Despite 
specific measures to reduce ex vivo platelet activation and residual platelet 
content, the strong correlation between miR-21 and TGF-b1 persisted. This 
strengthens the hypothesis that platelets are the mutual source of 
extracellularly circulating miR-21 and TGF-b1. 
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5.3 Platelets and miR-21 
 
The study of human plasma from the Bruneck cohort identified a link 
between miR-21 and TGF-b1 in platelets. In light of the literature, this may play 
an important role in the pathophysiology of fibrosis. We therefore went on to 
further analyse the effects of miR-21 on platelets using in vivo models. 
 
5.3.1 Immunodepletion of platelets in mice 
To study the correlation between miR-21, TGF-b1 and platelets, we first 
used an interventional model in mice. Through antibody-mediated platelet 
depletion in wild-type mice, we determined the consequence of reduced 
platelet counts on levels of both miR-21 and TGF-b1 after 48 hours. Our 
hypothesis of platelets being a major source for both, suggests that their levels 
would be reduced after platelet depletion. In the murine PPP, a significant 
reduction was indeed found for TGF-b1, along with platelet activation marker 
PF4, which is in line with previous literature.29 However, this decrease was not 
observed for miR-21 or for any of the other miRNAs that were measured, with 
miR-320 showing increased levels after platelet depletion despite it being 
described as platelet-enriched. 
 
Several reasons could explain why no effect of platelet depletion was 
seen for miR-21. Firstly, the half-life of miR-21 may exceed the 48-hour time 
frame that was used in this experiment. Studies have reported markedly 
varying half-life values for plasma miRNAs, ranging from several hours377 to 
weeks.378 This half-life can be expected to show a wide range across the 
circulating miRNA pool, as there is variation in the mechanisms that protect 
different miRNAs from degradation in the circulation.212 For miR-21, a previous 
study evaluated the effect of antiplatelet therapy on plasma levels. In patients 
on aspirin, evaluation of miR-21 levels 48 hours after initiation with additional 
antiplatelet drugs (clopidogrel or dipyridamole) showed no effect, whereas 
single or dual antiplatelet treatment initiation in therapy-naïve healthy 




Upon platelet depletion, we did find higher levels of miR-320 in plasma, 
whilst a trend in a similar direction was seen for several other miRNAs that are 
considered platelet-enriched. Rapid platelet aggregate formation and a drop in 
their count are seen upon administration of the anti-CD42b antibody.379 This 
may imply that platelet miRNAs are released into the circulation upon platelet 
aggregation. Platelet activation 48 hours prior to isolation of plasma may 
indeed explain why levels of platelet miRNAs are increased, in particular in the 
context of a relatively long half-life. Alternatively, circulating levels of miR-21 
may to a significant extent be dependent on non-platelet sources such as 
leukocytes, dampening the effect that is seen for miRNAs such as miR-320. 
Furthermore, to our knowledge it is currently unknown whether systemically 
delivered anti-CD42b antibody affects megakaryocytes and whether these 
constitute a potential source of circulating miRNAs upon activation or rupture. 
Further study into the half-life of miR-21 and circulating miRNAs in general are 
needed to characterise their dynamic profile upon secretion into the blood. 
 
5.3.2 Immunoprecipitation in megakaryoblastic cells 
Whilst we have so far shown dependency of miR-21 on platelets in the 
circulation, there is ongoing debate as to what extent platelet RNA has 
functional relevance.380,381 Generally, platelet RNA is considered to be a 
readout of the RNA signature in the megakaryocytes from which they are 
derived. Therefore, we used a cell line model of megakaryocytes to study miR-
21 levels. 
 
Megakaryocytes constitute a relatively small fraction of the bone marrow 
cell population and are therefore challenging to isolate in substantial amounts. 
Thus, megakaryoblastic cell lines are commonly used as a surrogate, in 
particular the human leukaemic cell line MEG-01. To study whether miR-21 
was actively processed and part of the silencing complex that mediates the 
function of miRNAs, we performed an immunoprecipitation in these cells using 
an Ago2-targeting antibody. In the co-precipitated RNA, we found marked 
enrichment of miR-21, along with miR-126 and miR-223 which are also 
commonly described platelet-enriched miRNAs.217 Conversely, U6 and 
RNU48 were used as non-miRNA controls, with, as expected, no enrichment 
being found. The fact that MEG-01 cells are oncological cells requires careful 
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interpretation from a translational perspective. However, in light of our other 
findings on miR-21 as an abundant platelet miRNA in both humans and mice, 
Ago2 immunoprecipitation in MEG-01 cells supports the hypothesis that miR-
21 has a functional role in megakaryocytes. This suggests that miR-21 may 
regulate protein synthesis within megakaryocytes as well as in platelets. 
 
5.3.3 Systemic inhibition of miR-21 in mice 
 
5.3.3.1 Oligonucleotide constructs and platelet aggregation 
We aimed to further study the effects of miR-21 in platelets by using in 
vivo miR-21 inhibition. As specific types of oligonucleotides were reported to 
induce platelet aggregation by interacting with the collagen receptor254, we first 
evaluated several anti-miR constructs ourselves. For this purpose, we isolated 
PRP from healthy volunteers and incubated the platelet suspensions with 
different types of oligonucleotides using similar concentrations as described in 
the report by Flierl et al. For our in vivo miR-21 inhibition studies, we selected 
a cholesterol-conjugated antisense antagomiR-21 construct with similar 
chemical properties as the inhibitors previously used in our group to 
systemically inhibit miR-29b185, miR-195281, miR-126217 and miR-122.280 None 
of the tested oligonucleotides showed an effect on platelet aggregation within 
40 minutes. 
 
Interestingly, our panel of oligonucleotides included several subtypes that 
met with the criteria to affect platelets as described by Flierl et al but failed to 
see induction of aggregation. A recent study further investigated the effect of 
oligonucleotide modifications on platelets.382 Here, platelet aggregation was 
induced by oligonucleotides with at least twelve consecutive phosphorothioate 
backbone modifications. However, LNA modification of the ribose moiety of 
the backbone, as also used for the majority of oligonucleotides that we tested, 
markedly reduced this pro-aggregation effect. The antagomiR construct that 
we tested contained two and four phosphorothioate modifications on either 
end, falling well below the reported minimum threshold to affect platelets. In 
summary, these studies and our results suggest that extensive 
phosphorothioate backbone modifications can induce platelet aggregation but 
this effect can be mitigated by additional modifications to the backbone. Given 
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the results from these studies as well as our own analysis, we proceeded to 
use the cholesterol-conjugated antagomiR-21 and a chemically corresponding 
non-targeting control-antagomiR for in vivo inhibition of miR-21. 
 
5.3.3.2 Effects of antagomiR-21 across tissues 
Systemically delivered antagomiRs remain stable for over 2 weeks after 
delivery. A different extent of downregulation is seen across tissues, 
depending on the bioavailability and the endogenous miRNA levels in each 
tissue.108 To achieve sustained inhibition, repeated injections are often used. 
In order to determine the efficacy of miR-21 inhibition across different tissues, 
we used qPCR analysis of isolated RNA. As a positive control for adequate 
antagomiR preparation and efficacy, RNA extracted from the liver is often 
used, being the organ that is most readily targeted after antagomiR injection. 
In our experiments, marked inhibition was indeed observed in the liver, as well 
as in the kidney. Major tissue penetrance has previously been reported in the 
latter organ as well, which is highlighted by selection of the kidney for the first 
clinical trial of miR-21 inhibition. Significant downregulation was also observed 
in the bone marrow and heart, although to a lesser extent. 
 
To evaluate off-target or secondary effects of antagomiR-21 treatment, 
we evaluated several key miRNAs in each of the above-mentioned tissues. 
Effects that are observed can be due to non-specific binding of the antagomiR 
to other miRNAs but is more likely to be the effect of the interference with 
transcription, processing or degradation of other miRNAs through various 
factors. In our analysis, a significant effect was observed for miR-1 in the heart, 
although the change in expression of less than 10% is unlikely to have a major 
impact on this highly abundant cardiac miRNA. 
 
Most studies using miRNA inhibition provide little information regarding 
the effects beyond the organ and miRNA of interest. One of the exceptions is 
the previously mentioned study by Ramanujam et al (see paragraph 5.1.5), 
using AAV9- and MMLV-mediated miR-21 inhibition in specific cell types within 
the heart.131 In this study, AAV9-mediated inhibition reduced miR-21 levels in 
cardiomyocytes as well as in the liver. Conversely, intra-pericardially delivered 
MMLV specifically targeted non-myocytes in the heart, with evaluation of miR-
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21 in kidney, liver, lung and spleen showing no effect. MiR-21 levels in the 
bone marrow were not reported. However, their supplemental information 
showed a minor effect of intra-pericardial MMLV-GFP injections on isolated 
bone marrow cells. Of note, cells were isolated using an anti-CD45 antibody, 
thereby excluding megakaryocytes and platelets. 
 
In the following paragraphs, we will discuss effects of systemic miR-21 
inhibition that could affect cardiac disease. Our findings highlight the need 
within the miRNA research field to evaluate effects beyond the organ and 
miRNA that are the focus of a specific study. This is increasingly the case as 
studies progress towards application of local miRNA targeting strategies. With 
this trend, the focus will be increasingly narrowed down to the area of interest 
without guarantees that the effect is actually occurring solely at this site. We 
have recently pointed out this note of caution in a commentary that 
accompanied a study using local miR-21 delivery to prevent atherothrombotic 
events.179,181 
 
5.3.4 Platelet count and aggregation after miR-21 inhibition 
Upon systemic treatment with antagomiR-21 by three intraperitoneal 
injections on consecutive days, the animals were kept for four days until 
collection of blood and other tissues. Mouse platelets are known to have a life 
span of approximately 5 days.383 By collecting samples 7 days after therapy 
initiation, it can be assumed that the vast majority of platelets in the circulation 
were synthesised by megakaryocytes that had been exposed to antagomiR-
21. Flow cytometry-based counting was performed using the forward and side 
scatter characteristic of platelets, as well as APC-labelled anti-CD41 antibody 
positivity. Neither of these measurements showed a significant difference in 
platelet count. To our knowledge, none of the previous studies have reported 
platelet counts after systemic inhibition of miR-21. 
 
In contrast to its pharmacological inhibition, genetic ablation of miR-21 
resulted in lower circulating platelet and leukocyte counts, as determined by 
automated cell counting. Whilst the monocyte and lymphocyte concentrations 
in miR-21 null mice did still fall within the normal range, these findings warrant 
further investigation as to whether the inflammatory response is affected (see 
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5.2.1). The contradicting findings between pharmacological and genetic 
inhibition of miR-21 on platelet counts puts further emphasis on the 
discrepancy between these two strategies. The increase in megakaryocyte 
numbers in miR-21 null mice may suggest compensatory upregulation of 
megakaryocyte proliferation in response to lower platelet counts. Alternatively, 
lower platelet counts in combination with higher megakaryocyte numbers may 
indicate a failure of megakaryocytes to mature towards the platelet-releasing 
differentiation stage. Further study is required to elucidate the underlying 
mechanisms for our observations. 
 
As pharmacological miR-21 inhibition did not affect platelet counts, we 
next assessed effects on the platelet aggregation response to different 
agonists. Being a key feature of the platelet response to surface receptor-
mediated activation, measurement of aggregation is widely used as a platelet 
function test. The most commonly used method in humans for this purpose is 
light transmission aggregometry. This method involves the isolation of PRP, 
which is then placed in a glass cuvette inside an aggregometer. This device 
detects transmission of light in real-time through the PRP-containing cuvette, 
where platelets in the suspension absorb light. Under continuous stirring and 
heating to 37°C, different platelet agonists are added. As platelets aggregate, 
transmission of light through the cuvette increases. 
 
As this method requires a volume of approximately 200 µl for each 
cuvette, it is not well-suited for the study of murine platelets. To address this 
issue, a low-volume adaptation of the aggregometry method has been 
designed, allowing for the assessment of aggregation response to a range of 
agonists whilst requiring markedly lower amounts of blood.384 We recently 
applied this method to determine the platelet aggregation response in mice 
after systemic inhibition of miR-126 (see Appendix 3).217 Here, this method 
identified significantly reduced aggregation to several platelet agonists. These 
findings highlighted both the ability of systemic inhibition of a miRNA to affect 
platelet function, as well as the ability of plate-based aggregometry 
measurements to detect such differences. Furthermore, we confirmed in this 
study that there was no difference between PBS-treated mice compared to 
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antagomiR-control, corroborating our in vitro findings that the antagomiR 
construct does not induce platelet aggregation. 
 
We used the same method to determine the platelet aggregation 
response after systemic miR-21 inhibition. Aggregation was seen in response 
to both concentrations of AA, as well as to the higher concentrations of PAR4 
amide and collagen. There was no significant difference across the different 
agonists between PRP from antagomiR-21-treated mice and controls, 
suggesting that miR-21 does not affect platelet activation. 
 
There are however several limitations of this approach. Firstly, subtle 
differences may not be identified as only a selected panel of agonists is used 
in the assay. MiR-21 may affect the response to secondary mediators of 
platelet activation that were not evaluated. Furthermore, as miRNAs fine-tune 
protein levels and effects are therefore often subtle, this assay may lack 
sensitivity to detect changes that occur in vivo. Our previous findings for miR-
126, however, do highlight that this method is capable of detecting miRNA-
related changes; a similar dosing regimen was used for miR-21 as for our 
previous analysis of miR-126. Moreover, plate-based light transmission 
aggregometry has been proven a valuable tool for the evaluation of platelet 
reactivity in humans.385 
 
5.3.5 The platelet releasate after antagomiR-21 treatment 
In addition to the platelet count and their reactivity to different agonists, 
we analysed the effect of systemic antagomiR-21 treatment on the platelet 
releasate. In terms of platelet function, it can be argued that the proteins 
released upon activation confer a major share. With regards to the role of 
platelets in haemostasis, the initial activation by external agonists such as sub-
endothelial collagen is rapidly followed by the release of factors that recruit and 
activate other platelets. The ‘snowball effect’ of secondary platelet activation 
is therefore highly dependent on the platelet releasate. Furthermore, as 
discussed in the introduction, proteins released by platelets are widely 
implicated in functions related to inflammation and tissue repair. Therefore, an 
effect of miR-21 on proteins in the platelet releasate may affect the 
pathophysiology of fibrosis. 
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5.3.5.1 Proteomic screen of the platelet releasate 
Although several pro-fibrotic proteins are known to be secreted from 
platelets, we pursued an unbiased proteomics approach to determine the 
effects of miR-21 inhibition. To do so, the releasate was isolated from platelets 
of mice upon pharmacological antagomiR-21 treatment, and was then 
analysed by untargeted gel-based MS. This method was similar to the one 
used to analyse the conditioned media of CF as well the human platelet 
releasate. Comparing human and murine platelet releasates revealed a major 
overlap, highlighting both the consistency of this method as well as the 
translational potential of findings in the murine releasate. 
 
Comparison of the releasate from antagomiR-21-treated mice with 
respective controls identified three proteins that were released at lower levels 
after systemic miR-21 inhibition, including TGF-b1. TGF-b1 is generally 
considered to be an a-granule constituent, as described in the introduction. 
Both other proteins that showed significantly lower levels in the antagomiR-21 
releasate are also found in these granules. As indicated by the GO analysis of 
the releasate, this comparison could suggest that reduced release was seen 
for several a-granule proteins. However, recent studies have contested the 
platelet granule classification, suggesting that here is heterogeneity in a-
granule content and release. This will be discussed later in this chapter. 
 
Of the proteins that showed higher levels in the platelet releasate of 
antagomiR-21-treated mice, none reached statistical significance. However, it 
can be noted that the majority of these proteins have been identified outside 
of the a-granule, highlighting the contrast with those that were found at lower 
levels in these releasates. For example, approximately 90% of platelet GAPDH 
has been reported to reside in the cytosol.386 Similarly, Src, a key mediator in 
platelet receptor-downstream signalling, is found in the cytosol where it is 
closely associated with the tails of membrane-bound receptors.387 Enrichment 
of this kinase in platelets is further indicated by the high correlation with miR-
21 in PPP, as we found in our analysis in the Bruneck study cohort (see Figure 
26). Catalase, involved in the decomposition of hydrogen peroxide, has been 
found in small amounts in peroxisomes, an organelle distinct from the other 
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platelet granules.388 Equal amounts of protein from each platelet releasate 
sample were injected into the mass spectrometer. Hence, the inhibited release 
of a-granule proteins from antagomiR-21-treated mouse platelets may have 
resulted in a relatively higher detection of proteins that reside outside of these 
granules. 
 
5.3.5.2 Validation by ELISA using different agonists 
We used MS analysis of the releasate as a screening tool for potentially 
affected proteins. No correction for multiple testing was performed, 
necessitating independent validation of findings using an alternative technique. 
Given its high sensitivity and specificity, we used ELISA measurements in the 
supernatant of platelets activated with different agonists. This allowed for the 
assessment of potential agonist-specific and dose-specific effects. Given the 
interest in TGF-b1 in the context of fibrosis, we focussed on this protein in 
particular. To determine a general effect on a-granules, PF4 was selected, 
being a widely used marker of release from these granules. 
 
First, TGF-b1 and PF4 levels were measured in PPP. No difference was 
found for either protein between antagomiR-21-treated mice and controls. For 
TGF-b1, this implies that pharmacological miR-21 inhibition does not lower 
TGF-b1 systemically. Furthermore, it discredits the possibility that lower TGF-
b1 levels found by MS analysis of the releasate can be attributed to plasma 
contamination. PPP levels of PF4 can be interpreted as a marker of in vivo 
platelet activation, due to its platelet specificity. As PF4 levels in PPP were not 
different after miR-21 inhibition in vivo, it can be inferred that there is no 
difference in platelet activation upon this treatment. This is in line with our 
findings for the aggregation response. 
 
In contrast, changes were observed when analysing the releasate in 
response to platelet agonists. For PF4, a significant increase was seen in 
response to increasing dosage of platelet agonist, indicating its correlation with 
platelet activation. Expectedly, this increase paralleled the aggregometry 
results that have been discussed previously. A similar response was seen for 
TGF-b1 levels in control-antagomiR samples, which increased with higher 
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concentrations of collagen and PAR4 amide. Strikingly however, antagomiR-
21 treatment attenuated the increase in TGF-b1 release from platelets at a 
high dosage of either agonist. Although a similar pattern could be discerned 
for PF4 release, this did not reach statistical significance. 
 
5.3.5.3 Changes in platelet or megakaryocyte TGF-b1 levels 
Decreased TGF-b1 levels in the platelet releasate after pharmacological 
miR-21 inhibition could depend on either lower levels in platelets or an 
inhibitory effect on its release. To assess its protein levels, platelets were 
isolated from mice upon antagomiR treatment and lysed for protein extraction. 
Using immunoblotting, no significant difference was seen between platelets 
isolated from antagomiR-control- and antagomiR-21-treated mice. To 
determine whether a difference could be observed in gene expression, bone 
marrow extracts from the same mice were assessed. Here, too, no significant 
difference was seen for Tgfb1 expression. Although TGF-b1 is enriched in 
platelets, other sources of this protein could in theory also affect platelet levels, 
given the ability of platelets to engulf proteins. However, Tgfb1 expression in 
the heart, kidney and liver was also unaltered, despite significant miR-21 
inhibition. This is supported by similar PPP levels after antagomiR-21 
treatment. 
 
As megakaryocytes form a small proportion of the bone marrow cell 
population, we determined TGF-b1 levels in this cell type by histological 
analysis. Megakaryocytes were identified by staining with a PF4 antibody and 
DAPI, revealing the characteristically large and lobulated nuclei. Strikingly, 
TGF-b1 levels were highly enriched in megakaryocytes, whereas there was 
very little signal beyond PF4-positive cells. This is in line with earlier 
observations by others, where the localisation of TGF-b1 was specifically 
ascribed to a-granules in porcine bone marrow sections.75 Although somewhat 
circumstantial, these findings suggest that the gene expression signal of whole 
bone marrow extracts should to a large extent reflect megakaryocyte 
expression levels. Furthermore, comparison between bone marrow from 
antagomiR-21-treated mice and respective controls appeared to show a 
similar number of PF4- and TGF-b1-positive cells. Intensity of TGF-b1 signal 
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did not markedly differ between both treatments, in line with immunoblot 
findings in platelets as well as the gene expression levels in bone marrow cells. 
 
5.3.6 Mechanisms affecting platelet degranulation 
Analysis of TGF-b1 levels in isolated platelets and bone marrow indicated 
that decreased releasate levels may reflect reduced TGF-b1 secretion rather 
than content. We have discussed in the introduction that TGF-b1 is generally 
considered to be contained within platelet a-granules. Although several other 
a-granule proteins also showed a trend towards lower release after systemic 
antagomiR-21 treatment, most did not reach statistical significance. This may 
be explained by the relatively small sample size, which is limited due to the 
number of animals that are required to isolate sufficient platelets for proteomic 
releasate analysis. Alternatively, these findings could imply that platelet 
release of TGF-b1 and other granule proteins does not always occur 
simultaneously. 
 
Platelets contain two distinct channel systems389: the open canalicular 
system, consisting of tortuous, tubular invaginations of the plasma membrane, 
and the dense tubular system. The latter system can be considered the platelet 
equivalent of the endoplasmatic reticulum. With regards to granule content, 
platelets carry lysosomes, and platelet-specific granule types generally 
referred to as a- and d- granules. a-granules contain and release a vast 
number of proteins282, with often opposing function. It has therefore been 
suggested that multiple subtypes of a-granules must exist.390 Resolution of 
current imaging techniques limits the ability to test this hypothesis 
adequately.391 The granule content is thought to be released upon fusing with 
the membrane, without being consumed by the membrane.  
 
There have been several reports suggesting differential release of 
proteins from a-granules.392 Italiano et al used immunofluorescence and 
immunoelectron microscopy to show that pro- and anti-angiogenic factors 
were stored in different subtypes of a-granules. These were released by 
activation of different thrombin receptors.393 A subsequent study from the 
same group showed that this could differentially affect angiogenesis and that 
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aspirin treatment could attenuate the pro-angiogenic effect of platelets.394 A 
similar differential packaging was seen for VWF and fibrinogen, which was 
attributed to VWF being megakaryocyte-derived whilst fibrinogen is acquired 
through endocytosis.395 Interestingly, the proteomics analysis in our study 
showed a significant decrease in VWF release, whilst lower release of all three 
fibrinogen chains did not reach statistical significance. It remains to be 
elucidated what the mechanisms are that regulate fusion with the membrane 
for specific subtypes of granules. As potential mediators of this differential 
release, members of the soluble N-ethylmaleimide-sensitive factor attachment 
protein receptor (SNARE) family have been suggested. Platelets carry at least 
four subtypes of vesicular SNAREs (VAMP-2,-3,-7 and -8), and differential 
kinetics upon platelet activation for granules carrying these proteins have 
previously been reported.396 Altogether, this indicates that a specific effect on 
TGF-b1 release is indeed plausible, although the known mechanisms to 
explain such an effect are currently limited. 
 
5.3.6.1 Control of platelet TGF-b1 release by WASp 
With the focus of our analysis on TGF-b1 due to its role in wound healing 
and fibrosis, we aimed to identify specific mechanisms that control its release 
from platelets. Kim et al77 reported that the secretion of TGF-b1 from platelets 
in both humans and mice is curtailed by WASp as well as by actin 
polymerisation. 
 
WASp has extensively been described as a regulator of actin 
polymerisation in neutrophils, macrophages and lymphocytes397, being 
expressed solely in hematopoietic cells.398 WASp itself has no catalytic activity, 
but functions as a scaffold that brings together the actin-related protein 2/3 
complex with monomeric globular actin, which then acts as a starting point for 
actin ‘nucleation’ (i.e., filamentous actin polymerisation onto existing 
filamentous actin). Most WASp in the cytoplasm is present in an auto-inhibited 
form, conferred by non-covalent interaction of the verprolin homology, cofilin 
homology and acidic region domain with the GTPase-binding domain. Cell 
division control protein 42 homolog has been described as the main mediator 
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for the release of this auto-inhibition. In addition, phosphorylation is a key 
requirement for WASp activity, for which the mechanism is described below. 
 
Whilst WASp is present in platelets, it is not required for platelet 
spreading, despite the importance of cytoskeletal filamentous actin 
polymerisation and doubling in this process.399 This was confirmed by 
observing normal actin assembly upon thrombin-receptor activation in murine 
Was null platelets and human platelets treated with a WASp inhibitor.77 This 
suggests a redundancy in the regulation mechanisms of actin polymerisation. 
From a translational point of view, this could indicate that potential side effects 
are limited when using platelet WASp as a therapeutic target. 
 
In order to confer its effect on TGF-b1 release, WASp requires 
phosphorylation at Tyrosine-291 (or Tyrosine-293 in mice) by Fyn and 
hematopoietic cell kinase, both Src family kinases.400 This phosphorylation 
occurs within minutes from platelet activation through collagen receptor 
glycoprotein VI401,402 as well as the thrombin-activated receptors.403 Kim et al 
further showed that upon thrombin-mediated platelet activation, 
phosphorylated WASp preferentially localises with TGF-b1-containing 
granules inside the platelets.77 Pharmacological blocking of Src kinases prior 
to platelet activation increased the release of TGF-b1 from both humans and 
wild-type mice platelets, but not from Was null mice. These results indicate 
that the modulating effect of platelet TGF-b1 is Src family kinase-dependent 
and occurs in response to both thrombin- and collagen-mediated activation. 
Strikingly, this is in line with our findings in platelets from antagomiR-21-treated 
mice; a significantly lower release of TGF-b1 was seen for thrombin and 
collagen receptor-mediated activation but not for arachidonic acid. 
 
5.3.6.2 Identification of WASp as a direct miR-21 target 
To determine whether systemic miR-21 inhibition affected WASp levels, 
we performed immunoblot analysis in isolated platelets. This analysis 
confirmed higher levels of WASp in platelets from antagomiR-21-treated mice. 
With platelet TGF-b1 levels previously identified to be unaffected, increased 
WASp levels may have indeed resulted in a restriction of TGF-b1 release, 
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resulting in our observations by MS and ELISA quantification. Direct targeting 
of the Was gene was further implied by the significant increase of transcript 
levels in bone marrow cells. Although the change in platelet WASp abundance 
and bone marrow Was expression is relatively modest, this is not unexpected 
when interpreted in the context of miRNAs as ‘fine tuners’ of protein levels. 
 
In silico target prediction for miR-21 is notorious for being affected by a 
high false-positive rate (see Supplemental table 5). The vast number of 
predicted targets for miR-21 is in line with this perception. Similarly, the large 
number of experimentally validated miR-21 targets that are only predicted by 
one out of twelve algorithms suggests that this method suffers from a high 
false-negative rate as well. Both limitations of current prediction algorithms is 
commonly described in the literature but as of yet, no methods with higher 
specificity are available.92 Our analysis of the effects of systemic miR-21 
inhibition revealed a phenomenon for which a mechanism had already been 
unveiled, therefore bypassing the need for miR-21 target prediction as a 
starting point for analysis. In silico prediction did however reveal the Was gene 
as a potential target, supporting further analysis by luciferase reporter assay. 
 
Despite the identification of a specific interaction between miR-21 and 
the 3’ UTR of the Was gene transcript using target prediction, we evaluated 
the entire 3’UTR in the reporter assay in light of the false-positive risk of in 
silico findings. The use of a dual reporter assay to assess miRNA interaction 
with a transcript 3’ UTR can be seen as the gold standard to confirm canonical 
miRNA targeting.404 In three independent experiments, a significant reduction 
of Was reporter activity was seen. This finding in itself merely indicates the 
ability for miR-21 and the 3’ UTR of Was to interact. However, in combination 
with the immunoblot and gene expression analysis in platelets and bone 
marrow, respectively, as well as the observed effect on platelet TGF-b1 
release, these findings imply Was as a bona fide direct target of miR-21. 
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5.4 Study limitations 
 
In this study, we have used an in vitro approach to study effects on CF. 
This approach disrupts potential interaction with other cell types in the 
myocardium as well as potential endocrine effects that may alter fibroblast 
biology. It has been reported that cultured fibroblasts are more representative 
of a myofibroblast-like phenotype, implying that in vitro study does not 
adequately reflect mechanisms that may be at play in quiescent cells. Results 
obtained from miR-21 null hearts are more likely to reflect the ECM in presence 
of resting fibroblasts. The use of serum-free conditions during culture may 
have repressed the secretory effects of cultured cells, potentially masking 
effects of miR-21. This is discussed in paragraph 5.1.2. Furthermore, the use 
of a relatively small sample size decreases the power to detect potential 
changes. As pointed out earlier, HPLC-MS/MS detection is biased towards 
abundant and large proteins, implying that smaller ECM or regulatory proteins 
may have fallen below the detection threshold. However, previous studies 
have been able to detect marked differences in ECM secretion using similar 
conditions.185,291 
 
The data obtained from human plasma samples is based on 
associations. It is therefore not valid to assume a causative link between 
platelet activation and levels of miRNAs and proteins. Observed associations 
should only be interpreted as an indication for their shared source. 
Furthermore, we have discussed the challenges regarding sample preparation 
in light of platelet and leukocyte contamination of plasma. We have used 
specific methods to minimise the level of carryover or activation of cells. 
Nonetheless, we cannot assume that the observed protein or miRNA signal 
solely reflects their extracellular levels. Similarly, platelet isolation methods 
confer a risk of co-isolating leukocytes. Results from experiments with isolated 
platelets or PRP may therefore be partially derived from leukocytes. Study of 
TGF-b1 and proteins used as markers of platelet activation are likely to be 
platelet-derived, in light of their high enrichment in platelets and 
megakaryocytes. Levels of WASp, however, are more likely to be susceptible 
to the risk of leukocyte contamination. We have not assessed leukocyte 
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numbers after pharmacological miR-21 inhibition and whether changes in cell 
counts may have contributed to observed differences. 
 
We have shown that miR-21 may affect fibroblasts directly but may also 
affect fibrosis in the heart and other organs by interfering with systemic 
contributors. Whether the observed effect of miR-21 on platelet TGF-β1 
release could affect cardiac fibrosis in presence of cardiac stress, remains 
speculative. Although previous studies imply that disrupting platelet TGF-β1 
release can benefit the cardiac morphology and function, it is currently unclear 
whether the effect of miR-21 inhibition on TGF-β1 levels could confer similar 
results. As our interventional data is based on mouse experiments, it remains 
to be studied whether the observed interactions are also present in humans. 
 
Whilst our findings imply that pharmacological miR-21 inhibition may 
affect fibrosis via megakaryocytes and platelets, we do not have direct 
evidence to support this hypothesis. If further experiments confirm this 
hypothesis and the fibrotic response in the heart can indeed be attenuated 
through a mechanism targeting the release of pro-fibrotic factors by platelets, 
this would be an interesting new strategy for potential therapeutic use. Shifting 
the therapeutic focus from the heart to the bone marrow would be beneficial in 
the context of anti-miR pharmacokinetics, as a relatively low dose treatment 
may suffice when targeting the bone marrow.  
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5.5 Future plans and outlook  
 
5.5.1 Further experimental plans 
Systemic treatment with a miR-21 inhibitor revealed a decrease in 
platelet TGF-β1 release, identifying a potential additional mechanistic 
explanation for previously observed anti-fibrotic effects. As mentioned in the 
previous section, the link between reduced platelet TGF-β1 release and 
fibrosis remains speculative, as we have not evaluated this directly. Other 
studies have however shown that platelet depletion and inhibition68–73, as well 
as the specific inhibition of platelet TGF-β1 release29,74, can attenuate cardiac 
hypertrophy and fibrosis. Whether this beneficial effect does indeed contribute 
to the overall effect of miR-21 inhibition requires further experimental 
evaluation. 
 
To investigate this direct link, several additional experiments could be 
performed. Firstly, an in vitro assessment of primary CF proliferation can be 
carried out in presence of the platelet releasate from mice treated with 
antagomiR-21 or control-antagomiR. In light of the established effects of TGF-
β1 on proliferation, this may provide a functional angle to the altered releasate 
content from antagomiR-21-treated mice. Furthermore, antagomiR-21 
treatment appeared to affect the release of other a-granule proteins as well. 
This experimental approach would provide an opportunity to disentangle the 
relative contribution of TGF-β1, through combining the platelet releasate with 
recombinant TGF-β1 or TGF-β1-neutralising antibody when added to CF in 
culture. 
 
Using an in vivo approach, much insight would be provided by 
establishing a megakaryocyte- and platelet-specific miR-21 knockout mouse, 
through cross-breeding miR-21fl/fl with PF4-Cre mice. These mice could then 
be evaluated in terms of their bone marrow and platelet phenotype, as well as 
in their response to cardiac overload and injury. The latter could be induced by 
commonly used models, such as infusion of angiotensin II, TAC, or the 
induction of MI by coronary artery ligation. Furthermore, an evaluation of the 
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bone marrow and circulating platelets would provide additional insights into the 
altered megakaryocyte and platelet numbers in total miR-21 null mice.  
 
An additional strategy would involve transplantation of miR-21 null bone 
marrow into irradiated wild-type mice and vice versa, followed by evaluation of 
fibrosis and remodelling in response to injury. Whilst this approach is less time-
consuming, it is also less specific, in particular given the abundance of miR-21 
in other bone marrow cells. Observations from these mice would determine 
the effect of miR-21 in megakaryocytes/platelets or the bone marrow, 
respectively. However, the potential discrepancy between genetic models and 
pharmacological inhibition remains (see section 5.3.4). Lastly, antagomiR-21 
treatment could be combined with antiplatelet therapy or platelet depletion in 
mice undergoing cardiac injury. A reduced benefit of miR-21 inhibition in 
absence of platelet activation would imply that platelets indeed play a role in 
the reported attenuation of fibrosis after antagomiR-21 treatment. 
 
In addition to experimental models, there are several insights that could 
be gained from patients. We observed in mice that platelets are a major 
determinant of circulating levels of TGF-β1. This link could be evaluated in 
patients with altered platelet numbers or function. Whilst patients suffering 
from immune-mediated idiopathic thrombocytopaenic purpura may form a 
human equivalent of our platelet depletion experiment in mice, blood from 
patients with essential or reactive thrombocythemia could provide the other 
end of the spectrum. Furthermore, a more specific assessment of a-granule 
release in relation to circulating TGF-β1 as well as the occurrence and 
progression of cardiac fibrosis could be performed in Gray Platelet Syndrome 
patients. This rare, inherited disorder is characterised by a strong reduction of 
a-granules within platelets.405 
 
From a pharmacological perspective, the outcome of the clinical trial 
that is currently evaluating systemic miR-21 inhibition will directly answer 
whether there is a benefit on renal fibrosis. The potential role of platelets 
warrants a subset analysis of patients on antiplatelet therapy and of patients 
with altered platelet counts or reactivity. This could provide further insight as 
to whether platelets alter the efficacy of miR-21 inhibition. An effect of 
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antiplatelet therapy would have major implications for the clinical use of miR-
21-targeting therapy. This would be particularly relevant when prescribed for 
the treatment of cardiac fibrosis, given the common use of antiplatelet therapy 
in heart failure patients. 
 
5.5.2 Scientific outlook 
Our results are a timely contribution given that miR-21-based therapies 
are progressing to clinical trials for Alport Syndrome. In recent years, there has 
been an emerging interest in local application of miRNA-based therapy. The 
current assumption is that miR-21 inhibition attenuates fibrosis predominantly 
through direct effects on CF. Whilst local therapy aims to decrease off-target 
effects, our findings emphasise the need to ensure that observed benefits are 
indeed occurring at the suggested site of delivery. In the context of our findings, 
local delivery of an anti-miR may in fact limit therapeutic efficacy if the 
beneficial effects occur indirectly. This is particularly relevant for miR-21, which 
is abundantly expressed in a range of tissues, including circulating cells that 
are implicated in inflammation, haemostasis and tissue repair. These features 
emphasise the importance of the systemic context of miR-21 targeting and of 
miRNA-based therapeutics in general. Further study would need to determine 
the relative contribution of miR-21 inhibition in different tissues. 
 
The observed effect of miR-21 may provide a method to selectively 
interfere with TGF-β1 activity. Previous studies have evaluated TGF-b1 as a 
therapeutic target, but its broad involvement in various biological mechanisms 
precludes a systemic approach. Selectively targeting the release of TGF-b1 
from platelets upon their activation could prove to be a more tailored approach 
where the effect is naturally directed to a site of injury. Targeting of miR-21 in 
this context could thereby provide an interesting strategy. In general, a broad 
appraisal of the multifaceted systemic response of targeting ubiquitously 
expressed miRNAs will aid the success of miRNA-based therapeutics in 




In this project, we have identified a novel mechanism through which 
pharmacological inhibition of miR-21 may affect the development and 
progression of cardiac fibrosis. As miR-21 has been implicated in the 
development and progression of fibrosis, it has been suggested as a potential 
drug target for this largely untreated feature of heart failure. Clinical trials are 
currently ongoing to evaluate its safety and benefits in the context of renal 
fibrosis. This highlights the need to thoroughly investigate the effects of miR-
21 inhibition. 
 
Using a combination of in vitro studies and the analysis of miR-21 null 
hearts, we observed a surprisingly limited direct effect of miR-21 on the cardiac 
ECM. In line with previous studies, miR-21 did show a pro-proliferative effect 
on CF in vitro. Notably, we found circulating miR-21 to be enriched in platelets. 
Here, pharmacological miR-21 inhibition attenuated the release of TGF-b1 
through de-repressing WASp, a newly identified direct miR-21 target. In miR-
21 null mice, we observed changes in circulating platelet and leukocyte 
numbers with concomitant bone marrow changes. These findings (see Figure 
48, panel A) may have implications for miR-21-based therapeutics, in 
particular for suggested use of locally delivered anti-miRs.  
 
Fibroblasts have been widely implicated as the main culprit in cardiac 
fibrosis. We have discussed the limitations of ascribing effects to this cell type 
within the myocardium, where the expression of miR-21 in resting resident 
fibroblasts may be overestimated. Cell type and organ specificity is of 
particular relevance in light of anti-miR therapy. Variation between miR-21 
targeting strategies has been suggested to explain conflicting study results. As 
miR-21 is particularly abundant in hematopoietic cells, effects of its inhibition 
may, at least in part, depend on circulating cells. A platelet contribution may 
explain why miR-21 inhibition has no effect on fibrosis in the absence of tissue 
injury, as tissue injury induces platelet activation. The emerging literature 
implicating inflammatory cells and platelets in the development and 
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progression of fibrosis emphasises the need to broaden the evaluation beyond 
the heart. 
 
Whilst effects of miR-21 on inflammation have been widely studied, its 
role in platelets remains to be largely unknown. In miR-21 null mice, we found 
significantly lower platelet counts. Translational relevance and implications of 
this finding remain to be explored. Upon pharmacological miR-21 inhibition, we 
did not find an effect on platelet numbers or their reactivity, but did observe 
miR-21 to affect the release of TGF-b1. The TGF-b pathway plays a central 
role in fibroblast activation and miR-21 can modulate TGF-b downstream 
signalling. Platelets are a major source of TGF-b1 and its release has 
previously been implicated in heart failure. Our observation of miR-21 affecting 
platelet TGF-b1 release suggests a feed-forward mechanism, where TGF-b1 
induces miR-21 expression in megakaryocytes, which subsequently enhances 
platelet TGF-b1 release through inhibiting WASp. Consequently, miR-21-
mediated release of platelet TGF-b1 may affect cardiac fibrosis (see Figure 





Reduced numbers of 
circulating platelets





























Figure 47. MiR-21 may affect cardiac fibrosis through effects on
megakaryocytes and platelets. A. Pharmacological inhibition of miR-21 in
mice increases megakaryocyte expression levels of Was, a direct target of miR-
21. Higher levels of the corresponding WASp protein suppress the release of
TGF-β1 from platelets. Genetic deletion of miR-21 in mice results in decreased
platelet counts but higher megakaryocyte numbers. B: Platelet-derived TGF-β1
was previously shown to enhance cardiac fibrosis in response to pressure
overload. TGF-β1 is a key mediator of fibroblast proliferation and differentiation.
Thus, observed protective effects of miR-21 inhibition in different fibrosis










Figure 48. Summary: miR-21 may affect cardiac fibrosis through effects on 
megakaryocytes and platelets. A. Pharmacological inhibition of miR-21 in mice 
increases megakaryocyte expression levels of Was, a direct target of miR-21. Higher 
levels of the corresponding WASp protein suppress the release of TGF-β1 from 
platelets. Genetic deletion of miR-21 in mice results in decreased platelet counts but 
higher megakaryocyte numbers. B: Platelet-derived TGF-β1 was previously shown to 
enhance cardiac fibrosis in response to pressure overload. TGF-β1 is a key mediator 
of fibroblast proliferation and differentiation. Thus, observed protective effects of miR-
21 inhibition in different fibrosis models might, at least in part, be dependent on bone 
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1. Supplemental table 1. ECM proteins identified in CF conditioned 
media following miR-21 mimic or inhibitor (LNA-21) transfection. 
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4. Supplemental table 4. Proteins identified in the releasate of washed 
murine platelets, isolated after antagomiR-21 or -control treatment. 
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Supplemental table 2. MiR-21 null cardiac gene expression analysis. Analysis 
was performed in RNA extracted from the heart ventricle of miR-21 null mice or 
littermate controls (n=6 vs. 6). Relative quantities were calculated with the 2-ΔΔCq 
method using Actb as the reference gene transcript. FDR-adjusted p-values (q-
values) were calculated using the two-stage step-up method of Benjamini, Krieger 
and Yekutieli. Q for significant discovery was set to 5%. 
Gene ID miR-21+/+ miR-21-/- p-value q-value 
Bgn 1±0.04 1.04±0.04 0.4873 0.8759 
Col1a1 1±0.05 1.05±0.05 0.5336 0.8759 
Col1a2 1±0.05 1.04±0.07 0.7007 0.8759 
Col3a1 1±0.05 1.05±0.06 0.5887 0.8759 
Col4a2 1±0.12 1.23±0.23 0.5050 0.8759 
Col5a2 1±0.06 1.13±0.07 0.1725 0.7547 
Col6a1 1±0.10 1.03±0.11 0.8754 0.9575 
Dcn 1±0.06 0.95±0.03 0.5716 0.8759 
Fbn1 1±0.04 1.15±0.10 0.2446 0.8759 
Fn1 1±0.03 1.14±0.07 0.1106 0.6767 
Fstl1 1±0.04 1.06±0.05 0.3253 0.8759 
Grn 1±0.04 1.04±0.06 0.6047 0.8759 
Hspg2 1±0.03 1.10±0.05 0.0814 0.6767 
Igfbp4 1±0.03 0.97±0.02 0.4624 0.8759 
Lama4 1±0.03 1.14±0.02 0.0040 0.1049 
Lamc1 1±0.04 1.00±0.03 0.9880 >0.9999 
Lgals3bp 1±0.03 1.12±0.06 0.1289 0.6767 
Nid1 1±0.03 0.98±0.04 0.6828 0.8759 
Pcolce 1±0.04 1.02±0.06 0.8677 0.9575 
Postn 1±0.07 1.05±0.07 0.6280 0.8759 
Serpine1 1±0.15 1.11±0.17 0.6601 0.8759 
Serpinf1 1±0.04 1.02±0.05 0.7662 0.9143 
Sparc 1±0.09 1.27±0.06 0.0217 0.2848 
Tgfb1 1±0.04 1.03±0.04 0.6256 0.8759 
Vcam1 1±0.04 1.05±0.06 0.5047 0.8759 
     
miRNA ID miR-21+/+ miR-21-/- p-value q-value 
miR-1 1±0.05 0.98±0.07 0.7465 0.9482 
miR-21 1±0.04 0.00±0.00 <0.0001 <0.0001 
miR-29b 1±0.04 0.92±0.04 0.1697 0.3592 
miR-30c 1±0.03 0.95±0.02 0.1842 0.3592 
miR-31 1±0.05 0.89±0.06 0.1754 0.3592 
miR-126 1±0.03 1.00±0.04 0.9499 0.9482 
miR-133 1±0.04 1.00±0.04 0.9642 0.9482 
miR-143 1±0.02 1.00±0.05 0.9726 0.9482 
miR-145 1±0.03 0.99±0.06 0.8119 0.9482 
miR-146a 1±0.08 1.08±0.09 0.5585 0.8470 
miR-499 1±0.04 0.79±0.05 0.0085 0.0583 
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Supplemental table 3. MiR-21 null cardiac ECM protein analysis. Analysis was 
performed using the three-step extraction method, involving sequential incubation in 
NaCl, SDS and GuHCl to enrich for ECM proteins. Combined analysis of the NaCl 
and GuHCl fractions by LC-MS/MS was annotated using the Matrisome database for 
murine ECM and ECM-associated proteins. Values indicate normalised total 
precursor intensity. FDR-adjusted p-values (q-values) were calculated using the two-
stage step-up method of Benjamini, Krieger and Yekutieli. Q for significant discovery 
was set to 5%. 
 
Protein ID Gene miR-21+/+ miR-21-/- p-value q-value 
CO1A1_MOUSE Col1a1 2.5E+10 2.2E+10 0.6351 >0.9999 
CO3A1_MOUSE Col3a1 2.5E+10 2.2E+10 0.7349 >0.9999 
CO1A2_MOUSE Col1a2 1.4E+10 1.2E+10 0.6783 >0.9999 
PGBM_MOUSE Hspg2 1.4E+10 1.2E+10 0.3143 >0.9999 
ANXA6_MOUSE Anxa6 9.5E+09 9.2E+09 0.7367 >0.9999 
NID1_MOUSE Nid1 7.5E+09 6.7E+09 0.5165 >0.9999 
A1AT2_MOUSE Serpina1b 6.1E+09 6.8E+09 0.5223 >0.9999 
LEG1_MOUSE Lgals1 4.8E+09 5.0E+09 0.7817 >0.9999 
ANXA5_MOUSE Anxa5 3.9E+09 4.4E+09 0.1604 >0.9999 
LAMA2_MOUSE Lama2 3.5E+09 3.2E+09 0.6058 >0.9999 
LAMC1_MOUSE Lamc1 3.5E+09 3.1E+09 0.5586 >0.9999 
PGS2_MOUSE Dcn 3.1E+09 2.9E+09 0.7459 >0.9999 
ANXA2_MOUSE Anxa2 3.0E+09 3.3E+09 0.6398 >0.9999 
SPA3K_MOUSE Serpina3k 2.7E+09 2.8E+09 0.8040 >0.9999 
TGM2_MOUSE Tgm2 2.6E+09 2.7E+09 0.7984 >0.9999 
CO6A1_MOUSE Col6a1 2.2E+09 2.5E+09 0.5046 >0.9999 
LAMB2_MOUSE Lamb2 1.7E+09 1.7E+09 0.9022 >0.9999 
LAMB1_MOUSE Lamb1 1.6E+09 1.4E+09 0.3810 >0.9999 
PZP_MOUSE Pzp 1.6E+09 1.6E+09 0.9815 >0.9999 
CO6A2_MOUSE Col6a2 1.5E+09 1.6E+09 0.8764 >0.9999 
MFAP5_MOUSE Mfap5 1.3E+09 8.0E+08 0.2806 >0.9999 
CO5A2_MOUSE Col5a2 1.2E+09 1.2E+09 0.8809 >0.9999 
SERPH_MOUSE Serpinh1 1.2E+09 1.5E+09 0.3230 >0.9999 
S10A1_MOUSE S100a1 1.1E+09 1.1E+09 0.7563 >0.9999 
COFA1_MOUSE Col15a1 1.1E+09 1.1E+09 0.9553 >0.9999 
HEMO_MOUSE Hpx 1.0E+09 1.0E+09 0.9673 >0.9999 
CATD_MOUSE Ctsd 1.0E+09 9.7E+08 0.8106 >0.9999 
NID2_MOUSE Nid2 9.7E+08 7.9E+08 0.2888 >0.9999 
CO4A1_MOUSE Col4a1 9.2E+08 7.8E+08 0.7734 >0.9999 
CO5A1_MOUSE Col5a1 8.2E+08 8.4E+08 0.9057 >0.9999 
CO4A2_MOUSE Col4a2 7.8E+08 5.9E+08 0.5286 >0.9999 
DERM_MOUSE Dpt 7.2E+08 6.3E+08 0.4697 >0.9999 
S10AA_MOUSE S100a10 7.1E+08 8.3E+08 0.2888 >0.9999 
ANT3_MOUSE Serpinc1 5.5E+08 5.2E+08 0.8099 >0.9999 
FBN1_MOUSE Fbn1 5.5E+08 5.0E+08 0.8727 >0.9999 
LUM_MOUSE Lum 5.2E+08 6.0E+08 0.4485 >0.9999 
KNG1_MOUSE Kng1 5.1E+08 4.7E+08 0.7729 >0.9999 
FINC_MOUSE Fn1 4.4E+08 6.8E+08 0.3155 >0.9999 
FIBB_MOUSE Fgb 3.9E+08 5.1E+08 0.4691 >0.9999 
LAMA4_MOUSE Lama4 3.8E+08 4.2E+08 0.6975 >0.9999 
ANXA7_MOUSE Anxa7 3.5E+08 2.1E+08 0.0790 >0.9999 
PGS1_MOUSE Bgn 3.4E+08 3.0E+08 0.8318 >0.9999 
ADIPO_MOUSE Adipoq 3.0E+08 3.3E+08 0.3310 >0.9999 
ANX11_MOUSE Anxa11 2.7E+08 3.1E+08 0.4079 >0.9999 
FIBA_MOUSE Fga 2.7E+08 3.0E+08 0.8466 >0.9999 
CATB_MOUSE Ctsb 2.5E+08 1.9E+08 0.3092 >0.9999 
PRELP_MOUSE Prelp 2.3E+08 2.0E+08 0.5583 >0.9999 
PPN_MOUSE Papln 2.0E+08 2.1E+08 0.9080 >0.9999 
FIBG_MOUSE Fgg 1.7E+08 2.9E+08 0.4163 >0.9999 
LAMA5_MOUSE Lama5 1.4E+08 1.5E+08 0.8689 >0.9999 
ANXA4_MOUSE Anxa4 1.4E+08 1.3E+08 0.8081 >0.9999 
TINAL_MOUSE Tinagl1 1.3E+08 8.4E+07 0.2736 >0.9999 
CO6A6_MOUSE Col6a6 1.1E+08 4.5E+07 0.0244 >0.9999 
AGRIN_MOUSE Agrn 8.4E+07 6.7E+07 0.5389 >0.9999 




































































































































































































































































Supplemental table 4. Proteins identified in the thrombin-induced releasate of 
washed platelets, isolated from mice treated with antagomiR-21 or -control. The 
platelet releasate was analysed by gel LC-MS/MS using an LTQ-Orbitrap XL. Values 
shown are mean±SEM of normalized spectral counts (NSpC), based on three 
biological replicates (each replicate consisting of pooled platelets from 4 mice) for 
each condition. Identified releasate proteins with an average NSpC >5 for at least one 
sample category are shown. FC reflect the ratio between the average NSpC in 
samples after antagomiR-21 treatment and after control-antagomiR with a t-test 




























































































































































































































































































































































































































































































































































































































































































































































































































Supplemental table 4 (continued) 
 
 234 
Supplemental table 5. Predicted targets of miR-21 in the mouse genome using 
miRWALK 2.0. The miRWALK score indicates the number of algorithms that 
predicted targeting miR-21 to occur. Included algorithms were miRWalk, Microt4, 
miRanda, mirbridge, miRDB, miRMap, miRNAMap, Pictar2, PITA, RNA22, 
RNAhybrid and Targetscan. As the full list includes 18332 predicted targets, the top-
237 predicted targets are shown, complemented with the predicted targets that were 
annotated as experimentally validated targets in the amiGO Gene Ontology (GO) 
database. This indicates the high false-positive and false-negative rate, given that the 
majority of predicted targets have thus far not been validated, whilst most validated 
targets were not predicted by most algorithms (including the newly identified miR-21 
target Was).
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MicroRNAs in Cardiovascular Disease
Temo Barwari, MD, Abhishek Joshi, BA, BMBCH, Manuel Mayr, MD, PHD
ABSTRACT
Micro-ribonucleic acids (miRNAs) are in the spotlight as post-transcriptional regulators of gene expression. More than
1,000 miRNAs are encoded in the human genome. In this review, we provide an introduction to miRNA biology and
research methodology, and highlight advances in cardiovascular research to date. This includes the potential of miRNAs
as therapeutic targets in cardiac and vascular disease, and their use as novel biomarkers. Although some miRNA therapies
are already undergoing clinical evaluation, we stress the importance of integrating current knowledge of miRNA biology
into a systemic context. Discovery studies focus on miRNA effects within one speciﬁc organ, whereas the expression
of most miRNAs is not restricted to a single tissue. Because most miRNA-based therapies act systemically, this may
preclude widespread clinical use. The development of more targeted interventions will bolster well-informed clinical
applications, increasing the chances of success and minimizing the risk of setbacks for miRNA-based therapeutics.
(J Am Coll Cardiol 2016;68:2577–84) © 2016 by the American College of Cardiology Foundation.
O nly 1% of the human genome codes for genesthat function in protein synthesis (1). Theremaining 99% of deoxyribonucleic acid
(DNA) was initially considered to be junk. It is now
recognized that the majority of the genome may have
biochemical functions, representing regulatory, non-
coding ribonucleic acid (RNA). Several subcategories
of noncoding RNAs exist, in particular, long noncoding
RNAs and small noncoding RNAs. Among the latter,
microRNAs (miRNAs/miRs) have thus far attracted
most attention since their discovery in Caenorhabditis
elegans (2). MiRNAs affect the production of proteins
by interacting with transcribed messenger RNAs
(mRNAs), thus silencing the expression of genes.
Here, we aim to provide an overview of miRNA biology
for clinicians, discussing their therapeutic and
diagnostic potential, as well as their limitations.
BASIC BIOLOGY OF miRNAs
MiRNAs are short (w22 nucleotides), noncoding RNA
molecules. They exert their function via the seed
region, a sequence of 6 to 8 nucleotides that binds to
messenger ribonucleic acid (mRNA), the so-called
miRNA targets (3). MiRNA synthesis and silencing
have both been extensively reviewed recently (4,5).
The key biological concepts are summarized in the
Central Illustration. Initially, a precursor transcript is
produced and then forms double-stranded RNA.
Later, the miRNA duplex undergoes unwinding,
whereby only a single strand, the so-called guide
strand, which is usually the functional unit, is loaded
in the RNA-induced silencing complex (RISC). The
other strand or passenger strand is often degraded,
but may also function as a mature miRNA (6). In the
RISC, the miRNA binds to its target mRNA, prevent-
ing its translation into a protein. Single miRNAs
suppress more than 1 gene, and miRNAs with similar
seed regions may suppress a similar, but noniden-
tical, set of genes, and to differing degrees. Gene
suppression is usually partial, rather than total, and a
single gene can have binding sites for multiple
miRNAs. This organizational complexity, illustrated
by a high false-positive rate of target prediction
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algorithms (7), presents challenges in both
understanding the functions of miRNAs and
manipulating their effects.
MEASUREMENT OF miRNAs
miRNAs are relatively stable, and can be
reliably measured in tissues, as well as in
bioﬂuids (8). Several techniques have been
developed to identify and quantify miRNAs.
Beneﬁts and disadvantages of different
techniques have been summarized previ-
ously elsewhere (8). Here, we brieﬂy discuss
the most commonly used methods.
Real-time quantitative polymerase chain
reaction has been the cornerstone for miRNA
quantiﬁcation and remains the most reliable tech-
nique for quantitative comparison of miRNA expres-
sion levels. This technique uses predeﬁned primers to
amplify and measure individual miRNAs in a sample.
Microarrays use hybridization of miRNAs to speciﬁc
primers, trading less accurate quantiﬁcation for
higher throughput and lower cost, and measuring
hundreds of miRNAs in parallel. Because both of
these techniques rely on predeﬁned primer se-
quences, they are not able to discover previously
uncharacterized miRNAs.
RNA sequencing techniques provide “hypothesis-
free” identiﬁcation of RNA species, allowing the
discovery of new miRNAs and quantitative analysis
of a comprehensive miRNA transcriptome. The
use of computational solutions to resolve reads
into miRNAs suffers from the risk of reporting
putative sequences that do not have real-world
correlates (9).
Without added spike-ins and standard curves, all
techniques rely on relative rather than absolute
quantiﬁcation, meaning that differences in miRNAs
are presented as a “fold change” between paired
samples, and not as an absolute unit, requiring in-
formation on the context of abundance. Experimental
work must show downstream effects of miRNA
changes as readout for miRNA function, speciﬁcally
by comparing the proﬁles of multiple miRNAs with
differential expression of target proteins. Ideally, the
miRNA/mRNA duplexes in the RISC are analyzed to
prove direct interactions.
THERAPEUTIC MANIPULATION OF miRNAs
The central action of miRNAs is to suppress protein
expression through binding and silencing speciﬁc
target mRNAs, which, in turn, reduces protein
synthesis. Therefore, miRNAs offer a tantalizing
mechanism for manipulating protein synthesis;
in most cases, overexpression of a miRNA will
suppress its direct targets, whereas inhibiting an
endogenous miRNA will de-repress their expression.
Unmodiﬁed RNA strands are degraded upon
administration; thus, miRNA therapeutics require
either efﬁcient methods of cell type-speciﬁc delivery
or modiﬁcations that enhance stability but preserve
miRNA function. For now, clinical studies with
miRNA therapeutics mainly use inhibitors of
miRNAs (anti-miRs). Anti-miRs are synthetic single
strands of RNA, consisting of complementary nucle-
otides to an endogenous miRNA. Various structural
modiﬁcations have been designed to increase their
half-life in the circulation, bypass degradation in
tissues and enhance intracellular delivery (10). Car-
diotropic adeno-associated viruses achieve efﬁcient
cardiomyocyte-speciﬁc miRNA delivery (11). The
translational potential of adeno-associated virus–
mediated oligonucleotide delivery has been reviewed
elsewhere (12). Currently, overexpressing a miRNA is
generally considered less safe than inhibiting an
endogenous miRNA.
Miravirsen is an anti-miR targeting miR-122 for
treatment of hepatitis C (13), which has completed a
multicenter phase 2a trial (14) and is currently in a
phase 2b trial. The choice of miR-122 as the ﬁrst
therapeutic target highlights the challenges when
targeting cardiovascular disease (CVD). First, miR-
122 shows exquisite tissue speciﬁcity, whereas most
miRNAs identiﬁed as treatment targets for CVD are
ubiquitously expressed, raising concerns for off-
target effects. Second, anti-miRs predominantly
accumulate in the liver and kidneys, circumventing
the need for tissue-speciﬁc targeting (13). The latter
is further illustrated by the evaluation of anti-miR-21
as a therapy for Alport nephropathy (15). These
ongoing clinical trials will provide more insight into
the practical use of miRNA therapeutics.
Targeting the heart or vasculature with systemic
anti-miRs would require signiﬁcantly higher dosing,
and efﬁciency may be low. Animal models have shown
nephrotoxicity at higher doses of some anti-miRs,
although the clinical trial of Miravirsen did not ﬁnd
evidence for renal injury in humans (14). The human
immune system has evolved to detect viral RNA.
Toll-like receptors recognize both single- and double-
stranded RNA (16). High doses of synthetic oligonu-
cleotides may elicit an immune response that could
compromise efﬁcacy and safety. Thus, cardiovascular
applications will require solutions for local or cell-
type–speciﬁc delivery, and clinically detectable,
reliable readouts to monitor successful target
engagement.
ABBR EV I A T I ON S
AND ACRONYMS
anti-miRs = inhibitors of
miRNAs
CVD = cardiovascular disease
ECM = extracellular matrix
MHC = myosin heavy chain
MI = myocardial infarction
miRNA/miR = micro-
ribonucleic acid
mRNA = messenger ribonucleic
acid
RISC = ribonucleic acid-
induced silencing complex
SMC = smooth muscle cell
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miRNAs IN HEART FAILURE
At the cellular level, heart failure is caused by car-
diomyocyte dysfunction and ﬁbrosis due to accumu-
lation of extracellular matrix (ECM). These processes
remain almost entirely untreated by standard heart
failure treatment regimens.
miR-133 is highly abundant in cardiomyocytes, but
is reduced in animal models of hypertrophy and in
patients with hypertrophic cardiomyopathy (17).
In vitro and in vivo studies showed increased hyper-
trophy upon miR-133 inhibition, and preserved car-
diac function upon miR-133 overexpression.
Targeting of the beta-1 adrenergic receptor pathway,
central to the progression and treatment of heart
failure, was implicated as the underlying mechanism
(18). In addition to the heart, miR-133 is also present
in skeletal muscle, albeit at lower levels than in car-
diomyocytes. Here, miR-133 inhibition again in-
creases responsiveness to adrenergic stimuli and
promotes differentiation to brown fat tissue (19).
miR-133 manipulation also seems to affect the cardiac
action potential (20).
MiR-1 is part of the same cluster as miR-133 and
shares its abundance, as well as its lower expression
in heart failure patients (21). Both increased (22) and
reduced (23) expression of miR-1 lead to electro-
physiological abnormalities. Interestingly, miR-1 tar-
gets insulin-like growth factor-1, which itself
represses processing of the pre-miR-1 transcript (21).
The insulin-like growth factor-1 pathway is an
important contributor to cardiac hypertrophy and
arrhythmias, and increasing miR-1 levels seems to
improve cardiac function (24).
MiR-208 is also highly enriched in cardiomyocytes,
and regulates the balance between the a- and
b-myosin heavy chains (MHC). Induction of the
b-MHC isotype is a known maladaptive response to
cardiac stress and reduces contractility (25). MiR-208
knockout mice, and rats treated systemically with
anti-miR-208, had preserved balance between both
MHC isotypes in response to experimental cardiac
stress, with better cardiac function (26). MiR-208 in-
hibition has therefore been suggested as a protective
treatment in heart failure. However, b-MHC expres-
sion is not altered in normal hearts of miR-208
knockout mice, indicating that effects of this miRNA
are either dependent on disease context or subject to
parallel controls (27). Furthermore, recent deep
sequencing data from human hearts suggest that miR-
208 expression is relatively low compared with other
cardiac miRNAs, such as miR-1 and miR-133 (28). Pre-
clinical trials using miR-208 inhibition in heart
failure were announced in 2011, but have not
progressed further.
In 1 study, miR-25 expression was repressed in
failing human hearts (29), but its expression was
increased in another study (30). Where the former
study described the targeting of deleterious embry-
onic gene programs that worsen cardiac function, the
latter showed repression of the sarcoplasmic/endo-
plasmic reticulum calcium adenosine triphosphatase
(SERCA), an important contributor to excitation–
contraction coupling in cardiomyocytes, and subse-
quent improvement in cardiac function. Differences in
timing and chemical properties of the anti-miR treat-
ment, as well as the study duration, could explain
these contradictory results. This highlights the formi-
dable task of determining optimal anti-miR chemistry,
given the combinatorial possibilities of modiﬁcations
that can be introduced, even in small oligonucleotides.
Different oligonucleotides targeting the same miRNA
may not achieve the same therapeutic beneﬁt.
miRNAs IN CARDIAC REGENERATION
MiRNAs have been proposed as an alternative to cell
therapy for cardiac regeneration. Studies on neonatal
rat cardiomyocyte proliferation highlighted miR-199a
and miR-590 as capable of inducing mitosis (31).
Injecting these miRNAs into rodent hearts after
myocardial infarction (MI) preserved cardiac func-
tion. Along similar lines, inhibition of miR-34a
improved cardiac function after MI in mice, attenu-
ating cardiomyocyte apoptosis and telomere short-
ening (32). MiRNA-based therapies for cardiac
regeneration and repair still require validation in
models with greater translational potential. A miRNA
that is pursued currently for therapeutic applications
in CVD is miR-92a. Inhibition of miR-92a reduces
endothelial inﬂammation (33) and promotes angio-
genesis and functional recovery in ischemic myocar-
dium (34). However, this miRNA is part of a cluster of
miRNA genes (miR-17w92), also known as oncomiR-1
because its members target cell-cycle regulation. This
raises concerns about potential side effects of miR-
92a therapeutics.
miRNAs IN CARDIAC FIBROSIS
Several miRNAs have been implicated in cardiac
ﬁbroblast survival and related signaling pathways.
Although some miRNAs directly target genes coding
for ECM proteins (35,36), others prevent cardiac
ﬁbroblasts from attaining an activated secretory
phenotype (37,38). In addition to its role in cardiac
hypertrophy, miR-133 is considered antiﬁbrotic
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through targeting of connective tissue growth factor,
a key regulator of the ﬁbrotic process (37), as well as
collagen I a-1, a main constituent of the cardiac ECM
(39).
MiR-21 has been studied most extensively in the
context of ﬁbrosis. This miRNA is increased in heart
failure patients and in cardiac ﬁbroblasts of ﬁbrotic
mouse hearts (40), and promotes ECM deposition in
mouse models of increased afterload (41) and
myocardial ischemia (42). In vivo inhibition of miR-21
attenuates the ﬁbrotic response and improves cardiac
function in mouse models of heart failure (41). These
results were not reproduced in a subsequent study
using a different anti-miR, reiterating the importance
of optimizing the anti-miR chemistry (43). MiR-21 also
serves as an example of a miRNA where both the
guide and passenger strands mediate function,
with the passenger strand being transferred from
ﬁbroblasts to cardiomyocytes, where it exerts a pro-
hypertrophic effect (6). This highlights another difﬁ-
culty in translating ﬁndings from preclinical models
to patients. If both strands mediate function, then
inhibition of just 1 strand by anti-miR treatment may
not recapitulate the phenotype observed in knockout
mice, where both strands are deleted from the
genome.
miRNAs IN NEOINTIMA FORMATION
AND ATHEROSCLEROSIS
In addition to its proﬁbrotic role, miR-21 enhances
neointimal growth through pro-proliferative and
antiapoptotic effects on vascular smooth muscle cells
(SMCs) (44). Inhibition of miR-21 reduces in-stent
restenosis in animals (45). The development of
miRNA-eluting stents (46) could overcome one of the
major challenges in miRNA therapies, because local
delivery decreases the risk of off-target effects. The
same can be argued for miR-29b, which represses
ECM production by vascular SMCs (47), whereas in-
hibition slows abdominal aortic aneurysm progres-
sion (48) and promotes favorable plaque remodeling
in atherosclerotic mice (49). Delivered locally,
miR-29b antagonism could more subtly alter the ECM
balance, if stents eluting anti–miR-29b were devel-
oped to inhibit aneurysm progression or to stabilize
symptomatic atherosclerotic plaques.
Key events in atherosclerosis are endothelial injury
and the switch of SMCs from a contractile to a syn-
thetic phenotype. MiR-143 and miR-145 are tran-
scribed together as a cluster and are highly abundant
in SMCs, with a marked down-regulation seen in
vessels with neointima formation (50,51). Together,
these miRNAs regulate vascular SMC differentiation
and, consequently, their loss contributes to SMC
dedifferentiation and atherosclerosis (52). MiR-126
is highly enriched in endothelial cells (53). It indi-
rectly enhances vascular endothelial growth factor
signaling, and therefore has been studied in the
context of angiogenesis and endothelial repair.
Interestingly, the endothelial effects of this miRNA
seem to be mediated by the passenger strand, rather
than the guide strand (54). Although miR-126 has
been described as endothelial cell-speciﬁc (53), this
miRNA is expressed in megakaryocytes and may have
a role in platelet function as mentioned elsewhere in
this paper.
miRNAs IN LIPID METABOLISM
MiR-122 is highly abundant in the liver (55,56). Phar-
macological strategies to lower miR-122 levels
decreased plasma cholesterol levels (13,55). Unfortu-
nately, initial optimism was dampened by subse-
quent studies that showed a simultaneous decrease in
high-density lipoprotein cholesterol levels (57).
Similar ﬁndings were obtained for miR-33, an miRNA
that regulates cholesterol metabolism. Short-term
inhibition was beneﬁcial (58,59), but long-term inhi-
bition in animals fed a high-fat diet had detrimental
effects, such as hepatic steatosis (60). More recently,
a study in human hepatic cells identiﬁed miR-148a as
a regulator of the low-density lipoprotein cholesterol
receptor (61). Systemic inhibition of miR-148a caused
a signiﬁcant reduction in plasma low-density lipo-
protein cholesterol, but also increased high-density
CENTRAL ILLUSTRATION Continued
MicroRNAs (miRNAs) originate from primary transcripts (pri-miRNAs) that are derived from introns (the noncoding regions within a primary mRNA transcript) of
protein-coding genes or from intergenic regions within the genome. Primary transcripts are processed in the nucleus to a hairpin-shaped pre-miRNA by the Drosha/
DGCR8 complex, transported to the cytoplasm, and then processed to mature miRNA duplexes by the Dicer complex. To exert its function, the mature miRNA is
incorporated into an RNA-induced silencing complex (RISC). This complex can then target mRNA through sequence complementarity: the sequence of the incorporated
miRNA, with the 6 to 8 nucleotide-long seed sequence on the 50 end in particular, binds to the targeted mRNA, usually to the untranslated region at the 30 end.
Depending on several factors, including the extent of sequence complementarity, this leads to cleavage or translation repression of the mRNA, preventing a protein from
being assembled. mRNA ¼ messenger RNA; RISC ¼ ribonucleic acid-induced silencing complex; tRNA ¼ transfer RNA.
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lipoprotein cholesterol levels. Long-term side effects
of miR-122 and miR-33 inhibition, combined with the
advent of novel therapeutic options for dyslipidemia,
may limit the clinical use of miRNAs to modulate lipid
metabolism.
miRNAs AS BIOMARKERS
MiRNAs are present, stable, and detectable in the
circulation (62), both in plasma or serum, where they
are either bound to protein complexes or contained in
microvesicles or lipoproteins. Microvesicle- and
lipoprotein-borne miRNAs have been suggested to
affect protein expression when delivered to cells
(63–66). For example, miR-223 is relatively abundant
in plasma, and may transduce an endocrine signal
between blood cells and vascular cells (67). Because
absolute levels of circulating miRNAs are low, it re-
mains to be proven whether miRNA transfer is sufﬁ-
cient to achieve effective target repression in
recipient cells.
Several cardiac miRNAs are detectable in blood
early after MI, potentially reducing time to diagnosis
(68). However, head-to-head comparisons with
established biomarkers, such as high-sensitivity tro-
ponins, found that detection of miRNAs did not
improve on the accuracy or usefulness of current
methods (69). Furthermore, current miRNA detection
techniques are time consuming and do not allow for
the rapid diagnosis required in patients with MI. In
the context of hypertrophic cardiomyopathy, higher
levels of miR-29a correlate with both hypertrophy
and ﬁbrosis (70), but its clinical beneﬁts beside cur-
rent diagnostic tools remain unclear.
New biomarker searches should focus on unmet
clinical needs, rather than areas where well-
performing, established markers already exist. For
example, current risk prediction models for MI could
improve. Three studies, albeit with differing meth-
odologies, have detected differentially expressed
miRNAs in patients who went on to suffer acute MI
(71–73). Karakas et al. (71) found a surprisingly strong
correlation of single miRNAs with the risk of cardio-
vascular death, although this was in a highly selected
population, and was not compared with traditional
risk models. No single miRNA conferred a clinically
signiﬁcant change in risk of acute MI in either the
study by Bye et al. (72) or by Zampetaki et al. (73), but
the combined usefulness of an miRNA panel
improved the predictive power of traditional Fra-
mingham risk models. The miRNAs selected by
Zampetaki et al. (73) also predicted mortality in a
cohort of patients with symptomatic coronary artery
disease (74). Mechanistic links have been reported
between 2 of these miRNAs and platelet function:
miR-126 (75) and miR-223 (76). Circulating miRNAs
can be derived from a range of cell types, but plate-
lets contribute substantially (75,76). Levels of circu-
lating miRNAs are affected by the administration of
antiplatelet therapy (77), and correlate with existing
platelet reactivity assays in patients post-MI (75).
Platelet miRNAs have been linked to hyper-reactive
platelets (78).
CONCLUSIONS
MiRNAs can regulate protein expression, and so are
the subject of intense interest in understanding and
treating CVD. Treatment strategies currently focus
on systemic anti-miR delivery, which raises concerns
for off-target effects, including platelet activation
(79). Future efforts should be aimed at evaluating
cell-type–speciﬁc strategies or local delivery. For
the cardiovascular system, enhanced targeting
could be achieved through the use of adeno-
associated virus vectors for cell-type–speciﬁc
miRNA delivery or nanoparticle-bound anti-miRs or
miRNA mimics (80).
Preclinical research has focused mainly on identi-
fying mechanisms within a single tissue or cell type.
However, caution needs to be exercised to avoid
moving toward clinical evaluation too quickly.
MiRNA regulation of protein expression is highly
dependent on context and cell type, and their ubiq-
uitous expression makes side effects of miRNA ther-
apies unpredictable. Targeting individual miRNAs
therefore requires meticulous evaluation of systemic
effects. A careful approach in advancing miRNA
therapies may slow progression toward clinical
application, but may spare miRNA therapeutics a
setback similar to gene therapy. The great potential of
miRNAs justiﬁes the exercise of apprehension before
large-scale clinical studies for CVD.
Circulating miRNAs are expressed differentially
across disease phenotypes and are implicated as
novel biomarkers. Their platelet origin could make
circulating miRNAs particularly relevant in the
context of CVD. Platelet reactivity may confer car-
diovascular risk, but there is no single accepted
biomarker. More mechanistic studies and validation
in larger cohorts are required to establish the clinical
utility of miRNA biomarkers.
REPRINT REQUESTS AND CORRESPONDENCE:
Professor Manuel Mayr, King’s British Heart
Foundation Centre, King’s College London, 125
Coldharbour Lane, London SE59NU, United Kingdom.
E-mail: manuel.mayr@kcl.ac.uk.
Barwari et al. J A C C V O L . 6 8 , N O . 2 3 , 2 0 1 6
MicroRNAs in Cardiovascular Disease D E C E M B E R 1 3 , 2 0 1 6 : 2 5 7 7 – 8 4
2582
RE F E RENCE S
1. Venter JC, Adams MD, Myers EW, et al. The
sequence of the human genome. Science 2001;
291:1304–51.
2. Lee RC, Feinbaum RL, Ambros V. The C. elegans
heterochronic gene lin-4 encodes small RNAs with
antisense complementarity to lin-14. Cell 1993;75:
843–54.
3. Condorelli G, Latronico MVG, Cavarretta E.
microRNAs in cardiovascular diseases: current
knowledge and the road ahead. J Am Coll Cardiol
2014;63:2177–87.
4. Ipsaro JJ, Joshua-Tor L. From guide to target:
molecular insights into eukaryotic RNA-
interference machinery. Nat Struct Mol Biol
2015;22:20–8.
5. Jonas S, Izaurralde E. Towards a molecular un-
derstanding of microRNA-mediated gene
silencing. Nat Rev Genet 2015;16:421–33.
6. Bang C, Batkai S, Dangwal S, et al. Cardiac
ﬁbroblast-derived microRNA passenger strand-
enriched exosomes mediate cardiomyocyte hy-
pertrophy. J Clin Invest 2014;124:2136–46.
7. Zampetaki A, Mayr M. MicroRNAs in vascular
and metabolic disease. Circ Res 2012;110:508–22.
8. Pritchard CC, Cheng HH, Tewari M. MicroRNA
proﬁling: approaches and considerations. Nat Rev
Genet 2012;13:358–69.
9. Wang Z, Gerstein M, Snyder M. RNA-Seq: a
revolutionary tool for transcriptomics. Nat Rev
Genet 2009;10:57–63.
10. van Rooij E, Olson EN. MicroRNA therapeutics
for cardiovascular disease: opportunities and ob-
stacles. Nat Rev Drug Discov 2012;11:860–72.
11. Ganesan J, Ramanujam D, Sassi Y, et al. MiR-
378 controls cardiac hypertrophy by combined
repression of mitogen-activated protein kinase
pathway factors. Circulation 2013;127:2097–106.
12. Borel F, Kay MA, Mueller C. Recombinant AAV
as a platform for translating the therapeutic po-
tential of RNA interference. Mol Ther 2014;22:
692–701.
13. Krützfeldt J, Rajewsky N, Braich R, et al.
Silencing of microRNAs in vivo with ‘antagomirs’.
Nature 2005;438:685–9.
14. Janssen HLA, Reesink HW, Lawitz EJ, et al.
Treatment of HCV infection by targeting micro-
RNA. N Engl J Med 2013;368:1685–94.
15. Gomez IG, MacKenna DA, Johnson BG, et al.
Anti-microRNA-21 oligonucleotides prevent Alport
nephropathy progression by stimulating metabolic
pathways. J Clin Invest 2015;125:141–56.
16. Dalpke A, Helm M. RNA mediated Toll-like
receptor stimulation in health and disease. RNA
Biol 2012;9:828–42.
17. Carè A, Catalucci D, Felicetti F, et al.
MicroRNA-133 controls cardiac hypertrophy. Nat
Med 2007;13:613–8.
18. Castaldi A, Zaglia T, Di Mauro V, et al. Micro-
RNA-133 modulates the b1-adrenergic receptor
transduction cascade. Circ Res 2014;115:273–83.
19. Trajkovski M, Ahmed K, Esau CC, et al.
MyomiR-133 regulates brown fat differentiation
through Prdm16. Nat Cell Biol 2012;14:1330–5.
20. Matkovich SJ, Wang W, Tu Y, et al. MicroRNA-
133a protects against myocardial ﬁbrosis and
modulates electrical repolarization without
affecting hypertrophy in pressure-overloaded
adult hearts. Circ Res 2010;106:166–75.
21. Elia L, Contu R, Quintavalle M, et al. Reciprocal
regulation of microRNA-1 and insulin-like growth
factor-1 signal transduction cascade in cardiac and
skeletal muscle in physiological and pathological
conditions. Circulation 2009;120:2377–85.
22. Yang B, Lin H, Xiao J, et al. The muscle-speciﬁc
microRNA miR-1 regulates cardiac arrhythmogenic
potential by targeting GJA1 and KCNJ2. Nat Med
2007;13:486–91.
23. Zhao Y, Ransom JF, Li A, et al. Dysregulation
of cardiogenesis, cardiac conduction, and cell
cycle in mice lacking miRNA-1-2. Cell 2007;129:
303–17.
24. Karakikes I, Chaanine AH, Kang S, et al. Ther-
apeutic cardiac-targeted delivery of miR-1 re-
verses pressure overload-induced cardiac
hypertrophy and attenuates pathological remod-
eling. J Am Heart Assoc 2013;2:e000078.
25. Krenz M, Robbins J. Impact of beta-myosin
heavy chain expression on cardiac function dur-
ing stress. J Am Coll Cardiol 2004;44:2390–7.
26. van Rooij E, Sutherland LB, Qi X, et al. Control
of stress-dependent cardiac growth and gene
expression by a microRNA. Science 2007;316:
575–9.
27. Montgomery RL, Hullinger TG, Semus HM,
et al. Therapeutic inhibition of miR-208a improves
cardiac function and survival during heart failure.
Circulation 2011;124:1537–47.
28. Kakimoto Y, Tanaka M, Kamiguchi H, et al.
MicroRNA deep sequencing reveals chamber-
speciﬁc miR-208 family expression patterns in
the human heart. Int J Cardiol 2016;211:43–8.
29. Dirkx E, Gladka MM, Philippen LE, et al. Nfat
and miR-25 cooperate to reactivate the tran-
scription factor Hand2 in heart failure. Nat Cell
Biol 2013;15:1282–93.
30. Wahlquist C, Jeong D, Rojas-Muñoz A, et al.
Inhibition of miR-25 improves cardiac contractility
in the failing heart. Nature 2014;508:531–5.
31. Eulalio A, Mano M, Dal Ferro M, et al. Func-
tional screening identiﬁes miRNAs inducing cardiac
regeneration. Nature 2012;492:376–81.
32. Boon RA, Iekushi K, Lechner S, et al.
MicroRNA-34a regulates cardiac ageing and func-
tion. Nature 2013;495:107–10.
33. Loyer X, Potteaux S, Vion AC, et al. Inhibition
of microRNA-92a prevents endothelial dysfunc-
tion and atherosclerosis in mice. Circ Res 2014;114:
434–43.
34. Bonauer A, Carmona G, Iwasaki M, et al.
MicroRNA-92a controls angiogenesis and func-
tional recovery of ischemic tissues in mice. Science
2009;324:1710–3.
35. van Rooij E, Sutherland LB, Thatcher JE, et al.
Dysregulation of microRNAs after myocardial
infarction reveals a role of miR-29 in cardiac
ﬁbrosis. Proc Natl Acad Sci U S A 2008;105:
13027–32.
36. Abonnenc M, Nabeebaccus AA, Mayr U, et al.
Extracellular matrix secretion by cardiac ﬁbro-
blasts: role of microRNA-29b and microRNA-30c.
Circ Res 2013;113:1138–47.
37. Duisters RF, Tijsen AJ, Schroen B, et al. miR-
133 and miR-30 regulate connective tissue growth
factor: implications for a role of microRNAs in
myocardial matrix remodeling. Circ Res 2009;104:
170–8.
38. Tijsen AJ, van der Made I, van den
Hoogenhof MM, et al. The microRNA-15 family
inhibits the TGFb-pathway in the heart. Cardiovasc
Res 2014;104:61–71.
39. Castoldi G, di Gioia CRT, Bombardi C, et al.
MiR-133a regulates collagen 1A1: potential role of
miR-133a in myocardial ﬁbrosis in angiotensin
II-dependent hypertension. J Cell Physiol 2012;
227:850–6.
40. van Rooij E, Sutherland LB, Liu N, et al.
A signature pattern of stress-responsive micro-
RNAs that can evoke cardiac hypertrophy and
heart failure. Proc Natl Acad Sci U S A 2006;103:
18255–60.
41. Thum T, Gross C, Fiedler J, et al. MicroRNA-21
contributes to myocardial disease by stimulating
MAP kinase signalling in ﬁbroblasts. Nature 2008;
456:980–4.
42. Roy S, Khanna S, Hussain SRA, et al. MicroRNA
expression in response to murine myocardial
infarction: miR-21 regulates ﬁbroblast
metalloprotease-2 via phosphatase and tensin
homologue. Cardiovasc Res 2009;82:21–9.
43. Patrick DM, Montgomery RL, Qi X, et al.
Stress-dependent cardiac remodeling occurs in the
absence of microRNA-21 in mice. J Clin Invest
2010;120:3912–6.
44. Ji R, Cheng Y, Yue J, et al. MicroRNA expres-
sion signature and antisense-mediated depletion
reveal an essential role of microRNA in vascular
neointimal lesion formation. Circ Res 2007;100:
1579–88.
45. McDonald RA, Halliday CA, Miller AM, et al.
Reducing in-stent restenosis: therapeutic manip-
ulation of miRNA in vascular remodeling and
inﬂammation. J Am Coll Cardiol 2015;65:2314–27.
46. Wang D, Deuse T, Stubbendorff M, et al. Local
microRNA modulation using a novel anti-miR-21-
eluting stent effectively prevents experimental
in-stent restenosis. Arterioscler Thromb Vasc Biol
2015;35:1945–53.
47. Zampetaki A, Attia R, Mayr U, et al. Role of
miR-195 in aortic aneurysmal disease. Circ Res
2014;115:857–66.
48. Maegdefessel L, Azuma J, Toh R, et al. Inhi-
bition of microRNA-29b reduces murine abdom-
inal aortic aneurysm development. J Clin Invest
2012;122:497–506.
J A C C V O L . 6 8 , N O . 2 3 , 2 0 1 6 Barwari et al.
D E C E M B E R 1 3 , 2 0 1 6 : 2 5 7 7 – 8 4 MicroRNAs in Cardiovascular Disease
2583
49. Ulrich V, Rotllan N, Araldi E, et al. Chronic
miR-29 antagonism promotes favorable plaque
remodeling in atherosclerotic mice. EMBO Mol
Med 2016;8:643–53.
50. Cheng Y, Liu X, Yang J, et al. MicroRNA-145, a
novel smooth muscle cell phenotypic marker and
modulator, controls vascular neointimal lesion
formation. Circ Res 2009;105:158–66.
51. Cordes KR, Sheehy NT, White MP, et al. miR-
145 and miR-143 regulate smooth muscle cell fate
and plasticity. Nature 2009;460:705–10.
52. Lovren F, Pan Y, Quan A, et al. MicroRNA-145
targeted therapy reduces atherosclerosis. Circula-
tion 2012;126:S81–90.
53. Wang S, Aurora AB, Johnson BA, et al. The
endothelial-speciﬁc microRNA miR-126 governs
vascular integrity and angiogenesis. Dev Cell
2008;15:261–71.
54. Schober A, Nazari-Jahantigh M, Wei Y, et al.
MicroRNA-126-5p promotes endothelial prolifer-
ation and limits atherosclerosis by suppressing
Dlk1. Nat Med 2014;20:368–76.
55. Esau C, Davis S, Murray SF, et al. miR-122
regulation of lipid metabolism revealed by in vivo
antisense targeting. Cell Metab 2006;3:87–98.
56. Willeit P, Skroblin P, Kiechl S, et al. Liver
microRNAs: potential mediators and biomarkers
for metabolic and cardiovascular disease? Eur
Heart J 2016 Apr 20 [E-pub ahead of print].
57. Elmén J, Lindow M, Schütz S, et al. LNA-
mediated microRNA silencing in non-human pri-
mates. Nature 2008;452:896–9.
58. Rayner KJ, Suárez Y, Dávalos A, et al. MiR-33
contributes to the regulation of cholesterol ho-
meostasis. Science 2010;328:1570–3.
59. Najaﬁ-Shoushtari SH, Kristo F, Li Y, et al.
MicroRNA-33 and the SREBP host genes cooperate
to control cholesterol homeostasis. Science 2010;
328:1566–9.
60. Horie T, Nishino T, Baba O, et al. MicroRNA-33
regulates sterol regulatory element-binding pro-
tein 1 expression in mice. Nat Commun 2013;4:
2883.
61. Goedeke L, Rotllan N, Canfrán-Duque A, et al.
MicroRNA-148a regulates LDL receptor and ABCA1
expression to control circulating lipoprotein
levels. Nat Med 2015;21:1280–9.
62. Mitchell PS, Parkin RK, Kroh EM, et al. Circu-
lating microRNAs as stable blood-based markers
for cancer detection. Proc Natl Acad Sci U S A
2008;105:10513–8.
63. Vickers KC, Palmisano BT, Shoucri BM, et al.
MicroRNAs are transported in plasma and deliv-
ered to recipient cells by high-density lipopro-
teins. Nat Cell Biol 2011;13:423–33.
64. Laffont B, Corduan A, Plé H, et al. Activated
platelets can deliver mRNA regulatory
Ago2$microRNA complexes to endothelial cells via
microparticles. Blood 2013;122:253–61.
65. Gidlöf O, van der Brug M, Ohman J, et al.
Platelets activated during myocardial infarction
release functional miRNA, which can be taken up
by endothelial cells and regulate ICAM1 expres-
sion. Blood 2013;121:3908–17, S1-26.
66. Tabet F, Vickers KC, Cuesta Torres LF, et al.
HDL-transferred microRNA-223 regulates ICAM-1
expression in endothelial cells. Nat Commun
2014;5:3292.
67. Shan Z, Qin S, Li W, et al. An endocrine genetic
signal between blood cells and vascular smooth
muscle cells: role of microRNA-223 in smooth
muscle function and atherogenesis. J Am Coll
Cardiol 2015;65:2526–37.
68. Wang G-K, Zhu J-Q, Zhang J-T, et al. Circu-
lating microRNA: a novel potential biomarker for
early diagnosis of acute myocardial infarction in
humans. Eur Heart J 2010;31:659–66.
69. Widera C, Gupta SK, Lorenzen JM, et al.
Diagnostic and prognostic impact of six circulating
microRNAs in acute coronary syndrome. J Mol Cell
Cardiol 2011;51:872–5.
70. Roncarati R, Viviani Anselmi C, Losi MA, et al.
Circulating miR-29a, among other up-regulated
microRNAs, is the only biomarker for both hyper-
trophy and ﬁbrosis in patients with hypertrophic
cardiomyopathy. J Am Coll Cardiol 2014;63:
920–7.
71. Karakas M, Schulte C, Appelbaum S, et al.
Circulating microRNAs strongly predict cardio-
vascular death in patients with coronary artery
disease—results from the large AtheroGene
study. Eur Heart J 2016 Jun 29 [E-pub ahead of
print].
72. Bye A, Røsjø H, Nauman J, et al. Circulating
microRNAs predict future fatal myocardial infarc-
tion in healthy individuals – the HUNT study. J Mol
Cell Cardiol 2016;97:162–8.
73. Zampetaki A, Willeit P, Tilling L, et al. Pro-
spective study on circulating microRNAs and risk
of myocardial infarction. J Am Coll Cardiol 2012;
60:290–9.
74. Schulte C, Molz S, Appelbaum S, et al. miRNA-
197 and miRNA-223 predict cardiovascular death
in a cohort of patients with symptomatic coronary
artery disease. PLoS One 2015;10:e0145930.
75. Kaudewitz D, Skroblin P, Bender LH, et al.
Association of microRNAs and YRNAs with platelet
function. Circ Res 2016;118:420–32.
76. Elgheznawy A, Shi L, Hu J, et al. Dicer cleav-
age by calpain determines platelet microRNA
levels and function in diabetes. Circ Res 2015;117:
157–65.
77. Willeit P, Zampetaki A, Dudek K, et al. Circu-
lating microRNAs as novel biomarkers for platelet
activation. Circ Res 2013;112:595–600.
78. Kondkar AA, Bray MS, Leal SM, et al. VAMP8/
endobrevin is overexpressed in hyperreactive hu-
man platelets: suggested role for platelet micro-
RNA. J Thromb Haemost 2010;8:369–78.
79. Flierl U, Nero TL, Lim B, et al. Phosphor-
othioate backbone modiﬁcations of nucleotide-
based drugs are potent platelet activators. J Exp
Med 2015;212:129–37.
80. Anand S, Majeti BK, Acevedo LM, et al.
MicroRNA-132-mediated loss of p120RasGAP
activates the endothelium to facilitate patho-
logical angiogenesis. Nat Med 2010;16:909–14.
KEY WORDS biomarkers, genetic therapy,
noncoding RNA, RNA therapeutic
Barwari et al. J A C C V O L . 6 8 , N O . 2 3 , 2 0 1 6




Published article:  
 
 
MicroRNA Biomarkers and Platelet Reactivity: The 
Clot Thickens. 
Sunderland N, Skroblin P, Barwari T, Huntley RP, Lu R, Joshi A, 
Lovering RC, Mayr M.  
 
Circ Res. 2017;120(2):418–435. 
 
 
Accepted for publication: 20 December 2016 
418
Platelets play a key role in hemostasis, initiating and propagating thrombosis.1 Dysregulation and inappropri-
ate activation of platelets underpin a wide range of important 
diseases, including stroke and myocardial infarction, whereas 
impairment of platelet function results in bleeding disorders. 
Platelets are anucleate and were previously considered to be 
simple cytoplasmic fragments of megakaryocytes. We now 
know that platelets house an array of molecules, including 
proteins, RNA, and the subcellular machinery of de novo 
protein synthesis. Platelets can synthesize new proteins, such 
as the integrin alpha3 (glycoprotein-IIIa) protein and the fi-
brinogen receptor.2,3 They contain messenger RNA (mRNA), 
which codes for around a third of human genes.4,5 More re-
cently, the discoveries that platelets are an abundant source of 
microRNAs (miRNA),6 and that miRNA expression profiles 
within platelets correlate with platelet reactivity,7 raised the 
exciting possibility of novel therapeutic targets and disease 
biomarkers.
Initial studies by Mitchell et al8 revealed that not all miRNAs 
in the circulation are intracellular. This pool of extracellular 
circulating miRNA consists of miRNA within microvesicles, 
exosomes, or bound to proteins. The finding that miRNAs can 
also be measured in cell-free serum and plasma was surprising, 
given their high RNase activity. Compared with mRNAs, miR-
NAs remain relatively stable in the circulation through several 
protective mechanisms: association with RNA-binding pro-
teins and lipoproteins, or housing in shed microvesicles, such 
as exosomes or microparticles (MPs).9–12 Platelets release MPs, 
particularly during activation. These vesicles contain a host of 
proteins, inflammatory mediators, and noncoding RNAs.13–15 
Microvesicles might be taken up by other cells, introducing 
another layer of complexity in terms of intercellular signaling 
by potentially allowing direct regulation of the recipient cell’s 
mRNA profile and gene expression.16,17 Given this emerging 
role for circulating miRNAs, plasma and serum miRNA pro-
files may find use in clinical practice as novel markers of dis-
ease, organ function, and prognosis.18
In this review, we bring together nearly a decade’s experi-
ence with circulating noncoding RNAs, with particular focus 
on platelet-derived and associated miRNAs, YRNAs, long 
noncoding RNAs (lncRNAs), and circular RNAs (circRNAs). 
We conducted a literature search in PubMed as queried on 
November 23, 2016, using the search terms “platelet* AND 
(miRNA [MeSH Terms] OR micro RNA [MeSH Terms] OR 
micro-RNA OR microRNA)”. Four hundred and thirty-four 
results were retrieved, of which 75 were relevant primary re-
search papers and 39 were relevant literature reviews. From 
the literature to date, we collate the known platelet repertoire 
of noncoding RNAs and contemplate their physiological sig-
nificance. We also examine their disease associations and 
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potential clinical applications. Finally, we discuss the prac-
tical challenges in measuring and comparing miRNA levels, 
highlighting obstacles that will need to be overcome for this 
relatively new field to come of age.
Noncoding RNAs in Platelets and the 
Circulation
Different noncoding RNAs have been described (Figure 1).
miRNAs
The human genome codes for small (≈22 nucleotide) reg-
ulatory RNA molecules, termed miRNAs or miRs. Since 
miRNAs were first discovered in 1993, over 2500 have 
been defined.19,20 They are highly evolutionarily conserved 
and important in the posttranscriptional regulation of pro-
tein expression—about one third to half of the human genes 
are estimated to be regulated by miRNAs.21–23 MiRNAs act 
by imperfect Watson–Crick base pairing to the 3′untrans-
lated region (UTR) of target mRNA to affect translation 
or induce degradation.24,25 MiRNAs can be expressed as 
stand-alone scripts or alongside the parent gene mRNA. 
In either case, the primary miRNA transcript is processed 
by the nuclear microprocessor complex consisting of the 
endoribonuclease Drosha and the double-stranded RNA-
binding protein Pasha/DGCR8.26,27 The resultant hairpin 
pre-miRNA is then transferred to the cytoplasm by the nu-
clear membrane protein exportin-5 and further processed 
by the endoribonuclease Dicer.28 The resulting mature 
miRNA duplex associates with an Argonaute (Ago) pro-
tein, which unwinds the double strand and incorporates one 
of the 2 complementary miRNA strands, forming the RNA-
induced silencing complex.29 The RNA-induced silencing 
complex stabilizes the miRNA strand and guides it to its 
target mRNA. Because platelets do not have a nucleus and 
thus cannot transcribe miRNAs, it is currently thought that 
they inherit their miRNA content during the shedding pro-
cess from megakaryocytes.30 Thus, the platelet miRNAome 
in the circulation may provide insights into megakaryocyte 
function in the bone marrow.
There are many more miRNAs encoded in the human 
genome than there are detectable in the circulation.31 For 
example, we detected >200 miRNAs using next-generation 
sequencing (NGS) in plasma samples.32 Detectable miRNAs 
greatly vary in abundance. Not all miRNAs that are present 
in the circulation can be consistently quantified with cycle 
threshold (Ct) values of <32 by quantitative polymerase chain 
reaction (qPCR), even after preamplification. Another strik-
ing observation is the high correlation among the abundant 
circulating miRNAs.33 This may be because of their common 
platelet origin: in response to antiplatelet drugs, circulating 
levels of many miRNAs are reduced in platelet-poor plasma 
(PPP).34 Research into miRNAs is hampered by the current 
lack of functional miRNA data in bioinformatics resources. 
Access to cataloged experimental data is crucial to enable 
simple questions to be asked, such as, Which miRNAs are 
present in the circulation?, as well as the ability to perform 
sophisticated pathway and network analyses.35 This lack of 
freely accessible data is being addressed by the addition of 
gene ontology (GO) annotations for cardiovascular-related 
miRNAs.36,37 To answer the question of circulatory miRNAs, 
we have created GO annotations for those miRNAs identified 
as being present in human plasma from our previous study.32 
In the parlance of GO, the annotations were created using 
the GO term extracellular space (GO:0005615) with the ad-
dition of contextual information describing the extracellular 
space as part of blood plasma (using the Uber Ontology term 
Uberon:0001969). A large number of miRNAs were identi-
fied in PPP and platelet-rich plasma (PRP).32 For those with 
marked enrichment in PRP, as well as significantly increased 
levels in a platelet spike-in experiment, we were additionally 
able to include in the annotation that the miRNAs present in 
the extracellular space are likely to have originated from plate-
lets (using the cell ontology term CL:0000233). In total, we 
have identified 230 human miRNAs as present in the circula-
tion, and the annotations providing this information are avail-
able in the GO database.38 Inclusion of functional annotations 
such as these into public databases will enable researchers to 
find and analyze miRNA data more easily, allowing for faster 
progression of their research.
YRNAs
In our most recent study, we have also identified YRNAs as an-
other species of circulating noncoding RNAs that is platelet-de-
rived.32 YRNAs are small noncoding RNAs, ≈100 nucleotides 
in length, that originate from 4 human genes (RNY1, RNY3 , 
RNY4 , and RNY5  and ≈900 pseudogenes).39,40 Using NGS in 
PPP and PRP, we observed a dominant peak at sequences of 
32 to 33 nucleotides long, which was mapped to YRNA genes 
(Figure 2A).32 The full-length YRNAs have cytoplasmic or 
nuclear localization and are involved in the initiation of DNA 
replication, as well as in ribosomal RNA quality control.41,42 
They are components of Ro ribonucleoproteins, which con-
stitute important autoantigens in autoimmune diseases, such 
as systemic lupus erythematosus and Sjögren’s syndrome.43 
YRNA fragments are present in the circulation, with 5′ frag-
ments being much more abundant than 3′ fragments for the 
majority of RNY genes.32,44 YRNA fragments are generated 
during cell stress or apoptosis. Given that YRNA fragments are 
abundant in platelets, and strongly correlate to platelet-derived 
proteins in the circulation (Figure 2B),32 we speculate that the 
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YRNA fragments are formed during the budding of platelets 
from megakaryocytes. In contrast to the processing of mature 
miRNAs from precursor miRNAs, YRNA fragments are gen-
erated by a Dicer-independent mechanism.45 Unlike miRNAs, 
we also failed to detect YRNAs in Ago2 complexes of MEG-01 
cells, a human megakaryoblastic cell line.32 The predominant 
platelet origin of YRNA fragments in human plasma is further 
supported by the results from platelet spike-in experiments.32
Ribosomal RNA
Ribosomal RNA is a key regulator of intracellular protein 
synthesis and is also detected in the circulation. Tissue dam-
age and unregulated cell death result in significant quantities 
of  ribosomal RNA shifting into the extracellular compart-
ment.46,47 As reviewed recently,48 extracellular ribosomal 
RNA may have several important pathophysiological roles 
in atherosclerotic plaques, including promotion of vascular 
hyperpermeability, initiation of coagulation and thrombus 
Figure 1. Overview of noncoding RNAs in platelets. Although platelets are anucleate, they contain genetic material in the form of noncoding 
RNAs. These include small noncoding RNAs, such as microRNAs (miRNAs) and YRNA fragments, as well as long noncoding RNAs, such as 
circular RNAs (circRNAs). Secondary structures of RNA sequences were predicted using RTips (http://rtips.dna.bio.keio.ac.jp).
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formation, recruitment of leukocytes, promotion of a proin-
flammatory phenotype of monocytes/macrophages, and pro-
motion of cardiomyocyte death. 
Long Noncoding RNAs
Recently, attention has shifted from small noncoding to ln-
cRNAs. Unlike miRNAs and YRNA fragments, which are 
mainly found in the cytosol, lncRNAs are predominantly re-
tained in the nucleus.49 This nuclear localization has important 
implications for their release mechanism. Although miRNAs 
and YRNA fragments are secreted as part of any budding pro-
cess of microvesicles with cytoplasmic components, even in 
the absence of injury, the secretion of lncRNAs may be depen-
dent on cellular damage that is sufficient to release nuclear ma-
terial. On release, the lncRNAs require protection from RNase 
degradation. In general, lncRNAs may be more susceptible to 
RNase activity than small noncoding RNAs because the lon-
ger sequence is more vulnerable to cleavage and not as easily 
complexed and protected by RNA-binding proteins. Although 
lncRNAs are readily detected in whole blood, levels in plasma 
or serum tend to be low, at least in healthy individuals without 
tissue injury. The release of mitochondria-associated lncRNAs 
has been described in patients with myocardial infarction.50 
It is possible that mitochondrial lncRNAs are protected from 
RNase degradation. Further, because cardiomyocytes are par-
ticularly rich in mitochondria, these lncRNAs may indeed be 
cardiac-derived. However, unlike troponins, lncRNAs are not 
cardiac muscle-specific, so contributions from other cell types 
cannot be excluded.51 Because platelets are anuclear and have 
a low mitochondrial content, most lncRNAs may not be de-
tectable in platelets, with the notable exception of circRNAs.
Circular RNAs
Recent evidence suggests that platelets are relatively abun-
dant in circRNAs,52 an emerging class of noncoding RNAs 
that had been described as early as 1976.53 Development of 
advanced NGS techniques led to their recent rediscovery,54 
showing ubiquitous expression in both humans and mice.55 
Several pathways exist to generate circRNAs.56 Most com-
monly, they are derived from exons of protein-coding genes 
through back-splicing, whereas some arise from intronic or 
intergenic regions via alternative splicing. circRNAs are gen-
erally localized in the cytoplasm, but how they are exported 
from the nucleus remains unknown. RNA-binding proteins 
Figure 2. Small noncoding RNAs in 
plasma. A, Two peaks corresponding 
to miRNAs and YRNAs were observed 
by small RNA sequencing in plasma. B, 
Correlation of YRNA fragments to plasma 
levels of platelet factor 4 (PF4), proplatelet 
basic protein (PPBP), and P-selectin 
(SELP). Lipocalin 2 (LCN2) was used 
as control. N=667. NGS indicates next 
generation sequencing.
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like Quaking and Muscleblind are thought to affect the abun-
dance of circRNAs in human cells through binding of the 
specific RNA-binding proteins to flanking intronic sequence 
motifs. Interaction between the RNA-binding proteins on each 
end approximates both ends of the exon and facilitates the for-
mation of a circle. Quaking regulates human circRNA biogen-
esis, and knockdown of Quaking decreases the expression of 
abundant circRNAs.57 CircRNAs were found to be enriched in 
platelets, where they are generated by exon back-splicing.52 
Using RNase R to selectively remove linear transcripts, sever-
al distinct circRNAs were identified in platelets. Although the 
majority of circRNAs are not cell type-specific, human plate-
lets and erythrocytes were found to be highly enriched for cir-
cRNAs compared with nucleated cell types. Several circRNAs 
were expressed at much higher levels than the linear form of 
the RNA in platelets and erythrocytes. Interestingly, the rela-
tive proportion of circRNAs in cultured megakaryocytes is 
much lower compared with mature platelets. Combined with 
the finding that circRNA decays at a significantly slower rate 
than linear RNA, and platelets lose >90% of their progenitor 
mRNA, the enrichment of circRNA in platelets might be the 
result of linear RNA degradation.52 This process has a pro-
found effect on the composition of RNA because anucleate 
platelets cannot transcribe new RNA. Recent reports demon-
strated that circRNAs can serve as miRNA sponges, which 
are believed to negatively regulate miRNAs by sequestering 
miRNA molecules.58 This raises questions of how circRNAs 
interact with miRNAs and mRNAs in platelets and how cir-
cRNA transcripts are formed in platelets. With their enrich-
ment being a signature of mRNA decay, platelet circRNAs 
may reflect platelet function or ageing.
miRNA Repertoire of Platelets
Landry et al6 first reported a large number of platelet miRNAs 
by using locked nucleic acid–based microarray profiling. NGS 
has enabled the discovery of novel miRNA species. Plé et al59 
identified nearly 500 species, with the let-7 family of miRNAs 
comprising nearly 50% of the total. Since then, Bray et al4 have 
identified many more, bringing the total of recognized platelet 
miRNAs to ≈750. The variation in reported platelet miRNA 
expression is not solely because of interindividual differences, 
such as sex and age.60 Sample preparation, storage, normaliza-
tion procedures, and measurement platforms play an important 
role. Studies aimed at defining the platelet miRNA profile use 
a variety of techniques, including microarrays, qPCR-based 
methods, and NGS. For example, Wang et al61 demonstrated 
platform-associated amplification differences in miR-107, 
which showed much higher amplification with locked nucleic 
acid–based assays compared with TaqMan assays. In clinical 
laboratory conditions, Yu et al62 showed upregulation of sev-
eral apoptosis-related platelet miRNAs after prolonged blood 
bank storage of platelets. As platelet preparation from whole 
blood can lead to contamination with leukocytes and erythro-
cytes, themselves abundant sources of miRNAs, controlling 
cellular contamination of platelet preparations is essential.61 
Variation in preparation and storage conditions can drastically 
affect platelet miRNA expression, which may explain why in-
terstudy miRNA expression ranks are highly variable. Based 
on the current literature, a combined interstudy miRNA ex-
pression rank list is presented in Figure 3.
Association of Platelet miRNAs With Disease
Antiplatelet drugs reduce the risk of cardiovascular events, 
but patients on antiplatelet therapy still suffer thrombotic 
events. Ever more potent antiplatelet strategies carry the risk 
of bleeding complications. Ideally, a so-called “sweet spot” 
could be defined for each patient, which offers maximum 
platelet inhibition with minimal bleeding risk.63 For optimal 
platelet inhibition, platelet turnover is important: with a life 
span of 7 to 9 days, 10% to 15% of the platelet pool must 
be replenished every day, equivalent to 1010 to 1011 platelets 
per day.64 The platelet turnover rate may be important for the 
efficiency of drugs like aspirin with a short half-life. Aspirin 
irreversibly binds cyclooxygenase, so is effective for the full 
life span of the platelet. However, increased platelet turnover 
can lead to budding of new platelets without inactive cyclo-
oxygenase between doses. Furthermore, newly formed plate-
lets are larger, more reticulated, more reactive, and more 
prone to participate in thrombus formation compared with 
older platelets. They also contain a higher amount of RNA 
and are more able to produce proteins, in particular, alpha 
granule proteins. Counting the subset of reticulated platelets 
may be a parameter for platelet turnover. However, the in-
trinsic properties of platelets could be even more important 
for platelet reactivity than their turnover rate.65 In light of the 
enrichment of miRNAs and circRNAs, and the described ef-
fects of mRNA degradation during the lifetime of platelets, 
the noncoding RNA content of platelets may better reflect 
their intrinsic properties.
Platelet miRNA expression profiles in healthy volunteers 
remain stable over the life-span of a platelet.66 This expression 
profile is significantly altered in various disease states, includ-
ing myocardial infarction,67,68 diabetes mellitus,69 and cancer.70 
There is, therefore, the opportunity to find new biomarkers 
or therapeutic targets and increase our understanding of the 
pathophysiological mechanisms of these diseases. Anucleate 
platelets lack transcriptional control, so differences in miRNA 
signatures during platelet-activating disease states have been 
ascribed to several mechanisms: shedding of MPs,71 synthesis 
of mature miRNA from precursor miRNAs,69 and posttran-
scriptional modifications.59 We undertook the first systematic 
analysis of circulating miRNAs in a large population-based 
study (the Bruneck study) and revealed a loss of miRNAs in 
type 2 diabetes mellitus.72 Subsequent studies indicated that 
this loss may be attributed to activation of calpain, which can 
affect platelet levels of Dicer.73 Because this endoribonuclease 
is key in the processing of precursor miRNAs to mature miR-
NAs, its loss resulted in decreased levels of several platelet-
enriched miRNAs.69,74 These findings are in line with studies 
showing that circulating miRNA changes in cardiovascular 
risk can be attributed to platelets.32,34 Additionally, we dem-
onstrated that a combination of miRNAs may predict future 
cardiovascular events.75 This has been confirmed by other in-
vestigators.76 In continuation of our work on circulating miR-
NAs in diabetes mellitus,72 we have identified 2 angiogenic 
miRNAs as biomarkers for diabetic retinopathy.77
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Findings by other investigators and our group suggest that 
platelet miRNAs might not only reflect but also affect platelet 
function.
miR-96 and Vesicle-Associated Membrane Protein 8
In 2010, Kondkar et al78 reported a role for miR-96 in platelet re-
activity. They showed that miR-96 may act through regulation of 
vesicle-associated membrane protein 8 (VAMP8), an important 
SNARE protein involved in platelet degranulation. Healthy vol-
unteers’ platelets were categorized as either hyper- or hyporeac-
tive. mRNA profiling revealed differential expression of a range 
of scripts, including VAMP8 mRNA (4.8-fold decrease in the 
hyporeactive versus hyper-reactive platelets). This translated to 
a 2.5-fold lower VAMP8 protein expression in the hyporeactive 
Figure 3. Platelet miRNA levels. Relative 
abundance of miRNAs in platelets was 
reported in 8 studies (indicated by first 
author and year of publication). The 50 
highest ranking on average are presented 
here, indicating marked variation between 
different studies for the miRNAs beyond 
the top-10.
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platelets. miR-96 levels were upregulated in the hyporeactive 
platelets (2.6-fold higher). Transfection of VAMP8-expressing 
human colorectal cancer cells with miR-96 was associated with 
dose-dependent reductions in VAMP8 mRNA and protein lev-
els; a similar finding was reported in cells of a megakaryocyte 
lineage. miR-96 was predicted to bind the 3′UTR of VAMP8. 
In contrast with this study, Shi et al79 reported no association 
between platelet response to clopidogrel and miR-96 expression, 
and miR-96 was not among the most highly expressed miRNAs 
found in human platelets. Although this does not discredit a role 
for miR-96 in regulating platelet reactivity, these findings need 
to be validated and explained in a larger study.
MiR-376c, miR-599, and Platelet 
Phosphatidylcholine Transfer Protein
There is a racial disparity in survival in coronary heart disease 
between patients with Caucasian and Afro-Caribbean back-
ground, even after adjusting for all known factors. Edelstein et 
al80 investigated whether racial differences in platelet function 
underpin an increased thrombotic risk. One hundred and fifty-
four healthy black and white volunteers were recruited, and 
platelet reactivity to thrombin was measured. Higher aggre-
gation and platelet calcium responses to PAR4-AP (thrombin 
receptor 4 activating peptide) in Afro-Caribbean individuals 
were found. PCTP (phosphatidylcholine transfer protein)–
encoding mRNA was found to be upregulated in Afro-
Caribbeans. After profiling platelet miRNA signatures, 178 
miRNAs, including miR-376c, were predicted to target PCTP 
mRNA. miR-376c levels inversely correlated with PCTP 
mRNA levels, PCTP protein levels, and PAR4 reactivity. miR-
376c is part of a cluster of miRNAs differentially expressed 
by ethnic origin, which may underpin differences in platelet 
function. Interestingly, a statistical cluster of 24 miRNAs all 
mapped to chromosome 14q32.2. Among other differentially 
expressed miRNAs were some of the most abundant platelet 
miRNAs: miR-223, miR-21, miR-23b, miR-107, and let-7c. 
Plé et al81 also found evidence of miRNA regulation of PCTP. 
Their analysis predicted miR-599 targeting of the 3′UTR of 
PCTP mRNA and showed downregulation of a reporter gene 
containing the PCTP 3′UTR in HEK293 (human embryonic 
kidney) cells transfected with pre-miR-599.
miR-223 and P2Y12 Receptor Expression
miR-223 is highly expressed in platelets and megakaryocytes, 
where it is thought to regulate thrombopoiesis. One of the 
most interesting features of miR-223 is its ability to bind to the 
3′UTR of human P2Y12 receptor mRNA.6 The P2Y12 receptor 
mediates important platelet functions, including aggregation 
and granule secretion, and is activated by ADP, the physio-
logical agonist of this Gi2 protein-coupled receptor. Landry et 
al6 showed that platelet P2Y12 receptor mRNA coprecipitates 
with Ago2, suggesting that miR-223 could regulate receptor 
levels and, thereby, platelet function. Platelet response to ADP 
antagonists is clinically relevant given the widespread use 
of drugs such as clopidogrel, prasugrel, and ticagrelor in the 
treatment of myocardial infarction and ischemic stroke.
Because of the proposed regulation of P2Y12 receptor func-
tion, miR-223 has been the focus of many clinically orien-
tated studies. In particular, there is great interest in relation to 
platelet responsiveness to clopidogrel, a prodrug that requires 
hepatic cytochrome P450 enzymes to become active. Shi et al79 
reported decreased levels of platelet miR-223 in association 
with high platelet reactivity, despite treatment with clopidogrel. 
They looked at patients presenting with non–ST-elevation acute 
coronary syndrome, in terms of their platelet reactivity index, 
who were treated with aspirin and clopidogrel. In patients who 
had a reduced response to clopidogrel, platelet miR-223 was 
significantly downregulated, whereas miR-96 was unchanged. 
Platelet miR-223 also inversely correlated with the platelet re-
activity index. Of note, neither miR-223 nor miR-96 were sig-
nificantly different between normal and low responders when 
ADP-induced platelet aggregometry was used. These results 
suggest that platelet miR-223 may be a predictor of normal and 
low responders to clopidogrel. This is supported by the fact that 
P2Y12 mRNA can be found in Ago2 immunoprecipitates.6
In a preliminary report including 21 males presenting with 
non–ST-elevation acute coronary syndrome, Chyrchel et al82 
studied miR-223 plasma levels. Patients were treated with aspirin 
plus either clopidogrel, prasugrel, or ticagrelor. Although there 
were no differences in plasma miR-223 levels between drug 
types, when all the data were pooled, miR-223 positively corre-
lated with the level of platelet inhibition.82 These results seem in 
line with those of Shi et al79 who found that high platelet miR-223 
levels predicted efficacious platelet inhibition with clopidogrel. 
Similarly, Zhang et al83 report decreased plasma miR-223 to be 
associated with clopidogrel low responders. In this study of 62 
patients with unstable angina, miR-223 was found to be the only 
independent predictor of low responders to clopidogrel and was 
higher with greater degrees of platelet inhibition.
miR-223 is also expressed in mouse platelets. In response 
to high agonist concentrations, miR-223 knockout mice do not 
show any detectable alteration in aggregation, speed of clot re-
traction, platelet adhesion, or bleeding time. P2Y12 mRNA ex-
pression levels are also unchanged.84 This is probably because of 
mouse P2Y12 mRNA lacking the specific binding site for miR-
223, rendering mouse models difficult to interpret in this context. 
Nonetheless, Elgheznawy et al69 subsequently demonstrated that 
miR-223 deletion in mice did result in modestly higher platelet 
activation at lower agonist concentrations. Proteomic analysis 
revealed differential expression of kindlin-3 and coagulation fac-
tor XIII-A in platelets from miR-223-deficient mice.
Zampetaki et al75 found that serum miR-223 levels are in-
versely associated with risk of future myocardial infarction and 
showed a stronger association with fatal than nonfatal events. 
Badrnya et al85 showed reduced platelet microvesicle miR-223 
in smokers. These findings are potentially complementary to 
those relating low platelet miR-223 level to increased P2Y12 
activity in humans and to those showing higher platelet re-
activity in response to miR-223 deletion in mice. Subsequent 
clinical studies have investigated platelet miR-223, including 
in a small cohort of patients who suffered an ischemic stroke. 
Duan et al86 report that platelet miR-223 and miR-146a were 
lower in stroke patients with diabetes mellitus versus controls. 
Platelet miR-223 and miR-146a levels significantly correlated 
with platelet reactivity as measured by P-selectin expression 
and also correlated to plasma levels, suggesting that platelets 
are a major source of circulating miR-223.
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In summary, miR-223 targets the 3′UTR of the human 
P2Y12 platelet receptor mRNA. The P2Y12 receptor is impor-
tant in platelet activation and is the target of many drugs used 
to inhibit platelet function. Lower levels of platelet miR-223, 
therefore, may result in more P2Y12 receptor activity and, 
thus, higher platelet reactivity. In this way, lower platelet 
miR-223 levels may increase the risk of thrombotic disease, 
such as myocardial infarction. This also may underpin the 
observation that lower platelet miR-223 levels are associated 
with reduced efficacy of P2Y12 receptor antagonists, such as 
clopidogrel. Mice lack the specific miR-223-binding site on 
the P2Y12 mRNA, and so comparisons to human data is dif-
ficult. Nonetheless, miR-223-deficient mice do seem to have 
altered platelet function, perhaps through regulation of other 
proteins.
miR-126 and ADAM9 (A Disintegrin and 
Metalloproteinase Domain-Containing Protein 9)
Early studies, including one from our group,72 stated that miR-
126 is endothelial specific. Although miR-126 is enriched in 
endothelial cells and supports endothelial integrity, its circu-
lating levels cannot be attributed solely to endothelial cells. In 
fact, megakaryocytes and endothelial cells both express miR-
126, and circulating miR-126 levels seem to be predominantly 
platelet derived.34,77
de Boer et al87 investigated the effects of aspirin on the 
platelet contribution of circulating miR-126 in patients with 
type 2 diabetes mellitus. PRP from subjects was treated with 
either arachidonic acid (a platelet activator) or arachidonic 
acid plus aspirin. Once the PRP had been treated, it was cen-
trifuged to separate the platelets from the now PPP. Platelet 
activation resulted in a considerable transfer of miR-126 to 
the PPP fraction, and this could be rescued with the addition 
of aspirin. miR-223, miR-16, and miR-423 showed a similar 
pattern, suggesting that they are all released from platelets on 
activation and that aspirin attenuates this release. miR-126 
levels also correlated with platelet activation as measured by 
soluble P-selectin. As part of another clinical trial involving 
patients with type 2 diabetes mellitus, the platelet activation 
state (measured via P-selectin expression) was assessed in 
40 patients treated with increasing doses of aspirin. Platelet 
activation positively correlated with plasma miR-126 and 
aspirin reduced circulating levels of miRNA-126. Arguing 
against an endothelial origin of miR-126, the authors point 
out that aspirin primarily inhibits platelet-enriched COX-1, 
whereas the endothelium predominantly expresses COX-
2. They also demonstrated no change in circulating von 
Willebrand factor.87 Taken together, these findings suggest 
that aspirin has the potential to significantly alter the miR-
NA signature of plasma, and careful consideration should 
be given when designing clinical studies in pursuit of novel 
biomarkers.
In our experiments, we demonstrated that plasma miR-
126 levels (1) correlate to platelet MPs, (2) are reduced 
on platelet inhibition, and (3) are associated with markers 
of platelet activation in the general population.32 These as-
sociations were further substantiated by genetic evidence. 
The single nucleotide polymorphism rs4636297 is located 
in the primary transcript-encoding region of miR-126 and 
affects its processing to mature miR-126. The minor al-
lele is associated with increased processing of the primary 
miRNA to mature miR-126. In a population-based study, 
carriers of the minor allele had higher levels of miR-126 in 
plasma and in serum.32 The increase in circulating miR-126 
was associated with a rise in platelet activation markers, 
such as platelet factor 4 and proplatelet basic protein. The 
genetic data on miR-126 and platelet function were in line 
with findings in the Bruneck cohort, in which miR-126 se-
rum levels were positively associated with risk of myocar-
dial infarction after adjustment for miR-223 and miR-197, 
again with platelets being identified as the most probable 
source.75 A study by Yu et al88 showed that higher plasma 
miR-126 predicted major adverse cardiac events in 491 pa-
tients after a percutaneous coronary intervention, while on 
dual antiplatelet therapy.
In mice, inhibition of miR-126 by antagomiRs (synthetic 
inhibitors of miRNAs) decreased thromboxane A2-dependent 
platelet aggregation. This effect is likely because of mega-
karyocyte miR-126, but because antagomiRs are adminis-
tered systemically, the contribution of other cell types, in 
particular endothelial cells, cannot be excluded. However, 
inhibition of miR-126 expression in endothelial cells would 
be expected to result in endothelial dysfunction and increased 
platelet activation. Similarly, if the effects of the single nucle-
otide polymorphism rs4636297 were limited to endothelial 
cells, one might expect that higher miR-126 levels are pro-
tective for endothelial cells and, thus, reduce platelet activ-
ity. The opposite was observed in mice and men. In MEG-01 
cells, ADAM9 was confirmed as a direct miR-126 target that 
attenuates the adhesion of platelets to collagen. Inhibition of 
miR-126 by antagomiRs also had indirect effects on P2Y12 
expression levels, at least in mice. Thus, in addition to en-
dothelial cells, miR-126 affects megakaryocytes. It remains 
to be seen whether platelet-specific deletion of miR-126 can 
recapitulate the accelerated atherosclerosis phenotype seen in 
miR-126-deficient mice.89
In summary, higher plasma or serum levels of miR-126 
are associated with an increased risk of myocardial infarction 
and other major adverse cardiac events. This may, at least in 
part, occur via increased platelet activation. Inhibition of miR-
126 with antagomiR-126 reduces platelet activation in mice, 
which may be explained by blocking of ADAM9’s negative 
effect on platelet:collagen adhesion or via indirectly affecting 
platelet P2Y12 expression levels.
Cellular Crosstalk Via miRNAs?
Several studies suggest that secreted miRNAs may act as para-
crine mediators. The concept is appealing, but most evidence 
is currently limited to in vitro studies. By overexpressing a 
miRNA in one cell type, harvesting microvesicles from the 
conditioned media, and adding these microvesicles to re-
cipient cells, miRNA transfer and downregulation of miRNA 
targets is detectable, suggesting that the miRNA uptake has 
biological function. There are several caveats to these in vitro 
studies:
1. MiRNAs are not abundant in the circulation, and 
preamplification is usually required for all but the 
most abundant miRNAs for reliable detection by 
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qPCR. It is difficult to envisage how the few copies 
of miRNAs would have a potent effect on target gene 
expression. The amount of circulating miRNAs is several 
orders of magnitude below the cellular miRNA content, 
and exogenous miRNAs would have to compete with the 
endogenous miRNAs in the recipient cells for loading 
into the RNA-induced silencing complex. Unless there 
is a receptor that recognizes miRNAs and initiates a 
downstream signaling cascade, it is difficult to envisage 
how uptake of exogenous miRNAs could mediate bio-
logical effects.
2. MPs and exosomes are rich in proteins. The protein con-
tent of microvesicles may be functionally more impor-
tant than their miRNA load. RNase treatment does not 
unambiguously prove that the observed biological effect 
is because of miRNAs. Protein degradation may also oc-
cur during the RNase digestion step.
3. In situ hybridization studies for a particular miRNA tend 
to reveal a characteristic staining pattern. For example, 
staining for miR-126 is confined to endothelial cells, 
whereas staining for miR-143 and miR-145 is observed 
in vascular smooth muscle cells. If miRNA transfer was 
a common phenomenon, such specificity would not be 
detected, and a more homogenous staining pattern would 
be expected.
4. Importantly, the tissue architecture, including basement 
membranes and extracellular matrix, should act as a 
physical barrier for the exchange of microvesicles.
5. Routine cell culture uses fetal calf serum, which is a 
source of bovine microvesicles.
Thus, we currently lack convincing evidence that the ex-
change of miRNAs is more than an in vitro phenomenon. In 
uninjured tissues, cellular miRNA exchange might be low. It 
is conceivable that miRNA transfer could occur under patho-
logical conditions, such as platelet activation and clearance 
by inflammatory cells. Several experiments shed light on the 
role of platelet miRNA as a putative paracrine regulator of 
cellular function via regulation of other cells’ mRNA and 
protein expression. For abundant platelet miRNAs, such as 
miR-223, target genes have been described, many of which 
are associated with inflammation. This miRNA is also ex-
pressed in leukocytes, further indicating a potential role. 
Given that platelets are already heavily implicated in several 
disease processes with an inflammatory basis, an interplay 
between endothelial cells, leukocytes, monocytes, and oth-
er cell types by endogenous and transferred miRNA seems 
plausible and an important area for further investigation.
Jansen et al90
 sought to define the miRNA content of cir-
culating microvesicles and vesicle-free plasma in 176 patients 
with stable coronary artery disease undergoing coronary angi-
ography. Over 6 years follow-up, microvesicle miR-126 and 
miR-199a levels above the median were associated with sig-
nificantly fewer major adverse cardiac events and percutane-
ous coronary interventions. There was no association between 
miRNAs from PPP and cardiovascular events. Microvesicle 
miR-126 was significantly reduced, and miR-199a trended 
toward reduction, in coronary artery disease patients versus 
age-matched controls. Again, no such difference was found 
in the PPP. Through microvesicle typing of surface markers, 
they established that miR-126 expression is highest in CD31+/
CD42b− microvesicles (ie, endothelial), consistent with known 
expression patterns in endothelial cells, and miR-199a is 
highest in CD31+/CD42b+ microvesicles (ie, megakaryocyte-
derived). These results are in contrast to results for circulating 
miR-126 levels. However, this study by Jansen et al90 looked 
specifically at the microvesicular compartment, making cross-
study comparisons difficult.
Laffont et al17 showed that activated platelets can deliver 
regulatory Ago2–miRNA complexes to endothelial cells and 
that this occurs via MPs. First, they confirmed that activat-
ed platelets release substantially more MPs than quiescent 
platelets. Profiling the miRNA content of the MPs showed 
that the miR-223 content was greatly increased after plate-
let activation, suggesting selective packaging of miRNAs 
into platelet MPs. They then showed that the MPs contain 
functional Ago2:miR-223 complexes, which could cleave a 
complementary miR-223 RNA sensor, suggesting that these 
complexes are functionally relevant. Next, they used fluores-
cently labeled MPs to demonstrate internalization by human 
umbilical vein endothelial cells. Endothelial miR-223 levels 
increased 22-fold after incubation with MPs for 1 hour, an 
effect that persisted for 48 hours. Again addressing function-
al relevance, endothelial cells demonstrated a 44% reduction 
in a transfected reporter gene under miR-223 control when 
incubated with MPs. Significant downregulation of endog-
enous RNA levels occurred within 6 hours of exposure to 
platelet MPs, an effect that was rescued with the addition of 
an miR-223-neutralizing sponge.17
Pan et al91 also showed increased MP release and MP miR-
NA enrichment after platelet activation. In the apolipoprotein 
E-null mouse model of atherosclerosis, MP miR-223 content 
was higher than in controls. This finding was also tested in 
a small selection of humans, in whom miR-223 expression 
was found to be higher in platelets and MPs of patients with 
inflammatory diseases compared with healthy controls. The 
authors demonstrated that endothelial cells take up MPs in an 
ATP-dependent manner, and endothelial miR-223 levels in-
crease without an increase in pre-miR-223, suggesting that 
the increase was not because of de novo synthesis in recipient 
cells. Both an miR-223 mimic and incubation with MPs were 
shown to reduce insulin-like growth factor 1 receptor protein 
levels. This effect was blocked by anti-miR-223. miR-223 
delivery increased advanced glycation end products–induced 
apoptosis, potentially via reduced levels of the insulin-like 
growth factor 1 receptor.91
Finally, Gidlöf et al67 showed that patients with ST-
segment–elevation myocardial infarction had reduced levels 
of miR-22, miR-185, miR-320b, and miR-423-5p in platelets 
compared with controls and an even greater reduction in as-
pirated coronary artery thrombus. The authors concluded that 
this is because of platelet activation and miRNA release. In 
vitro, they demonstrated miR-22, miR-185, miR-320b, and 
miR-423-5p release into the supernatant after thrombin-in-
duced platelet activation. Using platelets transfected with a 
scrambled, fluorescently labeled miRNA, they showed effec-
tive transfer to endothelial cells when incubated with activated 
platelets. Furthermore, this was shown to be MP-dependent 
because the addition of brefeldin A (a vesicle formation 
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inhibitor) prevented miRNA transfer. Overexpression of miR-
22 and miR-320b in endothelial cells suggested that these 
miRNAs were involved in the regulation of intercellular adhe-
sion molecule 1. When endothelial cells were incubated with 
platelet releasate, intercellular adhesion molecule 1 expres-
sion was downregulated by 30%. Knockdown of endogenous 
endothelial miR-22 and miR-320b caused an increase in inter-
cellular adhesion molecule 1 expression, confirming that the 
effect was because of MP miR-22 or miR-320b. Interestingly, 
this could be rescued by incubating the cells with platelet 
releasate.
In summary, there is now good evidence that (1) platelets 
transfer miRNAs and (2) that this is mediated by MPs.92,93 
However, it is less certain whether this transfer is functionally 
relevant at physiological concentrations in vivo and to what 
extent the observed effects are mediated by the miRNA con-
tent rather than the protein content of the platelet MP mate-
rial. Although most studies have focused on platelet transfer of 
miRNA to endothelial cells, Risitano et al71 showed that RNA 
transfer can occur between circulating platelets and monocytes.
Guidance on How to Measure Circulating 
miRNAs
Research on circulating miRNAs is attracting increasing at-
tention because noncoding RNAs may constitute an entirely 
new entity of biomarkers. A prerequisite for advances in this 
area is the generation of comparative data by independent 
groups. To help this, we have suggested a set of minimum-
reporting standards and recommended methods for circulating 
miRNA data (Table).
Plasma or Serum?
A fundamental question is the choice of plasma or serum 
for measuring miRNAs (Figure 4). The origin of miRNAs in 
plasma and serum may not be the same because platelets are 
activated during clotting and may contribute a larger propor-
tion of miRNAs to serum compared with plasma. In plasma, 
the cells are removed by centrifugation in the presence of an 
anticoagulant. Citrate and EDTA are the preferred anticoagu-
lants. Heparin plasma, for the reasons outlined below, is less 
suitable for miRNA measurements. Platelet activation during 
plasma centrifugation is another concern. Serum, on the other 
hand, is obtained by clotting blood at room temperature for 30 
minutes to 1 hour. The clotting process involves the activation 
of thrombin, which cleaves fibrinogen to fibrin. Thrombin is a 
protease and its substrate specificity is not restricted to fibrino-
gen. The coagulation cascade involves a series of proteases, 
which may degrade carrier proteins of miRNAs. This might 
result in a loss of miRNAs, which can be mitigated by adding 
RNase inhibitors.94 If platelets release miRNAs on activation, 
then findings in plasma and serum might give opposite results: 
plasma miRNAs may reflect the platelet release prior to blood 
sampling, whereas serum miRNAs may reflect the extracel-
lular and platelet miRNA content combined—the more the 
release, the less the content. Thus, for our most recent studies, 
we used PPP to link miRNAs to in vivo platelet activation.32,34
Platelets, Microvesicles, and Exosomes
An understanding of which specific fraction of the circulation 
is being measured is of the utmost importance for reproduc-
ibility and adequate interstudy comparison. Ideally, one would 
be able to easily separate different circulating compartments: 
the cellular compartments (erythrocytes, leukocytes, and 
platelets), the microvesicle compartment, the exosome com-
partment, and the particle-free compartment devoid of mem-
brane-bound vesicles or cells. Although isolating erythrocytes 
and leukocytes is relatively easy based on their size and den-
sity, isolating the smaller and less dense compartments poses 
a greater challenge. Isolating platelets from PRP is done rou-
tinely but requires care to avoid activating the platelets during 
the early centrifugation steps. As platelets release microvesi-
cles on activation, this could affect the measured miRNAs in 
platelets, as well as plasma.
Table.  Minimum Reporting Standards and Methodological Recommendations for the Analysis of Circulating miRNAs
Minimum Reporting Standards Recommendations
1.Phlebotomy protocol Sample venous blood using butterfly or regular blood collection needle; standardize relevant preanalytical variables (eg, 
fasting, smoking, exercise).
2.Anticoagulant used Use citrate or EDTA; avoid heparin because of interference with qPCR.
3.Time until processing Start sample processing immediately or soon after sampling to minimize variability and degradation.
4.Sample processing Perform an initial soft spin to collect plasma, followed by a faster platelet depletion spin with added inhibitors of platelet 
activation, standardize clotting time for serum.
5.Sample storage Store samples at −80°C, avoiding freeze-thaw cycles prior to analysis.
6.RNA protocol Use a validated miRNA or total RNA extraction kit; use a carrier (MS2 RNA or glycogen); avoid potential batch effects by 
coisolating RNA from across compared groups.
7.miRNA measurement platform Avoid batch effects of different technical lots for used laboratory material and equipment.
8.Average Ct levels for each assay Assays with an average Ct value >32 (when using a 40-cycle protocol) should be avoided. Report average Ct values to 
facilitate adequate interpretation of presented fold changes.
9.Variability of the normalization 
reference
Across-sample variability of quality control markers such as an exogenous spike-in miRNA should not exceed 1 PCR cycle.
10.Normalization method(s) Normalize to the average Ct value of multiple assays or to an exogenous spike-in control.
Ct indicates cycle threshold; miRNA, microRNA; and qPCR, quantitative polymerase chain reaction.
 by guest on February 14, 2017
http://circres.ahajournals.org/
Downloaded from 
428  Circulation Research  January 20, 2017
Residual Platelets
Platelets contain a substantial amount of miRNAs and are 
likely to be major contributors to the circulating miRNA 
pool, as discussed earlier.34 This further complicates sample 
preparation for miRNA analysis: differences in plasma prep-
aration, centrifugation speed, duration of coagulation, and 
the residual platelet content will have an impact on multiple 
miRNAs.95,96 In RNA extracts from plasma samples, the de-
tection of the platelet- and megakaryocyte-specific transcript 
integrin α-IIb can be used to assess platelet content. Notably, 
the expression of integrin α-IIb correlates with the expression 
of abundant platelet-derived plasma miRNAs (miR-24, miR-
126, miR-191, and miR-223). If plasma samples have a high 
residual platelet content, their miRNA profile may be more 
similar to that of serum and reflect predominantly platelet 
miRNA content rather than platelet miRNA release. Plasma 
platelet content must be uniform to allow comparisons be-
tween samples because residual platelets may introduce con-
founding. When plasma samples have already been collected, 
an additional centrifugation prior to RNA extraction may re-
duce the platelet content.95 However, centrifugation of plas-
ma after freezing is still subject to the risk of contamination 
from platelets lysed during the freeze/thaw cycle. Ideally, a 
method for the preparation of PPP prior to storage should be 
used to minimize the effect of residual platelets on miRNA 
measurements.
Hemolysis
Erythrocytes are the most abundant cell type in blood. The 
rupture of erythrocytes can occur because of high shear forces 
in the needle during blood collection or improper handling 
during sample processing. Because hemolytic samples con-
tain a high amount of red blood cell–derived miRNAs, the 
levels of multiple miRNAs are altered in hemolytic samples.97 
Hemolysis can be assessed in plasma and serum by measuring 
hemoglobin spectrophotometrically or in the respective RNA 
extracts by analyzing miRNAs known to be affected by hemo-
lysis, such as miR-451.98 It is advisable to exclude hemolytic 
samples from further analyses. Alternatively, such compro-
mised samples can only be used for miRNAs of interest that 
are unaffected by hemolysis.99
Leukocyte Contamination
Cells shed miRNAs via MPs and exosomes into the extracel-
lular space. The miRNA content of the MPs and exosomes 
differs depending on the stimulus of the parent cells. However, 
the intracellular concentration of miRNAs is much higher than 
that in plasma or serum. Considering the low concentration of 
extracellular, circulating miRNAs, any contamination of plas-
ma or serum samples with cellular material, for example, leu-
kocytes, will greatly affect the miRNA profile. Thus, studies 
reporting a surprisingly large number of circulating miRNAs 
compared with other publications may have analyzed samples 
that were contaminated with cellular material.
Batch Effects
Batch effects can occur when analyzing the expression of 
miRNAs on multiple qPCR plates. To minimize their effect, 
several precautions should be taken to obtain reliable data: (1) 
to correct for variability between plates, a calibrator sample 
should be included across all plates. (2) The same batch of 
plasticware and reagents, such as PCR Mastermix, primers, 
and probes should be used for the entire study cohort. We 
have previously observed lot-to-lot-variability for miRNA re-
agents, even from leading manufacturers. (3) Reagents should 
be aliquoted because freeze-thaw cycles affect their quality 
and performance. (4) Samples from different groups should 
be distributed equally across all batches. These precautions 
minimize the effect of batch effects and help to obtain more 
reliable data.
Figure 4. Choice of samples. A, Workflow 
for the preparation of platelet-poor 
plasma (PPP) from platelet-rich plasma 
(PRP). Addition of prostacyclin inhibits 
platelet activation during centrifugation. 
B, Concerns with regards to miRNA 
measurements in the different samples 
range from a contamination with 
leukocytes in PRP, proteolytic activity in 
serum to residual platelets in plasma. PRP 
and serum should reflect platelet miRNA 
content; PPP platelet miRNA release; 
plasma samples will reflect extracellular 
miRNA content but may additionally reflect 
either, platelet miRNA content or release. 
This depends on the amount of residual 
platelets in the plasma samples or platelet 
activation during plasma preparation, in 
particular during centrifugation.
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Endogenous Normalization Controls
Normalization procedures should eliminate technical and ex-
perimental variation across samples to more reliably identify 
biological differences. In qPCR analysis, normalization con-
trols are used to correct for variability in RNA extraction, re-
verse transcription, and PCR. Ideally, a normalization control 
is stably expressed and not affected by experimental condi-
tions or clinical parameters. For the analysis of miRNAs in 
cells or tissue, small nucleolar RNAs are routinely used to 
normalize data. In general, they accurately reflect the small 
RNA content of a sample, although there are limitations and 
drawbacks. For example, small nucleolar RNAs can corre-
late with cancer pathology and prognosis, which can intro-
duce bias when they are used as normalization controls for 
cancer samples.100 For circulating miRNAs, however, there 
is no generally accepted endogenous control. Small nucleo-
lar RNAs are intracellular RNA molecules, and their levels 
in the circulation are very low. U6 RNA has been used as a 
normalization control in plasma and serum samples but cir-
culating levels of U6 display interindividual variability and 
are affected by inflammatory processes, reducing its reli-
ability.101 Single miRNAs or panels of miRNAs have been 
used or suggested as endogenous controls: miRNAs that have 
been used as normalizers include miR-16, miR-21, miR-93, 
miR-103, miR-191, miR-192, miR-423, and miR-425. These 
miRNAs, however, may well be affected by other uninvesti-
gated diseases or medications. Antiplatelet therapy, for exam-
ple, has been demonstrated to lower the circulating levels of 
plasma-derived miRNAs, including miR-21 and miR-191.34 
Alternatively, data can be normalized to the average Ct of 
multiple or all analyzed miRNAs.102 Generally, combinations 
of miRNAs may be a more robust approach, based on the 
assumption that overall miRNA expression is stable and not 
affected by disease to the same degree as individual miRNAs. 
The more miRNAs that are combined, the more robust the 
control should be. However, this normalization method can 
be problematic when several of the miRNAs used to normal-
ize are dysregulated in a similar direction, potentially causing 
false-positive or false-negative findings. Nonetheless, accept-
ing that no better alternatives exist, a combination of miR-
NAs represents the most stringent endogenous normalization 
control.
Exogenous Normalization Controls
The most commonly used exogenous normalization method 
for circulating miRNA analysis is the use of a spike-in control. 
For this purpose, synthetic oligonucleotides of miRNA se-
quences from other species are used, typically from the nema-
tode Caenorhabditis elegans (eg, cel-miR-39). Such spike-in 
controls are added in equal amounts to each sample during 
RNA extraction or reverse transcription. A spike-in control 
added at the RNA extraction step can normalize for differ-
ences in extraction efficiency, reverse transcription, or qPCR 
efficiency, which may be caused by the presence of inhibitors 
in the sample or pipetting errors. Spike-in controls generally 
reflect miRNA quantities in different samples, but we have 
observed that RNA samples display a lower quantity of cel-
miR-39 when they were stored at −80°C for a longer period of 
time, impairing analysis in older samples. Moreover, heparin 
medication can affect cel-miR-39, as well as the measurement 
of miRNAs, depending on their origin.103,104 The cel-miR-39 
measurements across samples must be stable. Variability ex-
ceeding 0.5 to 1 Ct values should be cause for concern.
MiRNA Measurements
The gold standard for miRNA measurements is qPCR. It pro-
vides independent and robust amplification and quantitative 
detection of minute RNA amounts across the wide dynamic 
range of miRNA expression levels. Among the drawbacks of 
the technology is the fact that its high-throughput capabili-
ties are limited. We have previously compared commercial 
qPCR assays and obtained good agreement between assays 
from 2 suppliers, for individual Taqman miRNA assays and 
customized qPCR plates from Exiqon. For customized qPCR 
plates, however, there is the possibility that variations in the 
manufacturing process remain undetected. This is less likely 
to occur in standard miRNA assays because multiple users 
will rapidly detect manufacturing problems. Thus, it is impor-
tant to know the expected measurement range for miRNAs of 
interest when using customized qPCR plates and to compare 
the results from each batch of customized qPCR plates with 
individual qPCR assays.
We and others have noted difficulties comparing miRNA 
measurements from different technologies. In particular, there 
is poor agreement between microarrays and qPCRs when as-
sessing quantitative changes. Microarray-based technologies 
use hybridization and are suitable for detecting the presence 
of miRNA species, but have limited quantitative accuracy and 
dynamic range. Similarly, NGS has several drawbacks, in 
particular, requiring much larger sample volumes than qPCR 
analysis and the introduction of amplification bias for certain 
miRNAs during library preparation. For example, in our study, 
we obtained most reads for miR-486, a miRNA that is present 
in the circulation but has a relatively high Ct value by qPCR, 
suggesting that it is much less abundant than other circulating 
miRNAs. Thus, miRNAs with more sequencing reads are not 
necessarily more abundant (Figure 5). Quantitative compari-
son must only be made by comparing sequencing reads for the 
same miRNAs.
Freedman et al used high-throughput microfluidic quanti-
tative PCR to analyze the miRNA signature in blood (whole 
blood, platelets, mononuclear cells, plasma, and serum) col-
lected from 5 healthy individuals. They screened for 852 
miRNAs in 83 patients undergoing diagnostic coronary an-
giography and categorized their patients into 2 groups: with 
coronary artery stenosis ≥70% (n=34) and without (n=49). 
Increased plasma levels of miR-494, miR-769-3p, and miR-
490-3p were associated with ≥70% coronary stenosis, and 
logistic regression analysis found that antihypertensive ther-
apy, smoking, and miR-769-3p were significantly associated 
with coronary status.105 In this study, few of the commonly 
reported highly expressed miRNAs were amongst the top 10 
ranking miRNAs in platelets (Figure 3). It is likely that there 
are similar discrepancies with plasma and serum miRNA 
measurements. One cause for this difference may be the high-
throughput BioMark Real-Time Fluidigm PCR system used 
in this study to increase the number of miRNA measurements 
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that can be performed simultaneously; no direct comparison 
with conventional qPCR was provided.
Potential for Clinical Translation
The miRNA biomarker field is currently nascent. Although 
there is much to link the expression of miRNAs to various dis-
eases, the clinical utility or validity of miRNA detection has 
not been demonstrated. Currently, miRNAs are manually ex-
tracted, presenting the largest obstacle to increasing through-
put. If new technological platforms provide the opportunity 
for faster miRNA extraction or direct analysis of miRNAs 
without the need for miRNA extraction, they will signifi-
cantly improve the ease-of-use in clinical settings. Increasing 
throughput, however, must not compromise the quantitative 
accuracy of the analysis for both low- and high-abundance 
miRNAs. Ideally, miRNA measurements need to be able to 
outperform current diagnostic methods to reach the clinical 
mainstream.
In addition to current practical limitations, miRNA bio-
markers will also need to be presented in the context of related 
miRNAs to be adequately interpreted. There are relatively few 
tissue-specific miRNAs, with miR-122 being an exception 
given its exquisite liver specificity.106 We have recently shown 
that high circulating miR-122 levels are associated with an 
adverse lipid profile and predict development of metabolic 
syndrome and diabetes mellitus type 2.107 However, most cir-
culating miRNAs are ubiquitously expressed, and numerous 
cell types can release miRNAs. This complicates the clinical 
application because levels of individual miRNAs can greatly 
vary between patients, without any pathological significance. 
Therefore, it is crucial to represent relative expression levels 
of a miRNA in relation to a network of several other miRNAs. 
The use of a so-called miRNA signature can greatly strength-
en the predictive and diagnostic value.
Because the origin of many plasma miRNAs is unknown, 
De Rosa et al108 investigated transcoronary gradients of various 
miRNAs in patients with acute coronary syndrome in a bid to 
define coronary-specific changes in the setting of myocardial 
damage. Samples were taken from the aorta and coronary si-
nus. They found an upregulation of the muscle-enriched miR-
499, miR-133a, and miR-208a in acute coronary syndrome 
patients, of which miR-499 correlated with troponin levels, an 
established clinical marker of myocardial damage. Contrary 
to their predictions, miR-126 decreased across the coronary 
circulation, despite its high expression in endothelial cells. 
They also described a negative trend for miR-223 across the 
coronary circulation in the acute coronary syndrome group but 
not in the stable coronary artery disease group; however, this 
did not reach statistical significance.108 An alternative expla-
nation for the reduction in miR-126 and miR-223 across the 
Figure 5. Discrepancy between miRNA quantification by reverse transcriptase quantitative polymerase chain reaction (RT-qPCR) 
and RNA sequencing. Average expression of 92 miRNAs was assessed in platelet-poor plasma (PPP) from healthy subjects (n=12), 
using custom-made Exiqon locked nucleic acid (LNA) qPCR plates. Cycle-to-threshold (Ct) values are shown as 40-Ct (x axis). Small RNA 
sequencing was performed with PPP from healthy subjects (n=2). miR-486-5p is highlighted, showing high sequencing reads (y axis), 
despite inferred midrange abundance by qPCR. CI indicates confidence interval.
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coronary circulation is the retention of platelets and platelet 
MPs in the affected myocardium or differential activation of 
platelets in venous and arterial settings.
Pharmacological inhibitors can be used to identify the 
cellular origins of miRNAs. By comparing plasma miRNA 
levels in the same individuals before and after initiation of 
antiplatelet therapy, we identified a set of plasma miRNAs that 
is responsive to antiplatelet therapy.34 The miRNA candidates 
were abundant in platelets, but they were not platelet-specific. 
Moreover, not every abundant platelet miRNA was equally 
affected by antiplatelet medication. Some miRNAs, despite 
their abundance in platelets, may be expressed at higher lev-
els in other cell types. Consequently, their plasma levels may 
be less dependent on platelets. Given the platelet origin of 
many abundant circulating miRNAs, it is not surprising that 
the same miRNAs are dysregulated in multiple diseases. The 
question, however, remains whether the circulating miRNA 
changes are cause or consequence. In cancer, for example, 
many of the circulating miRNA alterations may be because of 
platelet activation or inflammation, rather than the release of 
miRNAs from tumor tissue.
Early studies compared platelet samples from different 
individuals. Longitudinal sampling eliminates interindividual 
variability. For example, using serial measurements before 
and after antiplatelet medication, we investigated the effect 
of 10 mg prasugrel followed by the addition of an escalating 
aspirin dose regimen (75 mg daily in week 2 and 300 mg daily 
in week 3) on the PPP miRNA signature of healthy young vol-
unteers. Using custom-made miRNA qPCR plates, 92 targets 
were measured at 4 different time points. Antiplatelet therapy 
was associated with a reduction in plasma miR-223, miR-126, 
miR-15, miR-191, miR-20b, miR-21, and miR-24. The find-
ings were replicated in plasma of patients with recent symp-
tomatic carotid atherosclerosis who had begun treatment with 
dipyridamole or clopidogrel, in addition to aspirin. These pa-
tients showed a reduction in miR-223, miR-126, miR-150, and 
miR-191.34 The effect was less pronounced, presumably be-
cause the symptomatic patients were on aspirin medication at 
baseline and the follow-up measurement was only taken after 
48 hours. The reduction in platelet miRNAs on platelet inhibi-
tion complements previous findings by Zampetaki et al75 in an 
ischemia/reperfusion injury model by thigh cuff inflation, in 
which plasma miRNAs increased on platelet activation.
The clinical use of platelet function tests is limited at pres-
ent, despite clear differences in response to pharmacological 
platelet inhibition. In the case of clopidogrel, a prodrug, a 
large percentage of this variation can be attributed to differ-
ent cytochrome P450 isoforms involved in its bioactivation.109 
However, this in itself does not explain all of the variation in 
efficacy. Measurements of platelet activity by light transmis-
sion aggregometry are considered the gold standard, but this 
test is performed ex vivo and not well standardized between 
laboratories. Vasodilator-stimulated phosphoprotein (VASP) 
phosphorylation and VerifyNow P2Y12 assays measure plate-
let activation in full blood but only in response to a single 
pathway, ADP stimulation. Platelet miRNAs may offer an 
opportunity to obtain an alternative read-out for platelet ac-
tivation in vivo that integrates activation by multiple agonists 
rather than just ADP (Figure 6). Platelet miRNA measure-
ments, however, will only be useful if they provide diagnostic 
advantages. They also must be easy to perform and capable 
of discriminating the degree of interindividual variability in 
platelet inhibition or platelet turnover.
Conclusions
Initially, circulating miRNAs were thought to originate from 
tissue injury. This is indeed the case for cardiac miRNAs that 
are released after myocardial infarction akin to troponins. For 
basal miRNA levels, however, the importance of circulating 
cells is now apparent, and the contribution from anucleate 
cells such as erythrocytes and platelets must not be underesti-
mated. Several challenges face the accurate detection and use 
of plasma and serum miRNAs:
1. Variability in samples’ cell composition affect miRNA 
profiles. This includes anuclear cells such as erythro-
cytes and residual platelets. Preanalytic variation in sam-
ple preparation or handling must be minimized to avoid 
alterations of results. Given the platelet origin of many 
abundant circulating miRNAs, the use of PPP would 
seem to be an appropriate substrate for miRNA mea-
surements. In conventional plasma samples, the number 
of residual platelets can vary. Also, without inhibitors, 
platelet activation may occur during centrifugation. In 
serum, the stability of miRNAs may be affected, and 
miRNAs may get trapped in the clot. This could intro-
duce bias that affects results, in particular, if the clotting 
time varies between sampling.
2. The concentration of extracellularly circulating miRNAs 
is low, and the miRNA yield of plasma and serum is in-
sufficient for conventional quality control methods, such 
as optical densitometry or Bioanalyzer. Generally, equal 
volumes of plasma or serum are used for extraction. No 
correction is performed for RNA content. This approach 
of normalizing by volume is, however, analogous to 
protein measurements. In both cases, the total RNA or 
total protein amount of plasma or serum would not be a 
suitable normalization control for the miRNA or protein 
biomarker of interest.
3. Currently, there is no endogenous control for the nor-
malization of circulating miRNAs. Instead, exogenous 
spike-in controls are used for normalizing the extraction 
procedure. The values of spike-in controls such as cel-
miR-39 relate entirely to the consistency of the isolation 
procedure, not to the starting RNA quantity. By measur-
ing a broader panel of unrelated miRNAs, the mean Ct 
value can be used for normalization.
4. Circulating miRNAs are highly correlated. Assessing 
individual miRNAs without integration into a wider 
miRNA network is of limited utility. Relative changes 
in miRNAs to one another (so-called miRNA signatures) 
can be more informative than the changes of individual 
miRNAs.
These points will need to be addressed in future publications 
on miRNA biomarkers to facilitate comparability between stud-
ies, something that has been difficult with variations between 
measurement platforms and lack of guidelines for standardiza-
tion. Standardized miRNA measurement platforms are currently 
under development, which could reduce measurement variability, 
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while facilitating cross-study comparisons. In addition to the need 
for consensus on sample preparation and analytic procedures, fu-
ture research will need to move on from reporting on single miR-
NAs and focus more on miRNA signatures and integration with 
predicted target genes.77,107,110 These issues are not insurmount-
able, and once addressed, future studies can further evaluate the 
potential of miRNA biomarkers for clinical use and whether 
miRNA assays will outperform existing clinical measurements.
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Stabilizing atherosclerotic lesions and pre-
venting plaque ruptures can be seen as the
Holy Grail in vascular medicine. In this issue
of Molecular Therapy, Jin et al.1 suggest the
local delivery of microRNA-21 (miR-21)
mimics as a potential therapeutic strategy
to reduce plaque vulnerability. Interestingly,
inhibition of this microRNA has also been
proposed as a therapeutic approach for
in-stent restenosis, where the application
of anti-miR-21 oligonucleotides on stents
improved vessel patency.2
Atherosclerosis is a chronic inﬂammatory
disease resulting from the build-up of
lipid deposits in the innermost layer of an
artery. Apart from lipids, atherosclerotic pla-
ques comprise mainly smooth muscle cells
(SMCs), macrophages, calcium, and ﬁbrous
connective tissue. Upon rupture or erosion
of vulnerable atherosclerotic plaques, platelet
aggregation results in thrombus formation
that can occlude the vessel lumen. Stents are
metallic scaffolds placed into the occluded
segment of a diseased artery to hold it open.
Current drug-eluting stents (DESs) are de-
signed to inhibit vascular SMC proliferation
to reduce neo-intima formation within the
stent lumen. While greatly enhancing stent
patency in coronary arteries, these anti-pro-
liferative agents also inhibit the proliferation
of endothelial cells, thus delaying re-endothe-
lialization and arterial healing. After DES im-
plantation, dual antiplatelet therapy is there-
fore required to prevent the inherent risk of
thrombosis and stent occlusion. Alternatives
to current DESs that would inhibit SMC pro-
liferation without delaying re-endothelializa-
tion should result in less thrombogenicity.
In the vasculature, miR-21 has previously
been implicated as a determinant of SMC
proliferation.3 –6 For example, pharmacolog-
ical and genetic miR-21 inhibition markedly
decreased neo-intima formation in vein
grafts5,6 and balloon-injured carotid ar-
teries.3 These ﬁndings led to the explo-
ration of local therapeutic strategies by
coating stents with miR-21 inhibitors.
When deployed in denuded arteries in rats,
this approach prevented SMC-mediated
in-stent restenosis without delaying re-
endothelialization.2
Conversely, SMC proliferation can also be
beneﬁcial in stabilizing the vessel wall and
atherosclerotic plaques. For example, the
proliferative effects of miR-21 mimics in
SMCs reduced the expansion of abdominal
aortic aneurysms.7 The results presented by
Jin et al.1 in this issue propose the use of
miR-21 mimics to enhance plaque stability.
Unstable human plaques and atherosclerotic
lesions in apolipoprotein E (apoE)-deﬁcient
mice (Apoe!/!) exhibit lower miR-21 levels.
Based on in situ hybridization and immuno-
histochemistry, this expression pattern was
ascribed to SMCs. The authors further
show that plaques in Apoe/miR-21 double-
deﬁcient mice (Apoe!/!miR-21!/!) were
more prone to rupture. Additionally, the un-
stable plaques were shown to harbor lower
levels of the RE1-silencing transcription fac-
tor (REST). REST has been identiﬁed as a
regulator of miR-21 while also being a direct
target of miR-21. Subsequent in vitro anal-
ysis of SMCs revealed an anti-proliferative
effect of REST, conﬁrming the proliferative
role of miR-21. Finally, local delivery of
miR-21 mimics to carotid plaques using ul-
trasound-targeted microbubble destruction
enhanced plaque stability. These ﬁndings
suggest that, by increasing SMC prolifera-
tion, miR-21 mimics could stabilize the
SMC-rich ﬁbrous cap that shields the lipid-
ﬁlled core of atherosclerotic plaques.
As is the case for most miRNAs, miR-21
is ubiquitously expressed.8 It is particularly
abundant in circulating hematopoietic cells,
where it appears to act as an “emergency
brake” on inﬂammation. In macrophages,
miR-21 directly targets the pro-inﬂammatory
programmed cell death protein 4 (PDCD4),
thereby increasing the secretion of anti-in-
ﬂammatory interleukin-10 (IL-10).9 miR-21
also directly targets phosphatase and tensin
homolog (PTEN), steering macrophages
toward a reparative phenotype that pro-
motes resolution of inﬂammation and tissue
recovery.10 Thus, miR-21 may also modulate
tissue inﬂammation, in part, through mono-
cyte differentiation toward an anti-inﬂam-
matory macrophage phenotype.
A recent study by Canfrán-Duque et al.11
also focused on miR-21 in the context
of atherosclerosis. miR-21 accumulated in
murine atherosclerotic plaques along with
CD68, a macrophage marker. Deﬁciency of
miR-21 in bone marrow cells promoted
vascular inﬂammation and plaque necrosis
in low-density lipoprotein receptor (LDLr)
null mice. Compared to wild-type bone
marrow, transplantation of miR-21!/! bone
marrow into Ldlr!/! mice resulted in larger
and less stable atherosclerotic plaques due
to increased inﬂammatory cell inﬁltration.
Thus, miR-21 expression in murine hemato-
poietic cells attenuates vascular inﬂamma-
tion. The ﬁndings of Jin et al.1 also highlight
the impact of miR-21 on the inﬂux of macro-
phages. Apoe!/!miR-21!/! mice displayed
more advanced plaque formation at an early
age, with a concomitant increase of macro-
phage inﬁltration and foam cell formation.
In line with the recent ﬁndings of Canfrán-
Duque et al.,11 miR-21 null peritoneal mac-
rophages displayed an increase in oxidized
LDL uptake and foam cell formation through
enhanced nuclear factor kB (NF-kB)
signaling. Notably, secreted factors from
Apoe!/!miR-21!/! macrophages could sup-
press SMC proliferation in vitro.
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A common challenge in miRNA research
is to identify the cell types that are respon-
sible for the observed therapeutic beneﬁts.
Although the present study conﬁrms amech-
anistic link between miR-21 and SMC prolif-
eration, it remains unclear whether the bene-
ﬁcial effect relies predominantly on SMCs,
macrophages, or other cell types (Figure 1).
Using a multi-omics approach, we recently
identiﬁed a protein signature of symptomatic
atherosclerotic plaques that implied a shared
involvement of immune cells and SMCs.12
Also, the plasticity of SMCs is currently un-
der debate, with lineage tracing experiments
suggesting a potential SMC origin of macro-
phage-like cell types.13 ,14 Finally, apoE medi-
ates the reverse cholesterol transport,15 and
atherosclerosis is known to differ between
man and apoE null mice.16
Despite these notes of caution, the study by
Jin et al.1 advances our insight into the role
of miR-21 in vascular biology. This is a
timely contribution as miRNA-based thera-
pies progress to clinical application. Clinical
trials are currently underway in patients with
Alport syndrome, where systemic miR-21
inhibition is evaluated for the treatment of
renal ﬁbrosis. A better understanding of the
effects of miR-21 in the context of other dis-
eases is therefore highly relevant. The ﬁnd-
ings of Jin et al.1 implicate that local therapy
with miR-21 may indeed achieve higher drug
concentrations at the target site and could
minimize the risk of systemic side effects
from miRNA therapeutics. Nevertheless,
even local therapy for ubiquitously expressed
miRNAs could have potential systemic ef-
fects, for example, by affecting circulating
cells in the blood stream.
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Introduction
MicroRNAs (miRNAs) have been linked to cardiac remodeling, with miR-21 being implicated in cardiac 
fibrosis (1). Using different models of  tissue injury, several, but not all (2), studies reported a reduction of  
cardiac fibrosis with systemic miR-21 inhibition (3–5). miR-21 is ubiquitously expressed in mammalian 
cell types. Besides myocardial fibrosis (3–6), it has been linked to fibrotic kidney (7, 8) and lung disease (9), 
in-stent restenosis and vein graft failure (10–12), and aortic aneurysmal disease (13). As a mechanistic expla-
nation, studies of  miR-21 have suggested an effect on cardiac fibroblast (CF) survival and proliferation that 
may contribute to fibrosis (2–6). miR-21 may also enhance fibrosis through modulating fibroblast senescence 
(14). Surprisingly, miR-21–null mice did not show a difference in cardiac function at baseline or with cardiac 
injury (2). Using a proteomics approach, we have previously reported the first detailed characterization of  
the CF secretome, identifying numerous targets of  miR-29b among extracellular matrix (ECM) proteins 
(15). We pursued a similar approach to investigate the role of  miR-21.
Fibrosis is a major contributor to organ disease for which no specific therapy is available. 
MicroRNA-21 (miR-21) has been implicated in the fibrogenetic response, and inhibitors of miR-21 
are currently undergoing clinical trials. Here, we explore how miR-21 inhibition may attenuate 
fibrosis using a proteomics approach. Transfection of miR-21 mimic or inhibitor in murine cardiac 
fibroblasts revealed limited effects on extracellular matrix (ECM) protein secretion. Similarly, miR-
21–null mouse hearts showed an unaltered ECM composition. Thus, we searched for additional 
explanations as to how miR-21 might regulate fibrosis. In plasma samples from the community-
based Bruneck Study, we found a marked correlation of miR-21 levels with several platelet-derived 
profibrotic factors, including TGF-β1. Pharmacological miR-21 inhibition with an antagomiR 
reduced the platelet release of TGF-β1 in mice. Mechanistically, Wiskott-Aldrich syndrome protein, 
a negative regulator of platelet TGF-β1 secretion, was identified as a direct target of miR-21. 
miR-21–null mice had lower platelet and leukocyte counts compared with littermate controls but 
higher megakaryocyte numbers in the bone marrow. Thus, to our knowledge this study reports 
a previously unrecognized effect of miR-21 inhibition on platelets. The effect of antagomiR-21 
treatment on platelet TGF-β1 release, in particular, may contribute to the antifibrotic effects of 
miR-21 inhibitors.
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The “master switch” in fibrosis is widely regarded to be TGF-β1. In the heart, TGF-β1 expression is 
induced by an array of  factors, including angiotensin II and mechanical stretch (16). In addition to car-
diomyocytes and CFs, high TGF-β1 levels are also found in blood platelets, where its release is controlled 
by Wiskott-Aldrich syndrome protein (WASp) (17). The platelet releasate is supposed to be a key driver 
of  the inflammatory response in cardiac remodeling (18). It has been suggested that extravasated platelets 
are a major source of  TGF-β1 in the myocardium upon cardiac injury (16). Using megakaryocyte-specific 
TGF-β1–knockout mice, platelet TGF-β1 has indeed been implicated in the development of  cardiac hyper-
trophy and fibrosis in several models of  cardiac remodeling (19–21). We have previously established that 
many of  the abundant circulating miRNAs are of  platelet origin (22). Moreover, there is accumulating evi-
dence that abundant platelet miRNAs, such as miR-223 and miR-126, also affect platelet function (23–25).
In this study, we demonstrate that genetic ablation of  miR-21 reduces the number of  circulating plate-
lets, while pharmacological inhibition attenuates platelet release of  TGF-β1 through miR-21–mediated tar-
geting of  WASp. In contrast, changes in miR-21 levels alter CF proliferation but have no major effect on the 
secretion of  ECM proteins. Furthermore, we show that plasma concentrations of  TGF-β1 are dependent 
on platelets and correlate strongly with miR-21 levels. Thus, in addition to directly acting on fibroblasts, 
miR-21 may contribute to fibrosis indirectly through its effects on platelets.
Results
Mimics and inhibitors of  miR-21 affect murine CF proliferation. Previous studies have reported a role of  miR-21 
in cardiac ECM remodeling, predominantly ascribing the attenuation of  fibrosis upon miR-21 inhibition to 
the nonmyocyte or CF niche of  the cardiac cell population (3, 4, 6, 26). To study the direct effects of  miR-
21 on this cell type using proteomics, CFs were isolated from hearts of  8- to 10-week-old male C57BL/6 
mice as previously described (15). Cultured cells were transfected (Supplemental Figure 1) with a miR-21 
mimic or inhibitor (locked nucleic acid 21 [LNA-21]) and respective controls (n = 4 per group). qPCR 
analysis of  miR-21 levels confirmed a significant and specific effect of  the transfections (Figure 1A and 
Supplemental Figure 2). To assess CF proliferation, cells were plated and monitored using an electrical 
impedance-based assay (xCELLigence). Real-time recording revealed an increase in proliferation within 24 
hours after miR-21 mimic transfection, which was in line with previous findings (3). A concomitant reduc-
tion in proliferation was seen after miR-21 inhibitor transfection (Supplemental Figure 3).
Mimics and inhibitors of  miR-21 have a limited effect on ECM protein secretion. To study the effects of  miR-21 
on the secretion of  ECM proteins, isolated CFs were transfected, followed by stimulation with recombinant 
TGF-β1 or a vehicle control. After 48 hours of  culturing in serum-free conditions, conditioned media were 
collected and processed for secretome analysis (Supplemental Figure 4). As expected, TGF-β1 markedly 
increased secretion of  periostin (fold change [FC] = 4.5 and 10.3, P = 0.008 and 0.008 for miR-21 mimic and 
LNA-21–transfected cells, respectively) and biglycan (FC = 3.5 and 7.0, P = 0.016 and 0.008, respectively). 
No significant differences were observed for decorin and laminin γ1 (Figure 1B and Supplemental Figure 5).
Next, the secretome was analyzed using proteomics. Normalized spectral counts of  ECM proteins 
identified by liquid chromatography tandem mass spectrometry (LC-MS/MS) are provided in Supple-
mental Table 3. Consistent with the immunoblotting results, periostin levels were markedly increased 
by TGF-β1 stimulation (Supplemental Figure 6A). Importantly, secretome levels for the 20 proteins 
with the highest number of  identified spectra, which includes periostin, did not significantly differ after 
miR-21 mimic or inhibitor transfection (Figure 1C). Overall, a marginal effect of  miR-21 on ECM 
secretion was observed (Supplemental Figure 7). After miR-21 mimic transfection, only insulin-like 
growth factor–binding protein 4 (IBP4) and granulin (GRN) showed a significant upregulation in 
unstimulated CFs, whereas higher levels of  GRN, cathepsin L (CATL1), and the α-1 chain of  collagen 
11 (COBA1) were seen in TGF-β1–stimulated cells. Upon miR-21 inhibition, GRN showed a significant 
increase only in TGF-β1–stimulated cells, whereas galectin-3 binding protein (LG3BP) and VCAM-1 
were increased in both unstimulated and TGF-β1–stimulated CFs (Supplemental Figure 8).
To complement the proteomic findings, changes in gene expression were determined. In response to 
TGF-β1, expression of  commonly used markers of  the myofibroblast-like phenotype (Supplemental Figure 
6B), such as α smooth muscle actin (Acta2; FC = 1.6, P < 0.0001), periostin (Postn; FC = 3.2, P = 0.0001), and 
TGF-β1 itself  (Tgfb1; FC = 1.3, P < 0.0001), was increased. Evaluation of  transcripts corresponding to the 20 
proteins with the highest number of  identified spectra (Supplemental Figure 9) and those significantly chang-
ing in the secretome (Supplemental Figure 10) showed a trend toward higher expression of  periostin and the 
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Figure 1. Transfections of cardiac fibroblasts with miR-21 mimic and inhibitor. (A) Cardiac fibroblasts (CFs) were isolated from wild-type mice and 
transfected with miR-21 mimic or LNA-21 (inhibitor), followed by stimulation with TGF-β1 or control treatment. Overexpression and inhibition were 
confirmed by qPCR (n = 8 for each transfection condition; Wilcoxon matched-pairs signed-rank test; lines and error bars represent median [IQR]; 
note that in 3 samples miR-21 was undetectable after transfection with LNA-21). (B) Immunoblotting for several extracellular matrix (ECM) proteins 
showed effects of TGF-β1 treatment but not of miR-21 mimic or inhibitor transfection (n = 4 for each condition). Ponceau S staining was used as load-
ing control. C, control mimic/LNA; 21, miR-21 mimic/LNA-21; Mr, relative mass. TGF-β1 +/– indicates treatment 48 hours prior to conditioned media 
collection. (C) Proteomic analysis of the CF secretome after transfections with miR-21 mimic or inhibitor identified no significant changes in the 20 
most abundant ECM proteins. Four biological replicates were analyzed for each transfection type in the presence or absence of TGF-β1 treatment. No 
statistically significant difference was seen between miR-21 mimic or inhibitor and its respective control for any of the shown proteins, using a FDR < 
0.05, calculated with the Empirical Bayes method.
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transcript encoding LG3BP (Lgals3bp) after miR-21 mimic and inhibitor transfection, respectively. However, 
none of  the changes in expression upon miR-21 overexpression or inhibition reached statistical significance. 
In summary, miR-21 had no major effect on the expression and secretion of  ECM proteins by CFs in vitro.
The cardiac ECM is unaffected in miR-21–null mice. In contrast to the profound effects of  pharmacological 
miR-21 inhibition on the fibrotic phenotype, previous analysis of  miR-21–null mice reported a normal 
cardiac morphology and contractility (2). Since no comprehensive analysis of  their cardiac ECM has been 
performed to date, we evaluated the ECM of  ventricular cardiac tissue from miR-21–null mice and litter-
mate controls (n = 6 per group). qPCR analysis confirmed undetectable levels of  miR-21, whereas no differ-
ences were found for other abundant cardiac miRNAs (Figure 2A, top). Cardiac expression levels of  genes 
encoding various ECM constituents were unaltered in miR-21–null mice (Figure 2A, bottom).
Next, a comprehensive proteomics analysis of  the cardiac ECM was performed using our established 
3-step sequential enrichment protocol (27, 28). FDR-corrected comparisons between both genotypes 
revealed no difference in abundance for any of  the identified proteins (Figure 2B and Supplemental Table 
4) (29). Thus, consistent with our in vitro results, a combined transcriptomic and proteomic analysis of  the 
cardiac ECM revealed no major change upon genetic miR-21 deletion.
miR-21 correlates with levels of  platelet-derived profibrotic factors in the circulation. Given the limited effects on 
ECM secretion by CFs, we explored additional explanations for the observed profibrotic role of  miR-21. 
Previous studies have shown that miR-21 is abundant in hematopoietic cells and the circulation (23, 25, 30). 
We therefore measured 228 proteins in plasma from the community-based Bruneck Study (year 2000 eval-
uation, n = 660), using proximity extension assays, LC-MS/MS, and ELISA. These protein measurements 
were then correlated to circulating miR-21 levels, as determined by qPCR (Figure 3A). A significant correla-
tion was seen between miR-21 and the latency-associated peptide of  TGF-β1 (LAP-TGF-β1; r = 0.65, P < 
0.0001; Figure 3B) as well as several other profibrotic factors, such as PDGF subunit β (PDGFβ; r = 0.73, P 
< 0.0001), suggesting a common origin. Furthermore, miR-21 levels were significantly correlated with those 
of  markers of  platelet activity, such as proplatelet basic protein (PPBP) and platelet factor 4 (PF4), as also 
indicated by gene ontology (GO) analysis for the terms “platelet activation” and “platelet degranulation.” 
These findings are in line with our previous report indicating that circulating miR-21 levels are dependent on 
platelets (23). The correlation between circulating miR-21 and mature TGF-β1 was confirmed by qPCR and 
ELISA analysis, respectively, in platelet-poor plasma (PPP) collected during the 2015 follow-up (n = 332) of  
the Bruneck Study (Figure 3C). Our previous studies have also identified miR-21 as a major platelet miRNA 
(23, 31). To confirm enrichment of  this miRNA in megakaryocytes, argonaute 2 (Ago2) immunoprecipita-
tion was performed in a human megakaryoblastic leukemia cell line (MEG-01). Here, enrichment of  miR-21 
in the Ago2 complex was found, along with 2 previously identified platelet-enriched miRNAs (Figure 3D) 
(25). This suggests a functional role for miR-21 in megakaryocytes and platelets. Altogether, analyses in a 
community-based cohort study and in MEG-01 cells imply a role of  miR-21 in platelets.
TGF-β1 is enriched in megakaryocytes, and plasma levels are dependent on platelets. Colocalization of  TGF-β1 
with PF4 was demonstrated by immunofluorescence staining of  the murine bone marrow (Figure 4A). 
Further magnification of  TGF-β1/PF4–positive cells showed large and lobulated nuclei characteristic of  
megakaryocyte morphology (Figure 4B). TGF-β1 staining beyond the areas of  colocalization with PF4 
was negligible, demonstrating that megakaryocytes are the major source for TGF-β1 in the bone marrow.
To study the dependency of  plasma TGF-β1 levels on platelets, we used an antibody-mediated thrombo-
cytopenia model in wild-type mice (Figure 4C) (32). Successful platelet depletion was confirmed by a signifi-
cant reduction of  platelet-specific gene transcripts (Figure 4D) in whole blood as well as by reduced levels of  
PF4 in PPP (Figure 4E). Ptprc, an abundant transcript in leukocytes encoding the cluster of  differentiation 45 
(CD45), was not affected. Importantly, levels of  TGF-β1 in PPP were significantly decreased (median [inter-
quartile range], 1.9 [1.6–2.1] and 0.78 [0.73–0.84] ng/ml after control or depletion, respectively; P = 0.0025; 
Figure 4F). These findings confirm platelets as the major source of  TGF-β1 in the circulation.
miR-21 affects the release of  TGF-β1 from platelets. Next, we assessed the effect of  miR-21 inhibition on 
platelets using antagomiR-21 treatment in mice (Figure 5A). First, platelet counts were determined by 
flow cytometry using allophycocyanin-CD41 staining (Supplemental Figure 11). No significant difference 
in platelet numbers was found between mice treated with antagomiR-21 or control (Figure 5B). miRNAs 
have previously been shown to alter platelet function (22, 24, 25). To determine whether miR-21 inhibi-
tion altered platelet activation, we measured the aggregation response to various agonists using a similar 
approach as that previously described for miR-126 (25). Unlike miR-126, pharmacological inhibition of  
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miR-21 did not affect the platelet aggregation response to arachidonic acid, protease-activated receptor 4 
(PAR4) amide, or collagen (Figure 5C). In light of  the correlation between miR-21 and TGF-β1 levels in 
human plasma, we evaluated whether plasma levels and platelet release of  TGF-β1 were affected by antag-
omiR-21 (Figure 5D). Interestingly, platelet TGF-β1 release was significantly reduced in response to PAR4 
amide (P = 0.003) and collagen (P = 0.011). The release of  PF4, a marker of  platelet activation, was less 
affected. No differences were seen for levels of  either protein in PPP.
WASp is a direct target of  miR-21. Several platelet-derived factors, including TGF-β1, have previously 
been implicated in cardiac remodeling (19, 33). We therefore determined the effects of  pharmacological 
miR-21 inhibition on the platelet protein releasate in mice. Platelets were isolated from mice treated with 
antagomiR-21 or control, aggregation was induced with thrombin, and the platelet releasate was used 
for proteomic analysis (Figure 6A). In agreement with the findings presented in Figure 5D, TGF-β1 was 
Figure 2. The cardiac ECM of miR-21–null mice. (A) Hearts from miR-21–null mice and littermate wild-type controls were used for RNA isolation. Expres-
sion levels of miRNAs (top) and selected ECM genes based on the CF transfection experiments (bottom) were determined by qPCR. Expression levels of 
U6 and Actb were used as reference transcripts, respectively. (B) The same hearts were used for proteomics by combining our sequential ECM extraction 
procedure with analysis by mass spectrometry. Using normalized precursor intensities, no significant differences were observed between hearts from miR-
21–null mice and littermate controls. An FDR-based approach was used for all 3 analyses using a q < 0.05 for statistical significance. For all 3 analyses, n = 
6 miR-21-null mice vs. n = 6 control mice.
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among the differentially regulated proteins after miR-21 inhibition (log2 FC = –2.86, P = 0.047). Other 
differentially regulated proteins were von Willebrand factor (VWF; log2 FC = –2.67, P = 0.040) and 
fibronectin (FINC; log2 FC = –2.18, P = 0.030). GO annotation identified all 3 proteins with presence in 
the α-granule lumen. Several other proteins with this GO term showed a similar trend of  reduced release 
after antagomiR-21 treatment (Supplemental Table 5).
Platelet TGF-β1 release has previously been shown to be curtailed by WASp (17), an actin assembly pro-
tein selectively expressed in cells of hematopoietic origin (34). To evaluate levels of TGF-β1 and WASp by 
immunoblotting, platelets were isolated and lysed after antagomiR-21 or control treatment. While platelet lev-
els of TGF-β1 (FC = 0.98, P = 0.909) and PF4 (FC = 1.05, P = 0.473) were unaltered upon pharmacological 
miR-21 inhibition, levels of WASp (FC = 1.90, P = 0.047) were significantly increased (Figure 6B and Supple-
mental Figure 12). Analysis of WASp phosphorylation at tyrosine 293 (Y293; p-WASp), which constitutes the 
active form of WASp that restricts platelet TGF-β1 release (17), showed a similar trend (FC = 1.49, P = 0.056). 
Phosphorylation did not differ after normalization for total WASp levels (Figure 6B and Supplemental Figure 
12C). The effect on total WASp levels was confirmed by qPCR in the bone marrow of antagomiR-21–treated 
mice, showing increased Was gene expression levels (FC = 1.08; P < 0.001) (Figure 6C). Target prediction 
Figure 3. Plasma levels of miR-21 and TGF-β1. (A) Plasma miR-21 levels were measured using qPCR in samples from the year 2000 follow-up of the 
community-based Bruneck Study (n = 660). Pearson coefficients for the correlation of miR-21 with circulating proteins associated with cardiovascular 
disease and inflammation were calculated based on measurements by a combination of proximity extension assays, mass spectrometry, and ELISA. Each 
point indicates an individual protein, with its corresponding correlation coefficient on the y axis. PF4, platelet factor 4; PPBP, proplatelet basic protein; 
LAP-TGF-β1, latency-associated peptide of TGF-β1. Black points indicate FDR-adjusted significance < 0.05, with inverted triangles indicating significantly 
correlating proteins that were annotated with the “platelet degranulation” and “platelet activation” gene ontology (GO) terms. (B) The correlation of miR-
21 and LAP-TGF-β1 in plasma of the Bruneck study, year 2000 follow-up. Solid and dashed lines indicate linear regression and 95% confidence interval, 
respectively. NPX, normalized protein expression. q, FDR-corrected P value for Pearson correlation. (C) The correlation of miR-21 and mature TGF-β1, as 
measured by ELISA, using platelet-poor plasma (PPP) from the 2015 evaluation of the Bruneck Study (n = 332). r, Pearson correlation coefficient; P value 
for Pearson correlation. (D) Argonaute 2 (Ago2) immunoprecipitation was performed in lysates from a human megakaryoblastic leukemia cell line (MEG-
01) to isolate coprecipitated RNA. Analysis by qPCR showed enrichment for miR-21, along with miR-126 and -223 (25), suggesting a functional relevance for 
these miRNAs in megakaryocytes. U6 and RNU48 were used as control RNAs. n = 2 for each measurement.
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algorithms have a high false-positive rate (35), with a combination of commonly used algorithms yielding over 
14,000 putative genes for canonical miR-21 targeting (36). A luciferase reporter assay was therefore used to 
evaluate targeting of Was by miR-21. This indeed suggested direct targeting (FC = 0.71; P = 0.003) (Figure 6D). 
To assess whether miR-21 inhibition can affect the expression of WAS in human megakaryocytes, forward-pro-
grammed human pluripotent stem cell–derived (hPSC-derived) megakaryocytes (FoP-MKs) were used (37). 
Two independent lines with >95% megakaryocyte purity (Supplemental Figure 13A) were transfected with a 
Figure 4. TGF-β1 in the bone marrow and circulation. (A) Transverse femoral sections from wild-type mice were used for immunohistochemical analysis 
of the bone marrow (n = 7; representative images shown). Sections were stained for TGF-β1 (red) and PF4 (green). DAPI was used as a nuclear counterstain 
(blue). Scale bar: 200 μm. (B) Images (original magnification, ×60) identifying the cellular and lobulated nuclear morphology characteristic of megakary-
ocytes. Scale bar: 200 μm and 20 μm for ×20 and ×60, respectively.(C) Wild-type mice were treated with a monoclonal antibody directed against GPIbα 
(anti-CD42b; 4 mg/kg intraperitoneally) to deplete platelets. Whole blood and platelet-poor plasma (PPP) were collected 48 hours after injection. (D) 
Expression levels of several platelet genes, as well as Tgfb1, were significantly lower in whole blood after platelet depletion. Expression of Ptprc, widely 
expressed in leukocytes, was not altered. Gapdh was used as reference gene transcript. Lines and error bars represent median (IQR). Statistical analysis 
was performed with Mann-Whitney test; n = 5 (control) versus 7 (anti-CD42b). (E and F) Effect of platelet depletion in mice on PPP levels of TGF-β1 and 
PF4 (Mann-Whitney test, n = 5 for control, n = 7 for anti-CD42b antibody-treated mice). Lines and error bars represent median (IQR).
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nontargeting control or a miR-21 inhibitor, resulting in a significant decrease of miR-21 levels (Figure 6E). In 
line with our findings in murine bone marrow and platelets, as well as the luciferase assay for the murine Was 3′ 
UTR, inhibition of miR-21 resulted in a concomitant increase of WAS expression levels (Figure 6F). No signif-
icant effect was seen on megakaryocyte purity or maturity (Supplemental Figure 13, B–D). Thus, our findings 
indicate that pharmacological miR-21 inhibition leads to derepression of WASp, which has previously been 
shown to affect the release of TGF-β1 from platelets (17).
miR-21–null mice have a reduced number of  circulating platelets. Previous studies into miR-21 and cardiac fibro-
sis have highlighted a discrepancy between pharmacological and genetic inhibition of this miRNA (2, 3). miR-
21–null mice were reported to develop fibrosis in response to myocardial infarction or pressure overload that is 
equivalent to that of wild-type mice. ELISA measurements for TGF-β1 and PF4 in PPP showed no significant 
difference between wild-type and miR-21–null mice. Similarly, platelet levels of WASp and TGF-β1 were also 
Figure 5. Pharmacological inhibition of miR-21 decreases platelet TGF-β1 release. (A) Platelet counts and their aggregation response were assessed in 
whole blood and platelet-rich plasma (PRP), respectively, isolated from mice treated with antagomiR-21 or control antagomiR. ELISAs were subsequently 
performed in the supernatant of aggregated platelets. (B) Platelet counts were assessed by flow cytometry using a CD41-allophycocyanin antibody on 
gated platelets. Statistical analysis was performed with Mann-Whitney test; n = 5 antagomiR-21–treated mice vs. n = 5 control antagomiR-treated mice. 
Lines and error bars represent median (IQR).(C) Platelet aggregation in response to arachidonic acid (AA), protease activated receptor 4 (PAR4) amide, or 
collagen did not show a significant difference after antagomiR-21 treatment (2-way ANOVA with post hoc Šidák’s test; n = 5 for each treatment type). (D) 
TGF-β1 release from platelets in response to collagen and PAR4 amide was reduced after treatment with antagomiR-21. PF4 was less affected. TGF-β1 
levels in platelet-poor plasma (PPP) were unchanged. Statistical analysis was performed with 2-way ANOVA for agonists and Mann-Whitney test for PPP; 
n = 5 antagomiR-21–treated mice vs. n = 5 control antagomiR-treated mice for each condition; *P < 0.05; ***P < 0.001.
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unaffected (Supplemental Figure 14). To assess other potential changes in platelets from miR-21–null mice, we 
performed a whole-blood platelet count using a Hemavet hematology analyzer. In contrast to short-term phar-
macological inhibition of miR-21, blood from miR-21–null mice showed significantly lower platelet counts 
compared with wild-type littermates (Figure 7A). Lymphocyte and monocyte numbers were also reduced but 
still fell within the normal reference range. To determine the megakaryocyte response to the lower platelet 
count, immunohistological staining of the bone marrow was performed in decalcified femoral sections (Figure 
7B). A significant increase in megakaryocyte numbers was seen in miR-21–null bone marrow, with a median 
(interquartile range) count per mm2 of 84.7 (78.0–90.0) and 106.3 (99.5–121.2) for wild-type and miR-21–null 
mice, respectively (P = 0.003 for Mann-Whitney test) (Figure 7C). We next studied gene expression levels in 
the bone marrow of these mice (Figure 7D). No significant differences were seen for expression of Tgfb1, Ptprc 
(CD45), or Was. However, transcript levels of several megakaryocyte-specific genes were significantly higher 
(FC = 1.70 [P = 0.005] for Itga2b, 1.72 [P = 0.026] for Pf4, 1.90 [P = 0.030] for Ppbp). Furthermore, there was a 
trend toward higher expression levels for Tgfbr2 (FC = 1.32, P = 0.055), a previously described direct target of  
miR-21 (38). Altogether, platelet and megakaryocyte numbers are altered in miR-21–null mice.
Figure 6. Pharmacological inhibition of miR-21 affects platelet TGF-β1 release through targeting Wiskott-Aldrich syndrome protein. (A) The platelet 
releasate was obtained by thrombin-mediated activation of washed platelets collected from antagomiR-21– or control-treated mice. Proteomics 
analysis uncovered an attenuated release of TGF-β1 and 2 other α-granule proteins, von Willebrand factor (VWF) and fibronectin (FINC), from platelets 
isolated after antagomiR-21 treatment. Statistical analysis was performed using Welch’s t test (n = 3 vs. 3 biological replicates; pooled from n = 12 
antagomiR-21–treated mice and n = 12 control antagomiR–treated mice). (B) Platelets were isolated from mice after miR-21 inhibition. Immunoblots 
showed higher levels of Wiskott-Aldrich syndrome protein (WASp), while TGF-β1 content was unchanged (n = 4 antagomiR-21–treated mice vs. 4 con-
trol antagomiR–treated mice; statistical comparisons of densitometry using Welch’s t test). Similarly, WASp phosphorylation at tyrosine 293 (p-WASp; 
Y293) was unaffected.(C) Gene expression of Was in murine bone marrow after antagomiR-21 treatment was assessed by qPCR (n = 9 antagomiR-21–
treated mice vs. 9 antagomiR control–treated mice; Welch’s t test). Actb was used as a normalization control. (D) Transfection of HEK293T cells with 
miR-21 mimic significantly suppressed luciferase reporter activity using vectors harboring the 3′ untranslated region of Was (3 independent experi-
ments in triplicates [control] or quadruplicates [miR-21 mimic]; paired t test used for statistical comparison). (E and F) Megakaryocytes were produced 
by forward programming (FoP-MK) of human pluripotent stem cells (hPSCs). Upon transfection with a miR-21 inhibitor (LNA-21), miR-21 levels were 
markedly reduced. The inhibition of miR-21 was accompanied by increased gene expression levels of WAS (n = 6 LNA-control transfections vs. 6 LNA-21 
transfections; Welch’s t test). *P < 0.05, **P < 0.01, ***P < 0.001. Mr, relative mass.
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Discussion
In this study, we identify a potential novel mechanism for the antifibrotic effects of  miR-21–targeted therapy: 
notably, miR-21 minimally affects ECM protein secretion by CFs in vitro and in miR-21–null mice. Instead, 
miR-21 levels correlate with several platelet-derived profibrotic factors in the circulation, and its genetic 
ablation decreases platelet counts. Short-term pharmacological miR-21 inhibition attenuates the release of  
TGF-β1 from platelets. This suggests that pharmacological inhibition of  miR-21 acts systemically in addi-
tion to its effects on CF proliferation. On the other hand, genetic deletion of  miR-21 reduces platelet num-
bers and stimulates megakaryocyte proliferation. These findings may have implications for miR-21–based 
therapeutics, in particular with regard to local versus systemic delivery.
Direct effects of  miR-21 in the heart. There is strong evidence for the contribution of miR-21 in fibrosis. Sys-
temic inhibition could prevent and even reverse cardiac fibrosis in a pressure-overload model (3), which was 
confirmed in most (4, 5), but not all (2), studies. Fibroblasts are the primary contributors to fibrosis (39, 40), 
with the TGF-β pathway playing a central role in fibroblast activation. Despite enhancing CF proliferation, 
miR-21 had no major effect on cardiac ECM protein secretion. These findings are in stark contrast with previ-
ous studies that revealed major changes in ECM protein secretion using a similar approach for miR-29b (15) 
and hypoxia (41). Experiments in CFs were performed based on equal cell numbers prior to transfection and 
Figure 7. miR-21–null mice display 
lower platelet and leukocyte num-
bers but higher numbers of mega-
karyocytes. (A) Using Hemavet blood 
cell counting, significantly lower num-
bers of platelets, lymphocytes, and 
monocytes were found in miR-21–null 
mice (n = 6) compared with those in 
wild-type littermates (n = 10) (Welch’s 
t test). (B) Immunohistochemical 
analysis was performed for TGF-β1 
(red), PF4 (green), and a nuclear coun-
terstain (DAPI, blue), using femoral 
bone marrow sections of miR-21–null 
mice (n = 10). Representative images 
are shown. (C) Examination of bone 
marrow sections from miR-21–null 
mice revealed increased megakaryo-
cyte numbers, as identified based on 
morphology and PF4 positivity. Statis-
tical comparison was performed using 
the Mann-Whitney test; n = 6 vs. 10 
for littermate control and miR-21–null 
mice, respectively. Lines and error 
bars represent median (IQR). (D) qPCR 
analysis revealed increased expres-
sion levels of megakaryocyte-specific 
genes Itga2b, Pf4, and Ppbp in bone 
marrow cells isolated from miR-21–
null and littermate control mice. Tran-
script levels of Tgfb1, Was, and Ptprc 
(CD45) were not affected. Statistical 
comparisons using Welch’s t test; n = 
6 vs. 6. *P < 0.05, **P < 0.01.
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TGF-β1 treatment. Hence, it can be stated that, despite enhancing proliferation, this antiproliferative effect 
of miR-21 inhibition was insufficient to cause detectable changes in total ECM protein secretion. Previous 
discrepancies between studies on miR-21 and cardiac fibrosis have been ascribed to differences between phar-
macological and genetic miR-21 inhibition (42). In line with our in vitro findings and with functional cardiac 
analysis by others (2), the composition of the cardiac ECM did not significantly differ in miR-21–null mice. 
A recent study by Ramanujam et al. used viral vectors with different tropism to distinguish effects of miR-21 
inhibition in different cardiac cell types (26). While cardiomyocyte inhibition of miR-21 aggravated fibrosis, 
nonmyocyte targeting attenuated remodeling in a mouse model of cardiac overload. Importantly, effects of  
miR-21 on cardiac fibrosis are observed only in the presence of tissue injury (3–6).
miR-21 as a modulator of  the bone marrow. miR-21 is ubiquitously expressed and has been implicated 
in fibrosis in different organs (7–9). Furthermore, miR-21 is highly abundant in circulating cells, such as 
monocytes and platelets (43). Recent studies on atherosclerosis identified an immunomodulatory role of  
miR-21 in mononuclear cells (12, 30, 44). Leukocytes and platelets are major contributors to the tissue injury 
response (45). Thus, the widely reported induction of  miR-21 upon injury may be secondary to an immune 
cell infiltration or platelet deposition rather than induction of  miR-21 expression in resident cells (46). In 
addition, expression and processing of  the miR-21 precursor is enhanced by TGF-β signaling (47). A platelet 
contribution may explain why miR-21 inhibition has no effect on fibrosis in the absence of  tissue injury. Tis-
sue injury induces platelet activation. In addition to local fibroblast activation, platelet-derived proteins (33), 
including TGF-β1 (19), contribute to the onset and progression of  fibrosis. Platelet inhibition or depletion 
attenuates cardiac remodeling after myocardial infarction (48, 49) or in response to pressure overload (18, 
33). We have previously demonstrated that miR-21 is abundant in platelets and miR-21 plasma levels are 
decreased by antiplatelet therapy (23). Ago2 immunoprecipitation showed marked enrichment of  miR-21 
in a human megakaryoblastic leukemia cell line. Bone marrow cells are more readily affected by antagomiR 
treatment compared with cardiac tissue (50). This is in contrast with the absence of  miR-21 across tissues 
upon genetic ablation in mice. In miR-21–null mice, we found no major effect on cardiac ECM proteins, but 
we observed significantly lower platelet and leukocyte counts, accompanied by a marked increase in mega-
karyocyte numbers. Altogether, these findings imply that miR-21 inhibition alters the bone marrow.
Pharmacological miR-21 inhibition affects the platelet releasate. Platelets constitute a major source of  circu-
lating TGF-β1 (19). This is reflected in the strong correlation between plasma levels of  miR-21 and TGF-β1 
in the Bruneck cohort and by the reduction in TGF-β1 plasma levels upon platelet depletion in mice. In the 
bone marrow of  mice, we observed a striking colocalization of  TGF-β1 with megakaryocytes. Pharmaco-
logical inhibition of  miR-21 did not alter the platelet count or their aggregation response but significantly 
decreased the release of  several α-granule proteins. Our observation of  miR-21 inhibition affecting platelet 
TGF-β1 release suggests a feed-forward mechanism, where TGF-β1 induces miR-21 expression in mega-
karyocytes, which subsequently enhances platelet TGF-β1 release through inhibiting WASp. WASp has 
been described as a regulator of  actin polymerization in neutrophils, macrophages, and lymphocytes (51), 
being expressed solely in hematopoietic cells (34). While WASp is present in platelets, it is not required 
for platelet spreading, despite the importance of  cytoskeletal F-actin polymerization in this process (52). 
This indicates redundancy in the mechanisms that regulate actin polymerization in platelets. Consequent-
ly, miR-21–mediated titration of  WASp levels may be a refined way of  interfering with TGF-β signaling. 
Previous approaches of  TGF-β1–targeting therapy have thus far failed due to major side effects (53). Alter-
ing the platelet release of  profibrotic factors may provide a more targeted approach, as platelet activation 
occurs at sites of  tissue injury. In summary, our findings provide evidence that the reported antifibrotic 
effects upon miR-21 inhibition may, at least in part, occur through decreasing platelet release of  TGF-β1.
Study limitations. The culture of  CFs for secretome analysis was performed in serum-free medium. This 
may have suppressed some of  the effects of  miR-21 in these cells. In addition, ECM proteins were assessed 
only in miR-21–null mice without cardiac injury to promote fibrosis. Correlations between miR-21 and 
markers of  platelet activation or profibrotic factors do not rule out potential confounding by contaminat-
ing leukocyte subtypes. For TGF-β1, however, the immunohistochemistry results from the bone marrow 
indicate a high degree of  specificity for megakaryocytes. Our findings suggest that antagomiR-21 treat-
ment may reduce TGF-β1 release through derepressing WASp. While direct targeting was indicated by a 
luciferase reporter assay and by miR-21 inhibition in hPSC-derived megakaryocytes, in vivo evidence for 
this interaction is correlative. In addition, as suggested by the proteomic analysis of  the platelet releasate, 
antagomiR-21 treatment may affect release of  other α-granule proteins as well. Further studies are needed 
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to determine whether miR-21 has effects on the release of  other constituents of  platelets and on leukocytes, 
given that WASp is predominantly expressed in hematopoietic cells and Wiskott-Aldrich syndrome is char-
acterized by immune deficiency as well as thrombocytopenia (34).
Conclusions. This study is a timely contribution, given that miR-21–based therapies are progressing to 
clinical trials for Alport syndrome (7). The current assumption that miR-21 inhibition attenuates fibrosis pre-
dominantly through direct effects on fibroblasts is challenged by the marginal changes in ECM protein com-
position and secretion. Our findings after pharmacological and genetic miR-21 inhibition in mice indicate that 
other cell types, in particular bone marrow–derived cells, may also contribute. While local delivery of  miRNA 
therapeutics may decrease the likelihood for off-target effects (10), it could also limit therapeutic efficacy if  
the benefit is not solely mediated by local cells. A broad appraisal of  the multifaceted systemic response of  
targeting ubiquitously expressed miRNAs will aid the success of  miRNA-based therapeutics in clinical trials.
Methods
Detailed methods are provided in the Supplemental Methods.
RNA isolation, reverse transcription, and PCRs. RNA isolation, reverse transcription (RT), and preamplifi-
cation as well as individual quantitative real-time PCR (qPCR) for miRNA and gene expression were per-
formed as described previously (25). A comprehensive list of  assays is provided in Supplemental Table 1.
CF isolation and transfection for secretome analysis. Primary mouse CFs were isolated from the hearts 
of  male (8- to 10-week-old; n = 8) C57BL/6 mice (Charles River) by collagenase II–based digestion as 
described previously (15). Cells from different animals were maintained as separate biological replicates. 
Cells at passage 3 were used in all experiments. Transfections of  miR-21 mimic (Dharmacon) or miR-21 
inhibitor (LNA-21; Exiqon A/S) were each carried out, with corresponding controls in parallel using 4 
separate biological replicates. Lipofectamine RNAiMAX (Life Technologies) was used in reduced serum 
medium (Opti-MEM, Life Technologies) at a final concentration of  50 nmol/l for transfection of  all 4 
sequences. After 24 hours, CFs were stimulated with 10 ng/ml recombinant TGF-β1 (Peprotech) in serum-
free medium. After 48 hours, conditioned medium and cells were harvested for analysis. Samples were 
processed for qPCR analysis, immunoblotting, or proteomic analysis as described previously (15) and in the 
Supplemental Methods. See complete unedited blots in the supplemental material.
Proliferation assay in transfected CFs. A proliferation assay was performed using the xCELLigence RTCA 
DP Instrument (ACEA Biosciences). CFs were isolated and transfected using the same methods and con-
centrations as above. After 24 hours, cells (5 × 103 cells/well; 4 biological replicates per condition, in dupli-
cate) were seeded in an E-Plate VIEW 16 (ACEA Biosciences) in complete DMEM medium. Following 
plating, cells were allowed to attach while at room temperature for 30 minutes before placing the plate in 
the incubator at 37°C. Two wells per plate were loaded with media only to assess background levels. Cell 
index values were recorded by 150 sweeps per interval every 30 minutes using proprietary software, with 
the baseline recording reset at 4 hours. Data were analyzed using the difference (Δ) in cell index according 
to the manufacturer’s instructions with the baseline recording reset at 4 hours.
ECM extraction and analysis. ECM protein enrichment was performed on hearts from female miR-21–null 
mice or littermate controls, aged 14–16 weeks, using our previously published 3-step extraction method (28, 
54). Generation of  the miR-21–null mice has previously been described (2). Proteins in the sodium chloride 
and guanidine hydrochloride extracts were enzymatically deglycosylated, followed by denaturation, reduc-
tion, alkylation, and tryptic digestion. Peptides were purified using a C18 spin plate (Harvard Apparatus) 
and analyzed by LC-MS/MS. Identified proteins were annotated using the Matrisome database (29).
Bruneck cohort. The Bruneck Study is a community-based, prospective survey of  the epidemiology and 
pathogenesis of  atherosclerosis and cardiovascular disease (25, 55). At the 1990 baseline evaluation, the 
study population comprised an age- and sex-stratified random sample of  all inhabitants of  Bruneck (125 
men and 125 women from each of  the fifth through eighth decades of  age, all White). In the present study, 
citrate plasma samples from the 2000 (n = 660) and 2015 (n = 332) follow-up were analyzed. These samples 
were drawn after an overnight fast and 12 hours of  abstinence from smoking. During the 2000 follow-up, 
citrate plasma was prepared by single centrifugation and aliquots were immediately stored at –80°C. For the 
2015 follow-up, platelet-rich plasma (PRP) was first isolated by centrifugation at 175 g for 15 minutes with 
slow brake. An aliquot of  PRP was then supplemented with prostacyclin (PGI2, epoprostenol, 2 μg/ml; Toc-
ris Bioscience) and centrifuged at 1,000 g for 10 minutes to obtain PPP. Samples were immediately stored at 
–80°C. Levels of  miR-21 and a panel of  228 proteins were measured by RT-qPCR (25) and a combination 
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of  Olink Proseek Proximity Extension Assays (Proseek Multiplex CVD I and Inflammation panels, Olink) 
(55, 56) and mass spectrometry–based assays (PlasmaDive, Biognosys AG) (57), respectively, as described 
previously (25). In addition, TGF-β1 (DY240, R&D Systems), PF4 (DY795, R&D Systems), and PPBP 
(DY393, R&D Systems) levels were measured using DuoSet ELISA Development kits and DuoSet Ancil-
lary Reagent Kits 1 and 2 (R&D Systems) according to the manufacturer’s instructions. Absorbance at 450 
nm was measured on a plate reader (Tecan Infinite 200 Pro) using 570 nm as a reference wavelength. Results 
were calculated using a 4-parameter logistic fit.
Platelet immunodepletion in mice. Male C57BL/6J mice (Charles River) were treated with a rat anti-mouse 
GPIbα antibody (4 mg/kg, Emfret Analytics) or sterile PBS via intraperitoneal injection. Blood was col-
lected after 48 hours into acid-citrate-dextrose buffer by cardiac puncture, followed by preparation of  PRP 
and PPP using serial centrifugation at 100 g and 1,000 g for 10 minutes at room temperature, respectively. 
Samples were divided into aliquots, blinded, randomized, and immediately stored at –80°C. RNA isolated 
from whole blood was used for qPCR analysis. TGF-β1 (DY1679) and PF4 (DY595) levels were measured in 
PPP using DuoSet ELISA Development kits (R&D Systems) according to the manufacturer’s instructions.
Ago2 immunoprecipitation. Immunoprecipitation of  ribonucleoprotein was carried out in MEG-01 cells 
(ATCC, CRL-2021), as previously described (25, 58). Briefly, 50–100 million cells were lysed in 500 μl ice-
cold polysome lysis buffer (5 mM MgCl2, 100 mM KCl, 10 mM HEPES, pH 7.0, 0.5% Nonidet P-40), with 
freshly added 1 mM DTT, 100 U/ml RNase inhibitor (Life Technologies) and 1× protease inhibitor (cOm-
plete Mini, ethylenediaminetetraacetic acid–free [EDTA-free], Roche) for 15 minutes. Centrifugation was 
performed at 14,000 g at 4 °C for 10 minutes. The supernatant was mixed with 500 μl ice-cold NT2 buffer 
(50 mM Tris, pH 7.4, 150 mM NaCl, 1 mM MgCl2, 0.05% Nonidet P-40) containing freshly added 200 U/
ml RNase inhibitor, 0.5% vanadyl ribonucleoside, 1 mM DTT, 15 mM EDTA, and 50 μl mouse anti-hu-
man Ago2-coated (Abcam) sepharose G beads (Life Technologies). Incubation was carried out overnight 
at 4°C on a rocking platform. The following day, beads were washed 5 times with ice-cold NT2 buffer and 
used for RNA isolation.
Murine platelet and bone marrow analysis. For pharmacological miR-21 inhibition, male C57BL/6J mice, 
aged 10–12 weeks (Charles River), were injected intraperitoneally with cholesterol-conjugated antagomiR 
constructs (Fidelity Systems) targeting miR-21 or using a nontargeting sequence, as previously described (25). 
Sequences were designed to target miR-21 (5′-U*C*AACAUCAGUCUGAUAAG*C*U*A*-Chol*T-3′) 
or to serve as nontargeting control (5′-A*A*GGCAAGCUGACCCUGAA*G*U*U*-Chol*T-3′), with 
the asterisks denoting phosphorothioate backbone modification and “Chol” indicating cholesterol con-
jugation. Constructs were reconstituted in sterile PBS, and intraperitoneal injections of  500 μl were per-
formed on day 0, 1, and 2 in a dose of  25 mg/kg for the platelet releasate isolation and 40 mg/kg for the 
aggregometry experiments and the ELISA measurements in plasma. Treatment with both constructs was 
performed in parallel. On day 7, mice were anesthetized using pentobarbital for blood and tissue collection. 
Upon sample collection, samples were blinded and randomized prior to analysis. Blood and bone marrow 
samples were obtained from equal numbers of  male and female miR-21–null mice (Mir21atm1Yoli/J, Jax 
016856; The Jackson Laboratory) and littermate controls, aged 8–12 weeks. Mice were kept under constant 
temperature and humidity in a 12-hour-controlled dark/light cycle.
A Hemavet (Drew Scientific) blood cell counter was used for analysis of  miR-21–null blood samples. 
Platelet counting after antagomiR-21 treatment was performed on diluted whole blood incubated with an 
allophycocyanin-labeled anti-mouse CD41 antibody (BioLegend), using an Accuri C6 flow cytometer (BD 
Biosciences). Light transmission aggregometry was performed with PRP as described previously (25). Plate-
lets were isolated by blood collection into acid-citrate-dextrose buffer, followed by 2-step centrifugation and 
washing in modified Tyrode-HEPES buffer supplemented with prostaglandin E1. PPP was isolated by 2-step 
centrifugation, obtaining PRP followed by a second spin to obtain PPP. TGF-β1 and PF4 levels were mea-
sured in PPP and light transmission aggregometry supernatants using DuoSet ELISA Development kits 
(R&D Systems) according to the manufacturer’s instructions. Releasate was obtained by thrombin-induced 
platelet aggregation in platelets obtained from blood pooled from 4 mice, followed by gel-based LC-MS/MS 
analysis. Bone marrow cells were isolated from femora and filtered using a 100-μm cell strainer (Corning), 
followed by red blood cell lysis and subsequent RNA isolation for qPCR analysis. For immunohistochemistry, 
femora were fixed in 4% formaldehyde and then decalcified in a 0.38 mol/l EDTA solution at 4°C for 3 weeks. 
Bones were paraffin embedded and sectioned for staining. After primary antibody incubation (TGF-β1 and 
PF4; see Supplemental Table 2) overnight, sections were incubated with fluorescently labeled species-specific 
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secondary antibodies. Staining was visualized using an inverted spinning disc confocal microscope (Nikon 
Ti-Eclipse, teamed with a Yokogawa CSU-X1 Andor Spinning Disc with iXon EM-CCD camera). Imaging 
was performed with a 1.70 NA ×20 or 1.40 NA ×60 magnification objective lens.
Transfection of  miR-21 inhibitor in human megakaryocytes. Human megakaryocytes were obtained by for-
ward programming of  hPSCs as previously described (37). Transfections of  miR-21 inhibitor or a nontarget-
ing control (PowerLNA, Qiagen) were carried out in triplicate in 2 independent megakaryocyte lines. Con-
jugation to TurboFect reagent (Thermo Scientific) was used to enhance the transfection efficiency. A final 
concentration of  25 nmol/l was used for both oligonucleotides. After 48 hours, cells were collected for RNA 
isolation by centrifugation at 120 g and washed once in sterile PBS. Prior to transfection and during collec-
tion, an aliquot of  cells was incubated with anti-CD41a-APC-H7 and anti-CD42a-APC (BD Pharmingen) to 
assess megakaryocyte purity and maturity, respectively, using a Gallios flow cytometer (Beckman Coulter).
Statistics. Gel-based MS data were quantified using normalized spectral counts. Qspec (59) was used to 
detect differential expression in the CF secretome analysis. Qspec utilizes a hierarchical Bayes estimation 
of  a generalized linear mixed-effects model to share information across proteins, which increases the power 
to detect differential expression. The FDR was calculated using an Empirical Bayes method, and FDR < 
5% was considered significant. All other statistical analyses were performed with Microsoft Excel (version 
15.41) and GraphPad Prism (version 7.0d). Distribution of  data was analyzed using the Shapiro-Wilk 
normality test, where P > 0.05 was considered to indicate normal distribution. When at least 1 sample 
group within an experiment showed nonnormal distribution, nonparametric tests were used for the analy-
sis. For unpaired data, 2-tailed Welch’s t test or Mann-Whitney rank tests were performed for parametric 
and nonparametric distribution, respectively. For paired data, paired t tests or Wilcoxon’s matched-pairs 
signed-ranks tests were used, respectively. Where appropriate, a 2-way ANOVA was used, with post hoc 
analysis of  individual effects by Šidák’s test. Time course data of  the CF proliferation assay were analyzed 
using the nonparametric Friedman test with post hoc analysis of  differences between each targeting and 
nontargeting transfection type using Dunn’s multiple comparisons test. Comparison of  gene expression and 
ECM protein abundance between miR-21–null or wild-type mice was performed using an FDR approach 
with the 2-stage step-up method of  Benjamini, Krieger, and Yekutieli, with an FDR for significant discov-
ery set to 5%. Relationships between the concentrations of  plasma proteins and the relative quantities of  
miRNAs were investigated using Pearson correlations with P value adjustment (producing q values) using 
FDR adjustment according to Benjamini, Krieger, and Yekutieli. Data are shown as mean ± SEM unless 
stated otherwise. Where box-and-whisker plots are shown, the line indicates the median, bounds of  boxes 
indicate quartiles, and whiskers indicate the range. P < 0.05 or q < 0.05 was considered significant.
Study approval. The Bruneck study protocol was reviewed and approved by the ethics committees of  
Verona and Bolzano, Italy, and all participants provided written informed consent before entering the study. 
All animal studies were performed under protocols in strict accordance with the UK Animals (Scientific Pro-
cedures) Act 1986 or the Institutional Animal Care Use Committee of  Yale University School of  Medicine.
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